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Herbal medicines (HM) use and popularity as a form of complementary and alternative 
medicine (CAM) continue to increase globally. However, public health and safety concerns 
also continue to grow. Contamination of HM samples with chlorinated pesticides and heavy 
metals has been reported, likewise adulteration with prescription medication. 
 
In this research, an interdisciplinary method drawn from public health and forensic chemistry 
was adopted. It examined the knowledge and use of HM in Ekiti state, Southwest Nigeria, 
with a population of over two million. A survey was used to explore public knowledge, use, 
and perception of HM effectiveness and safety. Textual analysis, inferential and descriptive 
statistics were used to analyse survey data. Hospital data from the state was also examined 
to determine HM related casualty and fatality figures over a period of 5 years (2010 to 2014) 
and the findings were compared with the survey findings. Ten commonly used HM identified 
in the survey were then analysed for the possible presence of prescription medicines and 
heavy metals using Gas Chromatography-Mass Spectrometry (GC-MS) and Inductive 
Coupled Plasma-Optical Emission Spectroscopy (ICP-OES) respectively. 
 
Findings of this research showed that 85.0% of the respondents have used HM in the last 
two years. Although 57.0% had concerns about the safety of uncertified HM, 37.3% used 
them anyway, while 31.9% used both uncertified and certified HMs. The use of HM (85.0%) 
was attributed to its effectiveness by 39.6% of users; while poor service delivery was the 
primary reason 45.2% of respondents did not use the orthodox health system. There was a 
significant association between HM use and the age, gender, level of education, religion, 
annual income and occupation of respondents, using the Chi-square analysis at a 
significance level of 0.05. Hospital records of patients (n=94,323) showed a small number of 
HM associated paediatric admissions (0.5%), adult admissions (0.06%), paediatric deaths 
(3.2%) and adult deaths (0.2%). Analysis of all the studied HMs showed that cadmium and 
copper were detected at above World Health Organization (WHO) permissible limits and one 
of the samples also had lead and zinc above the limit. However, none of the target 
pharmaceutical compounds was detected in the HM samples. 
 
This research investigated the issues surrounding the use of HMs, their potential toxicity, 
casualties, and fatalities. The onset and progression of some medical problems as 
highlighted in this research may be connected with exposure to heavy metals when present 
above permissible limits. Additionally, even when metals are present below permissible 
limits, prolonged exposure may result in accumulative toxicity. Therefore this study highlights 
a major public health concern and a need to monitor and control HMs through appropriate 
legislative changes. This is the first multidisciplinary investigation of HMs in the study 
population and the wider public.  
 
Key Words: Herbal medicine, use, and perception, casualty and fatality, drug analysis, heavy 
metals.  
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CHAPTER 1:  INTRODUCTION 
1.1 Herbal medicine use in ancient times 
The dependence of humanity on nature for the provision of medicine through herbs has a 
long history (Barnes, Anderson and Phillipson, 2007). Plants have proved to be rich sources 
of medicine and highly beneficial to the management and treatment of diverse diseases 
(Bako et al., 2005). Herbal medicines (HM) have played important roles in the healing 
process as well as containing many pharmaceutically active compounds, which are now 
used in pharmaceutics and commercially produced (Principe, 1988; Pearce and 
Puroshothaman, 2002). Their use has been reported to be as far back as 60,000 years ago 
after a new cave was discovered in Iraq in 1960.  The cave contained a grave of a 
Neanderthal man which was adorned with specific flowers known for their medicinal 
properties (Solecki, 1975). A Sumerian cuneiform clay tablet dating to about 2100 B.C also 
provides one of the first documented references to an HM instruction containing depictions 
of plant ingredients and the mixing instructions (Janick, 2003).  
The ‗Papyus Ebers‘ documentation which dates to about 1500 B.C describes an asthma 
remedy prepared by hot brick heating of a herbal mixture to produce fumes (Ebers Papyrus, 
2011). The organised practice of Chinese HM is known to date back over 2000 years 
(Beinfield and Korngold, 1995). The Emperor‘s textbook of herbs that was put together 
around the first century B.C. was one of the earliest compilations on HM (Mabey, 1988). A 
huge HM pharmacopeia was also developed around 1000 A.D. by Muslim physicians and 
the knowledge was documented in ―The Canon‖, a book that was used by many medical 
schools for centuries (Dubick 1986; Saunders, 1965). In Europe, women practised healing 
arts especially after the fall of the Roman Empire in the 6th century (Buchman, 1979), a 
period in which previously acquired experience was used to determine when and what 
herbal remedies were needed, including dosage. In recent times medicinal plants have still 
constituted an efficacious component of various traditional (African traditional, Ayurveda, 
Chinese, Homeopathic and Unani) and modern medicines. However, many factors ranging 
from economic to scientific have influenced the use of herbal remedies in various parts of the 
world. In particular, an increase in scientific knowledge through rigorous research in HM has 
helped to identify its potential dangers and benefits, as further discussed in Section 1.6.  
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1.2 Complementary and alternative medicine (CAM)  
The term ―traditional, complementary and alternative medicine‖ (TCAM or CAM) has been 
used to summarise various nonconventional medical practices. Complementary and 
alternative medicine is a general description of a group of varying healthcare systems, 
medical practices and associated products. These are not regarded as part of conventional 
(or orthodox) medical practice nor are they included in public healthcare systems or 
administered by a practitioner in an orthodox medical setting (Adams et al., 2009). 
Complementary medicine therapies such as aromatherapy, acupuncture, massage, 
visualisation yoga and herbal medicine are practices used alongside modern medicine. 
Alternative medicines, on the other hand, are complete non-orthodox methods of healthcare. 
The World Health Organization (WHO) defined CAM to include all forms of healthcare 
practice which are not within the official health sector (Eisenberg et al., 1993). This definition 
included in CAM some of the traditional systems of medicine such as Unani, Ayurvedic, 
osteopathy, naturopathy, homeopathy, chiropractic, traditional healing and medicine men.  
Some of these practices now lie within the official health sector, especially in countries 
where local legislation supports them. Thus what is referred to as CAM or dietary 
supplements in some Western countries is actually an official health product in other 
countries such as China or India (Warude and Patwardhan, 2005). To avoid ambiguity, some 
of the healthcare provisions or practices which are not within the official health sectors of 
some developed countries are licensed as dietary and regulated as such, especially in the 
United States of America (Lewith, Jonas and Walach, 2010). 
Nonetheless, traditional medicine practices together with complementary and alternative 
medicine such as Ayurvedic and others around the world have herbal medicine as a 
component. Knowledge of plant ingredients is increasing, but information on their clinical 
pharmacology and their mode of action is still largely unavailable, reducing the potential for 
standardisation, evaluation and further use of HM (Ma et al., 2009). Herbal medicines are 
materials or preparations obtained from the parts of one or more plants either raw or 
processed, containing substances with therapeutic characteristics and other benefits to 
human health (WHO, 2008). The WHO fact sheet on traditional medicine (2008) explains the 
four HM types: 
I. Herbs:  Raw plant material such as fruit, stems, leaves, seed, flowers, bark rhizomes, 
wood, roots or other parts of the plant that can be powdered or fragmented. 
II. Herbal materials: Plant materials such as resins, gum, oil (fixed or essential), herbs, 
dried powder and fresh juice. These materials are often produced by different local 
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preparations which include roasting, steaming or honey stir-baking, mixing with 
alcohol or other substitutes.  
III. Herbal preparations: Powdered or comminuted herbal extracts or materials, fatty oils 
of herbal material. They are precursors of finished herbal products and are produced 
by fractionating, extracting, purifying and concentrating the herb. Heating of herbal 
materials in alcoholic drinks, honey or both, or in different media are among other 
preparation methods used. 
IV. Finished herbal products:  Herbal mixtures are produced from one or more herbs and 
often referred to as mixture herbal products when more than one is used. Mixture 
herbal products can contain excipients and active ingredients. But mixture or finished 
products are not considered herbal if there is an addition of any chemically active 
compound, including artificial compounds and/or constituents extracted and isolated 
from herbal materials.  
 
The World Health Organization has identified the contributions of traditional medicine (a form 
of CAM) in the 21st century, especially in management and prevention of various diseases 
which include malaria, tuberculosis and human immunodeficiency virus infection. Therefore, 
to further advance its prospect the WHO published its first comprehensive traditional 
medicine strategy 14 years ago for 2002 to 2005 (WHO, 2002), and a 2014 to 2023 strategy 
published 3 years ago (WHO, 2013). The 2014 to 2023 strategy is centred on traditional 
complementary and alternative medicine (TCAM) which includes:  
 Development  of suitable national policies for management of TCAM to improve the  
knowledge base. 
 Regulation of practices, products and practitioners for stronger quality assurance, 
safety, effectiveness and right use of TCAM.  
 Integration of TCAM options into healthcare service delivery and self-health care to 
increase universal health coverage. 
1.3 Examples of traditional medicine practice  
As stated by the WHO, it defines ―traditional medicine as including diverse health practices, 
approaches, knowledge and beliefs incorporating plant, animal, and/or mineral based 
medicines, spiritual therapies, manual techniques and exercises applied singularly or in 
combination to maintain well-being, as well as to treat, diagnose or prevent illness‖ (WHO, 
2018). A number of selected traditional medical practices are discussed below. 
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1.3.1 Traditional Chinese Medical Practice  
Traditional Chinese medicine (TCM) is made up of many distinct practices dating back over 
5,000 years, centring on ancient Taoist philosophy and is practised alongside western 
medicine in many of China‗s healthcare facilities (Katti et al., 2014). Traditional Chinese 
medicine is deployed in other countries such as the USA and the continents of Europe and 
Africa. An estimated 3.1 million adults in the USA used acupuncture in 2006; according to 
the National Health Survey of 2007 (Barnes and Bloom 2008). This survey reported that 
about 17% of adults used various natural products including herbs, and HM was the most 
common traditional medical therapy. TCM practitioners use various therapies in health 
propagation and treatment of disease, e.g. in Chinese herbal medicine and acupuncture, 
which are discussed below. 
1.3.1.1 Chinese herbal medicine 
 Chinese herbal medicine (CHM) is traditionally one of the most important components of 
TCM (Xu and Yang, 2009). It has an extensive and valuable treatment history first reported 
by Shen-Nong, who lived nearly 5,000 years ago (Lu et al., 2004).  Shen-Nong discovered 
over 70 herbs with medicinal value, describing their properties after tasting hundreds of the 
herbs daily and determining their suitability as herbal therapies (Kuang, 2000). Several 
books and documents have been discovered describing various Chinese herbal formulations 
and proprieties. An example is the book ―52 Bing-Fang‖ (recipes for 52 ailments) that was 
found in an ancient Chinese tomb and describes over 240 herbal medicines and 52 
prescriptions (Wang, 1992). Other ancient Chinese scripts also give details of herbal use; 
e.g.Shan-Hai-Jing, Zhou-Li and Li-Ji‘s book of rites, Shang-Shu and Shi-Jing‘s book of 
songs, and the Zuo-Zhuan script. Shi-Jing described the medicinal effect of herbs, recording 
about 170 types of CHM, including 80 plant species with their planting and harvesting times 
(Shi-Jing, 2013). The Chinese book of geography, ―Shan-Hai-Jing‖ recorded 45 species of 
plants of therapeutic value which include species for mood, general health, treatment of 
disease and also those that are poisonous to humans (Hu, 2008).  
Trade in herbs between China and other countries in Southeast Asia is extensive, spanning 
over 2,000 years and includes herbs such as poria, cinnamon, taurine, ginseng, velvet, kelp 
from Korea, and others such as saffron, clove, senna, myrrh, benzoin and frankincense 
(Xiao, Liu and Xiao, 2001). The development of CHM has come a long way through Chinese 
civilisation over thousands of years to meet contemporary need and demand. Despite the 
primitive and crude technology used in the olden days of CHM processing, modern research 
has supported the underlying concept (Zhao et al., 2010). More than 40 CHM dosage forms 
are now available. These include tincture, powder, bolus/pills, paste, granules, decoction, 
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tablets and liquids (injection and oral). Also available are plasters, liniment, poultices and 
ointment forms of CHM for external application. Aerosol and nanomised forms of CHM have 
also become available (Tang and Ling, 2007; Zhang, 2006; Ding and Hong, 2007; Zhao et 
al., 2010). 
1.3.2 Indian herbal medicine 
The history of Indian herbal medicine (IHM), also known as Ayurvedic medicine, dates back 
to the Hindu period of about 6000 to 4000 B.C with the earliest reference found in the Rig 
Veda (Tipton, 2008). The Rig Veda is an old collection of Vedic Sanskrit hymns that includes 
the Atharvaveda, which is the fourth and final documentation in Hindu literature. However, 
Bhava Prakasha‘s Bhava-Mishra is the most important herbal/plant document, which is also 
well respected among Ayurvedic practitioners in modern day practice (Dev, 1988; Prasad, 
2000; Prasad and Narayana, 2007). 
The oldest text of Ayurvedic medicine was written by Nagarjunan Rasa Vaisesika, who was 
regarded as an important Buddhist philosopher following the death of Buddha (Stanford 
Encyclopedia of Philosophy, 2013). This text, written during the 5th century, describes 
different principles of drug action and their composition (Ayurvedic medicine, 2013). 
However, the Charaka Samhita was the first documentation of the principles and practice of 
Ayurveda with therapeutic emphasis (Bagde et al., 2013). It divided drugs of plant origin into 
50 groups according to their pharmacologic and therapeutic characteristics. This text was 
translated into numerous languages including Tibetan and Chinese (300 CE), Greek (300 
BCE), Persian and Arabic (700 CE), which shows how useful and respected it was 
(Devarkar, Mane and Aswale, 2012).  
The World Health Organisation has already documented about 21,000 plants that are used 
for medicinal purposes globally. 2500 of the species originated from India and 150 of these 
are commercially very profitable products (Rajesham, Ravindernath and Bikshapathi, 2012). 
Often referred to as the world‘s botanical garden, India occupies the enviable position of 
being the largest producer of medicinal herbs globally (Seth and Sharma, 2004). About 20% 
of the world‘s plants species are indigenous to the Indian subcontinent and a large 
percentage of these are of medicinal value and still used in contemporary Ayurvedic practice 
(Singh, 2006). The medicinal plant species are mostly obtained from the wild (80%), with 
about 10% being cultivated for trade (Ibid).  
 About 50% of medicines documented in the British Pharmacopoeia are from western 
Himalayan medicinal plants (Dev, 1997). The western Himalaya provides about 80% of 
Ayurveda herbal medicines, 33% of orthodox and 46% of unani (Baragi, Patgiri and 
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Prajapati, 2008). Well over 7,500 plant species are used in contemporary IHM, and a larger 
number of plant species (about 25,000) are still being used in traditional medicine (Joy et al., 
1998). Contemporary use includes antimalarial therapy, tonics, antipyretics, aphrodisiacs, 
hepatoprotectants, expectorants, diuretics and antirheumatics (Aggarwal et al.,  2011; 
Mukherjee and Wahile, 2006) as well as therapy for certain central nervous system disorders 
(Kumar and Khanu, 2012; Kulkarni, Girish  and Kumar, 2012). The use of these herbs and 
herbal preparations (including spices) for medicinal purpose has been well documented for 
the management of chronic disease in humans, e.g. in diabetes and asthma (Sharma et al., 
2007).  
1.3.3 African traditional medicine  
African Traditional medicine (ATM) is a non-conventional system of disease management 
that employs various processes of consultation with herbalists, priests, media and diverse 
traditional deities together with herbal use (MacGaffey, 2016). The origin of HM use in Africa 
is difficult to ascertain due to poor documentation of ATM practice and development over 
time, which still continues to be a problem (Sowofora, 1993; Elujoba, Odeleye and 
Ogunyemi, 2005; Okigbo and Mmeka, 2006; Aniago, 2015; Masango and Nyasse, 2015). 
Historically knowledge of ATM was passed down orally from generation to generation and 
therefore not documented (Van Wyk, Van Oudtshoorn and Gericke, 1999). This has 
accordingly affected our understanding of the workings of the system and its practice.   
 The earliest recorded history of ATM is the ―Circa‖, of about 1770 B.C. in the code of 
Hammurabi Babylon and that of 1550 BC in the code of Egypt (Veileux and Steven, 2006). 
According to the document the history of herbs goes as far back as 5000 years and beyond 
to the Sumerians‘ description of the therapeutic use of plants such as caraway, thyme and 
laurel. Also documented was the 1000 B.C. old Egyptian ancient medicine‘s use of opium, 
garlic, wheat and barley for medicine. The practice of African traditional medicine has a 
spiritual and nonspiritual aspect, the latter defined as herbalism (Jolles and Jolles, 2000). 
The spiritual aspect of ATM entails healing, which is divine and anchored in religious belief 
which is supposed to allow for supernatural powers (Ibid). Conversely, in many cases there 
is no distinctness in the practice of a traditional healer as a divine or as a herbalist.  Before 
the establishment of orthodox medicine, ATM was the major medical system at the disposal 
of millions of people in urban and rural communities of Africa, but the advent of Europeans 
was a noticeable landmark in the annals of this ancient culture and tradition (Romero-Daza, 
2002; Abdullahi, 2011). 
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The traditional healer mainly diagnoses and treats disease in light of the underlying 
psychological concept and treats symptoms using medicinal plants (Gurib-Fakim, 2006 and 
Gurib-Fakim et al., 2010). This makes ATM holistic, ministering both to the body and the 
mind. African diversity is typified in its varying rich biological and cultural forms, 
characterised by regional contrast in healing practice (Gurib-Fakim, 2006). During the 
colonial regime, traditional medical practice was banned due to a general perception of its 
being magic and witchcraft. It was ruled illegal by the colonial powers, thereby generating 
conflict in areas where the native culture was regarded as witchcraft (Helwig, 2005). In this 
period efforts were also made to regulate the sale of HM as colonialism and Christianity 
spread through Africa. There was no investigation of the soundness of traditional medical 
practices because many foreigners were of the opinion that traditional medical practitioners 
were to be dismissed as superstitious (Onwuanibe, 1979). This opinion still persists because 
orthodox health practitioners, including doctors, have continually despised traditional 
practitioners and practice, despite its impact in meeting and securing the basic health of the 
population (Conserve Africa, 2002). Moreover, until recently HM in Africa was generally not 
thoroughly researched and only loosely regulated (Mills et al., 2005). But in recent times 
attempts to synergise both conventional and traditional medicine practice have yielded 
results. As observed from personal experience in clinical work in Nigeria, this collaboration is 
demonstrated by a series of training sessions for traditional birth attendants organised by 
conventional health professionals and the development of effective referral practice.  
1.4 Use and belief in traditional medicine in Ekiti State 
1.4.1 Traditional medicine belief in Nigeria 
About 75% of Nigerians still consult traditional healers for a variety of healthcare provision 
(Adefolaju, 2011). This shows that most Nigerians have retained a deep belief in traditional 
medical practice and its practitioners, hence relying on them for their various health care 
needs. There are many components of traditional medicine: maternity care, spiritual therapy, 
herbal medicine, circumcision, traditional orthopaedics, psychiatric care, aromatherapy, 
homeopathy, massage, music therapy and a host of others (Adefolaju, 2011). Practitioners 
of traditional medicine gained knowledge of herbal medicine through apprenticeship or 
inheritance. Historically a lot of the practitioners carried out their traditional medical practice 
as community service without financial reward, thereby enhancing the sincerity and 
effectiveness of the practice (Owumi, 1993). 
As a result, traditional medicine practitioners (TMP) were respected in their community and 
were entrusted to provide health care. This care is provided through the use of herbs, 
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mineral substances, animal products or a combination of these. The practice revolves 
around the cultural, social and religious background, knowledge, attitudes and beliefs that 
characterise the community with regard to causation of disease, disability, social, mental and 
physical wellbeing (WHO, 2005b). There are various kinds of traditional health care 
practitioner across the different ethnic groups in Nigeria (see section 1.4.2), aside from the 
provision of western health care system. 
 1.4.2 Traditional Medicine Practitioner and herbal medicine use in Nigeria 
Yoruba, being one of the ethnic groups in Nigeria to which Ekiti State belongs, calls a 
traditional medical practitioner ―Babalawo‖ (Olayiwola, 1987). Yoruba is also the local 
language spoken by this ethnic group. In Yoruba land, the Babalawo, a specialist in Ifa 
(Oracle) divination, plays an important role in traditional healing, while specialists in herbs 
are known as Onisegun (herbalist) (Ibid). The herbalist, unlike the Babalawo, is limited in his 
expertise of spiritual matters, but the use of HM is common to the practice both of Babalawo 
and Onisegun. Undoubtedly the development of a conventional health system especially in 
Yoruba land has been unimpressive; with over half of the populace lacking access to 
conventional health care. The unacceptable level of accessibility to conventional health 
facilities is noticed more in urban slums and rural settlements (Oluwatayo, 2015; Mafimisebi 
and Oguntade, 2011). This problem makes alternative medicine a convenient choice in 
disease control in such areas. However, with HM being an integral part of TM, various herbal 
medicines have been found to be therapeutic in Nigeria, e.g. Rauwolfia vomitoria (Afzel) 
applied in the treatment of insomnia, hypertension, convulsion and stroke (Amole, Yemitan 
and Oshikoya, 2009). Some further examples are included in Table 1.1. 
Table1.1: Examples of herbal medicine/ herbs and their therapeutic use in Nigeria 
Herbal medicines/ herbs Therapeutic use Reference 
Ocimum gratissimum  leaves Diarrheal diseases Ilori et al., 1996 
Parasidi Macfad  seeds Urinary tract infections  Oyelami et al., 2005 
Carica papaya L seeds Intestinal parasitosis Okeniyi et al., 2007 
Garcinia kola Heckel leaves Analgesic and anti-
inflammatory  
Adegbehingbe et al., 2008 
Aloe vera gel Scabies Oyelami et al., 2009 
Undisclosed herbal 
preparation 
Management of HIV Onifade et al., 2013 
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A study of the frequency of complementary and alternative medicine use among 
hypertensive patients attending hospital appointments at a Nigerian tertiary hospital reported 
lower use of CAM, of which herbal medicinal products were the most commonly used (Amira 
and Okubadejo, 2007). The reduced use of CAM among these hypertensive patients may be 
due to desirable results‘ being achieved by the use of orthodox antihypertensive medication. 
Hypertension has been known to be controlled with appropriate choice and dosage of 
medication, the efficacy of which can be directly observed by a blood pressure check (Spirk 
et al., 2018). However, complicated diseases such as cancer still have enormous scientific 
research on-going in determining more acceptable and effective measures in its prevention, 
cause and treatment. It is only natural for cancer patients to want to try alternative methods 
in the face of modern scientific efforts that have not been able to provide satisfactory 
treatment. 
In Ekiti State, a study conducted in one of the local government areas reported 74.3% of the 
521 respondents used HM in the treatment of malaria (Olorunniyi and Morenikeji, 2013). 
This is similar to a study in urban Lagos, in which 66.8% of the 388 respondents used HM 
for management of various ailments (Oreagba, Oshikoya and Amachree, 2011). Other 
studies have also reported high use of HM in Nigeria in recent times (Olorunniyi and 
Morenikeji, 2013; Awodele et al., 2014; Okoronkwo et al., 2014; Duru et al., 2016). The HMs 
used are either locally made, refined, imported, certified or uncertified. Vendors of various 
herbal remedies are now almost ubiquitous in Nigeria, selling in traffic gridlocks, on 
highways, at bus stops bus and stations, events and, surprisingly, in some orthodox health 
facilities. In addition studies have reported high use of uncertified HM among cancer patients 
in Nigeria (Ezeome and Anarado, 2007), among pregnant women for antenatal care 
(Fakeye, Adisa and Musa, 2009), in patients with epilepsy (Danesi and Adetunji, 1994), 
diabetes mellitus (Ogbera et al., 2010) and children suffering from chronic diseases such as 
asthma, epilepsy and sickle cell anaemia (Oshikoya et al., 2008).  
Extemporaneous HM is not included in the class of HM that needs the certification of the 
National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria 
(NAFDAC, 2005). They are preparations made by a practitioner and given on a one-to-one 
basis to a patient in the vicinity of preparation (NAFDAC, 2005). However, some 
extemporaneous HM samples have been commercialised, adding to the burden of 
uncertified HM use. Hence a review of the criteria for HM certification has become very 
necessary in Nigeria.  
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1.4.3 Traditional and orthodox medicine practice in Ekiti State 
 The orthodox and traditional medical system provides health care services in Ekiti State, 
coordinated by the state ministry of health (Ekiti State Hospital Development Project, 2011). 
The increased use of HM has been attributed to challenges with the availability and 
affordability of orthodox medicine. These challenges, such as affordability of service cost, 
quality of service rendered, closeness to home, staff attitude, neatness of the environment, 
availability of required services and drugs have been reported to influence patient‘s 
patronage of orthodox medicine in Ekiti State (Omotosho, 2010). Furthermore, of the sixteen 
local government areas (LGA) in Ekiti State, only two LGAs (Irepodun/Ifelodun and Ekiti 
East) have a higher number of their population benefiting from the health facilities located in 
their LGA (Odeyemi, 2014). Therefore the use of HM in Ekiti State is a combination of 
factors. The choice is made based on the situation of individuals at the time of decision-
making. A household poverty indicator by healthcare in Ekiti State reported 57.5% of 
respondents make use of HM for their health care, due to problems associated with the 
financial capacity to offset hospital cost and proximity of government hospitals (Oluwatayo, 
2008). Despite the availability of modern health care facilities in some communities and no 
sociocultural belief against its use, the inability of residents to afford the services has 
increased the use of HM (Adesiji and Komolafe, 2013).  
As an example, from an enquiry during a field study in Nigeria, an original artemisinin-based 
combination therapy (ACT) drug used in the treatment of malaria costs about 1 Naira, 500 
(US $4.9) in Ekiti State. Conversely, HM therapy for malaria costs an average of 200 Naira 
(US $0.57) (using the Central Bank of Nigeria exchange rate as of September 2018), and 
could even be self-prepared at no cost, provided the appropriate herb and preparation 
methods are known. Hence the choice is predictable, considering the cost of both options 
with ACT being over 70% more expensive. The poor coverage of the National Health 
Insurance scheme means that patients have to ―pay as you go‖ for healthcare, otherwise 
known as ―out of pocket― expenditure on health, which has further contributed to the 
challenges of the use of orthodox medical practice in Nigeria. A study on healthcare 
financing in Nigeria reported that about 69% of Nigerians expend on health through ―out of 
pocket financing‖ (Uzochukwu et al., 2015). Furthermore, the prevalence of drug-resistant 
strains of bacteria and malaria parasite in Nigeria may also explain the use of herbal 
medicine by patients in the treatment of infection and infestation, which to them have defied 
conventional solution (Nasir et al., 2015).  
In addition, countries in Africa are reported to be the most affected by increasing world-wide 
tuberculosis (TB) and malaria-drug resistance (WHO, 2010). The counterfeiting and 
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adulteration of modern antibiotics and other orthodox medication have further added to the 
problem of drug resistance. This is evidenced, for example, by an analysis of over 3,000 
orthodox anti-malarial medications bought in Enugu, Nigeria which showed 9.3% to be of low 
and substandard quality, containing suboptimal amounts of the active ingredient required 
(Kaur et al., 2015). In addition, it was reported that 1.2% of the samples were falsified and 
1.3% degraded. These present the risk of patients receiving incorrect doses and subsequent 
development of resistance in the malarial parasites. Other contributory factors to drug 
resistance were highlighted in the worldwide country-situation analysis response to 
antimicrobial resistance report (WHO, 2010). They included poor laboratory capacity, 
infrastructure and data management, as factors which discourage productive surveillance. 
The sale of antibiotics and other anti-infective medicines without a prescription, lack of 
standard treatment guidelines and growing potential for antimicrobial medicine overuse were 
also highlighted as discouraging factors (Ibid). The effects of these highlighted problems are 
likely contributors to the increase in use of herbal medicine as an alternative. The 
contribution of these and other factors has not been explored in Ekiti State, hence the need 
for this research to address the gap in knowledge.  
1.5 Use and trade of herbal medicine globally 
1.5.1 Developmental and economic implication  
The WHO has encouraged developing countries to develop and use local medication suiting 
individual circumstances, particularly for primary healthcare use (WHO, 2009). This call was 
important in other ways, to reduce the cost of drug importation by developing countries and 
also to look inwards in meeting their primary healthcare need. As a result, countries in far 
East Asia have achieved about 75% of their care need through traditional medicine practice, 
herbal medicine development and use (WHO, 2009). The Secretariat of the Convention on 
Biological Diversity (SCBD) reported worldwide use of herbal medicines has markedly 
increased, and estimated that sales of herbal products in U.S dollars globally reached $60 
billion in 2000 (SCBD, 2014). In 2008, an estimated world market of HM worth $83 billion 
was reported (Nutraceuticals World, 2013). This is an estimated increase of $23 billion in 8 
years. In 2017 the world market in herbal supplements and remedies was reported to be 
about $107 billion (Global Industry Analysts Inc, 2013). Obviously, this is not an economic 
trend contributed to by herbal product use in developing countries alone. In some countries 
with improved socioeconomic development and improved quality of health care, the use of 
herbal medicine has also increased. This is attested by the increased number of herbal retail 
outlets and medical facilities in these countries (Bloom and Standing, 2001). 
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 In the United Kingdom (UK) an estimated £1.6 billion annual CAM ―out-of-pocket‖ 
expenditure was reported (Ernst and White, 2000), herbal remedies being a well-known and 
widespread CAM form. The UK Medicines and Healthcare products Regulatory Agency 
(MHRA) conducted a study on the perception of HM and its use (MHRA, 2008). It was 
reported from the survey that 35% of adults (n=2,032) had used HM in the previous two 
years and 89% of these adults believed most HM were safe to use. It is crucial to emphasise 
the extent to which use and interest in HM are growing. In the last ten years about 40% of all 
healthcare delivery in China was HM related, while the use of HM at least once by 
population percentage in USA, France, Belgium, Australia and Canada is estimated at 42%, 
75%, 38%, 48% and 70%, respectively as seen in Figure 1.1 (Foster et al., 2000; WHO, 
2002).  
 The increased use of HM, despite advances and availability of orthodox medicine, 
especially in developed countries, poses some form of paradox. Use of alternative medicine 
should otherwise be more reduced with advances in orthodox medical care. However, the 
reasons for HM use may vary from personal, cultural, religious, economic and other 
perspective, as discussed in Section 1.4.3. But then poverty, lack of good medical facilities, 
a culture of self-care and self-medication have been reported to influence the use in 
developing countries (Van der Geest and Hardon, 1990; Oshikoya et al., 2008). Factors 
which influence the use in developed countries are different, as discussed further in Section 
1.5.2. 
Figure1.1: Herbal medicine and CAM use in selected developing and developed countries 
(WHO, 2002) 
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1.5.2 Cultural and socioeconomic aspects of herbal medicine use 
Social, cultural, socioeconomic and political factors have been found to influence the use of 
HM in otherwise industrialised or developed countries (Astin, 1998; Eskinazi, 2001; Ong and 
Bodeker, 2002). An example is the USA, where increases in the cost of prescription 
medicines and a renewed interest in natural products or organic alternative, has accounted 
for about 20% of the population‘s using HM (Bent, 2008). Also, as people migrate from 
different nations and cultures, cultural preservation may account for the use of HM in some 
ethnic minorities residing in developed countries (Ma 1999; Kronenberg et al., 2002).  
As humans interact and develop relationships through friendship, marriage, workplace, 
educational placement, tourism and sport, it is plausible that people pass on ideas and 
beliefs to others. As a result, a part of the ethnic majority of developed countries may have 
used HM due to various forms of multicultural interaction. It has also been suggested that 
the increasing side-effect of pharmaceutical drugs, increasing drug-resistant illness and 
general dissatisfaction with orthodox medicine are other reasons for increased use of HM in 
developed countries (Chan, 1996). In addition, orthodox medical practitioners are viewed as 
not paying much attention to body mechanisms and often intervening to block them (Chan, 
1996), unlike CAM practitioners, who support the body‘s natural capacity to regenerate and 
participate in the recovery of the patient. However, survival instinct is an inherent 
characteristic of humans, which often informs our choice including that of health care. Thus 
the use of HM is a complex combination of varying factors in individuals and localised 
population. Accordingly part of this research aims, through a survey, to understand the 
factors that influence the use of herbal medicine in Ekiti State, Nigeria. 
1.6 Safety and efficacy of herbal medicine  
1.6.1 Safety profile of herbal medicine 
Herbal medicines contain various pharmacologically active compounds and the constituents 
behind the therapeutic effect are sometimes undefined (Schulz, Hansel and Tyler, 2001). 
Plants constituents such as tannins, polysaccharides and mucilage regulate the action of 
any ―active principles‖ in the HM. Although these compounds occur naturally in the various 
plants used in the HM, adulterants and contaminants in HM can also produce significant 
pharmacological activity. The multi-active natural components of HM have made it difficult to 
test the efficacy and reproducibility of any positive therapeutic claim. Hence HM has to be 
viewed as a whole and characterised following clinical trials. Accurate characterisation will 
make reproducibility of analytical methods in HM research possible. Studies have revealed 
that the exact effect of the whole herb is not achievable or mimicked by administration of 
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purified and isolated components of the herb (Haq, 2004). Regardless, many HM 
randomised controlled trials (RCTs) have been reported with published meta-analyses and 
they include disease conditions such as early-stage breast and colon cancer, osteoarthritis 
of the knee and irritable bowel syndrome (Guo, Canter and Ernst, 2007; Li et al., 2013; Su et 
al., 2014; Hausenblas et al., 2015; Walton, Whitten and Hawrelak, 2016; Lee et al., 2016 
and Izzo et al., 2016).  
Research on HM poses several challenges, ethical, financial, study-design, product- 
standardisation, and regulatory before embarking on a new drug study in clinical trial. The 
WHO issued operational guidelines in 2005 on regulatory measures required to reinforce 
herbal products‘ clinical trial (WHO, 2005).  However, the widespread acceptance and use of 
HM may be indicative of their efficacy and safety. The lack of efficacy and safety guarantee 
of HM, on the other hand, is largely due to inadequate pharmacological, pharmacokinetic 
and clinical data on many herbal medicinal products. In many cases, the evidence presented 
in some literature is marked by flawed methodology and quality, with a risk of bias which 
limits its findings. As a result claims of effectiveness seem to be based largely on poor-
quality evidence from which firm conclusions cannot be drawn (Izzo et al., 2016). 
 HMs are, nevertheless, generally considered by some to be effective and a safe form of 
medication, which results in its yearly active patronage (Philomena, 2011). This belief in HM 
safety is understandable considering that a minimum of 100,000 people die in the USA 
annually as a result of pharmaceutical compound-related toxicity and about 8% of total 
admissions to hospital are as a result of adverse reactions to pharmaceutical drugs (Nasri 
and Shirzad, 2013). This fatality figure is about 3 times the number (of deaths) resulting from 
drunk drivers, meaning people are 3 times more likely to be killed by taking pharmaceutical 
medication than drunk driving (ibid). By contrast, death or hospitalisation due to HM is rare in 
the USA, as reported by the author. A detailed study of HM-related casualty also reported a 
significantly low incidence of adverse effect and a few severe clinical reactions (Posadzki et 
al., 2013; Di Lorenzo et al., 2015). However, as no similar data exist within the study 
population in this research, a study of HM-related casualty and fatality was carried out to 
ascertain the figures (Section 2.11). 
1.6.2 Contamination and adulteration of herbal medicine 
Regardless of the positive perception of the use of HM, its acclaimed therapeutic satisfaction 
and the disappointment with safety and effectiveness of orthodox medicines, the safety of 
herbal remedies continues to remain a dominant concern (Olorunniyi and Morenikeji, 2013; 
Awodele et al., 2014; Okoronkwo et al., 2014; Duru et al., 2016). Concerns have been 
repeatedly raised about the adulteration and contamination of HM (Ang and Lee, 2000; Ang, 
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2008; Ernst, 2002b; Snyman et al., 2005). Adulteration of HM is the substitution of HM in 
whole or in part with extraneous, impure, inferior or improper entities (Zhang et al., 2012). 
These improper entities include undeclared pharmaceutical compounds, which this research 
aims to investigate by analysing HM obtained from Ekiti State (see Chapter 4). According to 
a United States Food Drug Administration (US-FDA) study, undeclared pharmaceutical 
compounds were found in 572 dietary supplements between 2007 and 2014: sexual 
enhancers accounting for 238 of the entries, weight loss medication 228, and muscle 
builders 90 (Justa and Caldas, 2015). This further emphasises the seriousness of the issues 
at hand and a potential increase in trend if not promptly checked.  
On the other hand, contamination of HM is the unwanted addition of impurities with 
microbiological or chemical characteristics, or of other foreign matter, in a finished herbal 
product, its starting or intermediate product or during sampling, production, packaging, 
storage or transport (WHO, 2012). Such contaminants may include heavy metals, which are 
very dangerous to human health as further discussed in Section 4.4.2 to 4.4.11. While 
adulteration is illegal, efforts to reduce contamination are provided for by various legal 
guidelines issued by different countries (Corrigan, 2003; European Medicines Agency, 2005; 
Kunle, Egharevba and Ahmadu, 2012) and particularly for heavy metals as summarised in 
Table 4.3 (Chapter 4). Reports of heavy metals in HM, in addition to adulteration with 
prescription medications (Garg et al., 2011; Posadzki, Watson and Ernst, 2013), has 
increased the toxic potential of HM, especially the uncertified forms (Chan, Chiu and Lau, 
2003). Certification by regulatory bodies reduces the incidence of unpleasant effects from 
HM, through appropriate legislation and monitoring, although some HMs naturally contain 
harmful substances toxic to humans (Skoulidis, Alexander and Davies, 2005; Webb et al., 
2005; Moreira et al., 2014).  
Fung and Linn (2017) have shown that most HM adulteration is with prescription 
medications, which have therapeutic properties effective in treatment or management of 
medical conditions the HM is claimed to achieve. The detection of diuretic 
hydrochlorothiazide, sibutramine, bumetanide in sliming herbal medicine (Moreira et al., 
2013; Khazan et al., 2014) and dexamethasone in herbal medicine used for the treatment of 
joint pain (Park et al., 2016) are a few examples of this worrying trend of adulteration. These 
adulterants are typically cheaper than standard brands due to profitability, hence raising 
suspicion of their illegal sourcing. The US-FDA took action against such counterfeit, 
adulterated and dangerous dietary supplements and HMs (Burton, 2013). One publication 
found such adulteration in Nigeria, with the detection of HIV drugs in HM used by patients for 
the management of HIV (Gini et al., 2016). Nonetheless, Gini (2016) focuses mainly on HIV 
treatment, unlike this research which examines the possibility of commonly abused 
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pharmaceutical compounds‘ being added to HM as an adulterant in Ekiti State. Such 
adulteration will likely target a larger population with greater potential economic benefit to the 
manufacturer. No publication has examined any HM in Nigeria or Ekiti State for commonly 
abused pharmaceutical compounds; hence this research aims to address this gap and the 
choice of target pharmaceutical compound in this research is outlined in Section 3.2. 
Heavy metals such as selenium, thallium and arsenic have been detected in a few herbal 
products in Nigeria (Ajasa et al., 2004) and in other forms of HM around the world (Joob and 
Wiwanitkit, 2016). No publication has reported similar research in Ekiti State. Hence it has 
become essential to assess the safety of commonly used HM in Ekiti State by analysis for 
selected heavy metals as outlined in Section 3.3. Importantly, the toxic effects of heavy 
metals, particularly on human health, are not unknown. A study by Jin et al (2013) reported 
neural tube defect and anencephaly in babies and renal impairment in adults due to 
mercury, lead, cadmium and arsenic toxicity from various forms of environmental exposure. 
In south west Nigeria cases of acute renal failure associated with uncertified herbal medicine 
use and consequent fatalities were reported, though the particular component of the HM 
responsible for the damage was unknown (Kadiri, Arije and Salako, 1999). In addition, 
traditional HM-related liver fibrosis has been reported in Uganda (Auerbach et al., 2012); 
also the toxicity of various other herbal medicinal products (Ekor, 2014) and an 11-year 
retrospective study of aconite poisoning in mainland China (Li et al., 2016). Herbal medicine 
related fatalities were also reported in Ekiti State, after the deaths of two children (Olatunya 
et al., 2015). This unfortunate event has further reinforced the need for tighter HM control 
and evaluation. Therefore part of this research also aims to analyse HM used in Ekiti State 
for heavy metals and undeclared pharmaceutical compounds as a contribution to knowledge 
of HM safety.  
Various analytical techniques have been used in the past for the detection and quantification 
of pharmaceutical compounds and heavy metals in HM, which is further discussed in Section 
1.7.  
 1.7 Review of analytical methods for screening of pharmaceutical compounds and 
heavy metals in herbal medicine 
The analysis of HM for pharmaceutical adulterants and heavy metals has been carried out 
using several techniques. These are examined in sections 1.7.1 and 1.7.3. 
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1.7.1 Analytical method for the screening of selected pharmaceutical adulterants in 
herbal medicine 
Various analytical techniques exist for the screening of pharmaceutical adulterants in herbal 
products. These techniques include Liquid Chromatography (LC), Gas Chromatography 
(GC), Capillary Electrophoresis (CE), Flow Injection (FI), Ambient Mass Spectrometry 
(AMS), Attenuated Total Reflectance-Fourier Transform Infra-Red Spectroscopy (ATR-FTIR) 
and Thin Layer Chromatography (TLC). The use of any analytical technique is determined 
by the peculiarity of the analysis and the desired result. The volatility and thermal stability of 
a compound, for example, determine its analysis using Gas chromatography–mass 
spectrometry (GC-MS) (Rocha, Amaral and Oliveira, 2016). However, GC-MS enables a 
cost-effective analysis, with good quantitative results and high resolution, which makes its 
use beneficial (Sahil et al., 2011). Ambient mass spectrometry, on the other hand, has the 
advantage of providing data quickly and with little sample preparation (Zhou et al., 2011), 
while CE is fast, economical and requires a small sample size (Sombra et al., 2005). 
Hyphenated techniques improve accuracy; e.g. the Liquid chromatography quadrupole time-
of-flight mass spectrometry (LC-QTOF-MS) synchronised with Nuclear magnetic resonance 
(NMR), which can reliably identify and quantify adulterating compounds that may be present 
(Rundlöf et al., 2014). In addition, the technique does not require the use of a reference 
standard, as quantification may be carried out using an internal standard (Rundlöf et al., 
2010; Holzgrabe and Malet-Martino, 2011). A technique such as Attenuated total reflectance 
infrared spectroscopy (ATR-IR) needs no sample preparation which is one of its advantages, 
thus permitting the screening of samples in either liquid or solid state (Deconinck et al., 
2014). 
TLC is reported to have high-throughput potential, inexpensive verification of analyte quality, 
simple operation and portability. However, this technique is only preliminary and non-
confirmatory, requiring reference chemicals and a visualisation agent (Risha et al., 2008).  A 
comparison of some of these techniques is presented in Table 1.2 and Table 1.3 
summarises some of the analytical techniques that have been used in the screening of 
herbal products for pharmaceutical compounds.  
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Table1.2: Comparison of some analytical techniques used to analyse pharmaceutical 
adulterants in herbal products 
Technique Advantages Disadvantages 
 
Reference 
LC‑MS & 
HPLC  
Analyses  heavy, 
polar and organic 
compounds  
 
Commercial database is not 
available 
 
Vaclavik, Krynitsky and 
Rader 2014 
GC & GC‑MS  Fast, good accuracy, 
high sensitivity and 
resolution. 
Commercial 
database available 
 
Only separates volatile 
compounds 
 
Metz et al., 2007 
1H NMR Detects specific 
structural 
components  
 
Expensive, time-consuming. 
 
Thet, 2018 
CE & CE‑MS  Small sample size 
required, low cost, 
rapid analysis and 
high separation 
efficiency. 
 
Less accurate 
 
Chatham  and 
Blackband, 2001 
TLC & 
HPTLC  
Fast, simple, 
inexpensive, ability to 
use various solvents. 
 
Short stationary phase, less 
sensitive, temperature and 
humidity may affect results 
 
 
Labmate, 2018 
ATR-IR  No sample 
preparation and the 
instruments can be 
compact and 
portable. 
Less sensitive and not specific Deconinck et al., 2014 
LC-MS = Liquid chromatography-mass spectrometry; HPLC = High performance liquid chromatography; 
1
H NMR = Proton 
nuclear magnetic resonance; CE-MS = Capillary electrophoresis-mass spectrometry; HPTLC = High-performance thin-layer 
chromatography. 
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Table1.3: Selected analytical methods used for the screening of some pharmaceutical 
adulterants in herbal products 
Technique Analyte/ target compound Reference 
 
Mass spectrometry-based techniques 
LC-MS Hypoglycaemic pharmaceutical (metformin) 
 
Wu et al., 2012 
GC-MS Diphenoxylate and tramadol, 
58 pharmaceuticals including (stimulants, 
weight reducers, 
NSAIDs, steroids), Sildenafil, vardenafil, 
tadalafil 
 
Foroughi et al.,2017; 
AU et al., 2000 
Liu, woo and Koo, 2001; 
Man et al., 2009 
UHPLC steroids, hypoglycaemic products, and 
antihypertensive agents, non-opioid 
analgesics  and NSAIDs 
Becue, Van Poucke  and Van 
Peteghem,  2011; Kesting, Huang  
and  Sorensen, 2010; Li et al., 2010 
 
LC-QTOF-MS Phosphodiesterase 5 inhibitors such as 
sildenafil 
Aqai et al., 2013 and Aqai et al., 
2013 
 
FI-MS Phosphodiesterase 5 inhibitors, weight-losing 
pharmaceutical 
 
Song, El-Demerdash and Lee, 
2012; Song et al., 2014 
AMS and DART oral hypoglycaemic pharmaceuticals Zhou et al., 2011 
DCBI-MS weight-loss regimens fenfluramine, 
phenolphthalein, and sibutramine 
Wang et al., 2012 
 
Capillary electrophoresis 
MEKC with ESI NSAIDs, analgesics, antipyretic stimulants, 
and anxiolytics 
 
Cheng et al., 2001 
CE-MS Anorexic drugs, antidepressants and 
anxiolytics 
 
Almeida, Ribeiro and Polese, 2000; 
de Carvalho et al., 2010 
CE‑C4D Fluoxetine, flurazepam, fenproporex, 
sibutramine, sertraline, paroxetine, bupropion, 
and amfepramone  
 
de Carvalho et al., 2010 
Hyphenated techniques 
LC-DAD and 
LC-MS 
Sildenafil like compounds and analogue 
 
Schramek, Wollein and Eisenreich,  
2015 
LC-QTOF-MS with 
NMR 
Illegal drugs Johansson et al., 2014 
ATR-IR Sibutramine 
 
Deconinck et al., 2014 
LC-HRMS  and 
LC-MS-SPE/NMR 
Valsartan, indapamide and amlodipine William, 2012 
 
Thin-layered-based analytical techniques 
TLC-SERS Antidiabetic drugs, Phosphodiesterase 5 
inhibitors 
Zhu et al., 2015; Lv et al., 2015 
UHPLC = Ultra-High Performance Liquid Chromatography; FI-MS = Flow injection –mass spectrometry; DART = Direct analysis 
in real time; DCBI-MS Desorption corona beam ionisation - mass spectrometry; MEKC = Micellar electrokinetic 
chromatography; ESI = Electrospray ionization;  CE‑C4D  = capillary electrophoresis coupled  with contactless conductivity 
detection; LC-DAD = Liquid chromatography with diode array detector; LC-HRMS  = Liquid chromatography–high resolution 
mass spectrometry; LC MS SPE  = Liquid chromatography–mass spectrometry -solid phase extraction; TLC-SERS = Thin layer 
chromatography combined with surface-enhanced Raman spectroscopy; LC- MS-SPE = High performance liquid 
chromatography -photodiode-array-mass spectrometry. 
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As HM adulteration tries to evade detection, more advanced and sensitive techniques have 
been developed, such as wooden-tip electrospray ionisation mass spectrometry (Hu et al., 
2016), Core-shell Column Coupled to Tandem Mass Spectrometry (Al Lawati et al., 2017) 
among many others. In this research, GC-MS was used to screen selected HM for 
pharmaceutical adulterants, due its availability and the advantages highlighted in Table 1.2. 
The target analytes were non-volatile and thermally stable, making them suitable to be 
analysed with GC-MS.  
1.7.2 Sample preparation for the extraction of pharmaceutical compounds in herbal 
products 
The selection of a suitable sample preparation method for the extraction of pharmaceutical 
adulterants from herbal products depends on factors such as type and complexity of product 
matrix, product form (solid or liquid), analysis time and instrument sensitivity (Chen et al., 
2009). For LC–MS, CE–MS and direct MS techniques, simple ―dilute and shoot‖ sample 
preparation is generally used prior to instrumental analysis. This sample preparation method 
uses organic solvent such as methanol or acetonitrile or a mixture of both with water for 
extraction, and it is commonly used for solid samples such as powders, capsule contents, 
and homogenized tablets involving sonication or shacking (Vaclavik, Krynitsky and Rader, 
2014). Liquid samples are usually just mixed with a solvent and the mixture is then 
centrifuged, filtered and diluted, requiring no clean-up of the sample (Chen et al., 2009). The 
―dilute and shoot‖ method typically takes about 20 minutes but may take up to 30 minutes 
with the GC-MS method, where derivatisation may be required (Van Thuyne and Delbeke, 
2005). 
The Quick, Easy, Cheap, Effective, Rugged, and Safe (QuEChERS) method of sample 
preparation uses a mixture of the sample with water and acetonitrile followed by separation 
of the aqueous and organic phases by addition of salts for the extraction of the sample 
(Vaclavik, Krynitsky and Rader, 2014). The majority of the polar constituents of the sample 
are retained in the aqueous phase, while the analytes are transferred to the acetonitrile 
component of the solution (Anastassiades et al., 2003). This sample preparation method has 
been used in the analysis of herbal products (Lacina et al., 2012), although for improved 
extraction soaking of the sample for about 30 minutes may be essential for plant toxins. 
However, this is not required for the extraction of pharmaceutical adulterants because they 
are an anthropogenic addition to the sample and are not a constituent of the sample matrix 
(Vaclavik , Krynitsky  and Rader, 2014). 
In some other studies, a further sample clean-up step is used to differentiate a co-extracted 
matrix of the sample. Some of these further clean-up steps include removal of lipophilic 
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components by nonpolar solvents (Vaclavik, Krynitsky and Rader, 2014), mixed-mode 
octylsilyl (C8)- cation exchange (Becue, Van Poucke and Van Peteghem, 2011), solid phase 
extraction (SPE) using cation exchange (Wu et al., 2012) cartridges, or dispersive SPE 
(dSPE) using octadecylsilyl (C18) (Vaclavik, Krynitsky and Rader, 2014) or primary 
secondary amine (PSA) sorbents (Stepan,  Cuhra and  Barsova, 2008 ; Wu et al., 2014). 
1.7.3 Analytical method for the screening of heavy metals in herbal medicine 
 A number of analytical methods have been employed to screen herbal products for heavy 
metals. These include techniques such as Graphite furnace atomic absorption spectrometry 
(GFAAS), Flame atomic absorption spectroscopy (FAAS), Atomic fluorescence spectrometry 
(AFS), Inductively coupled plasma optical emission spectrometry (ICP-OES) or mass 
spectrometry (ICP-MS), Cold vapour atomic absorption spectrometry (CVAAS), X-ray 
fluorescence spectrometry (XRFS). The choice of analytical method, as discussed for the 
analysis of pharmaceutical compounds, is also dependent on the peculiarity of the analysis 
and the desired result. 
 Inductively coupled plasma-optical emission spectroscopy (ICP-OES) can be used to 
measure most elements in the periodic table. Additionally, it is a spectroscopic technique 
with a wide concentration range, which can measure elements at both high and trace 
concentrations, unlike other techniques used in elemental analysis (Mohammed, 2014). It 
has a low detection limit with limited spectral and matrix interference. Inductively coupled 
plasma-mass spectrometry (ICP-MS) has similar advantages and is also useful in isotope 
analysis; however, matrix effect is a disadvantage of ICP-MS (Perkin Elmer, 2004). The 
capital and operating cost of ICP-MS and ICP-OES are higher than that of FAAS. However, 
problems such as a poor detection limit, matrix effects, capacity for limited element analyses 
and longer analysis time are among the disadvantages of FAAS, unlike ICP-OES and ICP- 
MS (Macfadden, 2004). Most of the analytical methods are, however, destructive and the 
type of sample that can be analysed varies from liquid or gaseous in ICP-OES to solid 
samples in XRFS. Solid samples can be digested and analysed in liquid form for metal 
analysis, though it may increase analysis time (Perkin Elmer, 2004). A summary of the 
comparison of the various analytical techniques used in metal analysis is presented in Table 
1.4. 
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Table1.4: Comparison of selected elemental analysis techniques (Perkin Elmer, 2004) 
                                                     *ppb =parts per billion, **ppm = parts per million 
To achieve desired results, in view of the potentially complex plant matrix of HM samples, 
the correct choice of an analytical method is essential. The use of several analytical 
techniques in the screening of heavy metals in herbal products is summarised in Table 1.5.  
 
 
 
 
 
 
 
 
 
Properties Flame 
AAS 
GFAAS ICP-OES ICP-MS XRF 
Limits of 
Detection 
  
High ppm Sub ppb* Sub ppb Sub ppb Sub ppm** 
Analytical 
potential 
Single 
element 
Single 
element 
Simultaneous 
Multi-element  
analysis 
Simultaneous 
multi-element  
analysis 
Simultaneous 
multi-element  
analysis 
 
Usability Very 
easy 
More 
difficult 
 
Easy More difficult Easy 
Development 
of Method 
 
Easy Easy Fairly easy More difficult More difficult 
Automated 
Operation 
 
No Yes Yes Yes Yes 
Procurement 
Cost 
 
Low Medium High Very high Very high 
Operating 
Costs 
Low High Medium High Low 
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Table1.5: Selected analytical methods used to screen for heavy metals in herbal products 
Technique Analyte/ target compound Reference 
Flame atomic absorption 
spectrometry (FAAS) 
 
 
 
Cu, Zn, Pb, Cd Mn, Mg and 
Si 
 
Dong and Zhu, 2002; Wei et 
al., 2003; Qin et al., 2015; 
Gómez-Nieto et al., 2017 
Graphite furnace atomic 
absorption spectrometry 
(GFAAS) 
Pb, Cd, 
Cu, As, Hg, Cr and Ni 
 
 
Nie et al., 2008; Yuan et al., 
2009; Zhong, Ren and Zhao, 
2016 
Cold vapour atomic 
absorption spectrometry 
(CVAAS) 
As and Hg 
 
 
 
 
Yuan et al., 2009; Ang and 
Lee, 2006; Krishna and 
Karunasagar 2015 
Atomic fluorescence 
spectrometry (AFS) 
As 
 
 
Lu et al., 2017 
Inductively coupled plasma 
optical emission 
spectrometry 
(ICP-OES) 
Al, Ba, Ca, Cd, Co, Cr, Cu, 
Fe, Mg, Mn, Mo, Ni, Pb, Se 
and Zn 
 
 
Santos Júnior et al., 2017; 
Sium et al., 2016; Cindric, 
2013; Cindric et al., 2015 
Inductively coupled plasma 
mass spectrometry (ICP-MS) 
Cr, Zn, Mn, Se, Cu and V, 
Mg, Al, Ca, V, Cr, 
Mn, Fe, Co, Ni, Cu, Zn, Se, 
Sr, Sb, Ba, As, Cd, Hg and 
Pb, Cd, Mo and Sn 
 
Shao et al., 2007 
Nookabkaew et al., 2006; 
van der Voet et al., 2008; 
Christopher and Thompson, 
2013 
USN-ICP-OES and ETAAS Al, Cd, Pb, Fe and Vd 
 
 
Gomez et al., 2007 
X-ray fluorescence 
spectrometry (XRFS) 
Pb, Hg, As 
Zn, Mn Fe and AU 
 
 
 
Saper et al., 2004; Woolf et 
al., 2008; Wang et al., 2008; 
Sánchez–Pomales et al., 
2013 
Energy Dispersive X-ray 
Fluorescence Analysis 
(EDXRF) and Neutron 
Activation Analysis (NAA)  
 
Al, Ba, Br, Ca, Co, Cr, Cu, 
Fe, Hf, K, La, Mn, Na Rb, 
Sm, Sc, Th, V and Zn 
Gwarzo  et al., 2017 
Koch et al., 2007 
USN-ICP-OES = Ultrasonic nebulisation coupled to inductively coupled plasma optical emission spectrometry; ETAAS = 
Electro-thermal atomic absorption 
 
1.7.4 Sample preparation for the screening of metals in herbal products 
Sample preparation of herbal products for the analysis of metals takes into account 
variations in the matrix compositions such as oils, fat, and proteins, to mention a few.  
Particular attention is, however, needed to prevent contamination from reagents and lab 
ware such as vessels, and mortar and pestle (Sastre et al. 2002). Optimal workings of the 
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atomic spectrometric and plasma-based methods need a nebulisation system for the 
introduction of the sample. Accordingly, the sample needs to be in liquid form and properly 
digested (Smichowski and Londonio, 2018).  Digestion of the sample can be achieved e.g. 
by using microwave-assisted digestion, dry ashing or open-vessel digestion (Sium et al., 
2016).  
Microwave-assisted digestion is most used for the digestion of solid samples, although it is 
also useful for digestion of liquid samples which can be directly put into the 
polytetrafluoroethylene microwave oven vessels (Smichowski and Londonio, 2018). 
Microwave digestion reduces the risk of contamination from the environment and also 
ensures faster analysis. It uses several acids for its digestion, such as nitric acid (HNO3), 
hydrogen peroxide (H2O2), perchloric acid (HClO4), hydrochloric acid (HCl), sulphuric acid 
(H2SO4), phosphoric acid (H3PO4) and hydrofluoric acid (HF), which are often in mixture of 
various combinations and proportion, depending on the sample matrix (Konieczynski and 
Wesolowski, 2012, 2014; Pasias et al., 2010; Santos Júnior et al., 2017; Novotnik et al., 
2015; Basgel and Erdemoglu, 2006). 
 Dry ashing is a very useful sample preparation method which uses less acid and aids 
complete digestion of the organic constituent. Nonetheless, dry ashing presents limitations 
such as volatilisation losses of some elements including As, Hg, Cd, Se and Pb from high 
ashing temperature. To avoid loss of volatile metals and boost digestion efficiency ashing 
aids, magnesium nitrate (Mg(NO3)2) have been used in previous research (May, 1982; 
Cervera et al., 1994; Welna et al., 2011), while other studies pre-digested the sample with 
nitric acid (Brumbaugh and Walther, 1989). Considering the sustainability issues with the 
use of fewer chemicals and recovery efficiency, Mg(NO3)2 was used in this study. 
Furthermore, a pyrolysis temperature setting not exceeding 350°C has been said to prevent 
loss of volatile metals such as cadmium in the absence of a matrix modifier (Jorhem, 2000; 
Welz and Sperling, 1998; Schlemmer and Radziuk, 1999). Hence in this study, the pyrolysis 
temperature did not exceed 350°C, as stated in Section 3.6.3.2.1. The dry ashing method 
has been used in various publications for sample preparation of HM and the ash dissolved in 
various acids such as HNO3 and HCl (Santos Júnior et al., 2017; Pytlakowska et al., 2012) 
or a mixture of both acids (Malik et al., 2013). 
Open-vessel wet digestion or conventional wet digestion on hot plates using glass ware 
(tubes or beakers) or Teflon have been carried out for a long time (Welna et al., 2011). It is 
especially useful for simple samples such as food and plant products including HM, but not 
commonly suitable for samples requiring prolonged digestion times of up to 24 hours (ibid). 
Open-vessel wet digestion provides results that are reliable and accurate (Abentroth Klaic et 
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al., 2011; Türkmen and Ciminli, 2007; Kira and Maihara, 2007). Generally, HNO3, HCl, 
H2SO4, H3PO4, HClO4, HF and H2O2 are used for digestion of organic samples such as rock, 
soil, alloy, silicate and mineral (Uddin et al., 2016). However, they have now been used for 
wet digestion of herbal products (Altinting, Altundag and Tuzen, 2014; Gomez et al., 2007; 
Sium et al., 2016). Some of these digestion reagents are highly toxic, requiring special 
training and handling. Concentrated HNO3 is mostly used for digestion of organic materials, 
as a result of the higher solubility of its salt (nitrate salt) in water, accessibility, and 
affordability compared to other acid and their salts (Sastre et al., 2002). However, its low 
oxidation potential can cause incomplete digestion of substrates rich in organic constituents 
(Welna et al., 2011).  
Hence the addition of another acid improves digestion. Aqua regia (HCl with HNO3 (3:1) v/v), 
for example, is very useful for the digestion of complex matrices such as a combination of 
various plant and non-plant matrices used in this research (David, 2000). The addition of HCl 
is particularly safe in ICP-OES analysis and it is less viscous; therefore it prevents 
interference in the transport of solutions, unlike the addition of H2SO4 instead (Welna et al., 
2011). Other acid combinations have also been reported for optimal sample digestion, 
examples of which include; HNO3 and H2O2 (Santos Júnior et al., 2017), HNO3, H2SO4, H2O2 
and HCl (Sium et al., 2016), HNO3, HClO4 and HF (Gomez et al., 2007).  
1.8 Quality control of herbal medicine 
The quality of HM is influenced by many factors which range from medicinal herb cultivation 
to its end product. Hence standardisation is an important tool in quality control of HM. 
Standardisation of herbal medicines requires the setting of standard qualitative, consistent 
and quantitative values, reflecting quality assurance, safety, reproducibility and efficacy 
(Kunle, Egharevba and Ahmadu, 2012). Specific and precise standards are determined 
through research, leading to the development of a group of characteristics expected to be 
maintained by individual HM. As an example, electrophoretic, fluorescence and 
chromatographic data unique to different HMs and associated comparative chemometric 
analysis have been published (Mazina et al., 2015). However, challenges of HM quality 
control to a large extent still include factors such as variable quality and source of the raw 
material, varying chemical and natural components of plant materials, existence of chemo 
cultivars and chemo-varieties, inability to determine the active principle in many HMs and 
unavailability of analytical methods that are selective or commercially available reference 
standards (Kunle, Egharevba and Ahmadu, 2012). These issues are beyond the scope of 
this study. However, analysis for pharmaceutical compounds and heavy metals as 
performed in this research is essential for quality control measures in safeguarding public 
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health. A WHO report highlighted points of focus in the quality control of HM (WHO, 1998; 
2007a; 2007b and 2011), two of which are relevant to this research: 
1. Micro and macroscopic examination to identify safe variants and detection of  
possible adulterants  
2. Toxicological studies to determine potentially toxic elements such as pesticide 
residues, harmful microorganisms and other studies to determine the lethal dose 
(LD50).  
1.9 Regulatory framework of herbal medicine 
1.9.1 Global perspective 
There are various ways countries regard and define herbs, medicinal plants and their 
constituents. Countries have also developed different methods of manufacturing, licensing, 
trading and dispensing of herbal therapies to guarantee the quality, safety and efficacy 
(DSHE, 1994; Ameh et al., 2010; Human Medicine Regulation, 2012). 
 In the UK and EU, for example, if a herbal product is considered to be a medicine, it needs 
marketing authorisation (Product licence) or may be licensed employing a simplified 
Traditional Herbal Registration (THR), appropriate to use without medical supervision 
(Human Medicine Regulation, 2012). To attain THR for a product manufacturers or suppliers 
will have to show at least 30 years‘ history of traditional use of the herbal product (15 years 
of which should be  in the EU), compliance with appropriate manufacturing standards, 
evidence of safety and availability of appropriate product information to users (Human 
Medicine Regulation, 2012). The THR framework is for non-severe, self-limiting conditions 
such as respiratory problems, infections (bacterial, viral, and fungal diseases), cold, skin and 
other less serious conditions. Conversely, unlicensed remedies may be produced and 
distributed by a practitioner in meeting individual patient needs after a one-to-one 
consultation without any legal restriction. These unlicensed products are not allowed to be 
marketed as HM until a THR or full marketing authorisation (product licence) has been 
obtained (Ibid). 
 In the USA HM is categorised as a dietary supplement and is not recognised as a medicine. 
According to the Dietary Supplement Health and Education Act (DSHE 1994), a dietary 
supplement includes any product (aside from tobacco) aimed at supplementing the diet with 
dietary ingredients such as amino acids, minerals, vitamins, herbs or other botanicals. 
Classification as a food supplement makes its regulation less strict but the dietary 
supplements‘ current Good Manufacturing Practices (GMPS or cGMPs) are, however, 
enforced for all manufacturers of HM. The food GMPs focus on all manufacturing aspects 
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including positive identification and purity assurance for whole herbs using macro-
identification and organoleptic, use of techniques such as HPLC / TLC or microscopy for 
extracts and powders, identification of material source, detailed documentation, hygiene and 
personnel training (FDA, 2015). 
 In Asian countries such as India, Korea and China, traditional HM is accorded the same 
respect as modern pharmaceuticals with both included in the national health scheme (Ameh 
et al., 2010). The process of approving traditional HM includes approval for both clinical trial 
and marketing. The requirement for registration of HM includes pharmacological or 
toxicological data, pharmaceutical and general product data, and clinical data. Also required 
is the certification of manufacturers and marketers by the local drug regulatory agencies with 
an emphasis on good GMP and supply ethics (Ameh et al., 2010). However, HM regulatory 
frameworks are constantly evolving as more research is carried out on herbal products 
globally.   
1.9.2 Regulatory framework of herbal medicine in Nigeria 
The ability of regulatory bodies to monitor herbal products appropriately, coupled with the 
absence of appropriate legislation is a huge challenge in some countries like Nigeria and by 
extension Ekiti State. The National Agency for Food and Drug Administration and Control 
(NAFDAC), the Nigerian government regulatory agency‘s experience attests to this. A former 
head of the agency in a newspaper article highlighted lack of documentation, secrecy of real 
components, poor coordination of practitioners‘ activities and the challenges in determination 
of actual ingredients as among the difficulties faced in regulating HM in Nigeria (The Nation 
newspaper, 2008). This was attested by Akinleye (2008), who reported imprecise dosage, 
incorrect diagnosis, poor hygienic settings and secrecy of some healing methods and the 
lack of documentation on patients as among the challenges to safe HM practice in Nigeria. 
 According to the Director General of NAFDAC, compliance with manufacturing and 
regulatory standards by manufacturers of HM in Nigeria is still a herculean task, despite 
Nigeria‘s having a national policy on traditional medicine (Elujoba, 2013). Regulatory 
requirements were said to be perceived to create bureaucracies and discourage 
manufacturing. This perception still persists, due to a lack of local agenda for herbal 
medicine research and development by research institutions and the pharmaceutical 
industries in creating an indigenous phytomedicinal standardisation. This has made effective 
regulatory requirements difficult to achieve. As a result, current manufacturers‘ therapeutic 
claims and formulations are unverifiable and the regulators are also at a disadvantage. 
Conversely, guidelines are available for manufactured herbal products both imported and 
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local (WHO, 2003; NAFDAC, 2013). Herbal medicines have not yet been introduced in the 
essential health-care system in Nigeria. Regardless, a lot of people use HM in Nigeria.  
NAFDAC is saddled with the responsibility of controlling and regulating the importation, 
manufacture, export, sale, advertising, distribution and use of medical devices, drugs, 
cosmetics, food, chemicals and packaged water (NAFDAC, 2005). According to NAFDAC 
(2013), regulations guiding the operation of HM practice in Nigeria are: 
I. Herbal medicines and related products registration regulations, 2005 
II. Herbal medicines and related products advertisement regulations, 2005 
III. Herbal medicines and related products labelling regulations, 2005 
 
According to the NAFDAC (2013), the requirement for registration of HM in Nigeria include   
I. A detailed dossier on the source of each herbal product contained in the formulation 
II. An acceptable quality and safety analysis certificate for the accredited laboratory 
III. Factory certification for quality assurance 
IV. A licence to practise and certification of the herbal medicine practitioner 
 
Advertisement and labelling regulations also include various requirements to ensure safety 
and quality control of HM in Nigeria. Perhaps the most challenging problems with HM in 
Nigeria are the unavailability of safety regulations and inadequate standardisation 
(Ekeanyanwu, 2011). Standardisation of HMs may be particularly difficult because they 
contain hundreds of chemical constituents with little or no identification and no evidence of 
which constituent might be responsible for the claimed therapeutic effect (WHO, 2005). 
Nonetheless, advances in science have aimed to overcome these problems through quality 
control measures, as discussed in Section 1.8. Therefore the safety and control of HM needs 
to be reviewed in Nigeria; hence the need for this research as part of addressing the 
problems.  
1.10. Prospect of herbal medicine  
1.10.1 Global prospect of herbal medicine 
About 75% of the therapeutic compounds of plant origin used worldwide were derived from 
traditional/folk medicine; with 25% of prescription medicines available worldwide obtained 
from plant sources (Wachtel-Galor and Benzie, 2011). Findings on traditional medicine and 
medicinal plants practices for 35 years (1970-2005) in Nigeria showed the results in herbal 
medicine research and development activities (Osemene, Elujoba and Ilori, 2011a). The 
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publication reported the degree of contribution of HM in various aspects of medicine, such as  
in anti-infective drugs or anti-microbial drugs (32.48%), gastro-intestinal tract drugs (9.69%), 
analgesics, antipyretics and non-steroidal anti-inflammatory agents (8.69%), cardiovascular 
agents (5.41%), toxicity studies (5.27%), hypoglycaemic agents (4.27%) and molluscicidal 
(3.85%). Other areas where research was moderately undertaken were in oxytocic (2.85%) 
and dermatological agents (2.71%), insecticides (2.42%), anaesthetics (2.28%), drugs 
affecting the blood (2.28%) and tranquillisers (2.14%) (Ibid). The use of herbs in the 
advancement of modern pharmaceuticals will continue, especially in the event of multi-
resistant antibiotics and a need for more effective medication. Besides the use of herbs in 
pharmaceutical development, the growth of HM practice as an established system of 
medicine and efforts towards orthodox medicine standard is ongoing (Mukherjee and 
Wahile, 2006; Aggarwal et al., 2011; Kulkarni, Girish and Kumar, 2012). 
Traditional medicine is believed to be a cultural health practice developed over time and 
within a particular belief system (WHO, 2000). But this is also true of orthodox medicine, 
which also evolved over time and became an established healthcare system through 
rigorous scientific support. The improvement of traditional medicine through research and 
rigorous scientific study is paramount and vital to its advancement. Improved and increased 
research focused on the efficacy, safety, mechanism of action, regulation of standards for 
practice, training of medical students and conventional medical practitioners will be highly 
beneficial to the advancement of traditional medicine (Bhattacharya, 2000 and Marcus, 
2001).  
1.10.2 Prospect of herbal medicine in Nigeria 
The Federal Government of Nigeria (FGN) has taken steps to institutionalise traditional 
medicine in an attempt to expand healthcare coverage in the country. This necessitated the 
enunciation of the Traditional Medicine Policy for Nigeria (2007). The Nigerian Traditional 
Medicine Policy complies with the regional strategy implementation for the African region on 
promoting the role of traditional medicine in the health system (WHO, 2000). The objectives 
of the Nigerian medicine policy include (FGN, 2007): 
I. Development and facilitation of traditional medicine use in the official healthcare 
system in Nigeria 
II. Maximise the benefit and economic potential of traditional medicine practice to attain 
requirement of the National Economic Empowerment and Development Strategy 
(NEEDS). 
III. Establishment of an institutional framework for traditional medicine which will be 
country-specific. 
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However, this policy has not made any progress in the nine years since its implementation. 
Use of herbal medicine in Nigeria still faces challenges from government officials who regard 
it with disrespect and disdain (Adefolaju, 2011), as discussed in Section 1.3.3. Colonisation 
has been reported to have harmed the development of HM in Nigeria (Matthias, Osayi and 
Opara, 2012), but then India was also under colonial rule but seems to have developed her 
traditional medical practice way ahead of Nigeria. Successive Nigerian administrations have 
remained reluctant to accord herbal medicine a position in their national health-care delivery 
system as is the case in China, Ghana and even India (Adefolaju, 2011). Reportedly, HM is 
practised in contemporary Nigeria without any enabling legislation to standardise and 
regulate its practice, as is the norm in other parts of the world (WHO, 2011). The many 
challenges facing standardised orthodox medical practice in Nigeria may have hindered the 
progression of traditional medical practice for healthcare delivery. This does not, however, 
mean nothing is being done. Despite the hurdles, HM research and collaboration with the 
orthodox health system is on-going. The future of HM practice in Nigeria lies in the effective 
coordination of the various research outputs on HM, industrial collaboration and the sincerity 
of the government in providing direction and an enabling environment with an emphasis on 
safety. 
1.11. Research aim and objective 
Public health and toxicological analysis of herbal medicine and its use in Ekiti State have 
become essential, as is apparent from the literature review in this chapter, especially as 
shown in Section 1.6.2. Accordingly, this research seeks to fill the gap in knowledge by 
exploring the sociological and public-health aspect of HM use. Commonly used HMs are 
identified and samples analysed in the laboratory. Hospital data was then examined on HM-
related cases in the state. This is the first multifaceted study in Nigeria. The research 
process is presented in Figure 1.2.  
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Figure1.2: Flow diagram of the research process 
The findings from the public health survey, HM laboratory analysis and HM-associated 
hospital cases will provide a multifaceted understanding of HM use and its potential impact 
on the study population. Therefore the research aims to:  
I. Study the pattern and use of herbal medicine in Ekiti State, and the effect of socio-
economic factors using structured questionnaires. 
II. Study reasons for non-use of orthodox health facilities in Ekiti State using structured 
questionnaires.  
III. Determine the casualty and fatality figures associated with the use of HM using data 
obtained from 16 government hospitals in Ekiti State between the years 2010 and 
2014. 
IV. Identify and quantify heavy metals in uncertified and certified herbal medicine used in 
Ekiti State. Metals with known toxic profiles reported in the literature (arsenic, 
mercury, lead, cadmium, chromium, manganese, nickel, selenium, zinc and copper) 
will be analysed using ICP-OES. 
V. Identify organic constituents such as analgesics (acetaminophen) non-steroidal anti-
inflammatory drugs (ibuprofen, diclofenac), opiates (codeine, tramadol), steroid 
(dexamethasone), CNS stimulant (caffeine), antihistamine (chlorpheniramine), 
antidepressant/weight loss (fluoxetine) and benzodiazepine (diazepam) in uncertified 
and certified herbal medicine in Ekiti State using GC-MS 
VI. Propose an effective public health measure in herbal medicine use and control in 
Ekiti State through the deployment of research findings for policy recommendation.     
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Research questions posed in Section 1.11.1 were used to achieve the aims and objectives.  
1.11.1 Research questions 
I. What are the pattern and use of herbal medicine in Ekiti State and the influence of 
socio-economic factors?  
II. What are the reasons for non-use of orthodox health-care facilities in Ekiti State? 
III. What are the casualty and fatality figures associated with herbal medicine use in 
Ekiti State between the years 2010 and 2014? 
IV. What heavy metals and organic constituents are present in both uncertified and 
certified herbal medicine used in Ekiti State? 
V. What policy recommendations may be proposed through the findings from this 
study? 
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CHAPTER 2: SURVEY OF THE PATTERN AND USE OF HERBAL MEDICINE IN EKITI 
STATE  
2.1 Introduction 
Research into the complex reasons associated with preference for herbal medicine reveals 
the interplay of many factors. The role of personal and cultural beliefs, philosophical mindset 
on health and life come to bear (Ernst and White, 2000). Respondents‘ comparison of the 
experience of orthodox healthcare and complementary medicine systems also plays a vital 
role (Astin, 1998). Therefore in this chapter, the sociological and public health aspects of HM 
are the first research component explored, examining its stance within the social awareness 
and its popularity as an alternative to orthodox medicine. This is achieved through the use of 
an interview-based questionnaire centred on determining the general public‘s knowledge of 
HM in Ekiti State. The use and perception of HM against a socioeconomic and educational 
background was explored in addressing the following two research questions;  
  
 What is the pattern and use of herbal medicine in Ekiti State? 
 How do socio-economic factors influence the use of HM in Ekiti State? 
 
The analysed survey data offers a sociological framework which will be compared with 
analytical data of HM samples (see Chapter 4) obtained as part of this research. This is 
undertaken to see the correlation between peoples‘ perception and the reality in HM 
samples found in Ekiti State. In this study, HM refers to any material as defined in Section 
1.2. 
2.2 Research method 
2.2.1 Justification of study method 
A survey is an approach which may be used to gather information, to observe patterns of 
association between variables from particular studies (Sue and Ritter, 2012; Bryman, 2012). 
Surveys may employ qualitative methods, quantitative methods, or both mixed, and then 
data may be obtained either by use of structured interview, self-completion questionnaire, or 
a mixed-mode approach (De Vaus, 2001). 
 Qualitative research may be difficult to define appropriately due to its different, multifaceted 
paradigms (Hitchcock and Hughes, 2016, pg. 26). Some definitions of qualitative research 
have been criticised as too simplistic and neglecting other areas of the research design such 
as that which defines it as a form of research producing findings that are not reached by 
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statistical process or other quantification methods (Strauss and Corbin 1998, pg. 10-11). 
Another definition refers to qualitative research as a collection of comprehensive data on 
variables over a period, in a naturalistic environment, so as to gain awareness which may be 
impossible applying other research methods (Gay, Mills and Airasian, 2011, pg. 627). This 
definition‘s use of variables could be conflicting, as this epistemological postulation is based 
on complicated and interrelated social phenomena that sometimes cannot be defined by 
remote variables. Through condensation of a variety of literature, qualitative research may 
be defined as a developed method aimed at a descriptive interpretation of people‘s construct 
of meanings in relation to their experience of the world within their natural environment of 
phenomena or social occurrence through an inductive and interpretative approach (Patton, 
2015, pg. 39–41; Denzin and Lincoln, 2017, pg. 3; Miles, Huberman and Saldana, 2013, pg. 
6–7). 
 By contrast, quantitative research explains phenomena in terms of numerical data which are 
mathematically and statistically analysed. It may be defined as an empirical research method 
which examines social occurrences or human issues by testing proposed theories made up 
of variables that are measured using statistical analysis and numbers to determine how and 
to what extent the theory describes or forecasts phenomena that are of interest (Gay, Mills 
and Airasian, 2011; Creswell and  Creswell, 2017). A quantitative approach requires that the 
researcher uses a preconstructed standardised tool or response categorisation that the 
respondents‘ diverse views and experience are expected to fit. There are a lot of 
distinguishing differences between qualitative and quantitative research. In this study, 
quantitative approaches were adopted but with the use of some open-ended questions.  
 
Research methods are not limited only to qualitative and quantitative studies, but results are 
likely affected by the way they are used. The validity of the result of a study is more likely to 
be dependent on how right is the epistemology of the method. As long as the philosophical 
idea is the same in combined methods, their selection and application should not be 
problematic (Trochim, Donnelly and Arora, 2015). The aim, scope and the nature of inquiry 
are important in deciding the choice of research method, rather than a dichotomy between 
quantitative and qualitative methods (Siverman, 2015). The differences in an epistemological 
idea of some particular methods should not discourage a researcher employing qualitative 
method from using data collection methods typical of quantitative research, and vice versa, 
but instead use methods based on the rationale or justification of the methods to be used in 
the study (Howe, 1992; Johnson and Onwuegbuzie, 2004; Palinkas et al., 2011a, b, c). 
 
Aside from other qualities of qualitative research, it is more in-depth, takes more time and 
requires a small sample size. The large sample size in this study (Section 2.4.1) does not 
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favour a qualitative study likewise other characteristics. Therefore the use of textual data in 
quantitative research was adopted. This is one of the ways of combining qualitative and 
quantitative research method characteristics which has been called ―quantitizing‖ of 
qualitative data (Sandelowski, Voils and Knafl, 2009). Although it may be criticised as a non-
integrative approach which seeks to quantify otherwise qualitative data, pragmatic 
justification of the usefulness of this method in analysis of HM use and associated issues is 
more important. Textual data were collected by the use of expansion, substitution and 
general open-ended questions (O'Cathain and Thomas, 2004). 
 
Closed-ended questions are usually used in quantitative research; however, they may not be 
ideal for exploring complex and dynamic issues of HM use and health-seeking behaviour 
and unreported preference for HM in the population of interest in this study. Determination of 
various and prominent types of HM used by the sample population for subsequent laboratory 
analytical examination was better explored by open-ended questions. Other benefits of 
open-ended questions have been reported, such as their potential to increase response rate 
and identify new issues (Iversen, Bjertnæs and Skudal, 2014). A previous study reported 
that quantitative ratings were possibly more for positive than for the negative comments, and 
also observed qualitative comments helped validate quantitative ratings (Santuzzi, Brodnik 
and Rinehart-Thompson, 2009). Strength of open-ended responses is their potential to allow 
a direct view of a participant‘s line of thought. For instance, it has been argued that open-
ended questions explore views on the respondent‘s mind as at the interview time which were 
presumably salient before the question was asked and afterward (RePass, 1971). Similarly, 
it has been noted that open-ended questions have the characteristic ―nonreactivity‖ as an 
advantage, which does not prompt participants to think of specific causes or treatments, 
unlike close-ended question (Iyengar, 1996). 
 
Despite these advantages, open-ended questions are not as often used due to lack of 
knowledge of the best ways to obtain and present respondents‘ comments for intended uses 
especially in health research (Rijisk, Ammentorp and Kofoed, 2012). They have rarely been 
analysed as proper qualitative data and are also more rarely used in combination with 
quantitative results obtained from the same questionnaires (Stoneman, Sturgis and Allum, 
2013). Additionally, there is a vast number of published works on quantitative data collection, 
but few have been published in scientific journals about collection procedure and handling of 
data from open-ended questions (Iversen, Bjertnæs and Skudal, 2014; Gilles et al., 2017). It 
has been recommended that open-ended questions should not be asked unless replies will 
be analysed (Boynton and Greenhalgh, 2004). This may be a waste of participants‘ time and 
probably unethical. But resources and time required for data input and analysis may be a 
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major constraint (Mccoil et al., 2001). In addition, open-ended responses have 
conventionally been seen as more strenuous to analyse than the closed-ended question 
(Schuman and Presser, 1996), because human coding is almost always used. However, 
these factors should be factored in during the process of the study design, as was the case 
in this study. Open-ended responses have been categorised as qualitative (Stickler et al., 
1992; Bankauskaite and Saarelma 2003), some argue they are not (Boulton, Fitzpatrick and 
Swinburn, 1996), and some argue they are semi-qualitative (Murphy et al., 1998). Its use 
however, cuts across both qualitative and quantitative research. 
 
There has been debate on the usefulness of the open-ended questions with emphases on 
their advantages and disadvantages (Krosnick & Schuman, 1988; Schwarz & Hippler, 1991) 
and the debate is still ongoing.  Experts in this field have also identified the merits of each 
method (Lazarsfeld, 1944 and Krosnick, 1999). The usability of open-ended methods in 
research continues to be reported; likewise its relevance (Roberts et al., 2014). It was, 
however, reported that the benefit of using open-ended in addition to standard closed-ended 
questions was found to be practically nil in mental health prediction (Friborg and 
Rosenvinge, 2013), though the same study showed that open-ended questions revealed 
more comprehensive information than closed questions. Therefore, the choice will ultimately 
depend on the target result by individual researcher. Hence the need for open-ended 
question in this research is premised on the desired result which is to understand the pattern 
and use of HM in respondents‘ own words, including their opinion which can be measured to 
determine and predict the phenomenon of interest. 
 
The approach adopted in this study can be implemented by various means, e.g. either 
paper-based, online or telephone. Telephone response rates have drastically reduced in 
recent years and sample size coverage problems are increasing (Singer, 2006). The model 
selected for this research was the use of self-administered paper-based survey and face to 
face interview. A paper-based survey was used to prevent sample selection bias, 
considering the level of education, literacy and level of Information communication 
technology (ICT) access in the population sample. Ekiti State has only about 3.1% of her 
population with access to personal computers; about 7% of households have access to the 
internet and 2.2% of the population have access to internet (NBS, 2012). Although there was 
an improvement to about 27% of the estimated population having access to internet in 2016 
(NBS, 2016), this is still not adequate for an online survey. Hence the need for a paper-
based survey in this study. An online survey is cheaper and a more sustainable approach 
but loss of data and software error can be a real setback (Sue and Ritter, 2012). A paper-
based survey can be more time consuming and tedious to carry out than an online survey. 
37 
For this study adequate time was given for survey participants to rest, refresh and continue. 
The paper-based survey allows for verification of participants‘ identity because they are 
physically present. A comparison of the outcome of paper-based and online surveys has 
shown similar results were obtained (Hallfors et al., 2000). However, this study was carried 
out in the United States of America, with 87.4 % internet penetration and 42.6 % internet 
use, compared with Africa‘s 28.6 % internet penetration and 9.8 % internet use (Internet 
world statistics, 2015). Therefore in this survey, a mixed mode method was used which 
entails one sample, one-time duration, one questionnaire but different modes for different 
respondents, as seen in Section 2.2.2. 
2.2.2 Self-administered and face- to- face interview mix 
  A mixed-mode approach compensates for the deficiencies of each combined mode at an 
inexpensive cost and provides the best of both methods. The most economical method may 
not be adequate to a given study. However, a mixed-mode design explores an explicit 
adjustment between cost and error, especially measurement error, frame or coverage error 
(non-sampling error), and non-response error (Biemer and Lyberg, 2003; Palinkas et al., 
2015). There are at least four cognitive demanding steps required in answering a 
questionnaire; understanding of the question, memory recall of information needed, 
assessment of recalled information and link to the question asked, followed by 
communication of the answer (Tourangeau,1984; Bajekal et al., 2004). Therefore different 
questionnaire methods place different cognitive demands on respondents, such as the 
demand for literacy in the self-administration method. Face-to-face interview structured 
questionnaires only require verbal and listening skills, provided the question is asked in the 
language the respondents understand. This method was used in this survey for respondents 
with poor literacy levels and the questions were asked in the language they understood 
(Yoruba). A main disadvantage of the face-to-face interview method is interviewer bias 
(Lonna et al., 2014). However, interviewers were trained and the needs to be satisfied by 
each question were discussed extensively to overcome this bias. The use of a structured 
questionnaire was also very important in overcoming the bias. 
Thus this study adopted a quantitative approach, using some open-ended questions 
requiring textual analysis. The questionnaires were administered using the mixed mode 
approach (self-administered and face-to-face interview).  
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2.3 Research setting and sampling 
2.3.1 Research location 
This study was conducted in Ekiti State in Southwest Nigeria, one of the 36 states of the 
country. Ekiti State was created on the 1st of October 1996 out of Ondo State as a political 
structure, but the history and existence of Ekiti far outdates that political creation (Bello, 
2009, EKSG, 2016). Ekiti lies in the tropics, between latitudes 70°151′ and 80°51′ north of 
the Equator and longitudes 40°51′ and 50°451′ east of the Greenwich meridian (EKSG, 
2016). Figure 2.1 gives a pictorial view of the location of the study in the wider African 
landscape. 
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Figure 2.1: Map of Africa, Nigeria and Ekiti State (Malizumedia, 2018; Word press, 2013) 
 
Ekiti State has a land area of 5887.890 sq km bordering Kwara and Kogi State to the South, 
Osun State to the East, Ondo State to the East and South (EKSG, 2016)  
 Ekiti State is made up of 16 Local Government Councils, as shown in (Table 2.1), with a 
population of 2,384,212, of whom 1,215,487 are male and 1,183,470 female (NPC, 2006). 
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             Table 2.1: Local government areas in Ekiti State and their headquarters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 People and culture 
Ekiti State people also known as the ―Ekitis‖ are culturally homogeneous, form one of the 
biggest ethnic groups in Yorubaland and speak a form of Yoruba called Ekiti (Oguntomisin, 
1981). Ekiti is one of the several subgroups of the Yoruba nation (Olagunju, 2012). The 
Yorubas dominate the South-western part of Nigeria and some have been reported to be 
located in contemporary Republics of Togo and Benin in West Africa, Cuba and some 
Caribbean countries (Abimbola, 2006). The Nigerian Yoruba population is about 30 million, 
constituting about 21% of the total population of Nigeria (Ogundele, 2007). Ekiti people are 
mainly Christians and Muslims while some are traditional religionists and worship local 
deities such as Sango, Ifa and Ogun. 
 According to EKSG (2016), Ekiti State is made up of over various large, small, ancient and 
modern towns totalling about 127. In ancient times Ekiti men were mainly farmers, while 
women engaged in trade. However, in recent times the majority of residents have been 
either civil servant employed by the state or engage in various business enterprises, while 
farming has been left to a few who are peasant farmers in rural communities (EKSG, 2016). 
The rulers of the towns are known as Obas traditionally, but there are Local Government 
Area (LGA) chairpersons who are political administrators of LGAs comprising various towns 
and villages. 
SN Local Government  Headquarters 
1 Ado-Ekiti Ado-Ekiti 
2 Efon-Alaaye Efon-Alaaye 
3 Ekiti East Omuo-Ekiti 
4 Ekiti South West Ilawe-Ekiti 
5 Ekiti West Aramoko 
6 Emure Emure-Ekiti 
7 Gbonyin (Aiyekire) Ode-Ekiti 
8 Ise/Orun Ise-Ekiti 
9 Ido-Osi Ido-Ekiti 
10 Ijero Ijero-Ekiti 
11 Ikere Ikere-Ekiti 
12 Ikole Ikole-Ekiti 
13 Ilejemeje Iye-Ekiti 
14 Irepodun/Ifelodun Igede-Ekiti 
15 Moba Otun-Ekiti 
16 Oye Oye-Ekiti 
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2.3.3 Climate and  vegetation 
Ekiti State has a tropical climate with rainy and dry seasons. It has a tropical forest in the 
south and Guinea Savannah in the northern region (EKSG, 2016). 
2.3.4 Health system in Ekiti State 
The orthodox and traditional medical systems provide healthcare services in Ekiti State, 
coordinated by the state ministry of health (EKSHDP, 2011). At the Local Government Area 
(LGA) level, there are 283 primary healthcare facilities, made up of comprehensive health 
centres, basic health centres and maternity centres/dispensary centres. There are 17 
general hospitals, 3 specialist hospitals and 2 tertiary health facilities, one owned by the 
state and the other by the federal government. In addition, there are 163 registered private 
hospitals and 7 faith-based mission health centres (EKSHDP, 2011). The coordination of 
health service, manpower development in the health sector and formulation of health policy 
are all the responsibility of the state Ministry of Health. Despite the number of health facilities 
available, only two LGAs (Irepodun/Ifelodun and Ekiti East LGAs) of the existing sixteen 
have a higher number of her population benefiting from domiciled health facilities (Odeyemi, 
2014). This may not be unconnected with socio-economic factors such as age, sex, type of 
illness, perceived quality of service and access to services, which influence willingness to 
engage with certain medical options (Tipping and Segal, 1995; Akinnawo and Oguntimehin, 
1997).  
People have been reported to make choices between the orthodox and traditional health 
systems according to the type of illness (Orubuloye, 1999) and other factors as discussed in 
Section 1.4.3. These factors ultimately influence the choice between orthodox and the 
traditional health system. The challenges associated with the orthodox health system in Ekiti 
State, such as affordability of service cost, quality of service rendered, closeness to home, 
staff attitude, how neat is the environment, availability of required drugs and services have 
also informed patients‘ patronage (Omotosho, 2010).  
Accessibility of healthcare facilities has also been reported to affect medical service 
patronage (Omotosho, 2009). While there are no available data for Ekiti State, the doctor-to-
patient ratio in Nigeria is 1:2500 and nurse/midwives to people ratio is 1:1600, compared 
with the United Kingdom with a 1:357 doctor-to-people ratio and 1:114 nurse/midwife to 
people ratio (World Development Indicator, 2014). The ratio estimated by the WHO to 
provide adequate coverage for primary health care need is 1:400 for doctors, 
nurses/midwives to people ratio (World Health Report, 2006). Considering the poor coverage 
and exclusion of the Nigerian health insurance scheme, out-of-pocket expenditure on health 
is 71.1% in Nigeria, compared with 9.7% in the UK and 11.1% in the United States (World 
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Development Indicator, 2014). The poverty headcount revealed 46% of the rural population 
and 52.8% of the general population live below the poverty line (World Bank Indicator, 
2010).  An International Fund for Agricultural Development (IFAD) article reported that about 
70% of Nigerians live on less than US$1.25 a day, and 80% of its rural population live below 
the poverty line (IFAD, 2015). This is no different in Ekiti State. The poverty incidence in Ekiti 
state is 41.9%; while 38.3% consider themselves to be poor or very poor, 58% consider 
themselves moderately and 2.3% consider themselves to be rich (NBS, 2012). The state has 
a poverty gap of 22.7%, an absolute poverty rate of 55.9% and a 12.1% unemployment rate 
(NBS, 2012). Hence the correlation of these statistics with the ―out-of-pocket‖ expenditure on 
health gives a grim picture of effective healthcare delivery. Nevertheless, the five-year health 
strategic plan of Ekiti State sought to improve health care delivery (EKSHDP, 2011).  
 
Africans have been reported initially to administer traditional before orthodox medicine and 
resort to it when orthodox efforts fail (Omololu, Ogunlade and Gopaldsani, 2008). A study in 
Ido/Osi LGA of Ekiti State reported a majority (74.3%) of the 521 respondents used herbal 
medicine to treat malaria (Olorunniyi and Morenikeji, 2013). These include respondents who 
used HM together with orthodox medicine, while 21.7% of respondents only used orthodox 
medicine. The use and practice of traditional medicine with HM as the major component in 
localised communities of Ekiti State has been documented in other studies (Kayode and 
Kayode 2008; Egbebi, 2011; Olanipekun, Kayode and Akomolafe, 2013). However, no study 
has covered the entire state, examining the factors which influence the use of HM in Ekiti 
State. This is part of the gap in knowledge this research aims to bridge.   
2.3.5 Study population 
The study population was made up of residents of Ekiti State, at the time of the study with a 
population of 2,384,212 (NPC, 2006). 
2.3.5.1 Inclusion and exclusion criteria 
Participants were of 18 years of age and above, resident in Ekiti State at the time of the 
study and had lived in the state for at least 2 years. The study excluded persons below the 
age of 18 years and anyone who had not resided in the state for at least 2 years. In addition, 
those who did not consent to participate in the study and those who met the inclusion criteria 
but for reasons such as significant distress during the interview or those unable to sit for the 
interview /self-administered questionnaire were also excluded.  
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2.4 Sampling procedures and sample size 
 2.4.1 Determination of Sample size  
The formula for calculating a sample size based on a proportion of people who use HM was 
used (Cochran, 2007). The formula was developed for lager study population, which is the 
case in this survey. 
Equation 2.1:  
                         
 
Where n = required minimum sample size in the study 
z = Z-score or Standard normal deviation 
p = proportion of people who use HM in the study area 
q = 1-p 
d = the acceptable error level 
The sample size was calculated based on an acceptable error level of 3% (0.03) and a 
confidence interval of 95% corresponding to a Z-score of 1.96. These are social science 
research recommended values for standard deviation and error levels (Bryman and Cramer, 
1990). 
The proportion of HM users in Ekiti State is unknown from previous research, so maximum 
heterogeneity was assumed for the study (i.e. a 50/50 split in users and non-users of HM) 
with   
p = 0.5.  
 Therefore the sample size required for this study (n) = 
 
               1.96 x 1.96 x 0.5 x 0.5 
                      0.03 x 0.03                              n = 1067.11 
The minimum sample size required for this study was about 1067 participants, assuming 
50% of the population use HM.  
2.4.2 Sampling procedure  
The method of selecting a proportion of the entire population as representative of the 
population in a study is known as sampling (Polite and Hunger, 1999). In this research, a 
multistage sampling technique was used, which entails sample selection in at least two 
stages. The initial stage involves selecting clusters of population units containing more units 
than are required for a final sample (Mason, 2002). The first stage involved in this study was 
stratifying Ekiti State into the existing 16 LGAs, as shown in Table 2.1. Stratified sampling is 
n = z² x pq 
d² 
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a process of using stratification variables which may be geographical or non-geographical to 
increase the efficiency of a sample design (Patton, 2005). It involves the population 
stratification into homogeneous strata.  A geographical stratification variable was used in this 
study, and the homogenous nature of Ekiti State made this sampling appropriate (EKSG, 
2016). The strata which in this case are the LGAs that are non-overlapping, have precise 
borders, and collectively include everyone in the target population, with each person 
appearing in only one stratum i.e. an LGA. Stratified sampling enables application of various 
selection and estimation procedures to different strata; and a variety of information on the 
various strata can be obtained. It also permits analysis of different interests for different 
groups (Patton, 2005). The risk of forming a stratum where no information is available does 
arise; however, the use of HM is a state-wide phenomenon in the study population (Kayode 
and Kayode, 2008; Egbebi, 2011; Olanipekun, Kayode and Akomolafe, 2013). Therefore 
every stratum is sure to have information on the use and knowledge of HM in this study. 
Simple Random Sampling (SRS) was used at the second stage of sampling in the study. It is 
a selection process based on probability, with each sample in the population given the 
probability of being selected equally (Mason, 2002). The names of towns in each LGA were 
obtained, a list was made and numbers allocated to each town. The allocated numbers were 
written out on separate pieces of paper. The small pieces of paper were rolled into tiny bits 
by a different person who was not a participant in the research and all bits mixed together in 
a basket. The researcher picked from the basket with eyes closed. This was repeated for 
each LGA and two bits were picked each time, making a total of 32 bits. These 32 bits made 
up the 32 towns used for the study (Table 2.2). The same method was used in the third 
stage. The list of the residential quarters in each of the selected towns was made and 5 
residential quarters were picked as described above, making a total of 160. SRS is simple 
and easy to use but requires a complete list to be made of the entire unit in the study 
population (Patton, 2005). This can be particularly difficult for a large sample and can be 
expensive in a large geographical study such as this. However, the list of towns in each LGA 
was supplied by the respective LGA authorities, while the list of the residential quarters in 
each town was supplied by the traditional council of the towns. This helped considerably to 
reduce cost and time in this study. The list of town and villages chosen for the study is given 
in Table 2.2 
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Table 2.2: Selected location of study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Systemic random sampling was used in the fourth stage, in selecting 10 households from 
the selected residential quarters and one person from each household made up the final 
sample population. The houses in each residential quarter were assigned a number due to 
the poor house numbering practice in Ekiti State. Each residential quarter had an average of 
250 houses. The first local government studied had 236 households. A sampling factor was 
determined by dividing the population size (N) by the selected sample size (n) (Patton, 
2005). 
 
Equation 2.2:                              Sampling factor= N/n 
Where N = population size 
  n= selected sample size 
Therefore the sampling factor is calculated: 
S/N Local Government Towns /villages 
1 Ado-Ekiti                                                Odo
Bolorunduro 
2 Efon-Alaaye Efon 
Igbo-olofin 
3 Ekiti East Ilasa 
Isinbode 
4 Ekiti South West Ilawe 
Ogotun 
5 Ekiti West Erijiyan 
Aramoko 
6 Emure Sasere 
Eporo 
7 Gbonyin (Aiyekire) Aisegba 
Ijan 
8 Ise/Orun Ise 
Orun 
9 Ido-Osi Ifaki 
Ayetoro 
10 Ijero Iloro 
Ikoro 
11 Ikere Onigemo 
Odolofin 
12 Ikole Ayedun 
Ipao 
13 Ilejemeje Iye 
Eda 
14 Irepodun/Ifelodun Esure 
Awo 
15 Moba Igogo Ekiti 
Irare 
16 Oye Osin 
Itapa 
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N = 236 
n = 10   
236/10=23.6 ≈24 
Therefore 24 pieces of paper were numbered 1 to 24 and afterwards the start number ―5‖ 
was picked using SRS as described earlier. This means the 5th household in the residential 
quarters was the starting point and the 24th household followed i.e. house numbers 5, 29, 53 
77,101,125,149, 173,197 and 221 participated in the study. This process was repeated for 
all the earlier selected 160 residential quarters.  
Systemic random sampling is simple to use and offers the chance of even sampling of the 
population at equal distance. However, one disadvantage of systemic random sampling is 
periodicity bias (Mason, 2002), but no periodicity was observed because samples were 
randomly distributed in each sampling cycle. One person from each household participated 
in the study to make the sample size. In households with more than one person who met the 
inclusion criteria and who was willing to participate, simple random sampling was used to 
choose one person. This was done by secretly rolling papers of a ―yes‖ and many ―no‖ into 
bits and members of such household were asked to pick one. The person who picked ―yes‖ 
participated in the study. As a result, 50 people participated in the study from each of the 32 
towns from the 16 local government areas of Ekiti State. Thus there was a total of 1600 
participants representing 1600 households.    
2.5 Research instruments: design and measurements 
The data collection tool for this study was a questionnaire developed from previous studies 
on the use of HM (Ezeome et al., 2007; Okoronkwo et al., 2014; Kummet et al., 2015; Duru 
et al., 2016) as well as personal experience of the researcher. The questionnaire was 
focused on exploring the general public‘s knowledge of HM, its use and perception. The 
questions asked were both open- and close-ended. The open-ended questions enabled 
participants to give multiple and flexible responses and were employed to identify HM used, 
reasons for HM preference and non-orthodox preference. It also included adverse effects 
experienced, how they were managed and how the safety of uncertified HM can be 
achieved.  
The questionnaire was divided into three sections. The first recorded the bio-data of the 
participants, their age range, gender, level of education, religion, occupation and annual 
income. The second section elicited their knowledge and use of HM both certified and 
uncertified. It also investigated the type, name and frequency of HM used by participants. 
The third investigated the participant‘s perception of HM effectiveness, its safety, reasons 
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that informed the use of HM, why hospital assistance was not sought, and regulatory 
framework. Any adverse effect associated with HM use was also reported in this section and 
how it was managed by participants. Various steps were taken in developing the 
questionnaire, as listed below: 
 
I. Identification of key concepts and research question needs 
II. Development of questions to test these concepts and meet research question needs 
III. Input from other social science research in the questionnaire 
IV. Pilot testing of the questionnaire (Section 2.6.4) 
V. Discussion of field experience and effectiveness of the tool with the data collectors 
VI. Discussion with a statistician on the validity of the questionnaire 
VII. Corrections made and input added (Section 2.6.4) 
VIII. Development of the final questionnaire. 
 The full questionnaire can be found in Appendix XVI 
 
The questionnaires were either self-administered or interview-based. Literacy level and 
personal preference determined how they were administered. Respondents who were 
literate and willing to have the tool self-administered used self-administered questionnaires.  
Respondents who indicated that they were not literate or who were literate but preferred the 
interview method had the tool administered by an interview-based method. 
2.6 Organisation of the study 
2.6.1 Preparation for field work 
The field work commenced in January 2016, after ethical approval, enlisting and training of 
research assistants and research tool pilot testing. 
2.6.2 Ethical matters 
Prior to commencement of the study ethical approvals were sought from the Faculty of 
Science and Technology research ethics panel (FREP), Ekiti State hospital management 
board and Ekiti State university teaching hospital (for access to hospital data) (Appendix 
XIX). 
 Candidate participants were requested to give their consent to participate in the study by 
signing the participant consent form (Appendix XV) after reading the participant information 
sheet. Participants who were not literate had the participant information explained to them in 
Yoruba and verbal consent was accepted. 
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2.6.3 Enlistment and training 
Research assistants (RAs) were recruited for the study. They helped with data collection, 
especially coding to ensure intercoder reliability (Section 2.12.1). Recruitment was 
conducted by: 
I. Placing an advertisement for research assistants in a variety of public places; with 
qualification outlined. 
II. Received applications were examined and shortlisted applicants interviewed. 
III.  Successful applicants were enlisted and trained. 
 
The study questionnaire review, piloting and finalisation were part of the training component. 
It also gave guidelines on the field protocols, duties and roles of the RAs. Training focused 
on administration of the questionnaire and a unified translation of the questions to Yoruba for 
those who did not understand the English language. 
The study hired a total of 10 RAs for the survey. They had good knowledge and deep 
understanding of the culture of the indigenes, combined with English and Yoruba language 
proficiency. The RAs were aged between 22 and 34 years and helped in the administration 
of the questionnaires. Two of the RAs were later selected in light of good performance 
during the field work to help with the coding of the open-ended questions. The research 
assistants were trained using data from the pilot study in textual guidance so as to assign 
the same category to the same response in order to assess intercoder reliability and improve 
the coding process. 
2.6.4 Pilot study  
A pilot study is a fundamental aspect of a research process. It is the test of a method and 
process on a small scale before its use on a large (Porta, 2008). Thus the fundamental aim 
of undertaking a pilot study is to assess the feasibility of the research method before its 
application on a larger-scale study. This is essential to prevent possibly unexpected 
occurrences with grave consequence while undertaking a large-scale study which may 
eventually destroy all the research efforts and input. A pilot study can be employed in both 
qualitative and quantitative research (Lancaster, Dodd and Williamson, 2004). It helps in 
assessing the adequacy of the process (including unexpected answers, recruitment rate), 
resources (e.g. questionnaire completion time, training needs), management (e.g. questions 
and space needed for an answer, data variability) and research question (Van Teijlingen and 
Hundley, 2001). A pilot study cannot be used to test the research hypothesis since it 
requires a small sample and is correspondingly imprecise (ibid). 
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The pilot study was carried out to determine its feasibility on a large scale. The questionnaire 
intended for use in this study was piloted in two towns in two LGAs in the state. The 
questionnaires were pretested on the 12th of January, 2016. Each RA conducted at least 2 
self-administered and 2 interview-based questionnaires. This served as a form of field 
training for the RAs.  
 
Forty questionnaires were administered in each town, making a total of eighty obtained. The 
problems encountered during the fieldwork were discussed. It was observed that some of 
the questions on HM use were ambiguous and needed to be limited to a time frame. As a 
result the questions were rephrased to focus on the use of HM within the last two years:  
questions 9, 11 and 13 on the questionnaire (Appendix XVI). Also, some of the questions 
needed to be reworded to ask about HM in general rather than uncertified HM only, which 
gave a limited response. Afterwards, data collection started on 19th January 2016 and 
ended on 18th April 2016. 
2.7 Data quality assurance mechanisms 
Many actions were taken to guarantee quality assurance of the data, which makes the result 
reliable. The quality assurance mechanism required the constructs of dependability, 
credibility, transferability, trustworthiness and confirmability were enhanced (Flick, 2014). 
The coding of the data was performed by the researcher, who is experienced in data 
analysis and social research, and 2 research assistants who were trained. Meticulous 
transcription and analysis of the data were undertaken to ensure dependability of the result. 
The researcher was open to creation of new themes; and these were coded as they 
emerged to ensure confirmability (Flick, 2014). The initial data were analysed early to 
identify gaps and the guides were constantly reviewed as needed to bridge these gaps. This 
was carried out to maintain trustworthiness of the results produced. Data log sheets and 
questionnaire monitoring sheets were used to prevent double entry of data and entry errors. 
These steps helped to ensure the quality of the data. 
2.8 Data collection, management and analysis 
2.8.1 Data collection 
Data were collected using a questionnaire as the instrument. Each self-administered 
questionnaire was completed in about 10 minutes, the interview-administered in about 20 
minutes. Each RA together with the researcher administered about 10 questionnaires each 
day. The questionnaire was used to obtain both qualitative and quantitative data with open 
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and closed-ended questions. Completed questionnaires were checked for error and 
incomplete entries by the researcher. Identified mistakes or queries relating to the 
information were verified with the respondents or RAs. 
The respondents were warm and eager to tell more than was asked about their use of HM. 
They were particularly happy with the research interest in HM, believing it will help to 
improve knowledge and secure greater scientific input.  
2.8.2 Data management  
Completed questionnaires were compiled for the data entry. Data were entered into 
Statistical Software for the Social Sciences (SPSS) for Windows (version 20.0) for analysis 
after they had been coded. Each questionnaire was numbered according to its serial number 
on the SPSS to ensure accuracy and then archived. After entry by the researcher, each data 
set was cross-checked after every 50th entry to prevent entry error. Where errors were 
identified the affected questionnaires were retrieved and the error was corrected.  
 2.8.3 Data analysis  
Analysis of textual data from open-ended response can be performed manually or a 
computer automated system can be used and an instrumental or representational approach 
adopted. The latter was deployed in this study and manual coding of the response was 
employed. Manual coding is believed to be costly and time-consuming but so also is building 
a dictionary, although it may not be as expensive as manual coding. Manual coding is very 
helpful in combatting problems associated with ambiguity, such as recognizing homonyms 
(Roberts and Popping, 1996) and is also the most suitable for the representational approach 
adopted in this study. A vital point to consider in text analysis is the determination of the 
point of view at which the data is to be coded: that of the researcher‘s theory or respondents‘ 
point of view? The instrumental approach interprets texts according to the researcher‘s 
theory; the representational approach interprets text to understand author‘s point of view or 
meaning (Shapiro, 1997). 
Instrumental text analysis method identifies individual and societal traits which members of 
the society are possibly unaware of, while representational method characterises texts in a 
manner intended by the sources. It has been argued that requirements for semantic validity 
are better achieved through representational than instrumental views, although some 
researchers prefer the instrumental view since the associated computer-assisted coding is 
faster, though not cheaper; with the need for a dictionary to be developed (Popping, 2012). 
Semantic validity requires coding in line with the research question and placing answers in 
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appropriate category fit to reflect the category‘s meaning with an agreement between 
persons familiar with the understudied text and language (Krippendorff, 2012). So the 
representational approach was adopted in this study to map out the meaning intended by 
the participants with an understanding of the social circumstances in which the response 
originated. This perspective will help to clarify both reasons for the choice of use of HM and 
also for non-hospital use peculiar to and within the study population. 
2.8.3.1 Textual analysis 
There are three methods by which text can be analysed in textual analysis in quantitative 
design:  thematic, semantic and network (Roberts and Popping, 1996). In this study thematic 
text analysis was applied, requiring scanning for occurrence of themes in response to the 
question asked. While semantic text analysis employs the subject-verb-object (SVO) 
relationship seen in clauses or sentences and the explicit, implicit, inflected nature of the 
verb or related modifiers and the subject-object, the network text analysis organises the 
related SVO in a network (Ibid). Semantic and network analysis are usually employed in long 
responses. 
In using representational thematic analysis parts of the text were selected and themes 
assigned manually by the researcher and research assistant. This means of coding ensure 
interpretation of the manifest response and also an assessment of latent meaning, making 
the method better than computer-assisted coding. Coding which is the process of systematic 
transformation and aggregation of raw data into units enabling accurate description of 
pertinent content features (Holsti, 1969) was performed by multiple coders (Researcher and 
2 research assistants; (refer to section 2.6.3) to ensure intercoder reliability (Eccleston et al., 
2001; Weston et al., 2001). The codes generated were not mutually exclusive; some 
respondents had more than one response to some of the questions which fell into two or 
more categories. These were entered as individual response in the separate categories. 
Thus some of the total responses to some of the questions exceed the total of participants. 
An example of the coding of some of the responses is contained in Table 2.4.  
 
 It has been asserted that intersubjectivity of the results obtained from computer-assisted 
text analysis remains a fundamental advantage (Heinrich, 1996). However, the major 
objective of inter-coder reliability is to minimise subjective bias. There are calculations 
available to assess agreement among coders using the percentage agreement, Cohen‘s 
kappa coefficient, and for agreement between more than one coder using Fleiss kappa 
coefficient or the Scott‘s pi (Scott, 1955; Cohen, 1960; Fleiss, 1971; Neuendorf, 2002). 
Krippendorff's alpha coefficient is also used which is applicable to any number of coders 
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(Krippendorff, 2004b). There is a host of other tests used, such as the Pearson r and the 
Spearman Rho, the contingency coefficient, the concordance correlation coefficient, the 
intra-class correlation coefficient. Krippendorff‘s alpha (α) is the most reliable because it 
allows more than two coders, presents no issues with missing data in the calculation of 
alpha and all levels of measurement can be tested (Hayes and Krippendorff, 2007).  
Conversely, unlike other methods (with the exception of percentage agreement) which 
measure the agreement between the observed and expected outcome, Krippendorff‘s 
equation measures the disagreement between the observed and expected outcomes, which 
makes it conceptually and computationally difficult. Intercoder reliability was, however, 
carried out using the Krippendorff alpha method with the use of the online intercoder 
reliability calculator for three or more coders (Recal3) developed by Deen  Freelon,  which is 
suitable for the intended use in this study (Freelon, 2010). A α ≥0.800 is acceptable while α≥ 
0.667 is the lowest acceptable in case tentative conclusions are to be drawn (Krippendorff, 
2004a, pg. 241). 
 
 Aside from intercoder reliability‘s being calculated during the training period with the result 
from the pilot study, this was also performed 5 times during the coding period (14 days 
coding period). It was done at about 2 days interval, in the morning before the start of the 
coding day by coding responses from 20 questionnaires that were duplicated and shared 
among the 3 coders. Considering both face-to-face and self- administered questionnaires 
were used, it was essential to assess areas of agreement and disagreement in data 
interpretation. This allowed for a constant feedback on any coding problem and clarifying the 
appropriate category. Although this reduced the target volume of work to be done on such 
days, it was a quality-control measure that was essential to achieving a credible result. This 
is also essential to minimise factors such as leniency/stringency error, perception difference, 
stereotyping or halo effect which may affect intercoder reliability (Stemler, 2004). The coding 
concluded, data were analysed as described in Section 2.8.5. Data input was performed by 
the researcher, enabling a quality control check on the coded and processed data.  
2.8.3.2 Quantitative data analysis 
Inferential and descriptive statistics were carried out on the quantitative aspect of the data 
using SPSS for Windows version 20.0. Comparison of socio-demographic factors and the 
use or non-use of HM was made using inferential analysis. A Pearson Chi-square test was 
used to examine the influence of various independent variables on various phenomena in 
the study and a P value ≤ 0.05 was considered to be statistically significant. The test is 
inferential non-parametric statistics, which may be administered on frequency data. It is 
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employed in testing the differences between the expected and observed frequencies 
occurring asides sample error, either chance or other factors (Mehta and Patel, 2012). A 
two-way chi-square test was used to examine the difference between the socioeconomic 
characteristics and the use of HM (Table 2.20) and on the perception of HM safety (Table 
2.21).   
A minimum count of 5 on SPSS in each cell of the chi-squared table confirms the validity of 
the chi-squared test. However, for counts below 5, some exact tests can be used for data 
testing, such as the Monte Carlo Exact or Fishers Exact, to give a valid chi-squared statistic 
(Ibid). The test was used to compare the influence of education, gender and annual income 
on the use of HM and perception of its safety. The analysis helped further comprehension of 
the interplay of several factors in the use of HM.  
2.9 Data interpretation 
The mixed method of data interpretation used in this study included reduction, display and 
transformation correlation, intertwining comparison and integration of data (Section 2.8.3). 
The reliability of result and conclusion are further strengthened using the findings from this 
approach (Onwuegbuzie and Teddlies, 2003; Palinkas et al., 2015). Ensuring the interaction 
of the data enabled the selection of the right model that optimally reflected reality in the 
study and its internal validity (Palinkas et al., 2015). Once analysis is completed, the results 
will be disseminated to the Ekiti State Ministry of Health, Ekiti State Hospital Management 
Board and other stakeholders in the Ekiti State health sector for the development of a 
forward approach in HM use and regulation in Ekiti State. 
2.10 Role of the researcher 
The researcher‘s direct involvement in this study was likely to introduce various ethical and 
personal issues due to his positionality and reflexivity in the study as described in Sections 
2.10.1 and 2.10.2.  
2.10.1 Positionality 
Positionality is needed in exploring the phenomenon in a study without the researcher‘s 
influence on the outcome (Rose 1997; Bourke, 2014). Positionality is the way people are 
defined by their existing network of relationships, which may change and be analysed as the 
research progresses (Maher and Tetreault, 1994). It may include aspects of identity (class, 
gender, age) or research experience (such as involvement in previous projects, research 
training) which can affect the relationship between the researched and the researcher 
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(Hopkins, 2007). Understanding positionality and its effective role is vital to credible data 
collection and analysis because encounters, processes and outcomes of studies can be 
influenced by various identities of the researcher (Unluer, 2012).   
The researcher‘s being a health professional and a stakeholder in the Ekiti State health 
system created multiple identities (those of physician, government official, researcher and 
Christian) which might influence the research process. Although it is required by the 
methodological perspective to the study that the researcher be an ―outsider‖, he was an 
―insider‖ not least because of his familiarity with the study environment. Also, some of the 
participants referred to the researcher as an insider due to a common ethnic origin, shared 
local language and familiarity with the study environment. Some other participants, however, 
referred to the researcher as an outsider due to his socio-economic status, religion, 
education and profession. This mixed insider-outsider stance had its implication for the 
research. The researcher‘s ethnic similarity, local language proficiency and awareness of 
cultural expectations helped to develop a cordial and warm relationship with the participants 
(see also De Andrade, 2000; Harvey, 1996; Sheriff, 2001; Chavez, 2008; Throsby and 
Evans, 2013; Longhurst and Johnston, 2014). 
 
The researcher‘s being an insider helped with the logistics and procurement of materials and 
documents needed in this research. Being an insider afforded insight in understanding the 
emotional, cognitive, economic, psychological and cultural workings of the study participants. 
However, the insider position can predispose to interview bias harmful to the data collection 
process (Bourke, 2014). Therefore the researcher needed to be continually reminded of his 
research role. Participants who were familiar with his professional background might be 
inclined to respond in a way believed to please the researcher or absolve them of potential 
scrutiny (Lloyd and Hopkins, 2015). Beginning the interview with a disclaimer of a non-
judgemental stance encouraged participants to open up, especially about how they 
managed the adverse effects of HM use (DeLyser, 2001, Bourke, 2014). This disclaimer also 
helped promote discussion of the reasons for non-hospital use which the participants may 
want to say little about, believing the researcher knew what most of the problems were. In 
general, the insider-outsider identity presented methodological advantages and difficulties, 
especially on issues pertaining to research process positionality, the researcher‘s awareness 
of self and knowledge gained as a result of his position in the social strata (Chavez, 2008). 
The positionality of the researcher was properly managed in this study, drawing on his own 
diverse social identities (Unluer, 2012). It helped minimise biases in the research result while 
interacting with the study participants in order to carry out an ethical and reliable study 
(Hopkins, 2007). 
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2.10.2 Reflexivity 
The beliefs, values, education and interests of the researcher could influence research 
outcome, hence reflexivity was important in this study. Reflexivity is a self-examination which 
may result in in-depth understanding of selves and others in relation to particular social 
environments, fostering deeper awareness of how social context influences peoples‘ 
personality and behaviour (Danielewicz, 2001 pg.155). Reflexivity means the researcher‘s 
self-appraisal that helps to identify and take responsibility for role in and influence on the 
study and how it affects people and study settings, data collection and interpretation. It also 
challenges the views of the resulting knowledge as objective and independent of the 
researcher (Berger, 2015). Reflexivity entails a consciousness of the contribution to the 
establishment of definition by the researcher all through the research procedure and 
accepting the impossibility of being 'outside of one's subject matter during the research. In 
this study, the researcher had the same cultural background as the study population, which 
could have influenced his reflection on the actions and behaviour of respondents concerning 
the use, choice and efficacy of HM in the study environment.   
But as a result of his knowledge of the effects of such use, choice and perception, the 
researcher was careful not to influence the research process. Additionally, the use of a 
structured questionnaire in data collection reduced the involvement of the researcher in 
construction of meaning in the study. The use of theories necessitating data collection and 
analysis minimised researcher‘s bias especially with the provision of an option for self-
administered questionnaire which prevented influence from the researcher‘s interest.  
2.11 Herbal medicine associated casualty and fatality; method 
The HM-related causality and fatality figures were studied in Ekiti state. This study was 
carried out on a 5-year retrospective record of patients admitted to female and male medical 
wards, children‘s emergency wards and records of obstetric delivery in the 16 Ekiti State-
owned specialist and general hospitals and 1 tertiary hospital in Ekiti State (Ekiti State 
university teaching hospital). The period of study was from January 1, 2010 to December 31, 
2014 (5 years). The population under study was all patients admitted to the three wards, 
medical ward, children‘s emergency and labour ward. Available records on the wards from 
nurses‘ report, case notes obtained from the hospital‘s department of medical records and 
records from the Hospital Management Board (HMB) were used in the study. Only deaths 
that were certified were included in the study. The study narrowed search criteria to 
admissions and deaths due to poison agents, poisoning and herbal medicine for medical and 
paediatric study. HM related causality and fatality was then narrowed down. 
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A review of obstetric records of patients with stillbirth (SB) was identified and used for the 
study. SB was determined as the delivery of a baby with a birth weight equal or greater than 
1kg, of 28 weeks gestational age or more, of 35 cm or more in body length, who died prior to 
or during labour (WHO, 2004). Data were retrieved from SB case files of patients with 
maternal exposure to HM in pregnancy. The data obtained included maternal age, level of 
education, religion, occupation and possible cause of SB by Baird-Pattinson‘s classification 
which includes foetal abnormality, antepartum haemorrhage, unexplained intrapartum foetal 
death, intrapartum-related infection, hypertensive disorder, maternal disease, spontaneous 
preterm labour, and intrauterine growth restriction (Pattinson; De Jong and Theron, 1989). 
Unknown among the probable causes of death, foetal abnormality, intrauterine growth 
restriction, spontaneous preterm labour and unexplained intrapartum foetal death were 
identified and examined for history of HM use in pregnancy. SPSS package version 20 was 
used to analyse the obtained data. 
2.12 Results and discussion 
2.12.1 Introduction 
This section presents the analysis and results of the data collected from both the survey and 
hospital records. Analysis of the data is performed according to objectives I, II and III of this 
research (Section 1.11). The survey analysed the pattern and extent to which respondents 
use HM in Ekiti State and how socio-economic and educational factors influence this use. 
The study also explored their perception of safety, management of adverse effects and 
reasons for non-hospital use of HM. Cross-tabulation, frequencies, percentages and charts 
were used to present the results.  
2.12.2 Response rate, categorisation and reliability  
A total of 1600 respondents participated in the research, 984 of whom used self-
administered questionnaires and 616 interview-administered. However, 1265 respondents 
constituted the sample for the study due to exclusion of 335 questionnaires (Table 2.3). The 
excluded entries were either incomplete or damaged beyond use. The self-administered 
questionnaire had 253 entries excluded for incompleteness and 10 for damage (total 263), 
while interview-administered questionnaires had 64 entries excluded for incompleteness and 
8 for damage.  
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Table 2.3: Methods of questionnaire administration 
 Total 
respondents 
(%) 
Incomplete     
entry 
(%) 
Damaged 
questionnaire 
(%) 
Total     
excluded 
(%) 
Actual 
sample size 
(%) 
Self-administered 
questionnaire 
 
984 
(61.5%) 
253  
(25.7%) 
10 
(1.0%) 
263 
(26.7%) 
721 
(73.3%) 
Face to Face 
Interview  
administered 
questionnaire 
 
616 
(38.5%) 
64 
(10.4%) 
8 
(1.3%) 
72 
(11.7%) 
544 
(88.3%) 
Total 1600 317 18 335 1265 
 
There was a higher nonresponse rate among the self-administered than interview-
administered questionnaires, which is similar to findings from previous studies (Christensen 
et al., 2013; Ekholm et al., 2009). The exclusion of 64 participants due to incomplete entry 
from face-to-face interview-administered questionnaires (Table 2.3) could have been as a 
result of likely bias due to different RAs. However, without proper training of the RAs the 
number of respondents excluded through this data collection method could have been 
higher. Also, the highest number of incomplete entries arising in self-administered 
questionnaires might have been due to problems at any of the cognitive steps required in 
answering a questionnaire, as discussed in Section 2.2.2. However, RAs were present to 
assist where necessary, which likely reduced the potential number of excluded respondents. 
The responses of the participants were coded by placing them in various categories, as 
described in Section 2.8.3.1 and examples are shown in Table 2.4. 
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Table 2.4: Exemplar table of categorisation of participants‘ response 
Question: Why have you not used HM in the last two years? 
Response Category 
I prefer to visit a quality Doctor in the hospital Personal preference 
It can be poisonous  and can make me sick Attendant health risk 
I just don‘t like to take HM Personal preference 
Some of those HM you don’t know their 
source and what they really contain 
 
Lack of knowledge on available HM 
                            Question: Why have you used HM in the last two years? 
 
It is easy to find and buy Availability 
It really works for me when I use it Effectiveness 
It is not expensive for me Affordability 
My money can buy it and more if I need it 
again  and no need to be looking for where to 
buy drugs 
Affordability and availability 
Natural is the best no need to be taking  
artificial chemical into my system 
Natural(ity) 
 
The analysis of textual data was subjected to an inter-coder reliability test as described in 
Section 2.8.3.1. The inter-coder reliability test showed there was an excellent agreement 
between coders during the coding stage with the Krippendorff α >0.800 for all open-ended 
questions coded (see Table 2.5).  
         Table 2.5: Table showing inter-coder reliability at different periods of testing  
Test period Krippendorff α Inter-coder reliability 
Pilot stage (n=80) 0.823 yes 
Day 1 (n=20) 0.845 yes 
Day 3 (n=20) 0.896 yes 
Day 6 (n=20) 1 yes 
Day 10 (n=20) 0.949 yes 
Day 12 (n=20) 1 yes 
                                                                               α≥0.800 is acceptable 
When observed disagreement (Do) = 0 and α = 1, it is said to be perfect reliability. But when 
there is agreement as if results were obtained by chance, observed disagreement (Do) = 
expected disagreement (De) premised on an interpretation of chance and α = 0 which shows 
an absence of reliability (Krippendorff, 2011, pg. 1). Inter-coder reliability improved over time 
(as evidenced by increasing Krippendorff α in Table 2.5) which indicated better agreement 
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between coders and thus validates the reliability of the result from this study. Hence it can be 
used in answering research questions I and II (Section 1.11.1). 
2.12.3 Socio-demographic indicators 
Socio-demographic characteristics of the respondents, including age, sex, level of education, 
religion, occupation and annual income (Table 2.6). 
Table 2.6: Socio-demographic background of respondents 
Variable   Frequency (N=1265)      Percentage (%) 
Age (years) 
18-29 
30-49 
50-69 
70 and above 
 
322 
547 
358 
38 
 
25.5 
43.2 
28.3 
3.0 
Gender 
Male 
Female 
 
713 
552 
 
56.4 
43.6 
Level of Education 
No formal education 
Primary 
Secondary 
Tertiary 
 
191 
245 
340 
489 
 
15.1 
19.4 
26.9 
38.7 
Religion 
Christianity 
Islam 
African traditional religion 
 
879 
346 
40 
 
69.5 
27.4 
3.2 
Occupation 
Student 
Civil servant 
Farmer 
Self Employed 
Others 
 
84 
491 
76 
501 
113 
 
6.6 
38.8 
6.0 
39.6 
8.9 
Annual Income(Naira) 
Low Income (≤ 600,000) 
Middle income(601,000 to 2.4M) 
High Income (≥2.4M) 
 
1037 
179 
49 
 
82.0 
14.2 
3.9 
 
As outlined in Table 2.6, there were more male (56.4%) than female respondents (43.6%) in 
the study. This is not unusual when compared with the population distribution in the state: 
51.0% male and 49.6% female (NPC, 2006). The ages of respondents ranged between 18 
and over 70 years; 43.2% were aged 30-49, 3.0% above 70. The greater proportion were 
30-49, which corroborates previous population statistics, with a higher proportion of youth 
and middle-aged in the state (NPC, 2006). This is further noted when the age range 18-29 
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years, which made up 25.5% of the study population, is added, making a total of 68.7% of 
the study population between the age range 18-49 years. The latest statistical publication 
reports higher youth and middle-aged residents in Ekiti State aged 15-44 years, accounting 
for 38.8%, 45-69 accounting for 37.6 % and over 70 accounting for 6.32% (NBS, 2012). 
Formal education is the pursuit of knowledge, understanding and skill in the curriculum of an 
institutionalised educational environment (Livingstone, 1999). About 84.9% of the 
respondents had a form of formal education, while 15.1% were without (Table 2.6). Most had 
a tertiary level of education which included degrees from post-secondary institutions such as 
polytechnics, universities and colleges of education or agriculture. This group was followed 
by that with a secondary level secondary or grammar school qualification. Respondents with 
primary level of education were those who only completed elementary or primary school.  
The youth (15-24 years) and adult (25 years and above) literacy rate in any language 
including the English is 98.6% and 79.5% in Ekiti State respectively (NBS, 2012). A recent 
publication reports 73% of the Ekiti population are literate (NPC, 2015). As compared with 
the 57% having successfully self-administered questionnaires used in this study, the state 
can be said to have more literate people. This fact reflects the official state and widely 
acknowledged ascription, ―the fountain of Knowledge‖ (EKSG, 2016), the boast of higher 
educational qualification of state citizens as compared with those of other Nigerian states. 
Christianity is the most practised religion in Ekiti State, with 69.5% of adherent respondents, 
27.4% Muslim and 3.2% of African traditional religion, although before the introduction of 
Christianity to Ekiti in 1893 African traditional religion was the only religion practised (Bello, 
2009). Published data showed that in 1963 there were 10.6% Muslims, 79.0% Christians 
and 10.4% others among the Ekitis (Ostien, 2012). When compared with this study result, 
there is shown a marked decrease in the proportion of Muslims in the state, although African 
traditional religion was not mentioned in the previous study. However, the majority of Ekiti 
people still seem to hold their African religious belief, which may have influenced their use of 
HM, regardless of religion (Table 2.20), although further evidence from this study does not 
support this hypothesis. The findings of this study regarding the significance of religion in the 
use of HM are further discussed in Section 2.12.3. 
The majority of respondents were self-employed, with 39.6% engaged in various trades as 
their source of income. Most of these trade ventures are small scale businesses ranging 
from sales of mobile phone top-up cards, hairdressing and barber shops, to artisan 
workshops, small restaurants and food trade in the market. This group was followed by civil 
servants (38.8%), employed by the state and federal government as employees in various 
cadres. Students accounted for about 6.6% of the study population. The low student 
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representation may not be unconnected with most higher education institutions‘ being shut at 
the time of the study. This occurred following strike action embarked on by the staff of the 
institutions, due to non-payment of their salaries by the government. 
 Farmers constituted 6% of the study population. These were peasant farmers who resided 
mainly in the rural areas of the study environment. The other groups, such as retirees, 
priests and politicians constituted 8.9% of the study population and are categorised as 
―others‖ (occupation with a number of participants below 20). This reflects the non-
industrialised nature of the state, where the majority are either employed by the government 
as cleaners, clerks,  drivers, teachers, doctors, lectures or administrative officers or engaged 
in small-scale business. This affected the annual income of the respondents in this study 
(Table 2.6): most (82%) were in a low, a minority (3.9%) in a high-income class.  
The gap between the income classes was very wide, especially with few respondents n a 
middle-income class (14.2%). The high and middle-income classes often consist of senior 
civil servants, owners of big business, politicians and professionals. A study in Enugu 
Nigeria showed a similar result, with a low-income class accounting for about 76% of 
respondents, 19% middle-income class and 4.2% high-income class (Okoronkwo et al., 
2014). The findings from this study highlight the income inequality in the study population. 
Income inequality describes the extent of uneven distribution of income among a population. 
It can be measured in various ways such as the ―Gini coefficient‖ coefficient, which is 0 when 
everyone has the same income accrued to them and 1 when an individual has the whole 
income. Zero signifies perfect equality and a coefficient of one signifies complete inequality 
(OECD, 2017). 
The Gini coefficient for Nigeria is reported to be between 0.50 and 0.70, one of the most 
unequal (Bakare, 2012). The UK scores 0.358 and the US 0.394, making the US  slightly 
more unequal. By contrast, Iceland, a much more equal society has a score of 0.244 
(OECD, 2017). However, inequality and particularly income inequality is a global problem 
and it has been called a defining challenge of our time. A Pew Research Center (PRC) 
survey reported that over 60% of worldwide respondents consider the gap between the rich 
and the poor a major challenge (PRC, 2014). Income inequality has been reported to be due 
to people‘s and groups‘ differing productive potential, which in turn results in differing income 
and wage levels (Dabla-Norris et al., 2015). Income inequality and poverty have also 
theoretically been found to be inseparably connected with the presence of one usually 
implying that of the other (Bourguignon, 2004; Burtless and Smeeding, 2002). 
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About 70% of Nigerians live on less than US $1.25 daily, and 80% of its rural population 
lives below the poverty line (IFAD, 2015), which reduces life expectancy. A recent study 
reported that the life expectancy rate and unemployment create inequality (Ogbeide and 
Agu, 2015). While there is no correlation between unemployment and poverty in Nigeria, the 
report found a direct correlation between inequality and poverty and at the same time an 
indirect correlation between them via unemployment‘s creating inequality and inequality 
leading to poverty. The majority of respondents in this study (39.6%) are self-employed 
(Table 2.6). Although the majority can be said to be employed, a good number of them may 
be said to be underemployed with a consequent effect on their income. Underemployment 
can be defined as insufficient in maximising skills or potential and generating an income 
relative to a standard of living (Maynard and Feldman, 2011). Hence, in addition to the 
finding of Ogbeide and Agu (2015), the link between poverty and income inequality may be 
through underemployment, although a further study on the skills and type of employment 
engaged in by the population under study may be needed to confirm this view. How these 
socio-demographic characteristics statistically affect the use of HM and perception of its 
safety is discussed Section 2.12.10. 
2.12.4 Knowledge of herbal medicine  
Question 2.1: Do you know what HM is? 
All the respondents in this study (100%, n=1265) have heard of and know what HM is.  
Question 2.2: Do you know the difference between certified and uncertified HM? 
 
Table 2.7: Respondents‘ knowledge of certification of herbal medicine 
Response Frequency Percentage (%) 
Yes 1139 90.0 
 No 126 10.0 
Total 1265 100.0 
 
All the respondents (100%) have heard about HM and know what it is. This is not unusual 
considering the long history of HM use not only in Ekiti State but in Yoruba land traditionally 
and historically (Borokini and Lawal, 2014), as discussed in Section 1.3.3. Orthodox 
medicine was introduced to Nigeria in the Yoruba land of Abeokuta in the 1860s by Roman 
Catholic missionaries (Metz, 1991). Before then HM was extensively practised and HM 
practitioners were an integral part of the Yoruba community, with various degrees of 
specialisation (Bello, 2009; Olagunju, 2012). This historical and cultural fact is reflected in 
the knowledge of HM reported by participants. However, with modernisation and advances 
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in almost all spheres of life, the need for regulation and standardisation of HM was 
inevitable. Some HMs are now being properly packaged, subjected to laboratory tests and 
approved for public use by NAFDAC (Oguntade and Oluwalana, 2009). These are the 
certified form of HM, while a lot of others are still not registered or regulated. According to 
Table 2.7 the majority of respondents (90%) knew the difference between government 
certified and uncertified HM. The high level of knowledge about certified and uncertified HM 
may be attributed to the various campaigns and public awareness of NAFDAC of fake and 
counterfeit drugs in Nigeria (Ofuani, Kuye and Ogundele, 2015). The national campaign was 
successful in urging people always to check for the NAFDAC number on any medication 
before it is consumed. This awareness is thus reflected in this study and is an indicator of 
the effectiveness of the government effort at informing the public. 
2.12.5 Use of herbal medicine in Ekiti State 
Question 2.3: Have you used HM in the last two years? 
 The reported use of HM was high in this study: 85.0% of the respondents had used HM in 
the previous two years (Table 2.8). The high percentage of HM users in this study (85.0%) is 
similar to a finding of a previous study carried out in a small part of Ekiti State where 74.3% 
of the 521 respondents had used herbal medicine in the treatment of malaria (Olorunniyi and 
Morenikeji, 2013). 
Table 2.8: Respondents‘ use of herbal medicine in Ekiti State 
 
 
 
 
This is also similar to findings of studies in urban Lagos and the UK in which 66.8% of the 
388 respondents used HM in Lagos and an average one-year prevalence of 64.2% HM use 
in the UK (Oreagba, Oshikoya and Amachree, 2011; Posadzki et al., 2013). Previous 
studies, as stated earlier, have focused on specific HMs or were carried out outside Ekiti 
State, which makes comparative analysis difficult. However, findings on HM use in this 
research are higher than those in Lagos and the UK, which could indicate that the use of HM 
is prominent in Ekiti State. 
 
 
Response Frequency Percentage (%) 
Yes 1075 85.0 
 No 190 15.0 
Total 1265 100.0 
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Question 2.4: Why have you not used herbal medicine in the last two years? 
Although the reasons for HM use vary, respondents who have not used HM in the last 2 
years in this study attributed their non-use to various factors. These include potential health 
risk (61.1%), personal preference (25.8%), and lack of knowledge of particular HMs (13.2%) 
(Table 2.9).  
Table 2.9: Respondents‘ reasons for non-use of herbal medicine in Ekiti State 
 
 
 
 
 
A previous study reported that 26.4% of the 129 non-HM users attributed their reluctance to 
safety concerns (primary reason among respondents who gave an answer), although, 31% 
of the respondents gave no reason, while the remaining 43% gave different reasons 
(Oreagba, Oshikoya and Amachree, 2011). Findings from this study also showed more 
people (61.1%) cited safety concerns. These factors were influenced by personal experience 
or that of friends and family as expressed by the respondents. In addition, the effort of the 
Nigerian government through various print and audio-visual media to raise awareness of the 
health risks of consuming unregistered products may be responsible for the high ―risk to 
health‖ response among non-users. This is because more people are aware of NAFDAC‘s 
warnings and sensitisation about consumption of unregistered medicinal and food products 
(Ofuani, Kuye and Ogundele, 2015). However, the results from this study still show high use 
of uncertified HM despite government efforts (Table 2.10). This further emphasises the need 
for this research in identifying underlining reasons for the trend. 
Question 2.5: What type of HM have you used in the last two years? 
Table 2.10: Class of herbal medicine used by respondents in Ekiti State 
 
 
 
 
Response Frequency Percentage (%) 
Risk to health 116 61.1 
Personal preference 49 25.8 
Lack of knowledge about 
specific HM 
25 13.2 
Total 190 100.0 
Response Frequency Percentage (%) 
Uncertified 401 37.3 
Both 343 31.9 
Certified 331 30.8 
Total 1075 100.0 
65 
According to Table 2.10, among the respondents who had used HM in the previous 2 years, 
uncertified HM was the most used (37.3%) followed by respondents who used both. This 
finding is novel because there are no published studies in this regard distinguishing certified 
and uncertified HM and comparing their use even in Nigeria. Despite its being a novel 
finding, it is of significant concern, especially to public health. Accordingly, the commonly 
consumed HMs are further analysed for their toxic potential in Chapter 4. The difference 
between the use of certified and uncertified HM may be small, probably due to public 
awareness, but the category of people who use both (31.9%) may make a difference to the 
actual result where respondents cite order of use. Table 2.12 better explains this use, giving 
a clearer assessment of the type of HM used by respondents. 
Question 2.6: How many times have you used HM in the last two years? 
Table 2.11: Frequency of herbal medicine use by respondents 
 
 
 
 
The frequency of HM use in this study varied from once to over 10 times in the previous 2 
years, which is important in assessing health impact. The majority of respondents (53%) 
used HM over 10 times in the previous 2 years (Table 2.11). This highlights the high 
frequency of HM use in the study population. Similar studies reported frequent use of HM in 
Nigeria, especially among specific groups such as pregnant women and people living with 
chronic illness (Ezeome and Anarado, 2007; Fakeye et al., 2009; Osamor and Owumi, 
2010). Publications on the frequency of use are limited for other countries, but a publication 
reported lifetime use of HM among 65.3 % (n=118) of Americans of Hmong ethnicity (Lor et 
al., 2016). This may allude to the cultural influence of HM use, as previously discussed in 
Section 1.5.2.  
Question 2.7: What is the name of the HM you have used in the last two years? 
The high use of uncertified HM (Table 2.10) is reflected in the name of the HM commonly 
used by the respondents. 
 
 
 
Response Frequency Percentage (%) 
Once- twice 142 13.2 
3-10 times 363 33.8 
Over 10 times 570 53.0 
Total 1075 100 
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                 Table 2.12: Types of herbal medicine used by respondents in Ekiti State 
 
In total, uncertified and unregulated HM was the most commonly used type, accounting for 
66.1%, while certified HM accounted for 33.3% (Table 2.12). This further alludes to the 
findings in Table 2.10, which showed uncertified HM as the most used form of HM. 
According to Table 2.12, 0.6% of the respondents used other types of HM which included 
different brands, some certified and some uncertified. The HMs identified by respondents 
(Table 2.12), with the exception of local herbal mixture, were analysed for heavy metals and 
the possible presence of pharmaceuticals as part of this research (see Chapter 4). This 
would help to identify potential toxic components in these HMs. 
2.12.6 Preference for herbal medicine use and Hospital use 
Question 2.8: Why do you prefer to use herbal medicine? 
The reasons for HM preference varied among the respondents, 39.6% of whom cited its 
effectiveness, 31.9% its affordability and 21.5% its availability (Table 2.13).      
 
 
 
              
Response Frequency Percentage (%) Type 
M and T Capsule 104 6.8 certified 
Original malaria/yellow fever 
and typhoid 
76 4.9 uncertified 
Aromalegun 100 6.5 uncertified 
Body pain 93 6.0 certified 
Supa A1 105 6.8 certified 
Eroxy 5000 211 13.7 certified 
Wadco total blood cure 110 7.1 uncertified 
Male tonic 178 11.6 uncertified 
YK original malaria 107 6.9 uncertified 
Wadco pile and dysentry 89 5.8 uncertified 
Local herbal mixture 358 23.2 uncertified 
Others 
 
10 0.6  
Total 1541   
Certified 513 33.3  
Uncertified 1018 66.1  
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Table 2.13: Reasons for preference of herbal medicine use 
 
 
 
 
 Effectiveness of HM was a major factor in the choice of HM in this study. Its role as a major 
factor in HM preference has also been reported previously (Mafimisebi and Oguntade, 2011, 
Adesiji and Komolafe, 2013). Affordability was the second most important determinant, 
followed by availability. These reasons for HM use have been reported in the literature, 
where several factors were found to have contributed to the resurgence of public interest in 
HM, including claims of its effectiveness, a preference for natural therapies and alternative 
medicines, dissatisfaction with orthodox pharmaceutical outcomes, high cost and side 
effects of orthodox medicine, distrust of physicians‘ abilities and self-medication habit 
(Bandaranayake, 2006). Anecdotal information from friends, religious influence and level of 
spiritual consciousness has also been known to influence the use of HM (Astin, 1998; Zeil, 
1999; Parle and Bansal, 2006). The high use of HM in developing countries was reported to 
be likely due to its acceptability, availability, accessibility and affordability by the majority of 
the populace (Elvin-Lewis, 2000). Some of these factors have also been identified in this 
study across age and gender (Figure 2.2 and 2.3). 
 
 
Response Frequency Percentage (%) 
Effectiveness 538 39.6 
Affordability 434 31.9 
Availability 292 21.5 
Naturality 96 7.1 
Total 1360 100.0 
68 
 
 
Figure 2.2: Reasons for HM use by age 
 
 
 
Figure 2.3: Reasons for HM use by gender 
 Although only 7.1% of the respondents in this study attributed their use of HM to its natural 
and organic properties, the misconception of the natural properties‘ being non-toxic and free 
of adverse effects is a common belief in both developed and developing nations (UNESCO, 
2013). Perception of HM as natural and thus a reason for its use is not peculiar to the 
sample population in this study. 
  Belief in the effectiveness of HM as a major reason for its use cut across the economic and 
educational attributes of the respondents (Figures 2.4  and 2.5) including age and gender, 
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as seen in Figures 2.2 and 2.3. The effect of background characteristics on the use of HM 
and statistical correlation is further discussed in section 2.12.10. 
 
Figure 2.4: Reasons for HM use by economic background 
 
Figure 2.5:  Reasons for HM use by educational background 
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In view of the findings on the reasons for preference of HM use it was appropriate to 
examine the effectiveness of orthodox medicine in Ekiti State and Nigeria as a whole for 
purposes of comparison.  
The WHO currently estimates that about 10% of pharmaceuticals in circulation worldwide 
and 25% in developing countries are fake (Amadi and Amadi, 2014). An estimated 75% of 
these fake drugs are produced in India, 7% in Egypt and 6% in China (OECD, 2008). While 
Indian law prohibits the sale of fake drugs in the country, there is no prohibition of their 
export (Aminu et al., 2011). The problems of manufacture, importation and sales of fake 
drugs in Nigeria has markedly improved from 41% in 2002 to 10% in 2011 (Amadi and 
Amadi, 2014; Akunyili, 2007). However, a WHO study has shown that about 70% of 
pharmaceutical medication in circulation in Nigeria is either adulterated or fake (Wertheimer 
and Wang, 2012, WHO, 2015). This consequently affects the effectiveness of the medicines 
for their intended purpose. The near ubiquity of counterfeit medicine in hospital pharmacies 
and outside pharmacies together with poor service delivery in hospitals and health centres 
has possibly contributed more to the level of dissatisfaction with orthodox health care. 
Dissatisfaction might have indirectly increased HM use. But more important is the concern at 
possible adulteration of HMs as patronage increases and a desire to make it very effective. 
Therefore in this research HMs are analysed for possible pharmaceutical adulterants.  
Question 2.9: Why do you not prefer to use conventional health facilities? 
Dissatisfaction with orthodox health care was further highlighted in this study as the majority 
of respondents (45.2%) attributed poor service delivery in the hospital to non-use of 
hospitals (Table 2.14). The poor services experienced included long hospital waiting times, 
the hostile and rude attitude of health workers, poor infrastructure and lack of 
communication. A comparative assessment of herbal and orthodox medicine in Nigeria 
reported HM was rated higher than orthodox medicine in terms of efficacy, affordability, 
availability, safety and level of advertisement (Osemene, Elujoba and Ilori, 2011).   
             Table 2.14: Reasons for non-use of conventional health facilities in Ekiti State 
 
 
 
 
 
 
 
      Response Frequency Percentage (%) 
Poor service delivery 534 45.2 
High hospital cost 396 33.5 
Unorthodox belief 141 11.9 
Do visit the hospital 110 9.3 
Total 1181 100.0 
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The role of quality service delivery in patient‘s choice of healthcare is vital, and this has been 
reported previously (Cheraghi-Sohi et al., 2008; Faber et al., 2009; Aikins, Ahmed and 
Adzimah, 2014). Poor service delivery, as pointed out in this study was identified across the 
educational levels of the respondents (Figure 2.6), although the majority of respondents with 
no formal education blamed prohibitively high hospital costs for failure to use hospitals. 
 
Figure 2.6: Reasons for not using hospitals by educational background 
Tangibility, reliability, responsiveness, assurance and empathy are vital tools for quality 
healthcare service delivery (Aikins, Ahmed and Adzimah, 2014). While most orthodox health 
facilities in Ekiti State lack many of these, HM practice has been shown to be empathic, 
responsive and assuring, although its tangibility and reliability remain controversial. 
The high cost of hospital service was also cited by 27% of respondents as a reason for 
avoiding use of hospitals. Using the Central Bank of Nigeria (CBN) currency exchange rate 
on the 27th September 2018 of one United State Dollar (1USD) to 305 Nigerian Naira (CBN, 
2018) as discussed in Section 1.4.3, orthodox health care can be very expensive for an 
average Ekiti family, where the majority live on less than US $1,967 annually (Table 2.6). 
Hence, there is a plausible choice between the use and non-use of HM as further discussed 
in Section 2.12.10.  
A household poverty indicator by healthcare in Ekiti State reported 57.5% of 240 
respondents make use of HM in their health care, due to (problems associated with financial) 
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incapacity to meet hospital costs and proximity of government hospitals (Oluwatayo, 2008). 
This may be responsible for prohibitive hospital cost being the second most commonly cited 
reason for not using hospitals (33.5%) (Table 2.14) and affordability being the second most 
frequently cited reason for use of HM (31.9%) (Table 2.13). A comparative study has shown 
that social deprivation is strongly related to overall life-expectancy and mortality (Daniels, 
Kennedy and Kawachi, 2000). The middle-income class in relatively unequal societies like 
Nigeria have worse health than even poorer residents in a more equal society like the UK. 
The gap between the income class in this study is wide, with 82% of respondents in the low- 
income class, 3.9% in the high-income class and 14.2% in the middle-income class (Table 
2.6) in a health system still largely financed by out-of-pocket expenditure (69% by patients in 
Nigeria), as shown in Figure 2.7, compared with 11% out-of-pocket expenditure in the UK 
(Wilson, 2017). 
 
Figure 2.7: Sources of health-care financing in Nigeria (Uzochukwu et al., 2015). 
This explains how income inequality can lead to health inequality. Health insurance helps in 
health care financing as everyone contributes in proportion to their capacity a percentage 
regardless of their income, with high-income earners contributing more. This makes for more 
equal access to healthcare and reduces health inequality. 
Considering the study environment and despite the availability of modern health-care 
facilities in communities, the inability of residents to afford hospital services has likely 
contributed to the increased patronage of HM (Adesiji and Komolafe, 2013). However, the 
inability to afford hospital costs might not be attributed to poverty; as affordability and poverty 
cannot be said to be the same even though they are not mutually exclusive. Further 
statistical analysis sheds light on this issue in Section 2.12.10. A published report showed 
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that the average per-subject cost of treating headache in the UK is £39 and can go up to 
£42,000 for more complex cases (Fineberg et al., 2013). But for the health insurance policy 
in the UK, treatment would likely not be affordable for an average UK citizen who earns £528 
average gross weekly on a full-time basis (ONS, 2015). Conversely, poverty seems to be 
used to mean affordability in many contexts. Although more respondents in the low-income 
class ascribed high hospital cost to non-use of hospitals, poor service delivery was still the 
reason most frequently cited (Figure 2.8).  
 
Figure 2.8: Reasons for not using hospitals by economic background 
Figure 2.8 shows that, apart from the health-care financing issues in the study environment, 
poor service delivery by orthodox health facilities has become as serious a problem which 
requires serious intervention. But then poor service delivery in orthodox health-care facilities 
in this study cannot be viewed in isolation, without relating it to other factors in this study. It 
has been argued that societies with high-income inequality, as found in this study, are the 
most unlikely to invest in human capital resources and social services such as health care 
(Kaplan et al., 1996; Kawachi et al., 1997). The consequences are more serious for low- 
income and middle-income earners who may not be able to afford the luxury which health 
care has become, while high-income earners can seek help at higher cost. Suffice to say 
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that egalitarian societies have been found to achieve a better health outcome (Wilkinson, 
1996). 
About 11.9% of the respondents in this study cited unorthodox belief for not attending 
hospital, while 9.3% both attend hospital and use HM. The unorthodox belief of some 
respondents may, however, not be unconnected with dissatisfaction and disappointment with 
the orthodox medical system as discussed earlier in this section.  
2.12.7 Perception of safety and effectiveness of herbal medicine 
 Question 2.10: Was the HM effective for its intended use? 
This study showed the majority of respondents (83.6%) affirmed the effectiveness of the HM 
they had taken (Table 2.15). Various studies have also reported the effectiveness of herbal 
preparations on the various diseases and conditions studied (McClure, Flower and price, 
2014). A study carried out in Nigeria reported the effectiveness of HM on HIV patients and 
also revealed instances where orthodox medicine produced worse results than those 
produced by HM (Onifade et al., 2013). A review of clinical studies of herbal therapy in 
irritable bowel disease (IBD), for example, showed much difference in the efficacy of HM 
than placebo (Ng et al., 2013).  
Table 2.15: Perception of Effectiveness of herbal medicine 
Response Frequency Percentage (%) 
Yes 899 83.6 
No 176 16.4 
Total 1075 100.0 
 
Other studies have also reported findings alluding to the perception of effectiveness of HM 
(Oh et al., 2010; Teng et al., 2010; Puataweepong et al., 2012; Gary and Rutledge, 2013; 
Ladas et al., 2014). Satisfaction with results produced by HM is evident from this study, 
although a comparative use of orthodox medicine was not possible and the types of aliment 
for which HM was used may provide more clues as to its effectiveness. 
Question 2.11: Do you think it is safe to take uncertified HM?  
This study showed that more than half (57.3%) of the respondents who took HM believed it 
is not safe to take uncertified HM, while 42.7% believed it was safe (Table 2.16). The 
perception of HM safety noted here is corroborated by previous findings in this study which 
showed that 61.1% of respondents who did not use HM cited its possible risk to health as a 
reason for its avoidance. (Table 2.9). Regardless, most respondents (37.3%) used 
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uncertified HM and 31.9% used both certified and uncertified concurrently (Table 2.10). 
Evaluation of the types of HM used by respondents (Table 2.12) also showed that 66.1% 
used HM that was uncertified. 
                       Table 2.16: Perception of safety of herbal medicine 
Response Frequency Percentage (%) 
Yes 464 42.7 
No 623 57.3 
Total 1087 100.0 
 
By contrast, a study of the use of HM in Ikorodu Lagos State Nigeria reported that the 
majority (82.4%) of 400 respondents believed HMs are safe for use  and  9.7% believed they 
may not be safe; though the study did not distinguish between certified and uncertified HM 
(Awodele et al., 2014). The same study also reported that 12.6% of 400 respondents had 
experienced adverse effects, while 61.9% had not. These differ from the findings in this 
study, where 48.3% reported adverse effects ranging from nausea and vomiting to 
generalised bodily weakness, while 52.7% experienced no adverse effects (see Table 2.17).  
HM-related adverse effects depend on the type, form and quantity of HM taken. Like 
orthodox medicine, HM also causes different adverse effects on the user. Those associated 
with various forms of HM have been reported in literature to include headache, abdominal 
discomfort and allergic reaction (Posadzki, Watson and Ernst 2013; Awodele et al., 2014; 
Awodele et al., 2013; Duru et al., 2016). It is clear from this study that adverse effect 
monitoring (pharmacovigilance) of HM must be adequate and discussion on monitoring of 
pharmacovigilance of HM is imperative. Regardless of adverse effect, 83.6% of the 
respondents said the HM they used was effective for the intended purpose, while 16.4% said 
it was not (Table 2.15). As a result of the increase in use of HM, as previously discussed in 
the literature review (Chapter1), the safety testing of herbal medicine has become essential.  
Although there are perceptions of prejudice against the safety of herbal medicines (Zhang et 
al., 2015), several publications have raised safety concerns about HM and its practice. 
Studies have reported HMs as containing pharmaceutical adulterants and heavy metal 
contamination (Ajasa et al., 2004; Ernst and Pittler, 2002; Posadzki, Watson and Ernst 
2013). Some HMs naturally contains harmful substances which have been reported to be 
toxic to humans (Moreira et al., 2014) and contamination of HM with microorganisms in Ekiti 
State has also been reported (Oluyege and Adelabu, 2010). Given the high rate of HM use 
found in this study (Table 2.8) and the high perception of uncertified HM‘s being unsafe 
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(Table 2.16), it is important to determine how safe the HMs used in Ekiti State are and 
Chapter 4 undertakes this. 
2.12.8 Herbal medicine’s adverse effects and their management 
Question 2.12: What adverse effect did you experience with herbal medicine use?  
As discussed in Section 2.12.17 above, over half of the respondents (52.7%) did not report 
any adverse effect (Table 2.17). Those who experienced an adverse effect reported severity 
ranging from mild to severe, which necessitated the type of intervention the respondents 
took, as shown in Table 2.18. 
Table 2.17: Result showing adverse effect of HM experienced by respondents 
Response / Effect Frequency Percentage (%) 
None 566 52.7 
Abdominal discomfort 150 14.0 
Nausea and Vomiting 201 18.7 
Headache 82 7.6 
Stooling 62 5.8 
Generalised bodily 
weakness 
14 1.3 
Total 1075 100.0 
 
Question 2.13: How did you manage the adverse effect?  
Among the respondents, 42.5% managed the adverse effect by resting, while effects wore 
off, 25% attended hospital, 21.6% took orthodox medicine (self-prescribed), and 10.9% took 
other types of HM to counteract the effect of the previous HM (Table 2.18).  
Table 2.18: Result showing how adverse effects of HM were managed by respondents 
 Response      Frequency Percentage (%) 
Take other HM 56 10.9 
Rest until it self-limits 219 42.5 
Visit the hospital 129 25.0 
Take orthodox medicine 111 21.6 
Total 515 100.0 
 
Apparently, mild effects were managed by rest, moderate effects by taking other HM or 
orthodox medicine and severe effects mostly by resort to the orthodox health system in the 
hospital. In developed countries, adverse effects of HM are mainly treated in orthodox ways 
(Posadzki, Watson and Ernst, 2013).  
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2.12.9 How can safety of herbal medicine be improved? 
 Question 2.14: How do you think the safety of HM can be achieved? 
It is known that HM practice has a long cultural history in many societies including Yoruba. 
As a result, some practitioners may still be comfortable practising without regulation, relying 
on personal experience for treatment and hinging on tradition to legitimise practice. With 
advances in science, analysis and a regulatory framework for HM use are now more 
realisable. In this study, 46.5% of the respondents believed improved government monitoring 
would help to achieve safety of HM, while 40.1% believed public enlightenment would help. 
Also, 11.1% believed use of appropriate production and good hygienic preparation would 
help improve the safety of HM, while 2.3% said they do not know how its safety could be 
improved (Table 2.19). The government was believed to have a great responsibility for 
ensuring the safety of HM by the majority of participants. It can possibly be achieved through 
law on appropriate manufacturing standards, prevention of false claims and circulation of 
hazardous herbal products. 
Table 2.19: How respondents think herbal medicine safety can be improved 
Response Frequency Percentage (%) 
Government monitoring 577 46.5 
Use of appropriate production 
material and hygiene 
138 11.1 
Public enlightenment 498 40.1 
Do not know 29 2.3 
Total 1242 100.0 
 
 The guidelines of NAFDAC stipulate that no manufacturing, import, advertisement, sale or 
distribution of herbal medicinal and related products should be carried out in Nigeria until it 
has been registered in conformity with the necessary regulations (NAFDAC, 2005). The 
guidelines did not include extemporaneous preparations made by a practitioner and given to 
a patient on a one-to-one basis in the area in which it was prepared (NAFDAC, 2005). 
However, 23.3% of the respondents in this study used local herbal mixtures (Table 2.12), 
most of which can be classified as extemporaneous. Thus it is important that the safety of 
those who use these preparations be secured through the development of a thorough public 
enlightenment scheme, monitoring, screening, and legislation for extemporaneous HM. The 
publication and dissemination of these research findings will help to promote this course of 
action and also form a template for further policy formulation on HM use, especially in Ekiti 
State. 
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2.12.10 Effect of background characteristics on use of herbal medicine and perception 
of safety 
The association between the use of herbal medicine and the socioeconomic background of 
respondents was evaluated using Chi-square (2) analysis. The information thereby obtained 
will help to understand if there is a significant influence of any of the social, economic or 
demographic characteristics of the respondents on the use of HM. A level of significance p ≤ 
0.05 will mean a significant association between the observed factor and the use of HM, 
while a level of significance p > 0.05 will mean no significant association. 
According to Table 2.20 a significant number of men in this study used HM (89.9%), more 
than women (78.6%) (p < 0.001, 2=31.008 and df =3). This finding is not consistent with 
those of studies from developed countries, where women showed greater use than men; 
12.7% of women and 1.1% of men (Harrison et al., 2004), 8.3 % women and 2.9% men (Raji 
et al., 2005) and the same in other studies (Gardiner et al., 2007; Bakhotmah and Alzahrani, 
2010). A previous study in Nigeria, however, found no significant association between being 
female and use of HM (Onyeka et al., 2012). 
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Table 2.20: Significance of background characteristics on use of herbal medicine 
Socio-demographic 
characteristics 
Use of HM Non-use of HM Total p-value 
Age (years) 
18-29 
30-49 
50-69 
70 and above 
Total 
 
    274 (85.1%) 
    474 (86.7%) 
    289 (80.7%)           
    38 (100.0%) 
  1075 (85.0%) 
 
    48 (14.9%) 
    73 (13.3%) 
69 (19.3%) 
0  
  190 (15.0%) 
 
   322 (100%)  
   547 (100%) 
   358 (100%) 
     38 (100%) 
 1265 (100%) 
 
p = 0.005* 
2 =12.996 
df= 3 
 
 
Gender 
Male 
Female 
Total 
 
    641 (89.9%) 
    434 (78.6%) 
  1075 (85.0%) 
 
      72 (10.1%) 
    118 (21.4%) 
    190 (15.0%) 
 
   713 (100%) 
   552 (100%)               
 1265 (100%) 
 
p < 0.001* 
2= 31.008 
df = 1 
 
Level of Education 
No formal education 
Primary 
Secondary 
Tertiary 
Total 
 
 
    169 (88.5%) 
    224 (91.4%) 
    287 (84.4%) 
    395 (80.8%) 
  1075 (85.0%) 
 
      22 (11.5%) 
        21 (8.6%) 
      53 (15.6%) 
      94 (19.2%) 
    190 (15.0%) 
 
   191 (100%) 
   245 (100%) 
   340 (100%) 
   489 (100%) 
 1265 (100%) 
 
p = 0.001* 
2 =16.670 
df= 3 
 
Religion 
Christianity 
Islam 
African traditional religion 
Total 
 
    751 (85.4%) 
    284 (82.1%) 
    40 (100.0%) 
  1075 (85.0%) 
 
 
  128 (14.6%) 
    62 (17.9%) 
0  
    190 (15.0%) 
 
   879 (100%) 
   346 (100%) 
     40 (100%) 
 1265 (100%) 
 
p = 0.009* 
 2=9.493 
df= 2 
 
Annual Income(Naira) 
Low Income(≤ 600,000) 
Middle income (601,000 to 2.4M) 
High Income (≥2.4M) 
Total 
 
    890 (85.8%) 
    158 (88.3%) 
      27 (55.1%) 
  1075 (85.0%) 
 
  147 (14.2%) 
    21 (11.7%) 
    22 (44.9%) 
  190 (15.0%) 
 
 1037 (100%) 
   179 (100%) 
     49 (100%) 
 1265 (100%) 
 
 
p < 0.001* 
 2 = 36.366 
df= 2 
Occupation 
Student 
Civil servant 
Farmer 
Business 
Other 
Total 
 
      69 (82.1%) 
    395 (80.4%) 
    76 (100.0%) 
    431 (86.0%) 
    104 (92.0%) 
  1075 (85.0%) 
 
    15 (17.9%) 
    96 (19.6%) 
0  
    70 (14.0%) 
        9 (8.0%) 
  190 (15.0%) 
 
     84 (100%) 
   491 (100%) 
     76 (100%) 
   501 (100%) 
   113 (100%) 
 1265 (100%) 
 
 
p < 0.001* 
2 = 26.701 
df= 4 
*Significant association; df = Degree of Freedom 
 
It has been reported that women take fewer risks than men (Harris and Jerkins 2006 and 
Hoffman et al., 2013), and this may be true of the sample population of this study.  A majority 
of female respondents cited risk to health and lack of knowledge of most of HM widely 
available as their chief reasons for avoiding HM. Their male counterparts, by contrast, cited 
personal preference mainly followed by risk to health (Figure 2.9). Findings of this study also 
show that more males took uncertified HM than did female respondents (Figure 2.10). 
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 It was also observed from this study that a significant number of males believe it is safe to 
take uncertified HM, while a significant number of females believe it is not (Table 2.21). 
Studies have also reported that more women than men tend to seek orthodox health care 
(Green and pope, 1999; Bertakis et al., 2000; Chang et al., 2012). 
 
 
Figure 2.9:  Reasons for not using herbal medicine by gender 
 
 
Figure 2.10: Type of herbal medicine used by gender 
Other factors contributed to the use of HM, e.g. level of education. The use of HM was 
highest among respondents for whom the highest level was primary education (Table 2.20). 
Though the use of HM was lowest among respondents with a tertiary education, still notable 
is the high use of HM among respondents with tertiary level of education (see Table 2.20). 
There was a significant relationship between respondents‘ level of education and use of HM 
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(p = 0.001, 2=16.670, df =3). There was a significant association between annual income 
and HM use (p < 0.001, 2=36.366, df =2); highest use among respondents of the middle-
income class, while the least use was among the high annual income group. A previous 
study published that about 85% of Nigerians use HM for healthcare, psychological and social 
benefit due to dissatisfaction with orthodox medical care and poverty (Oshikoya et al., 2008). 
While dissatisfaction with orthodox medical care has been highlighted as the main reason for 
not using hospitals, it has also been observed that poverty was not the main reason 
respondents used HM in this study.  
A higher level of education may be associated with increased ability to make informed 
choice; higher income makes these choices more realisable. Low level of education and 
income power have been reported to influence the choice of HM use (Gardiner et al., 2007; 
Barnes and Bloom, 2008; Okoronkwo et al., 2014). The studies associated low income with 
use of HM; which is different from what was found in this study, where the highest use was 
not among the low-income earners. Reinforcing this point, a Nigerian study reported a 
similar finding among pregnant women attending a tertiary health facility, where use of HM 
was higher among respondents who earned more (Duru et al., 2016). However, studies in 
developed countries have reported an insignificant relationship between income and HM 
use, but a significant relationship between higher level of education and HM use (Du et al., 
2014; Kummet et al., 2015). Another study reported no significant relationship between 
levels of education and HM use (Oreagba, Oshikoya and Amachree, 2011). These variations 
may be due to factors such as respondents‘ socioeconomic characteristics or peculiarities of 
the study population, such as culture. Hence the findings in this study reflect the likely 
peculiarity of the people living in Ekiti State, where middle income was associated with more 
use of HM. 
There was a significant association between the age of the respondents and use of HM in 
this study (p = 0.005, 2 =12.996, df =3). Respondents of 70 years and above have all 
(100%) used HM in the last 2 years, followed by the age group 30-49 years of whom 86.7% 
have also used HM during the period. A publication about the general population and HM 
use reported a significant relationship between age and use of HM (Gardiner et al., 2007), 
while another study reported no significant difference (Okoronkwo et al., 2015). This study 
showed that the use of HM increased with the age of the respondents, although the age 
group 50-69 years did not follow the trend. The occupation of the respondents was also 
significantly associated with HM use (p < 0.001, 2=75.504, df = 8) as more farmers (100%) 
used HM (Table 2.20) than did other occupation and this may relate to the annual income of 
the respondents, which had a significant association with HM use in this study (Table 2.20). 
The type of occupation largely determines accruable income.  
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There was 100% use of HM in the last 2 years among respondents who practised African 
traditional religion and 85.4% use among Christians. There was a significant relationship 
between religious affiliation of the respondents and HM use (p = 0.009, 2=9.493, df = 2) 
(Table 2.20). The use of HM as an integral part of African traditional religion is documented; 
this is in addition to the role of African traditional religionist as the custodian of African 
traditional medicine (White, 2015). Although some studies reported no significant association 
between religion and HM use (Hughes et al., 2013; Adesiji and Komolafe, 2013; Opara and 
Osayi, 2016), other studies have reported otherwise (Hulela and Thobega, 2013; Ethel and 
Amy, 2014). Furthermore, research has shown that the religious beliefs and spiritual 
practices of patients have a powerful influence on their decisions about treatment choice, 
coping with chronic disease and end of life care (Puchalski, 2001; McCormick et al., 2012). 
This study has shown the potential influence religion has on the use of HM, with 100% of 
respondents practising African traditional religion having used HM in the last two years. 
There is apparently a correlation between their religious belief and their choice of health 
care. 
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Table 2.21.Significance of background characteristics on the perception of safety of HM 
*Significant association; df = Degree of Freedom 
The influence of demographic characteristics of the respondents on their perception of safety 
was also studied. This is to examine how the safety of HM is viewed across economic, 
educational, religious and other characteristics of the respondents. According to Table 2.21, 
there was a significant association between age, gender, annual income, occupation and 
perception of HM safety. The exception was religious belief, which had no significant 
association (p = 0.278, 2=2.558 and df =2). The significant influence of education on the 
perception of safety of HM was reported in the literature (Fakeye, Adisa and Musa, 2009), 
and is consistent with the findings of this study. The non-significant association between 
religion and perception of safety of HM in this study may be attributed to the cross-cultural 
Question 10.1: Do you think it is safe to take Uncertified HM 
Socio-demographic 
characteristics 
 
Yes No Total p-value 
Participant age(years) 
18-29 
30-49 
50-69 
70 and above 
 
107 (39.1%) 
195 (40.8%) 
130 (43.8%) 
  32 (84.2%) 
 
167 (60.9%) 
283 (59.2%) 
167 (56.2%) 
    6 (15.8%) 
 
274 (100%) 
478 (100%) 
297 (100%) 
  38 (100%) 
 
p < 0.001* 
2=29.104 
df=3 
Gender 
Male 
Female 
 
 
294 (45.3%) 
170 (38.8%) 
 
355 (54.7%) 
268 (61.2%) 
 
649 (100%) 
438 (100%) 
p = 0.034* 
2=4.499 
df=1 
Level of Education 
No formal education 
Primary 
Secondary 
Tertiary 
 
 
111 (64.2%) 
101 (45.1%) 
126 (43.9%) 
126 (31.3%) 
 
  62 (35.8%) 
123 (54.9%) 
161 (56.1%) 
277 (68.7%) 
 
173 (100%) 
224 (100%) 
287 (100%) 
403 (100%) 
 
p < 0.001* 
2=54.801 
df= 3 
Religion 
Christianity 
Islam 
African traditional religion 
 
 
316 (41.4%) 
127 (44.7%) 
  21 (52.5%) 
 
447 (58.3%) 
157 (55.3%) 
  19 (47.5%) 
 
763 (100%) 
284 (100%) 
  40 (100%) 
 
p = 0.278 
2 =2.558 
df=2 
Occupation 
Student 
Civil servant 
Farmer 
Self Employed 
Others 
 
 
  33 (47.8%) 
140 (34.7%) 
  53 (69.7%) 
199 (45.7%) 
  39 (37.5%) 
 
  36 (52.2%) 
263 (65.3%) 
  23 (30.3%) 
236 (54.3%) 
  65 (62.5%) 
 
  69 (100%) 
403 (100%) 
  76 (100%) 
435 (100%) 
104 (100%) 
 
p < 0.001* 
2 =36.688 
df=4 
 
Annual Income(Naira) 
Low Income (≤600,000) 
Middle income (601,000 to 2.4M) 
High Income (≥2.4M) 
 
403 (45.1%) 
  57 (36.1%) 
    4 (11.4%) 
 
491 (54.9%) 
101 (63.9%) 
  31 (88.6%) 
 
894 (100%) 
158 (100%) 
  35 (100%) 
 
p < 0.001* 
2 =18.891 
df=2 
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belief in HM use in the sample population. This hypothesis may be further supported by the 
high number of respondents across religious divides that use HM (Table 2.20).  
Therefore, much as there is a significant influence of religion on the use of HM among 
participants (Table 2.20), it had no significant influence on the perception of safety of HM 
(Table 2.21). A significant number of male respondents, of 70 years and above, having no 
formal education, farmers, in low annual income class believe it is safe to take uncertified 
HM. On the other hand, a significant number of youths between 18-29 years of age, females, 
and respondents with tertiary level of education, civil servants and high-income earners 
believe it is not safe to take uncertified HM. This is expected, considering that level of 
education and annual income affect the level of exposure which may have informed the 
views expressed by these groups of respondents. 
The relationship between an exposure and an outcome is quantified using the odds ratio 
(OR), representing the odds of an outcome‘s occurring, provided a certain exposure to the 
odds of the outcome happening in the absence of the exposure being studied (Szumilas, 
2010). While modelling of the data and a logistic regression would have helped predict future 
characteristics associated with the use of HM, not enough predictor variables were 
examined in this study to make such prediction reliable (Peduzzi et al., 1996). A future study 
may explore this subject employing more variables.  
2.13 Herbal medicine related casualty and fatality in Ekiti State hospitals 
A five-year retrospective study of casualties and fatalities related to HM between 2010 and 
2014 from 17 government hospitals (see Section 2.11) examined 94,323 patient records.     
Findings showed that 0.5% of general paediatric admissions were related to herbal medicine 
use and 3.2% of the general paediatric deaths were related to herbal medicine use (Table 
2.22).  
Table 2.22: Herbal medicine related paediatric casualty and fatality 
Total admission Total Death HM related 
Admission 
HM related 
death 
23363 1146 107(0.5%) 37(3.2%) 
 
 In a separate four-year retrospective study carried out in a tertiary hospital in Ekiti State 16 
(0.3%) of the total paediatric admissions (5,256) were as a result of HM use. Although the 
total paediatric deaths were not stated, 2 of the 16 patients died (Olatuya et al., 2015). The 
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HM related paediatric casualties in this research (0.5%) are higher than published research 
(0.3%) (Ibid): although this study is a five-year retrospective analysis. However, in this 
research HM related casualties and fatalities in adult patients revealed lower figures (see 
Table 2.23). HM related medical admissions were only 0.06% of the total medical 
admissions over the study period and HM related death was 0.2% of the total deaths 
recorded (Table 2.23).  
Table 2.23: Herbal medicine related medical casualty and fatality in adults 
Total Admission Total death HM related 
admission 
HM related 
death 
52871 1964 34 (0.06%) 4 (0.2%) 
 
Although about 25% of the respondents in the survey who experienced an adverse effect 
after taking HM (n=515) indicated that they attended hospital for treatment of the effects 
(Table 2.18), this is not corroborated in reality, with 0.06% of the medical admissions‘ 
(n=52871) being HM related. An explanation may be that some patients do not disclose their 
use of HM to doctors in the hospital (Shen et al., 2002; Downer et al., 1994; Ezeome and 
Anarado, 2007; Farooqui et al., 2016; Djuv, Nilsen and Steinsbekk, 2013). Doctors have also 
been reported to underestimate the use of HM by patients and so often do not ask about it 
when taking the clinical history from patients (Giveon, 2003). Conversely, there are a 
number of publications on HM related casualties and fatalities (Cosyns et al., 1999; Ernst, 
2002; Assiri, 2012), and it is likely that the severity of the HM adverse effects often 
warranted a disclosure and probably made the doctor search more for possible causes to 
the point of exploring HM use. 
Nonetheless, socio-demographic characteristics of the adult casualties and fatalities also 
obtained from the hospital records showed the highest casualties among the age group 30-
49, male patients, patients with a primary level of education, Christians, and patients who 
were self-employed (Table 2.24). The fatalities were also highest among the age group 30-
49, but then among patients with tertiary level of education, female patients, African 
traditional religion worshipers and civil servants. 
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Table 2.24: Socio-demographic characteristics of HM associated casualty and fatality of 
adult medical patients 
Socio-demographic factors of 
patients 
Outcome of effect 
Survived  
%  
(n=30) 
Fatality  
% 
           (n=4) 
Casualty 
 % 
(n=34) 
Age (years) 
18-29 
30-49 
50-69 
70 and above 
Total 
 
 
    4 (100.0%) 
16 (84.2%) 
 7 (87.5%) 
   3 (100.0%) 
30 (88.2%) 
 
0 
3 (15.8%) 
1 (12.5%) 
0 
 4 (11.8%) 
 
 4 (11.8%) 
19 (55.9%) 
 8 (23.5%) 
    3 (8.8%) 
 34 (100.0%) 
Gender 
Male 
Female 
Total 
 
 
27 (90.0%) 
  3 (75.0%) 
30 (88.2%) 
 
3 (10.0%) 
1 (15.0%) 
4 (11.2%) 
 
30 (88.2%) 
4 (11.6%) 
34 (100.0%) 
Level of Education 
No formal education 
Primary 
Secondary 
Tertiary 
Total 
 
 
0 
13 (92.9%) 
10 (90.9%) 
  7 (77.8%) 
30 (88.2%) 
 
0 
1 (7.1%) 
1 (9.1%) 
  2 (22.2%) 
  4 (11.2%) 
 
0 
14 (41.2%) 
11 (32.3%) 
  9 (26.5%) 
  34 (100.0%) 
Religion 
Christianity 
Islam 
African traditional religion 
Total 
 
 
25 (92.6%) 
 4 (80.0%) 
 1 (50.0%) 
    30 (88.2%) 
 
        2 (7.4%) 
  1 (20.0%) 
  1 (50.0%) 
  4 (11.2%) 
 
27 (79.4%) 
 5 (14.7%) 
    2 (5.9) 
 34 (100.0%) 
Occupation 
Student 
Civil servant 
Farmer 
Business 
Others 
Total 
 
  2 (100.0%) 
0 
   1 (100.0%) 
25 (92.6%) 
    2 (100.0%) 
30 (88.2%) 
 
0 
    2 (100.0%) 
0 
2 (7.4%) 
0 
  4 (11.2%) 
 
2 (5.9%) 
2 (5.9%) 
1 (2.9%) 
27 (79.4%) 
2 (5.9%) 
  34 (100.0%) 
 
Comparison of the socio-demographic characteristics of HM users in the survey study (Table 
2.20) and that of adult HM related casualties from hospital records showed that the age 
group 30-49 years, the second highest users of HM, had the highest casualties and fatalities 
(Table 2.25). This finding mirrors the survey findings revealing how involved this age group 
is in HM use, with attendant health consequences. Hence this is worth signposting as a 
potential target group for future HM related policies and awareness programmes. Similarly, 
more males than females used HM (Table 2.20) and males also accounted for the highest 
casualty figures, although fatalities were higher in females (Table 2.25). People who 
practised African traditional religion used HM the most; they also had the highest fatalities of 
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the group admitted, although the lowest casualties. African traditional religion being the 
epicentre of HM practice (White, 2015), belief in HM is sacrosanct. This is also apparent 
from the survey data, where 100% of African traditional worshipers have used HM in the last 
two years (Table 2.20). As a result, they may likely use more HM and probably use other 
HMs to counteract undesirable effects, as observed in Table 2.18. The efficacy of such 
practice may be responsible for the low casualty rates recorded when it is successful and the 
cumulative damage when it fails may be responsible for the high fatalities recorded when 
they eventually attend hospital (Table 2.25). However, this needs further evaluation by 
proper history taking of HM use in hospital patients. A comparison of the results obtained 
from the survey study on the use of HM and the findings from the hospital record is shown in 
Table 2.25. 
Table 2.25: Table comparing the use of HM with adult casualty and fatality figures 
Socio-demographic factor Use of HM  
(%) 
(n=1139) 
HM related casualty 
(%) 
(n=34) 
HM related fatality 
(%) 
(n=4) 
Age(years) 
18-29 
30-49 
50-69 
70 and above 
 
 
85.1 
86.7 
80.7 
    100.0 
 
11.8 
55.9 
23.5 
8.8 
 
0 
15.8 
12.5 
0 
Gender 
Male 
Female 
 
89.9 
78.6 
 
88.2 
11.6 
 
10.0 
15.0 
Level of Education 
No formal education 
Primary 
Secondary 
Tertiary 
 
 
88.5 
91.4 
84.4 
80.8 
 
0 
41.2 
32.3 
26.5 
 
0 
7.1 
9.1 
22.2 
Religion 
Christianity 
Islam 
African traditional religion 
 
 
85.4 
82.1 
    100.0 
 
79.4 
14.7 
5.9 
 
7.4 
20.0 
50.0 
Occupation 
Student 
Civil servant 
Farmer 
Self Employed 
Others 
 
82.1 
80.4 
    100.0 
86.0 
92.0 
 
5.9 
5.9 
2.9 
79.4 
5.9 
 
0 
100.0 
0 
7.4 
0 
 
The use of HM was highest among farmers in the survey, whereas casualties were highest 
among self-employed people and fatalities were highest among civil servants (Table 2.25). 
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This is not unusual considering that the self-employed constituted the largest percentage of 
the participants in this survey (39.6%), followed by civil servants (38.8%), while farmers were 
the least represented (6%) (Table 2.6). This may, therefore, be a reflection of the population 
distribution and hospital admissions along occupational lines in Ekiti State, which these 
fatality and casualty figures further highlight. The annual income of patients could not be 
obtained from the hospital data, therefore the economic correlation with the casualty and 
fatality figures could not be ascertained. But from Table 2.25, the level of education may be 
helpful, considering that the highest use of HM and casualties were among people with a 
primary level of education. Conversely, fatalities were highest among patients with a tertiary 
level of education. Therefore the impact of the undesirable effects of HM seems to be more 
serious in people with tertiary education, who likely form the bulk of respondents in the high-
income class.  
Obstetric fatalities in the form of stillbirth (SB) related to HM were 26 (3.9%) of the total 668 
stillbirths. Herbal medicine related SBs were further divided according to the Baird-Pattinson 
aetiology (Section 2.11). Stillbirths with a history of HM use in pregnancy were only identified 
within four Baird-Pattinson classifications: spontaneous preterm labour (SPL) (42%), foetal 
abnormality (34%) intrauterine growth restriction (IUGR) (15.4%) and unexplained 
intrapartum foetal death (UIFD) (7.7%) (Table 2.26). The use of HM among pregnant women 
is common in Nigeria (Duru et al., 2016; Adisa, Agbom and Fakeye 2015; Fakeye, Adisa and 
Musa, 2009). However, people respond and react differently to different HM. A study has 
shown intrapartum use of HM in healthy babies (Louik et al., 2010), while other studies have 
reported foetal abnormalities (Chuang et al., 2006; Johnson and Sibeko, 2003; Jurgens, 
2003; Low, 2009). In addition, HM-induced IUGR and foetal abnormalities in experimental 
animals have been reported (Wang et al., 2012; Li et al., 2012).  
Table 2.26: Herbal medicine related obstetric fatalities 
 
HM-associated stillbirth has also been reported in the literature (Choi, Han and Ahn, 2013; 
Neogi et al., 2016), and a 3-year retrospective study in Ghana reported HM to be associated 
with 5.7% of the total stillbirths (Alhassan et al., 2016), which is higher than the finding in this 
study of 3.9% (Table 2.26). Nevertheless, other studies have shown no significant 
Total birth Stillbirth HM-related 
fatality 
HM-related fatality 
(n=26) 
SPL Foetal 
abnormality 
IUGR UIFD 
18089 668 26 (3.9%) 11 (42%) 9 (34%) 4 (15.4)% 2 (7.7%) 
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association between HM use and negative foetal outcome (Singh et al., 2015). The source of 
toxicity in some of the HM could be related to direct toxicity from the herbal medicines, 
misuse, contamination (with heavy metals, pesticide among others), adulteration (e.g with 
known pharmaceutical compounds) or uncontrolled confounding. Unlike the adult and 
paediatric HM- related casualties and fatalities where a diagnosis was made as regards HM 
culpability, this is not the case in an obstetric setting. Other factors could have been 
responsible for the obstetric outcome and most of the hospital records examined in this 
study only pointed to continuous use of HM by the patients, but no other definitive diagnosis 
was made. In addition, use of a control group would be useful in drawing a stronger 
inference. Nonetheless, more work needs to be done to ascertain the safety of HM,  as later 
undertaken in Chapter 4. 
2.14 Conclusion 
This study has shown that a majority of the population have used HM in the last 2 years, 
cutting across economic class and with the highest use among the middle-income class. 
This does not suggest that poverty was a major factor in the use of HM, especially 
considering the income inequality in the population and the lack of universal health 
coverage. The use of HM was commonest among respondents with a primary level of 
education, of African traditional religion, the self-employed and respondents of 70 years of 
age and above. More males used HM than did females. The effectiveness of HM was a 
major and most frequently cited reason for respondents‘ use of it. The personal experience 
of the majority attested to the intended effectiveness of HM. Though the majority of 
respondents knew the difference between certified and uncertified HM, uncertified HM was 
most commonly used. 
 A majority of the study population believed it was not safe to take uncertified HM, although, 
more than half had not experienced any adverse effect associated with its use. Those who 
had suffered adverse effects reported different ways of ameliorating their condition, 
depending on its severity. A retrospective study of HM-related casualties and fatalities 
reinforced some of the survey findings, e.g. male predominance in the use of HM and 
casualty figures. These casualty and fatality figures could appear to be not too alarming and 
could be mitigated. This mitigation is essential in preserving lives and preventing waste of 
hospital resources.  
Paradoxically, participants revert to orthodox medical care, especially when their illness gets 
out of control and/or HM adverse effects become severe. This further highlights the need for 
adequate investment in the health care system as it becomes the last resort in severe cases. 
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This is important, considering the findings of this study on reasons‘ for not using hospitals 
corroborating the health infrastructural / service deficit, which possibly contributed to the use 
of HM. However, the choice is limited to acclaimed effective HM and an orthodox health 
system‘s offering an unsatisfactory service. While affordability was also an important 
consideration for people who used HM in this study, high hospital cost was another reason 
for which they did not patronise the orthodox medical service. It is a choice between 
affordable HM and an expensive orthodox medical service, especially in the absence of 
adequate health insurance coverage. This study has shown that there is a significant 
association between annual income, education, gender, age, religion, occupation and the 
use of HM. There is also an impact of HM use reflected in the number of HM- related 
hospital admissions and deaths. Although there is a cultural history of HM use in the study 
population, socio-economic and socio-demographic factors were determinants of its use in 
light of prevalent income inequality and absence of adequate health provision.  
2.15 Limitations of the study 
The following three limitations to this study have been identified: 
I. There were more incomplete entries in the self-administered questionnaires than on 
the interview-administered method, which reduced the number of eventual 
participants in the study. 
II. Poor record keeping practice in most of the hospitals made it difficult to examine the 
casualty and fatality figures associated with HM use. 
III. Most of the towns were visited during the day, at which time some of the farmer 
residents would usually be at work far away from the residential areas. This led to the 
exclusion of some of this group of people from the likelihood of participation in the 
study. 
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CHAPTER 3:  GC-MS AND ICP-OES METHOD DEVELOPMENT AND VALIDATION FOR 
THE DETECTION OF PHARMACEUTICALS AND HEAVY METALS IN SELECTED 
HERBAL MEDICINE 
3.1 Introduction to method validation 
The aim of validating an analytical method is to present its suitability for a planned purpose 
(Ellison, Barwick and Farrant, 2009). After the development and validation of an analytical 
method, it can be deployed in analysing target compounds. Accordingly the adopted method 
for Gas Chromatography-Mass Spectrometry (GC-MS) and Inductively Coupled Plasma-
Optical Emission Spectrometry (ICP-OES) in this research was validated to make it suitable 
for the detection and quantification of target analytes (selected pharmaceutical compounds 
and heavy metal) in selected HM samples.  
Guidelines and publication for method development and validation such as the International 
Conference on Harmonisation (ICH) guideline, Scientific Working Group for Forensic 
Toxicology (SWGTOX) standard practices for method development, International 
Organization for Standardisation (ISO) and other guidance documents are widely available 
(ISO, 1990; ICH, 2005 and SWGTOX, 2013). The ICH guideline was used in this research 
for method validation, alongside the use of the ISO (1990) for the statistical assessment of 
the linear calibration function (ICH, 2005; ISO, 1990).  
The validation studies conducted include specificity, accuracy, precision, linearity, linear 
range, limit of detection and limit of quantification. Although not all of the validation 
parameters are applicable for all types of test, these are typical validation parameters and 
are needed to determine the suitability of the method for the intended analytical use in GC-
MS and ICP-OES. Autosampler stability was, however, added to the parameters required for 
the validation of GC-MS method. 
3.1.1 Selectivity 
 Selectivity is defined as the capacity for unequivocal assessment of analyte in the presence 
of matrix which is likely present; such as impurities and degradation products (ICH, 2005). 
3.1.2 Linearity and linear range 
Linearity is defined by ICH (2005) as the ability of a method to produce results within a 
range, which correspond to the target analyte concentration in the sample. Linearity is 
examined over an extensive range of concentration from low to high. Determining the linear 
range, aside from the aim outlined by the definition, also helps in the assessment of the 
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sensitivity of the analytical instrument and method (Ellison, Barwick and Farrant, 2009). 
There are both instrument and method linearity. Instrumental linearity is defined as the 
capacity of the detector to produce effects that are directly, or by means of set mathematical 
variation, proportional to the standard concentration. Method linearity, however, starts from 
extraction of samples to instrumental analysis and is assessed at the same concentration 
range as the analyte concentration (Ibid). Instrument linearity was examined in this study as 
shown in Sections 3.7.5 and 3.8.2. 
3.1.3 Limits of Detection (LOD) and Limits of Quantification (LOQ) 
The LOD and LOQ are calculated at the lower limit of the linear range. LOD is described as 
the lowest concentration at which an analysed compound can be detected but not reliably 
quantified. Limit of quantification is the lowest concentration at which an analysed compound 
can be quantified within permissible precision and accuracy (Peters, Drummer and Mussholf, 
2007). LOD can also be defined as the lowest concentration of analyte that can be validly 
differentiated from the blank (Thompson, Ellison and Wood, 2002). The LOD and LOQ were 
determined using the ICH method, based on the slope and the standard deviation of the 
response (ICH, 2005). 
Limit of detection = 3.3 σ/ S       (Equation 3.1) 
Limit of quantitation = 10 σ/S     (Equation 3.2) 
Where σ = the standard deviation of y (intercepts of the linear regression line) 
S = the slope of the calibration curve 
The standard deviation of the y-intercepts is obtained from the calibration curve of the 
triplicate run of analyte plotted in Microsoft Excel (see Figure 3.12), while the slope is 
obtained from the average linear regression equation. LOD and LOQ are statistically 
calculated using this method which accounts for both instrumental and sample preparation 
uncertainties. When the LOD is calculated from the standard deviation (SD) of replicates of 
several analyses of the same solution the uncertainty also accounts for the error obtained 
from the autosampler (Thompson, Ellison and Wood, 2002). 
3.1.4 Precision and accuracy 
According to ICH (2005) precision is defined as the degree of concurrence between 
repeated multiple sampling of a homogenous sample. This is often also reported as standard 
deviation or Percentage Relative Standard Deviation (%RSD). In this study, precision is 
examined for both the standards and sample. This method ascertains the total precision of 
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the method, adding the contributions of uncertainties from instrumental analysis and sample 
preparation. Precision is often measured as repeatability and reproducibility (Peters, 
Drummer and Musshoff, 2007). Repeatability is the precision of the analytical technique by 
replicate assessment within a limited period. Reproducibility refers to the precision between 
laboratories. Accuracy is the nearness of concurrence between the real and experimental 
values (Miller and Miller, 2010), often reported as the % recovery from the true 
concentration. 
3.1.5 Autosampler stability 
Stability assesses possible reduction in the concentration of analyte (due to decomposition) 
in both the sample and standard over a given time in storage ambience. This is assessed 
through analysis of a mixed standard at specified time intervals, using the previously 
validated analytical method (SWGTOX, 2013). The stability of the mixed pharmaceutical 
compounds on the autosampler for the entire duration of a typical run is examined in Section 
3.7.4 
3.1.6 Matrix effect 
The phenomenon of matrix effect is the combined effect of all components, besides the 
analyte which co-elute with the compounds of interest. This was examined for the GC-MS 
analysis because these co-eluents interfere with the ionisation process in the mass 
spectrometer causing suppression or enhancement of the ionisation process that negatively 
affects quantification of the desired compounds (Kebarle and Tang, 1993). The assessment 
and management of matrix effects are essential when a method is validated because they 
can lead to inaccurate measurement of the selected analyte (Chambers et al., 2007; Chiu et 
al., 2010). For GC-MS matrix effect examination post-extraction spiked matrix comparison 
was used in this study (Matuszewski, Constanzer and Chavez-Eng, 2003) as shown in 
Section 3.6.4.5. 
In ICP-OES analysis matrix effect may deter its ability in qualitative identification and 
quantitative measurement of target compounds by its effect on intensity and resolution of 
observed signals. The ionic-to-atomic line intensity ratio may be examined in order to detect 
plasma-related matrix, but then proper digestion of the complex sample matrix significantly 
reduces matrix effect (Todolí et al., 2002). Hence this parameter was tested in this research 
considering the complexity of the plant-based matrix in the herbal medicine samples and its 
potential effect on quantification of compounds of interest.  
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3.2 Introduction to target pharmaceutical compounds 
As discussed in section 1.6.2, the increase in the adulteration of HM with undeclared 
pharmaceutical compounds has been reported extensively (Patel et al., 2012; Zhang et al., 
2012). Bearing in mind the economic worth of HM global trade, as discussed in Section1.5, 
adulteration with pharmaceutical compounds to provide quicker effects for monetary gain 
have been reported (Wheatley and Spink, 2013). Hence this research seeks to explore 
possible adulteration of HM in Ekiti State as no publication exists on the subject. 
The analytes of interest in this study include 9 commonly abused pharmaceutical 
compounds and one central nervous system (CNS) stimulant. The drugs of interest are an 
analgesic (acetaminophen), non-steroidal anti-inflammatory drugs (ibuprofen, diclofenac), 
opiates (codeine, tramadol), a steroid (dexamethasone), a CNS stimulant (caffeine), an 
antihistamine (chlorpheniramine), an antidepressant (fluoxetine) and a benzodiazepine 
(diazepam). These target compounds are substances that have been reported in 
publications to be present in some HM (Vaclavik, Krynitsky and Rader, 2014b) and are also 
known to be medications commonly abused in Ekiti State (Akindutire and Adegboyega, 
2012; Atoyebi and Atoyebi, 2013). Further rationale for the choice of target pharmaceutical 
compounds has been previously discussed in Section 1.6.2. The chemical characteristics of 
the target compounds are summarised in Table 3.1. 
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                                                    Table 3.1: Properties of the pharmaceuticals of interest (U.S. Pharmacopeia, 2012) 
Analyte name 
and structure 
Class of 
compound 
Molecular 
weight(g/mol) 
pKa Acidic/ 
Basic 
Analyte name and 
structure 
Class of 
compound 
Molecular 
weight(g/mol) 
pKa Acidic/ 
Basic 
Acetaminophen  
 
Analgesic 151.163 9.5 
 
Acid Dexamethasone 
 
Steroid 392.46 12.14 Neutral 
Caffeine 
  
CNS 
Stimulant 
194.191 14.0 
 
Basic Diazepam              
 
Anxiolytic 284.74 3.4  Basic 
Chlorpheniramine   
 
Anti –
histamine 
274.789 9.47 
 
Basic Diclofenac  
 
NSAID 296.149 4.15   Acidic 
Codeine  
 
Opiate 
analgesic 
299.37 10.60 
 
Basic Fluoxetine  
 
Antidepressant
/weight loss 
309.32   9.8  Basic 
Ibuprofen  
 
NSAID 206.281  4.91   Acidic Tramadol  
  
Opioid 
analgesic 
263.38 9.23 
 
 
Basic 
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3.3 Introduction to target heavy metals 
Agricultural sector practice (such as the use of pesticides and herbicides) and industrial 
sectors (such as inappropriate waste disposal) have contributed to an anthropogenic 
introduction of heavy metals into virtually all forms of the ecosystem (Lokhande, Singare and 
Pimple, 2011). These heavy metals find their way into plants, herbal medicine (HM), 
cosmetics and other products through the contamination of soil and the aquatic environment 
(Leung, Cai and Wong, 2006). Although some heavy metals are naturally present in the 
environment and required for optimal body functioning at trace levels, they may become very 
toxic at higher concentrations (Lane and Morel, 2000; Plum, Rink and Haase, 2010). Due to 
the potential toxicity of heavy metals to humans, it has become necessary to determine their 
concentration in products consumed by humans, one of which is herbal medicine.  
The heavy metals in this study were selected on the basis of the European Medicines 
Agency‘s (EMA) Committee for Medicinal Products for Human use (CHMP) metals of safety 
concerns (EMA, 2008), the WHO publication of toxic metals found in herbal medicines 
(WHO, 2007) and from previous publications on metals detected in Nigerian herbal medicine 
(Ajasa et al., 2004 and Orisakwe et al., 2006). The British and European Pharmacopoeias 
(MHRA, 2013; EDQM, 2013) state the minimum metals that should be analysed in all herbal 
remedies to include cadmium, mercury and lead.  
Hence the following metals were selected to be analysed in HM in this study; arsenic (As), 
cadmium (Cd), chromium (Cr), copper (Cu), lead (Pb), manganese (Mn), mercury (Hg), 
nickel (Ni), selenium (Se) and zinc (Zn). Scandium, a rare earth isotope, was used as an 
internal standard as recommended by EPA (EPA, 2013). Scandium has excellent recovery 
on ICP and no spectral interference with the selected metals in this study as reported in a 
previous publication (Chiweshe et al., 2016), therefore it meets the criteria for an internal 
standard. 
3.4 Selection of GC-MS method 
The identification and quantification of pharmaceutical compounds from HM samples were 
carried out using GC-MS. This is a well-used technique in HM analysis for pharmaceutical 
compounds and it possesses various advantages, as discussed in Section 1.7. The volatility 
and thermal stability of target analytes are the major determining factors for GC analysis 
(Rocha, Amaral and Oliveira, 2016), which is a major consideration in this study. In addition, 
the product analysis of GC-MS chemical reactions (such as products of hydrolysis) is found 
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to be useful and further helps to elucidate and identify structures (Patel et al., 2014; 
Vaclavik, Krynitsky and Rader, 2014a and 2014b).  
3.4.1 Selection of internal standard  
 An internal standard (IS) is essential for GC-MS analysis. It is a reference compound used 
to establish the consistency of the standard instrumental efficiency of individual sample 
analysis and to confirm consistency and reproducibility of samples (Carlin and Dean, 2013). 
A good internal standard must possess certain qualities such as an ability to elute near 
peaks of the target compounds without overlapping them. In addition, a good IS should be 
stable and have similar chemical properties to those of the target compounds without any 
interference or reaction with their analysis (McNair and Miller, 2009). These characteristics 
were considered when deciding on a suitable internal standard for GC-MS analysis in this 
study (fluoxetine–d5). 
3.4.2 Selection of extraction technique for herbal medicine analysis 
The isolation of pharmaceutical compounds from HM samples required a general extraction 
protocol that enabled the simultaneous detection of compounds with varying chemical 
characteristics (Table 3.1) and solubility. 
The acidity or basicity of the pharmaceutical compound to be extracted is often considered, 
as shown in Table 3.1. Chloroform and ammonium hydroxide have been used in a previous 
study for the simultaneous extraction of basic pharmaceutical compounds from HM (Au et 
al., 2000). Conversely, a single extraction method with methanol and/or ethanol has been 
used for the extraction of both acidic and basic pharmaceutical compounds similar to those 
of this study in HM samples (Liu, Woo and Koh, 2001; Lau et al., 2003; Kim et al., 2014). 
However, methanol was used in this study following results from a prior solubility study of 
target pharmaceutical compounds (Section 3.7). 
3.5 Selection of ICP-OES method 
The identification and quantification of heavy metals from HM samples were carried out 
using ICP-OES due to its availability and suitability to the research, as discussed in Section 
1.7. 
98 
3.5.1 Selection of digestion method for herbal medicine analysis 
Dry ashing and open vessel digestion methods were used in this study due to their 
availability and suitability to the research. The sample preparation methods have been 
discussed previously in Section 1.7. 
3.6 Materials and method  
All the porcelain crucible, tongs, spatula and glassware was cleaned by soaking in aqua 
regia overnight for 12 hours and rinsed with ultrapure water before use for ICP-OES 
analysis. 
3.6.1 Chemicals and reagents 
 Technical grade acetaminophen, caffeine, chlorpheniramine maleate, codeine, 
dexamethasone, diazepam, diclofenac sodium, ibuprofen sodium, tramadol hydrochloride 
(all powder), fluoxetine hydrochloride and fluoxetine- d5 (liquid), and HPLC grade methanol 
were purchased from Sigma-Aldrich, Haverhill, UK. This is in addition to a 65% v/v (high-
purity trace metal content) nitric acid and 37% v/v hydrochloric acid (trace metal grade) 
which were used for sample digestion and trace metals recovery. Ashing agent 99.99% 
magnesium nitrate hexahydrate (trace metals grade) was also purchased from Sigma-
Aldrich, Haverhill, UK. Multi-elemental stock solutions of 100 ppm ICP standard As, Cd, Cr, 
Cu, Hg, Pb, Se, Mn, Ni and Zn were obtained from SPEXertificate® (Stanmore, Middlesex, 
United Kingdom). A certified reference material (CRM) IAEA-359 and 1000 ppm of scandium 
purchased from Sigma Aldrich UK was used for recovery studies and internal standard 
respectively. Ultrapure water (resistivity 18.0 MΩ) obtained by an Elga purelab option s7 
system (Elga lab water, Wycombe United Kingdom) was used for all dilutions and infusions. 
Preparation of calibration standards was performed by dilution of reference multi-elemental 
standard solution in deionised water.  
3.6.2 GC-MS method  
The solubility of pure pharmaceutical standards at 1 mg/ml (0.8 mg/ml highest concentration 
used in this research) in various organic solvents (chloroform, ethyl acetate, acetone and 
methanol) and ammonium hydroxide was evaluated prior to further analysis. 
3.6.2.1 Calibration standard preparation  
Individual standards were analysed, followed by a mixed standard in the presence of the 
internal standard (fluoxetine-d5) to obtain each compound‘s retention time and mass 
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spectrum for possible identification. To detect and quantify possible pharmaceuticals in 
samples of herbal medicine in this research a 14-point calibration was developed for the 
target pharmaceutical compounds, except for acetaminophen and dexamethasone, which 
had 10- point calibration. Standards ranging from 0.002 to 0.8 mg/ml (0.01 to 0.8 mg/ml for 
dexamethasone and acetaminophen) were prepared in methanol following solubility results 
in Section 3.7. The 10-point calibration for acetaminophen and dexamethasone was due to 
non-detection of peaks below 0.01 mg/ml, as compared with others at 0.002 mg/ml from 
preliminary studies. The calibration standards were made by addition of a known volume of 
prepared standard at 2 mg/ml starting concentration in methanol, an internal standard 
solution (fluoxetine–d5) at 0.5 mg/ml starting concentration and made up to 1 ml for the final 
concentrations and subsequent analysis. The concentration of internal standard used was 
0.25 mg/ml at each sample injection, which is within the sample concentration range.  
3.6.2.2 Sample preparation  
Extraction was performed by weighing out 200 mg of HM samples, thoroughly homogenised 
and extracted using 1 ml of methanol with internal standard (0.25 mg/ml fluoxetine-d5). The 
mixture was vortexed for 1 minute and ultra-sonicated for 30 minutes. The mixture was then 
centrifuged at 4000 rpm for 5 minutes and the resultant supernatant was collected and 
filtered using 0.2 µm membrane filters. The solution was made up to 2 ml with addition of 
methanol and transferred into GC-MS glass vials for analysis. This step was repeated for all 
HM samples studied. All analysis was conducted in triplicate unless otherwise specified. 
3.6.2.3 GC-MS parameters 
A PerkinElmer Clarus 500 GC-MS was used for instrumental analysis. An Equity-5 column 
was used, which is made up of a cross-linked poly 5% diphenyl/95% dimethylsiloxane 
stationary phase, with 30 m length by 0.25 mm internal diameter and a 0.25 μm film 
thickness.  
The GC-MS parameters used to analyse the pharmaceutical standard and HM samples are 
shown in Table 3.2. This instrumental method was adapted from two previous publications 
on the analytical screening of Chinese proprietary medicine and herbal weight loss 
supplements for undeclared therapeutic substances and pharmaceuticals (Liu, woo and Koo, 
2001 and Khazan et al., 2014). The method was subsequently validated according to the 
ICH guidelines.  
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Table 3.2: Adapted GC-MS method 
Parameters Method used in this study 
Instrument PerkinElmer Clarus 500 GC-MS 
Capillary Column Equity-5ms ; 30 m Length,  
0.25 mm diameter,0.25 μm film 
Initial oven temperature 80°C 
Initial temperature hold time 1 min 
Ramp rate 15°C/ min 
Final oven temperature 300°C 
Final temperature hold time 5 mins 
Total running time 26 mins 
Injection port temperature 250°C 
Transfer line temperature 300°C 
Injection volume 1 μL 
Split/Splitless mode Splitless 
Carrier gas Helium  
Carrier gas flow rate 1 mL/min 
 
Mass spectrophotometer 
Ionization mode Electron Impact (EI) 
Ionization energy 70 eV 
Solvent delay 2 mins 
Scan range 40 – 350 amu 
 
The samples were run in scan mode and also in selected ion monitoring (SIM Mode) using 
three ions shown in Table 3.4. Data were obtained using the compatible software 
TurboMassTM (PerkinElmer, 2006), and analysed using Microsoft excel package 2013. 
3.6.3 ICP-OES method 
 3.6.3.1 Calibration standard preparation  
The multi-element standard (As, Cd, Cr, Cu, Hg, Pb, Se, Mn, Ni and Zn) was prepared in 5% 
nitric acid at 100 ppm stock solution by the manufacturer.  A working solution of 10 ppm was 
made and subsequent concentrations were made in deionised water. The internal standard 
was prepared in 5% nitric acid at 1000 ppm stock solution by the manufacturer. A working 
solution of 10 ppm was made in deionised water and a final concentration of 0.1 ppm was 
used throughout this study as the internal standard. To detect and quantify the chosen heavy 
metals in herbal medicine samples in this study a 12-point calibration was prepared for the 
target heavy metals ranging between 0.001and 5 ppm. 
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3.6.3.2 Sample preparation 
Herbal medicine samples were thoroughly homogenised and subsequently analysed using 
dry ashing and wet digestion method, as described below.  
3.6.3.2.1 Dry ashing  
The modified method of Pytlakowska et al (2012) was adopted. Firstly a 1 mg/ml solution of 
Magnesium nitrate hexahydrate (Mg(NO3)2) ashing agent was prepared in deionised water, 
boiled and filtered (Narwal, Dhankhar and Sangwan, 2012). Afterwards, 1 g of the respective 
HM samples were weighed out into a porcelain crucible and 1.0 ml of Mg(NO3)2 was added. 
The mixture was swirled gently and evaporated on the hot plate at about 1800 C. The 
crucible containing the sample was placed in the cold muffle furnace. The furnace 
temperature was gradually increased to 350 0C in an hour and then maintained over another 
9 hours. The resulting ash was then dissolved in a 10 ml hot 20% HCl solution v/v and 
filtered through a Whatman filter paper. The solution was then brought to volume (25 ml) 
with deionised water. Blanks were prepared in the same way as the samples. Three 
replicates were prepared and analysed for each sample. The blank digests were similarly 
processed. 
3.6.3.2.2 Open vessel wet digestion 
According to a modified method of David (2000) and Orisakwe et al (2006), 1 g of each 
sample was carefully weighed and 15.0 ml of aqua-regia (1:3, HNO3: HCl) was added to the 
sample for digestion in a beaker. The beaker was then heated on a hot plate at 150oC in the 
fume cupboard for 2 hours. Afterwards the beaker was cooled then filtration and rinsing 
followed. The filtrate was then made up to 25 ml with deionised water for analysis. Samples 
were analysed in triplicate and blanks were prepared in the same way and analysed.  
3.6.3.3 ICP-OES parameters 
 ICP-OES instrumental parameters are shown in Table 3.3, using an axial viewing Vista-
MPX™ (Varian, UK). The analytical signal was measured by triplicate analysis and a two-
point background correction. To prevent any possible instrumental memory effect wash time 
with deionised water was set at 120 seconds to ensure complete washout between samples 
analysis. High-purity argon (99.995%) (Supplied by BOC Cambridge, UK) was used as the 
carrier gas and to maintain the plasma. 
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Table 3.3: ICP-OES instrument parameters 
 
3.6.4 Method validation for GC-MS and ICP-OES  
3.6.4.1 Selectivity  
For GC-MS analysis selectivity of the method was assessed by monitoring the blanks for any 
interference and interpreting the mass spectra of the analysed standards in scan mode to 
distinguish between the co-eluting compounds, and then selected ion monitoring (SIM) mode 
to ensure a selective and sensitive method. During analysis methanol blanks were analysed 
before, during and at the end of each sample. 
Assessment of selectivity for ICP-OES analysis was made in combination with an accuracy 
study (Section 3.8.4) to check for possible spectral interference using a multi-elemental 
mixed standard at a concentration of 0.2 ppm and matrix interference using a spiked CRM 
standard. To choose the optimal analytical wavelengths three wavelengths (nm) were 
measured for each target heavy metal. The three wavelengths were selected by visual 
examination based on non-overlapping peaks and non-spectral interference. The 
wavelengths that met these criteria and had the highest intensity were selected. The validity 
of the wavelength selection for non-spectral interference was further examined with the 
RSD% of the recovery (20% accepted criterion) (Peter, Drummer and Musshoff, 2007) at the 
ICP-OES instrument 
Instrument Name Vista-MPX™ 
Company 
Software              
Varian Analytical Instrument 
ICP-Expert  
Optical system Echelle  Polychromator 
Wavelength range 175-785 nm 
RF generator 40 MHz 
Detector Megapixel  charged-coupled device   
detector 
Plasma view Axial 
Nebuliser type Concentric 
Sample uptake method  Peristaltic pump 
Peristaltic pump tube and diameter White/white 1.02 mm 
Optical system resolving power Normal 
Plasma torch  Quartz, fixed, 3.0 mm injector tube 
Parameters Values 
Rf power 1200 watts 
Nebuliser gas flow rate 1 L/min 
Auxiliary gas flow rate 1.5 L/min 
Sample introduction rate 15 rpm 
103 
3 wavelengths. One wavelength was then selected for each target heavy meal for a further 
validation study by the RSD% values and visual examination of spectra. 
3.6.4.2 GC-MS autosampler stability and repeatability study 
Repeatability, precision and autosampler stability of the studied analyte were tested at three 
concentrations (low, middle and high concentrations) 0.008, 0.08 and 0.8 mg/ml, with the 
exception of acetaminophen and dexamethasone where the lowest concentration was 0.01 
mg/ml. Each concentration was investigated in triplicate and repeated 11 times. The ratio of 
the analyte response to the internal standard response known as the Peak Area Ratio (PAR) 
and its standard deviation (n=33) were documented over a 50 hours period. The various 
RSDs were calculated and examined within the acceptable range to assess the stability of 
the analytes. A similar method was used to assess the auto-sampler stability of the internal 
standard. 
3.6.4.3 Linearity and linear range 
The linearity of the GC-MS method was determined by analysis of 14 concentrations of the 
mixed drug standard and 10 concentrations for dexamethasone and acetaminophen in 
triplicate injections, as stated in Section 3.6.2.1. 
The linearity of the ICP-OES method was evaluated by preparing multi-element standard 
solutions (as described in Section 3.6.3.1) at 12 concentrations in the presence of a 0.1 ppm 
internal standard (scandium). A linear plot of the instrument response (ratio of intensity of 
analyte and that of the internal standard for ICP-OES and ratio of peak area of analyte and 
that of internal standard for GC-MS) against the concentration was obtained. A linear 
regression line of best fit was obtained from least squares and the linear regression equation 
was calculated (Ellison, Barwick and Farrant, 2009; SWGTOX, 2013). 
SPSS was used to conduct a Shapiro-Wilk statistical test of normality of the residual and 
runs test for randomness, with a given p-value. For Shapiro-Wilk the null hypothesis is 
retained when the p-value is greater than the chosen 0.05 significant value, meaning a 
normally distributed residual. This is similar to runs test where a p-value greater than the 
chosen 0.05 significant level also retains the null hypothesis; indicating randomly distributed 
data (Peters, Drummer and Musshoff, 2007). 
3.6.4.4 Limit of detection (LOD) and limit of quantification (LOQ) 
As described in Section 3.1.3, using the calibration results (Sections 3.6.2.1 and 3.6.3.1), the 
standard deviation of the y-intercepts was calculated from the calibration graph of the 3 
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replicates data using Microsoft Excel, while the slope was also obtained from the calibration 
graph. 
 3.6.4.5 Matrix effect 
Two sets of samples were prepared for determination of the matrix effect in GC-MS at 
concentrations used for calibration (see Section 3.6.3.1). The first samples were prepared 
using a neat mixed standard in methanol solution and the second set of samples was 
prepared by spiking an extracted HM sample (HM Sample 9 was used) with mixed standard 
at the same concentrations as the neat mixed standard solution in methanol. All samples 
were subsequently analysed using the GC-MS method (as shown in Table 3.2). The matrix 
effects which are expressed as matrix factor (MF) were calculated by comparison of the 
target analytes‘ mean peak area ratio (MPAR) in post-extraction spiked samples with the 
mean peak area ratio (MPAR) of the target analyte in the standard solution (Silvestro, 
Tarcomnicu and Savu, 2013) as seen in (Equation 3.3).  
Equation 3.3: 
Matrix Factor (MF) = MPAR in presence of matrix ions/MPAR in the neat solution           
The result obtained is interpreted as: 
MF=1 shows no matrix effect 
MF<1 shows ion suppression 
MF>1 shows ion enhancement  
The matrix effect in ICP-OES is carried out along with recovery and accuracy studies using 
CRM. 
3.6.4.6 Recovery and accuracy  
Recovery studies were used to assess selectivity, accuracy, precision, repeatability and 
matrix effect. A pretested HM (HM6) sample which had none of the analyste was spiked with 
target compounds (Table 3.1) at three concentrations 0.008 mg/ml (0.01 mg/ml for 
acetaminophen and dexamethasone), 0.08 mg/ml and 0.8 mg/ml as for the stability study 
(see Section 3.6.4.2). The spiking is performed with a mixed standard, where the ratio of the 
standards‘ concentration relates to their unspiked sample‘s concentrations, as shown in 
Equation 3.4. Samples were then prepared using the method described in Section 3.6.2.2 
and subsequently analysed. Analyses were performed within a 12-hour period and repeated 
three times for the intra-day repeatability study in GC-MS analysis. Spiked and unspiked 
levels are established with replicates (n = 9) for recovery study. The standard calibration was 
used to calculate the amount recovered from the initial concentration added. This was done 
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using the formula as expressed in Equation 3.4 (Matuszewski, Constanzer and Chavez-Eng, 
2003). 
Equation 3.4: 
Recovery = C0 – (C1/C2) X 100                                    
C0= Concentration of target compound in unspiked sample 
C1= Concentration of recovered target compound from spiked sample 
C2= concentration of target compound added to spiked sample 
 
The recovery study for ICP-OES was carried out using a CRM by spiking it prior to sample 
preparation with the multi-elemental standard at low, intermediate and high concentration 
(0.002, 0.2 and 2 ppm respectively). The spiked CRM was then prepared in the same way 
as the other samples, as described in Section 3.6.3.2. The concentration of metals in the 
CRM is shown in the certificate (Appendix XVIII). Results were calculated using Equation 3.4 
and reported on a dry weight basis as mean ± standard deviation (SD) (see Table 3.19). 
For both GC-MS and ICP-OES accuracy was assessed by percentage recovery and 
precision by the relative standard deviation (%RSD). According to the United States 
Pharmacopeia Convention (2012), a precision level of less than 20% is acceptable, while 70-
150% recovery is acceptable for accuracy studies.  
3.7 Result and discussion of GC-MS method validation 
Prior solubility evaluation showed pharmaceutical standards were completely soluble in 
methanol at 1 mg/ml. Thus the extraction solvent used in this study was methanol. Several 
studies have also used methanol for the extraction of pharmaceutical compounds from 
herbal medicine (Pang et al., 2009; Bogusz et al., 2006; Balayssac et al., 2009).   
3.7.1 Identification of compound  
The authentication of the identity of a sample is examined in several ways through the use of 
a chromatogram and mass spectrum. A chromatogram is collected from a standard such as 
the chromatogram shown in Figure 3.1 and the peak retention time is compared with sample 
retention time or relative retention time. For mass spectrometry the fragmentation pattern 
and the relative abundance of selected ions are specific to individual molecules; hence it 
provides a valid identity for the compound. For unknown samples, library databases exist, 
such as NIST (NIST, 2006), which can be used for tentative identification. These databases 
compare mass spectra of known samples with the unknown sample to provide an initial 
identification. Confirmation can then be obtained using the presumed known standard. 
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,  
Figure 3.1: Chromatogram of ibuprofen (0.5 mg/ml) and internal standard  
fluoxetine-d5 (0.25 mg/ml) 
 
The chromatogram above (Figure 3.1) indicates two peaks; peak A which is of a known 
standard (ibuprofen) was documented at 10.26 minutes while peak B at 13.87 minutes was 
the internal standard fluoxetine-d5. 
 
Figure 3.2: Chromatogram of mixed standard (0.5 mg/ml) (1) ibuprofen, (2) acetaminophen, 
(3) caffeine, (4) fluoxetine+fluoxetine-d5, (5) tramadol, (6) chlorpheniramine, (7) diclofenac, 
(8) codeine, (9) diazepam, and (10) dexamethasone. 
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Figure 3.2 shows an example of a chromatogram where 10 analyte and an internal standard 
were detected simultaneously for a mixed drug standard. Standards were initially analysed 
individually to obtain retention time data with the internal standard, before the mixed 
standard analysis. Two sets of information on an analysed sample can be obtained from the 
chromatogram. The first is the retention time (RT), which is the first time the peaks were 
detected. The RT for compounds is obtained by running known standards of the compounds 
prior to attempts at identifying any unknown samples. 
Retention times of all the compounds were recorded, as shown in Table 3.4, alongside the 
relative retention time (RRT). RRT is an expression of an analyte retention time relative to 
the internal standard‘s retention time and is considered a reliable measure for compound 
identification (EPA, 2017). 
Calculation of the standard deviation of the retention time shows there is a little deviation 
between the RT ranging from ±0.026 to 0.005 minutes across all target compounds. The 
relative retention time (RRT) of a sample is expected to be within ±0.06 of the RRT of the 
standard for valid identification (EPA, 2017). 
Table 3.4: Retention times, relative retention times and major ions of target compounds 
Analyte 
 
RTa   (mins) RRTb Major ions m/z and  % abundance 
  Q        C1      C2 
Acetaminophen   11.39 ± 0.026* 0.82 109                 151      30% 43       24% 
Caffeine  13.24 ± 0.007 0.96 194                  109      74% 67       45% 
Chlorpheniramine 15.15 ± 0.006 1.09 203                  58       64% 274     10% 
Codeine   18.81 ± 0.005 1.36 299                  162      55% 115     32% 
Dexamethasone 22.82 ± 0.006* 1.65 122                  121      40% 392     5% 
Diazepam   19.24 ± 0.005 1.39 256                 283      95% 284     72% 
Diclofenac  16.47 ± 0.006 1.19 214                  242      46% 296     15% 
Fluoxetine  13.64 ± 0.005 0.98 44                    104      53% 309     10% 
Ibuprofen 10.24 ± 0.005 0.74 161                  91       75% 206     47% 
Tramadol   14.65 ± 0.005 1.06 58                    263      38% 59       36% 
Fluoxetine-d5 13.87 ± 0.007 - 43                    109      35% 314     10% 
a 
Retention Time (mean RT ± SD) (n=42);  * (n=30); 
 b
 Relative retention time; Q = quantifying ion (100%), C1 and  
C2 = confirmation ions 
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Figure 3.3: Exemplar mass spectrum of ibuprofen standard 
The spectrum above (Figure 3.3) shows the obtained fragment ions for the ibuprofen 
standard in the mixed drug standard. The quantifying ion for ibuprofen was m/z 161 at 100% 
relative intensity, while the other ions recorded were m/z 91 (confirmation ion) at 74.69% 
relative intensity and second confirmation ion m/z 206 at 46.72% relative intensity (Table 
3.4). In addition, compounds can be quantified by employing the mass spectrum; using the 
abundance ratio/peak area of the base ion of unknown sample to the internal standard 
against various standard concentrations (Fiehn, 2016). 
3.7.2 Selectivity 
During analysis of methanol blanks before, during and at the end of each analyte run no 
interference at the retention times of the analysed compounds was observed. Figure 3.4 
shows a mid-run methanol blank. 
 
Figure 3.4: Mid-run methanol blank 
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Acetaminophen, caffeine, chlorpheniramine, codeine, dexamethasone, diazepam, 
diclofenac, ibuprofen, tramadol and fluoxetine-d5 were all resolved in scan mode (see Figure 
3.2) while fluoxetine and fluoxetine-d5 exhibited co-elution at 13.70 ± 0.14 minutes, which is 
expected because the latter is the isotopically labelled form of fluoxetine culminating in 
structures that are chemically alike, with a 5 atomic mass units difference, thus matching 
retention times on the chromatogram. With different molecular and confirmation ions, 
extracted ion chromatogram (EIC) was employed for data analysis (see Figure 3.5) to 
distinguish the two compounds. 
                            
 
Figure 3.5: EIC of fluoxetine (a) and fluoxetine–d5 (b) (0.25 mg/ml) 
Scanning for target ions only allows SIM to differentiate between co-eluting compounds, 
which makes it more selective. By implementing the selected ions m/z 44, 104 and 309 for 
fluoxetine and m/z 43, 109 and 314 for fluoxetine-d5 the compounds were separately 
identified. Hence, as a result of the selectivity of the analytical method in SIM and scan 
mode, method results were obtained from analysis using SIM. 
3.7.3 Internal standard stability 
The stability of the internal standard fluoxetine-d5 (0.25 mg/ml) in a mixed standard over 50-
hour duration was investigated using a simultaneous detection method in selected ion 
monitoring mode (selected ions in Table 3.4). Over the 50 hours the IS (0.25 mg/ml) was 
stable in the autosampler; with fluctuations less than 10% RSD in most hours, as indicated 
by the standard deviation of error bars at respective hour (see Figure 3.6). These deviations 
are within the recommended ±10% RSD for most of the studied time (Peters, Drummer and 
Musshoff, 2007) and those that are outside the recommended RSD (i.e 15, 30 and 40 hours) 
(b) 
(a) 
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are random throughout the runs. In Figure 3.6 the horizontal lines indicate the 15% RSD and 
the mean relative response factor (Rc).  
 
Figure 3.6: 50-hour stability results for internal standard fluoxetine-d5 (mg/ml)  
mean peak area 
 
As shown in Figure 3.6, although responses at 15 and 30 hours seem to fall outside 10% but 
within 15% RSD, these may be a result of fluctuation in instrument reading, as the other nine 
points were within 10% RSD. The mean concentration at each level is expected to be within 
±15% of the nominal concentration (EMA, 2012). Therefore the plot presented above in 
Figure 3.6 shows that the internal standard is stable across 50-hour storage (directly on the 
autosampler), which covers the analytical run used in this research. This result shows its 
suitability and selection, as discussed earlier in Section 3.4.1. 
3.7.4 Autosampler stability of target compounds 
The 50 hours autosampler stability study for all the target compounds can be found in 
Appendices II, III and IV; however, an example is shown in Figure 3.7, which shows a 
graphical representation of the stability study of ibuprofen at 0.008, 0.08 and 0.8 mg/ml. As 
decreasing concentration is analysed, the peak areas and the resulting ratio also decrease, 
resulting in increased errors and larger variance, as seen in the stability study of the 
compounds (Saar et al., 2012). 
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(a) Stability study of ibuprofen at low concentration (0.008 mg/ml) 
 
(b) Stability study of ibuprofen at mid concentration (0.08 mg/ml) 
 
(c) Stability study of ibuprofen at high concentration (0.8 mg/ml) 
 
Figure 3.7: Stability plot of mean PAR (n=3) over 50 hours for ibuprofen at different 
concentrations. Horizontal lines indicate the acceptance criteria of mean ±20% and ±10% 
respectively. 
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All compounds have points within the acceptable 10% RSD at the lowest concentration, with 
the exception of ibuprofen (Figure 3.7), caffeine, codeine, acetaminophen, tramadol and 
dexamethasone which were within ±20% RSD (Appendix II).  An RSD of 20% is accepted, 
especially at the lowest concentration (Peters, Drummer and Musshoff, 2007). The higher 
deviation may be explained considering the LOD for ibuprofen is 0.007 mg/ml (Table 3.8) 
which is close to the minimum concentration (0.008 mg/ml) used in the stability study. The 
lowest concentration is, however, within the linear range (Table 3.8) for all analytes. 
Nonetheless, at the mid-range concentration (0.08 mg/ml) and high concentration (0.8 
mg/ml) all RSD were within ±10% RSD, as shown for example in Figure 3.7 for ibuprofen. 
Overall all compounds are within the recommended RSD at various concentrations 
(Appendix II, III, and IV) and thus stable over the 50-hour period.  
3.7.5 Linearity and linear range  
As shown in Figure 3.8 for ibuprofen, other compounds have also resulted in a linear 
relationship with an increase in concentration resulting in an increase in analytical response 
(Appendix I). As expected it was, however, apparent that some compounds did not follow a 
linear trend over the whole concentration range (0.002 mg/ml to 0.8 mg/ml), as in the 
examples of caffeine, ibuprofen and acetaminophen (refer to Appendix I). There are points 
that will tail off and plateau expectedly at very high and very low concentration with non-
linear instrumental response (Peters, Drummer and Musshoff, 2007). These concentration 
points are considered to be beyond the compound linear range. 
 
Figure 3.8: Linearity plot of ibuprofen; mean peak area ratio against concentration  
0.006 mg/ml to 0.4 mg/ml (n=3) 
y = 3.5382x - 0.0063 
R² = 0.9997 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45
M
e
an
 P
e
ak
 a
re
a 
ra
ti
o
 (
P
A
R
) 
Concentration of ibuprofen in mixed standard (mg/ml)  
113 
Correlation coefficients (R2) were obtained from linear plots (refer to Table 3.5). The 
correlation coefficient ranges from 0.0 to 1.0, measuring the extent of the linear relationship 
between x and y residuals. The larger the R2 value, the closer the data points‘ correlation. 
An R2 value of 1 represents a tentative perfect fit, which needs further assessment, as 
discussed subsequently in this section. Furthermore, an R2 value of 0.99 would be needed 
for a 10% relative uncertainty in the linear range (Ellison, Barwick and Farrant, 2009). 
Compared with the R2 data obtained from the linearity study, all conform to 10% relative 
uncertainties. It is, however, paramount to note in general that R2 cannot be used as an 
evaluation of linearity. It is only used to show good linearity when data are evenly distributed 
and without anomaly (SWGTOX, 2013). 
Table 3.5: Mean calibration equation and R2 values at 0.002 mg/ml to 0.8 mg/ml 
Analyte Regression equation R2 
Acetaminophen*   y = 1.0032x - 0.0088 0.9948 
Caffeine  y = 3.0128x - 0.0234 0.9959 
Chlorpheniramine  y = 6.6113x + 0.0031 0.9976 
Codeine   y = 8.4886x + 0.0254 0.9978 
Dexamethasone* y = 3.7532x - 0.008 0.9993 
Diazepam   y = 3.331x - 0.0168 0.9964 
Diclofenac   y = 2.6065x - 0.0164 0.9960 
Fluoxetine   y = 9.4254x - 0.0263 0.9975 
Ibuprofen  y = 4.3082x - 0.0542 0.9893 
Tramadol   y = 3.6051x - 0.0126 0.9971 
   
                                                                     *Concentration at 0.01 to 0.8 mg/ml 
Evaluation of linearity data was further carried out by a graph of the mean peak area ratio of 
each compound divided by their corresponding concentration against the log of the 
concentrations (Huber, 2007). If acceptable linearity is attained, the ensuing plot is then 
expected to be within ±10% of the mean relative response factor. The mean relative 
response factor (Rc) in this case was the mean peak area ratio of the corresponding 
compound. There is a possibility of predicting the linear range as the method is considered 
linear untill the relative response drops outside the accepted 10% RSD. Figure 3.9 shows 
the plot for ibuprofen where data points outside the linear range were seen at the lowest and 
highest concentrations.  
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Figure 3.9: Peak area ratio of ibuprofen/concentration versus log concentration 
These data points move the regression line, leading to a change in the intercept with an 
ensuing correlation coefficient farther away from the accepted 0.99, as was the case with 
other target compounds, as seen in Appendix V. 
The data points for ibuprofen shown in Figure 3.9 are spread around the mean, while the 
non-linear data points at the higher end of the concentration range are outside expected 
parameters, thus showing a loss of linearity. Upon examination of the log graphs (Appendix 
V), linear graphs were plotted for a predicted linear range. Results that showed outliers and 
―tailing off‖ and ―plateauing‖ responses at the higher and lower concentrations were removed 
until the data points fell within the accepted RSD limits. In the case of ibuprofen, the linear 
range was 0.006 to 0.4 mg/ml. As previously mentioned, log plots should not be used in 
isolation in making a judgment of linearity and linear range. 
To check the predictions the residual can be useful in identifying problems through a poorly 
fitting curve (Ellison, Barwick and Farrant, 2009). For a good data fit the residuals are 
supposed to be scattered randomly around zero. A problem is suspected in the data when 
there is a deviation from this pattern of distribution. As an example, a curved pattern of 
distribution may point to the line of best fit‘s being forced through data points with a non-
linear course (ibid). 
On analysis of the residuals tailing and plateauing were apparent at lower and upper 
concentrations. This caused a non-random distribution of the residual around zero and thus 
pointed to a loss of linearity. As with the log graphs, on removing the non-linear data points, 
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residual plots were obtained. Figure 3.10 shows for ibuprofen the random distribution of 
residuals around zero in a linear range 0.006 to 0.4 mg/ml. 
 
Figure 3.10: Residual plot of ibuprofen 
On similar analysis all compounds and their corresponding residual analysis (Appendix VI), 
concentration ranges were evaluated and the linear range obtained is presented in Table 
3.8. Correlation coefficients and associated standard deviations show a strong linear 
correlation between data.  
Additional residual plots analysis was carried out to assess the normality of the results using 
the Shapiro-Wilk test (S-W test) from IBM SPSS Statistics. This analysis is built on the 
correlation between the data and their normal scores (Peat and Barton, 2005) and gives a 
capacity preferable to that of the Kolmogorov-Smirnov test (K-S test), regardless of Lilliefors 
correction (Steinskog, 2007). The Shapiro-Wilk test has been recommended as the foremost 
alternative for normality testing of data where the sample size is less than 50 (Thode, 2002; 
Elliott and Woodward, 2007). 
The S-W test involves a comparison of predicted analytical response and analytical 
response, PAR, acquired through the residual analysis (linear range as per Table 3.8). The 
residuals are then obtained by calculating the difference between the two analytical 
responses (Miller and Miller, 2007). The statistical test retains a null hypothesis if there is a 
normal distribution of error. An average, together with the standard deviation and a p-value 
are generated. p-values denote the probability of an observed value greater than or equal to 
the critical value i.e. 0.05 if the null hypothesis is true, meaning a normal distribution. There 
are two summations of interpreting these values: if the p-value is lower than the significance 
level of 0.05, the null hypothesis must be rejected, which means a result that is significantly 
different from non-normal distribution; if the p-value is higher than the significance level of 
0.05 the hypothesis is retained, as the results are of normal distribution (Bressolle, Bromet-
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Petit and Audran, 1996). A 95% confidence limit has been used throughout the statistical 
analysis of the linearity study; hence the significance level p ≤ 0.05 was used. 
Normality is depicted by Gaussian distribution or the typical bell-shaped curve. Alongside the 
data produced by the SPSS statistical analysis, graphical presentations of the data analysed 
in the test are displayed on distribution histograms. The histogram is symmetrical around the 
mean, thus showing normal distribution.  
Skewness, a measure of symmetry or its absence, and kurtosis, a measure of the data being 
peaked or flat as compared with a normal distribution (NIST, 2011), were recorded for all 
compounds (see Table 3.6). Caffeine, e.g., has a skewness value of 0.298, which would 
suggest that the data are skewed slightly to the right as it is a positive as opposed to a 
negative value that would indicate data are skewed to the left. It is also very close to 0, 
which indicates symmetry and normal distribution (ibid). In kurtosis, a higher value indicates 
more distinct peaks near the mean, which then decline rapidly resulting in heavy tails. A 
lower and negative value indicates a flat rather than a sharp peak near the mean. Similarly, 
value of 0 indicates normal distribution (ibid). 
Table 3.6: Results of Shapiro-Wilk test; null hypothesis and corresponding p-value 
  Analyte Kurtosis Skewness p-value Accept the  
null hypothesis 
Acetaminophen 1.263 0.093 0.915 Yes 
Caffeine 1.607 0.298 0.058 Yes 
Chlorpheniramine 1.630 0.321 0.071 Yes 
Codeine 0.612 0.191 0.420 Yes 
Dexamethasone 1.451 -0.379 0.097 Yes 
Diazepam 0.215 -0.361 0.231 Yes 
Diclofenac 0.905 -0.263 0.209 Yes 
Fluoxetine 2.447 -0.849 0.141 Yes 
Ibuprofen 3.095 -0.736 0.070 Yes 
Tramadol 3.204  0.855 0.059 Yes 
 
Employing the S-W test for all compounds, the null hypothesis was retained throughout the 
linear range as determined by residual statistics, which indicates a normal distribution of 
error. All p-values were above the required 0.05 confidence limit and ranged from 0.058 to 
0.915.   
After the S-W test, it was important to evaluate the randomness of the errors with the Wald-
Wolfowitz runs test (Wapole et al., 2012). A small positive or negative residual from the line 
of best fit is expected in linearity, which is to occur at random. But then, considering the 
earlier summation of the tailing off and plateauing at low and high concentrations, forcing the 
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line of best fit to pass through set of data points on a curve can lead to series of non-random 
positive and negative residuals, which are technically a series of ―runs‖. Using the same 
principle as of S-W test for Runs test, if the errors are normally distributed, the statistical test 
returns a null hypothesis, a mean, with corresponding standard deviation and a p-value. 
When the p-value is less than the significance level of 0.05, the null hypothesis is rejected, 
indicating a result significantly different from a random distribution. If the p-value is higher 
than the significance level of 0.05, the hypothesis is retained as the results are of random 
distribution (Epshtein, 2004).  
 
Figure 3.11: Runs Test showing Gaussian distribution curve for ibuprofen data based on 
residuals 
The runs test checks the number of runs and uses the measure of how small it is either to 
accept or reject the null hypothesis of random distribution at 95% confidence limit (Epshtein, 
2004). A sample of the graphical representation returned by the software SPSS statistical 
package for ibuprofen is shown in Figure 3.11. If the p-value is less than the 0.05 confidence 
interval, then the number of runs is within one of the two tails. The p-value will increase as 
the number of runs nears the centre of peak, thus indicating normal distribution and mutually 
independent errors. As illustrated in Figure 3.11 with the red line and description across it, 
the number of observed runs was 4, with a p-value of 0.164 (Table 3.7); this means the null 
hypothesis of normal distribution can be retained. 
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Table 3.7: Result of Wald-Wolfowitz runs test; null hypothesis and p-values 
 
 
 
 
 
 
 
  
Therefore the null hypothesis was retained for all compounds with p-values ranging from 
0.056 to 1.000 for peak area ratio values, indicating a random distribution of error(s) 
(Table.3.7). 
Therefore the data obtained were linear, normally disturbed and randomly distributed error; 
hence their suitability for use in this research. 
3.7.6 Limits of detection and quantification 
To calculate the LOD and LOQ of pharmaceutical compounds which were in salt form 
(chlorpheniramine maleate, diclofenac sodium, fluoxetine hydrochloride, ibuprofen sodium 
and tramadol hydrochloride) the calculations below were used. All other analytes were 
already available as the free base form. 
 
              Figure 3.12: Calibration graph for triplicate analysis of tramadol hydrochloride 
y = 3.5896x - 0.0104 
R² = 0.9991 
y = 3.4568x + 0.0007 
R² = 0.9967 
y = 3.7689x - 0.0279 
R² = 0.9956 
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Analyte p-value Accept  the  
null hypothesis 
Acetaminophen   0.094 yes 
Caffeine  0.120 yes 
Chlorpheniramine  1.000 yes 
Codeine   0.056 yes 
Dexamethasone 0.429 yes 
Diazepam   0.239 yes 
Diclofenac   0.132 yes 
Fluoxetine   0.131 yes 
Ibuprofen  0.164 yes 
Tramadol   0.520 yes 
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Calculation 1: According to Equation 3.1, using the standard deviation of the intercept 
(0.0138) and slope (3.6051) for tramadol hydrochloride in Figure 3.12;  
LOD= (3.3 X 0.0138)/ 3.6051 = 0.0126 mg/ml 
Calculation 2:- concentration converted to base form from salt form  
Molecular weight (MW) of Tramadol = 263.4 (Table 3.1) 
 MW of Tramadol HCl. = 299.8  
263.4 / 299.8 = 0.88 
Therefore the free base concentration = LOD concentration x 0.88  
0.0126 x 0.88 = 0.0111 mg/ml 
Hence the LOQ and LOD of compounds in salt form have been adjusted accordingly, as 
presented in Table 3.8. All other LOD and LOQ were calculated in similar manner to 
tramadol hydrochloride.as exemplified in Figure 3.12 and presented in Table 3.8. 
The LODs ranged from 0.003 mg/ml for chlorpheniramine to 0.012 mg/ml for codeine, the 
LOQs from 0.008 mg/ml for chlorpheniramine to 0.036 mg/ml for codeine. By contrast, the 
LODs in this research are lower than those reported in the literature for ibuprofen, 
acetaminophen, caffeine and dexamethasone. As shown in Table 3.8, LODs were calculated 
at 0.007, 0.010, 0.008 and 0.010 mg/ml respectively. These are remarkably lower than those 
reported at 0.070, 0.020, 0.028 and 0.116 mg/ml (Liu, woo and Koh, 2001; Belal, Awad and 
Clark, 2009). LODs obtained for chlorpheniramine and diazepam (0.003 and 0.009 mg/ml 
respectively) are slightly higher than those reported by Liu, Woo and Koh (2001); LODs of 
0.002 mg/ml and 0.001 mg/ml respectively.  
The LOD for diclofenac in this study (0.011 mg/ml) was higher than that reported in the 
literature (Liu, woo and Koh, 2001); though the literature employed the use of LC-MS, as 
was the case for ibuprofen, which had a lower LOD in this study than was reported in the 
publication.  A comparative study of Liquid chromatography-tandem mass spectrometry (LC-
MS-MS) versus GC-MS for the analysis and detection of some benzodiazepines from urine 
reported that LC-MS-MS had lower LOD and LOQ values than GC-MS (Perez et al., 2016). 
While this research alludes to the finding with the LOD of diclofenac being higher, on the 
other hand, there may be an indication of enhanced sensitivity of the GC-MS method used in 
this study for the detection of ibuprofen, considering its lower LOD (Table 3.8). 
 
120 
Table 3.8:  LOD and LOQ table of target analyte compared with other GC-MS publications 
1
Belal, Awad and Clark, 2009; 
2
 Liu, Woo and Koh 2001; 
3
Gambaro et al., 2003; 
4
Crifasi , Le  and  Long, 1997 
The LODs, with the exception of acetaminophen, were within the linear range shown in 
Table 3.8. This asserts the reliability of the calibration curve in quantifying pharmaceutical 
compounds around the LOD concentration. The LOD of acetaminophen (0.010 mg/ml) was, 
however, close to the lowest concentration within the linear range (0.02 mg/ml). Hence this 
may not be a major concern. In addition, it is important to consider that this method is used 
for the simultaneous detection of these compounds. For multiple compounds, one method 
may not be quite optimal for all. This is demonstrated in the high LODs for tramadol and 
fluoxetine compared with those in Table 3.8. This does not, however, affect the method 
being validated. 
3.7.7 Matrix effect 
Matrix effect can be expressed in two ways: ion enhancement or ion suppression (Panuwet 
et al., 2016). According to (Table 3.9), the matrix factors of the HM matrix on the entire target 
compound were less than one, suggesting ion suppression (see Section 3.6.4.5). This ion 
suppression of the target compound is likely caused by ions of naturally occurring 
compounds in the matrix. Unlike ion enhancement, where explanations are available as to 
why it occurs, the mechanism of ion suppression has not yet been explained. A hypothesis 
suggests that matrix constituents can compete with or suppress the ionisation potential of 
the analyte in the gas phase. It also competes with the binding of target ions through 
opposite electron affinity, causing loss of intensity in electron ionisation (EI) (Panuwet et al., 
2016). However, suppression effects caused by co-eluting compounds can be seen in GC 
with either electron or chemical ionisation (CI). Co-eluting matrix constituents such as 
aliphatic acids, aldehydes, sterols, phthalates, alcohol and caffeine contribute to such effects 
Analyte LOQ 
(mg/ml) 
LOD 
(mg/ml) 
Linear range 
(mg/ml) 
LOD in Literature 
(mg/ml) 
Acetaminophen   0.031 0.010   0.02 - 0.6 0.0201 
Caffeine  0.024 0.008 0.006 - 0.4 0.0282 
Chlorpheniramine  0.008 0.003 0.002 - 0.8 0.0022 
Codeine   0.036 0.012 0.006 - 0.8 0.0042 
Dexamethasone 0.032 0.010   0.01 - 0.8 0.1162 
Diazepam   0.027 0.009 0.006 - 0.2 0.0012 
Diclofenac    0.033 0.011 0.004 - 0.6 0.00042 
Ibuprofen  0.020 0.007 0.006 - 0.4 0.0702 
Tramadol    0.034 0.011 0.004 - 0.8 0.00001,3 0.0061 
Fluoxetine  0.012 0.004 0.004 - 0.8 0.00014 
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(Yu and Xu, 2012). Some of these compounds are naturally present in most plant products 
such as HM samples analysed in this research. 
Table 3.9:  Table showing matrix factor of target compound in spiked HM sample 
 
 
 
 
 
 
 
The degree of ion suppression may vary from compound to compound and from sample to 
sample, and can also be dependent on the sample preparation method (Bonfiglio et al., 
1999). Methanol‘s being the solvent used for sample preparation (Section 3.6.2.2) had some 
of the naturally occurring compounds in the HM analysed soluble in it (see Section 4.3.1) 
and may thus have contributed to the ion suppression.  
 The concentration of the analyte monitored, which relates to the matrix/analyte ratio, may 
also be responsible for ion suppression (Van Hout et al., 2000). However, use of analyte 
concentrations which reflects those that will be encountered in real conditions helped to 
eliminate this possibility. While there are no acceptable levels of matrix effect yet available, 
the result of the recovery and accuracy study in (Table 3.10) shows that the matrix effect 
observed does not significantly affect the detection or quantification of the target analyte 
from HM samples. In addition, use of the isotopically labelled analogue of the target 
compound as an internal standard is the most efficient way to tackle matrix effects (Colby 
and McCaman, 1979; Berg and Strand, 2011). In theory, the same level of ion suppression 
or enhancement will be seen for the target compound and its isotopically labelled analogue. 
Therefore the ratio of the two signals should be unaffected, allowing for accurate 
quantification (Ibid). Thus use of an isotopically labelled analogue (fluoxetine-d5) of one of 
the target compounds (fluoxetine) as the internal standard helped to evaluate the matrix 
effect. 
Analyte Matrix Factor 
Acetaminophen 0.986 
Caffeine 0.936 
Chlorpheniramine 0.918 
Codeine 0.931 
Dexamethasone 0.916 
Diazepam 0.927 
Diclofenac 0.936 
Fluoxetine 0.934 
Ibuprofen 0.935 
Tramadol 0.916 
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3.7.8 Recovery and accuracy 
The recovery study using spiked HM matrix was used to assess the method‘s precision and 
accuracy, as previously mentioned in Section 3.6.4.6. Figure 3.13 shows exemplar SIM 
chromatograms of a spiked HM sample (HM9) used for the recovery study scanning three 
ions as shown in Table 3.4 
 
Figure 3.13: Exemplar SIM chromatogram of spiked HM sample at 0.8 mg/ml (HM9) showing 
the target compounds at retention times (bottom to top) of 10.23, 11.37, 13.25, 14.65, 15.16, 
16.48, 18.80, 19.24, and 22.81 minutes respectively 
Table 3.10 shows the recovery data calculated using Equation 3.4 in Section 3.6.4.6. For 
example, using HM9 containing no ibuprofen (C0) spiked with ibuprofen at 0.8 mg/ml (C2) 
and 0.795 mg/ml (C1) mean concentration (n = 9, SD = 0.032) was recovered. Recovery is 
then calculated using:  
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Recovery = 0.8/0.795 X 100 = 99.38% 
%RSD = 0.032/0.795 X 100 = 4.03 
The recovery (%) and %RSD was also calculated for the other two concentrations of 
ibuprofen and the three concentrations of all the other analytes, as shown in Table 3.10 
At all concentrations (low, middle and high), the recovery ranged from 70-103.75% and 
method precision was between 3.4 -11.4%. According to the United States Pharmacopeia 
Convention (2012), a precision level of not more than 20% is acceptable, while 70-150% 
recovery is acceptable for accuracy studies. 
   Table 3.10: Results obtained from recovery studies of target analytes in spiked HM sample 
 
Analyte Amount Added 
(mg/ml) 
Amount recovered  
(mg/ml)±SD (n=9) 
Recovery 
(%) 
RSD 
(%) 
Acetaminophen 
 
0.01 0.007±0.0008 71.20 11.4 
0.08 0.078±0.004 78.00 5.1 
0.8 0.690±0.051 86.25 7.4 
Caffeine 
 
0.008 0.006±0.0004 76.25 6.6 
0.08 0.068±0.005 85.00 7.4 
0.8 0.830±0.030 103.75 3.6 
Chlorpheniramine 0.008 0.007±0.0006 90.00 8.3 
0.08 0.077±0.005 96.25 6.5 
0.8 0.760±0.026 95.00 3.4 
Codeine 
 
0.008 0.006±0.0004 77.50 6.5 
0.08 0.066±0.005 82.50 7.8 
0.8 0.740±0.051 92.50 6.9 
Tramadol 0.008 0.006±0.0005 71.25 8.8 
0.08 0.075±0.004 93.75 5.6 
0.8 0.780±0.053 97.50 6.7 
Dexamethasone 
 
0.01 0.007±0.0006 73.00 8.2 
0.08 0.076±0.0041 95.00 5.4 
0.8 0.820±0.041 102.5 5.0 
Diazepam 0.008 0.006±0.0005 78.75 7.9 
0.08 0.078±0.004 97.50 5.4 
0.8 0.790±0.054 98.75 6.9 
Diclofenac 
 
0.008 0.006±0.0005 70.00 8.9 
0.08 0.068±0.004 85.00 6.0 
0.8 0.720±0.059 90.00 8.2 
Ibuprofen 
 
0.008 0.003±0.0002 70,00 7.1 
0.08 0.066±0.004 82.64 6.2 
0.8 0.795±0.032 99.38 4.0 
Fluoxetine 0.008 0.007±0.0005 86.25 7.3 
0.08 0.074±0.004 92.50 5.3 
0.8 0.821±0.056 102.63 6.9 
Fluoxetine-d5 
(internal standard) 
0.25 0.192±0.013 76.80 
 
6.6 
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Thus these results are within an acceptable range. The recovery studies show the potential 
of the selected method for the detection of the compounds of interest in this research using 
methanol as the extracting solvent with little interference from the matrix. 
3.7.9 Precision study 
Data from the stability study (Section 3.7.4) were used to assess instrument precision, while 
data from the recovery study were used to assess method precision (Section 3.7.8). Table 
3.11 shows the data obtained for a mixed standard at three concentrations, with their 
corresponding PAR. 
Table 3.11: Result of repeatability study of the target analyte over a 50-hour period 
Analyte Intra-assay PAR repeatability (n=33)a 
0.008 mg/ml RSD 
% 
0.08 mg/ml RSD 
% 
0.8 mg/ml RSD 
% 
Caffeine  0.023±0.002 8.7 0.241±0.007 3.3 2.211±0.133 6.0 
Chlorpheniramine 0.049±0.003 6.1 0.513±0.040 7.8 5.326±0.212 4.0 
Codeine   0.076±0.004 5.3 0.712±0.024 3.4 6.676±0.301 4.5 
Diazepam   0.023±0.002 9.1 0.264±0.009 3.4 2.346±0.123 5.2 
Diclofenac  0.021±0.002 9.5 0.160±0.012 7.5 2.102±0.142 6.8 
Ibuprofen 0.028±0.002 7.1 0.264±0.016 6.1 3.464±0.143 4.1 
Tramadol   0.028±0.002 7.1 0.283±0.008 2.8 2.654±0.120 4.5 
Fluoxetine 0.076±0.004 5.3 0.726±0.023 3.2 7.540±0.323 4.3 
Acetaminophen  0.005±0.0004b 8.0 0.068±0.003 4.4 0.915±0.051 5.5 
Dexamethasone   0.035±0.003b 8.6 0.270±0.015 5.6 3.141±0.180 5.0 
 a 
Triplicate analysis at 11 time points from stability study (Section 3.8.4); 
b
Concentration at 0.01mg/ml; PAR: Peak area ratio. 
 All studied compounds had precision less than 10% RSD at low concentration (Table 3.11), 
although up to 15% RSD is acceptable (Peters, Drummer and Musshoff, 2007). Diclofenac 
had the highest RSD at 9.5%, followed by caffeine at 8.7% at the lowest concentration 
analysed but the values still fall within acceptable levels. Although these are below 10% 
RSD, the lowest concentration of analysed diclofenac is below the LOD (0.011 mg/ml), while 
caffeine is at the LOD concentration (0.008 mg/ml) (Table 3.8), which may be the reason for 
the increased %RSD.  
The PAR of the lowest concentration for acetaminophen and dexamethasone (0.01 mg/ml) 
show higher fluctuations in %RSD than those recorded at 0.8 mg/ml. This is to be expected 
(Ellison, Barwick and Farrant, 2009) because at this concentration the analytes are closer to 
their LOD (Table 3.8), and fluctuations in the analytical response may be more predominant, 
making peak areas less precise. Despite this, some compounds of interest had a lower 
%RSD than those recorded at the mid-range concentrations, e.g. chlorpheniramine with 
6.1% RSD at 0.008 mg/ml compared to 7.8% at 0.08 mg/ml. This eventually improved at 0.8 
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mg/ml with RSD of 4.0% and may be as a result of increased sensitivity at the highest 
concentration, as compared with the fluctuations at low and mid concentrations.  
All studied analytes were within 10% RSD at a concentration of 0.08 mg/ml. At this mid 
concentration range, precision was improved in all the compounds except for 
chlorpheniramine. At the highest concentration (0.8 mg/ml) all compounds were within 10% 
RSD. The results for the compounds are more precise than those recorded at the lowest 
concentration. This may be as a result of an improved signal of the analytical instrument at 
higher concentrations than the LOQ. 
In general, the results obtained show that all the compounds at the studied concentrations 
are repeatable within the 50-hour period (Section 3.7.4) and all are within 10-15% RSD. 
Furthermore, with increasing concentration, the method precision is improved.  
3.8 Result and discussion of ICP-OES method validation 
3.8.1 Selectivity 
The selectivity of the ICP-OES method was carried out as described in Section 3.6.5.1 to 
assess spectral interference. The three wavelengths selected by visual examination based 
on non-overlapping peaks, non-spectral interference and highest intensity are shown in 
Table 3.12. This is with the exception of selenium, which had only one wavelength that met 
the criteria. Wavelengths 206.279 nm and 203.985 nm for selenium had spectral 
interference with zinc wavelengths at 206.200 nm and 202.548 nm. Although the two 
interfering wavelengths for zinc could have been removed instead, they had higher intensity 
and less spectra interference than selenium. 
Table 3.12: Wavelength selection using multielemental mixed standard at 0.2 ppm 
                            *Interference with wavelength 1 of zinc ** Interference with wavelength 3 of zinc. 
Both*and ** not used 
Element Wavelength 1(nm)  Wavelength 2 (nm) Wavelength 3 (nm) 
Arsenic 188.980 193.696 234.984 
Cadmium 214.439 228.802 226.502 
Chromium 276.653 276.259 267.716 
Copper 324.754 222.778 224.700 
Lead 220.353 405.781 283.305 
Manganese 257.610 259.372 260.568 
Mercury 194.164 184.887 253.652 
Nickel 222.486 221.648 231.604 
Selenium 196.026 206.279* 203.985** 
Zinc 206.200 213.857 202.548 
Scandium (IS) 335.372 361.383  
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In addition, the results of the recovery study as discussed in Section 3.8.4 showed the 
selected wavelengths were specific for all the elements, with recoveries within an acceptable 
range. This implies that the examined wavelengths were devoid of significant spectral and 
matrix interference using the multi-elemental mixed standard and the spiked CRM standard. 
In addition, analysis of the blank solution after measuring the 1 ppm calibration standard 
showed no memory effect and inspection of the spectrum at each wavelength chosen to 
detect each analyte found no signal. Hence one wavelength was selected from the 
selectivity study. The wavelengths that had the highest emission intensity and without 
spectral and matrix interference were selected, as shown in Table 3.13.  
Table 3.13: Wavelength used in this study 
Element Wavelength 
(nm) 
Arsenic 188.980 
Cadmium 214.439 
Chromium 276.653 
Copper 324.754 
Lead 220.353 
Manganese 257.610 
Mercury 194.164 
Nickel 222.486 
Selenium 196.026 
Zinc 206.200 
Scandium (IS) 335.372 
 
This is with the exception of selenium, which had only one wavelength at 196.026nm with 
high emission intensity and no spectral interference. These selected wavelengths were used 
for subsequent analysis in this study and for method validation. 
3.8.2 Linearity and linear range 
The calibration graph for chromium, as an example, is shown in Figure 3.14 with a smaller 
graph within highlighting the linearity at lower concentrations (calibration graph for other 
metals is included in Appendix VII). The linear regression equation and the correlation 
coefficient (R2) are shown in Table 3.14. 
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      Figure 3.14: (a) Linearity plot of chromium with (b) linearity plot at lower concentration  
 
At highest or lowest concentration range, concentrations showing non–linear behaviour were 
removed, giving a better R2 value as closer to 1, as shown in (Table 3.14). These improved 
standard concentrations were then used as the working range. The linearity of the working 
range was subsequently assessed in this section using the same method, as described in 
Section 3.7.5 for GC-MS. 
Table 3.14: Regression equation and R2 values using the working range concentrations 
Element Regression equation R2 
Arsenic Y = 0.2848x + 0.0004 0.999 
Cadmium Y = 1.4458x -  0.005 0.999 
Chromium Y = 1.0867x -  0.0185 0.997 
Copper Y = 2.9884x + 0.0097 0.999 
Lead Y = 0.1113x + 0.005 0.999 
Manganese Y = 17.978x -  0.0418 0.998 
Mercury Y = 0.0508x + 0.001 0.998 
Nickel Y = 0.1927x + 0.0024 0.999 
Selenium Y = 0.0171x -  0.0005 0.999 
Zinc Y = 0.1799x -  0.0003 0.998 
 
A plot of the ratio of peak intensity and concentration (Rc) against log of concentration, as 
described in Section 3.6.4.3, was used for further assessment of the linearity data. If ideal 
linearity is attained, then the ensuing plot should be within ±10% of the mean relative 
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response factor. Figure 3.15 is an example of this plot of chromium (in a mixed standard), 
showing the lowest concentration (0.001 ppm) is outside of 10% RSD. Therefore the linear 
range in Table 3.17 reflects this for chromium (0.002-5 ppm). The same approach was taken 
for the other metals analysed. 
                          
                                       Figure 3.15: Log-linear plot of chromium 
 The data points shown in Figure 3.15 are spread around the mean, while the non-linear 
data point is at the lower level of the concentration range (0.001 ppm) thus showing a loss of 
linearity. The log-linear plot was run for other target metals (Appendix IX) to determine their 
linear range, as presented in Table 3.17. 
 Nonetheless, as also discussed in Section 3.7.5, a residual plot which allows checking for 
outliers, for example, those outside ±3 standard deviation (SWGTOX, 2013), corroborates 
earlier findings. The residual plot of the linear range showed that the calibration model was 
linear, as seen in Figure 3.16, for chromium and the rest of the selected metals, as shown in 
Appendix VIII. Although the residual plot for chromium in Figure 3.16 may appear to have a 
pattern, Shapiro-Wilk statistical analysis shows a normal distribution of the residuals (Table 
3.15).  
                      
                                   Figure 3.16: Residual plot of chromium 
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The Shapiro-Wilk statistical test performed for all the metals produced p-values ranging from 
0.052 to 0.378 throughout the tested linear range residual (Table 3.15). These p-values were 
greater than the level of significance of 0.05; hence the null hypothesis was accepted, 
indicating normal distribution. 
Table 3.15: Test for normality using Shapiro-Wilk test 
 
 
 
 
 
 
 
 
As discussed in the GC-MS linearity study in Section 3.7.5, a normal distribution is not 
assumed in deriving the skewness and kurtosis tests. However, values close to symmetrical 
were obtained; e.g. chromium with kurtosis of 3.172 and skewness of 0.572. 
It is also important to examine the randomness of the error using the Runs test. The Runs 
test produced p-values between 0.095 and 1.000 (Table 3.16), which were all greater than 
the 0.05 significance level. Hence the null hypothesis was accepted, which shows a random 
distribution of error. 
                                             Table 3.16: Values for Runs test 
                             
 
 
 
 
 
 
       
 
Element Kurtosis Skewness p-value Accept the  
null hypothesis 
Arsenic 2.338 0.999 0.090 yes 
Cadmium 1.025 -0.790 0.139 yes 
Chromium 3.172 0.572 0.073 yes 
Copper 1.225 0.399 0.378 yes 
Lead 3.275 0.339 0.055 yes 
Manganese 2.637 -1.202 0.095 yes 
Mercury 2.617 0.82 0.056 yes 
Nickel 3.455 0.112 0.054 yes 
Selenium 2.781 -0.845 0.091 yes 
Zinc 3.964 -0.748 0.052 yes 
Elements p-value Accept  the 
null hypothesis 
Arsenic 0.565 yes 
Cadmium 0.095 yes 
Chromium 0.145 yes 
Copper 0.835 yes 
Lead 0.835 yes 
Manganese 1.000 yes 
Mercury 0.145 yes 
Nickel 0.145 yes 
Selenium 0.095 yes 
Zinc 0.405 yes 
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3.8.3 Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
Calculations of LOD and LOQ were carried out using the method outlined in Section 3.1.3 
 The values obtained are shown in Table 3.17, which showed LOD ranged between 0.010 
and 0.035 ppm and LOQ ranged between 0.031 and 0.107 ppm for all the metals. The 
analysed LOD for arsenic and selenium are much lower than those reported in the literature 
at 0.017 ppm and 0.022 ppm in dry plant mass (Støving et al., 2013; Xiea et al., 2013; Senila 
et al., 2014; Ibrahim et al., 2011). Støving et al (2013) also reported similar LOD for copper 
(0.01 ppm) when analysing elemental impurities in tablets, according to US Pharmacopeia. 
Other metals have varying LODs compared with those reported in other research, as shown 
in Table 3.17. This variation may not be unconnected with varying sample preparation 
methods, instrument calibration and properties of the metals in various mixed standard. 
While there are some volatile metals involved in this study, such as selenium and lead, the 
obtained LOD compared with those reported in the literature showed improved detection. 
Cadmium has a higher LOD (0.035 ppm) than reported in the literature. However, the result 
from the accuracy and precision study (Table 3.9) showed good recovery and %RSD of all 
the target metals including cadmium. 
Table 3.17: LOD and LOQ values compared with other ICP-OES analysis of target element 
 
 
 
 
 
 
1
Støving et al., 2013 , 
2
Xiea et al., 2013, 
3
 Senile et al., 2014, 
4
Mihălţan et al., 2012, 
 
5
 Ibrahim et al., 2011,  
6 
Milani et al., 2015 
 
In addition, the LOQ values are lower than the published permissible level for various metals 
in herbal medicine (EMA, 2008). Thus the method is suitable for the quantification of metals 
in HM samples below permissible limits. The LOD values also fall within the linear range of 
the linearity data in this study. Thus this method is suitable for the detection and 
quantification of the target metals.  
Element LOD 
(ppm) 
LOQ 
(ppm) 
Linear range 
(ppm) 
LOD in literature 
    (ppm) 
Arsenic 0.017 0.052 0.005 - 5 0.051, 2.242, 0.0453 
Cadmium 0.035 0.107 0.001 - 5 0.011,2 &4, 0.0193,  
Chromium 0.026 0.081 0.002 - 5 0.021, 0.12,0.0753, 0.134 
Copper 0.010 0.031 0.001 - 5 0.011, 0.252, 0.123,0.24 
Lead 0.023 0.068 0.001 - 5 0.011&4, 0.122, 0.0433 
Manganese 0.031 0.094 0.005 - 5 0.011, 0.052,0.0303, 0.374 
Nickel 0.026 0.078   0.005 - 0.5 0.021, 0.752,0.133,0.014 
Selenium 0.022 0.068   0.005 - 0.2 0.452, 0.55 
Zinc 0.027 0.082      0.010 - 5 0.251, 0.102, 0.223,0.016 
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3.8.4 Recovery and accuracy 
Following the method described in Section 3.6.4.6, the average recovery at three spiked 
concentrations across the three wavelengths (except selenium as discussed in section 3.8.1) 
were examined. They were within the recommended recovery range of 70-150%, according 
to the US Pharmacopeia and also with %RSD less than 10% across the selected 
wavelengths. Therefore one of the wavelengths was selected while considering other factors 
discussed in Section 3.8.1. The wavelengths used for method validation are thus selected in 
Table 3.12.  
The detailed recovery study of the selected wavelength at the three levels of concentration 
analysed is shown in Table 3.18. The calculation for the recovery study is done as for GC-
MS in Section 3.7.8. The recovery efficiency using the two digestion methods described in 
Section 3.6.3.2 was determined in order to select the best digestion method. It was observed 
from the recovery study that wet digestion was more efficient in the recovery of the target 
metals than dry ashing when percentage recovery from both methods was compared (Table 
3.18). Similar studies have supported the efficiency of wet digestion as compared with dry 
ashing for most of the metals in this study (Yang et al., 2013; Zheng et al., 2013).  
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              Table 3.18: Recovery studies from wet and dry ashing digestion method  
 
 
This is particularly so for the volatile metals in this study, such as arsenic, cadmium and zinc. 
Nonetheless, the recovery of metals using the dry ashing method had recovery within the 
acceptable range of between 70-150% even for volatile metals. This may be associated with 
the use of magnesium nitrate as the ashing aid, as discussed in Section 1.7.4. Thus both 
digestion methods seem efficient in the recovery of the target metals. Conversely, values 
from the open vessel wet digestion for selected HMs were subsequently presented and 
discussed in chapter 4 because of its higher recovery, as shown in Table 3.18. Other studies 
have also found wet digestion to be more efficient (Soylak et al., 2004). 
  Wet Digestion Dry Ashing 
Elements Amount 
Added 
(ppm) 
Amount 
recovered 
(ppm)±SD 
(n=3) 
% 
Recovery 
% 
RSD 
Amount 
recovered 
(ppm)±SD 
(n=3) 
% 
Recovery 
% 
RSD 
Arsenic 0.02 0.016±0.002 80.00 12.5 0.015±0.002 75.00 13.3 
0.2 0.180±0.013 90.00 7.2 0.163±0.016 81.50 9.8 
2 1.983±0.121 99.15 6.1 1.765±0.133 88.25 7.5 
Cadmium 0.02 0.016±0.002 80.00 12.5 0.014±0.002 70.00 14.3 
0.2 0.178±0.014 89.00 7.9 0.157±0.015 78.50 9.6 
2 2.120±0.150 106.00 7.1 1.725±0.160 86.25 9.3 
Chromium 0.02 0.017±0.002 85.00 11.8 0.014±0.001 70.00 7.1 
0.2 0.231±0.022 115.50 9.5 0.182±0.018 91.00 9.9 
2 2.070±0.160 103.50 7.7 1.919±0.180 95.95 9.4 
Copper 0.02 0.015±0.001 75.00 6.7 0.014±0.001 70.00 7.1 
0.2 0.201±0.016 100.50 7.8 0.174±0.015 87.00 8.6 
2 1.982±0.113 99.10 5.7 1.858±0.101 92.90 5.4 
Lead 0.02 0.020±0.002 100.00 10.0 0.018±0.002 90.00 11.1 
0.2 0.180±0.012 90.00 6.7 0.168±0.016 84.00 9.5 
2 2.315±0.155 115.75 6.7 1.874±0.138 93.70 7.4 
Manganese 0.02 0.019±0.002 95.00 10.6 0.019±0.002 95.00 10.5 
0.2 0.198±0.017 99.00 8.6 0.188±0.014 94.00 7.5 
2 2.093±0.113 104.65 5.4 2.112±0.120 105.6 5.7 
Mercury 0.02 0.018±0.002 90.00 11.1 0.018±0.001 90.00 5.6 
0.2 0.152±0.013 76.00 8.6 0.171±0.013 85.50 7.6 
2 1.887±0.141 94.35 7.5 1.899±0.129 94.95 6.8 
Nickel 0.02 0.021±0.002 105.00 9.8 0.018±0.002 90.00 11.1 
0.2 0.218±0.012 109.00 5.5 0.176±0.015 88.00 8.5 
2 1.995±0.159 99.75 8.0 1.894±0.129 94.70 6.8 
Selenium 0.02 0.018±0.002 90.00 11.0 0.014±0.002 70.00 14.3 
0.2 0.189±0.014 94.50 7.4 0.161±0.012 80.50 7.5 
2 1.927±0.121 96.35 6.3 1.667±0.104 83.35 6.2 
Zinc 0.02 0.019±0.001 95.00 5.3 0.019±0.001 95.00 5.3 
0.2 0.215±0.019 107.50 8.9 0.196±0.016 98.00 8.2 
2 2.071±0.164 103.55 7.9 2.111±0.155 105.55 7.3 
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3.8.5 Precision study 
The same data shown in Table 3.18 were used to assess method precision. The precision 
studies showed that the %RSD were within the 15% acceptable range for all the metals at 
the chosen concentrations (0.02, 0.2 and 2 ppm). A 20% RSD is said to be acceptable for 
concentrations near the LOQ of the method (Perter, Drummer and Musshoff, 2007). 
Nonetheless, all the values were below 20% RSD for all analysed metals at all 
concentrations. Arsenic and cadmium had the highest RSD at 12.5% at a concentration of 
0.02 ppm by wet digestion; this may be as a result of their potential volatility, as discussed in 
Section 1.7.4; although this is also expected at low concentrations and an allowance of up to 
20% is permissible (Peter, Drummer and Musshoff, 2007). The high %RSD may be as a 
result of intensity inconsistency at the near LOQ concentration (0.052 ppm) for arsenic, for 
example (Table 3.17), as compared with higher concentrations (Ellison, Barwick and farrant, 
2009). However, this is within the acceptable limit, as discussed earlier in this study, and 
therefore shows reproducibility. The same explanation applies to chromium, manganese and 
selenium which also had RSDs above 10% at 11.8%, 10.6% and 11.0% respectively. These 
RSDs improved at higher concentrations, as shown in Table 3.18. At 2 ppm the %RSD for all 
the metals were within 10%. Generally, these results suggest that the metals at the three 
concentration studied were precise, repeatable and within the acceptable range for accuracy 
and 15% RSD.  
3.9 Summary 
The results of method validation showed that the method to be used for the detection and 
quantification of the selected metals and pharmaceutical compounds in the selected HM is 
specific, linear and with a linear range that is suitable for the intended purpose. The LOQ 
concentrations in ICP-OES analysis are below the permissible levels of metals 
recommended by WHO (Table 4.3). The LOQ concentrations for target pharmaceuticals 
from GC-MS analysis were also below the usual therapeutic dose expected to be found in 
HM samples. The LOD for both ICP-OES and GC-MS were lower than those obtained from 
similar studies for most of the metals and pharmaceutical compounds. The results of the 
accuracy and precision studies show the reliability of the quantification that will be carried 
out on studied pharmaceutical compounds and metals. 
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CHAPTER 4: ANALYSIS OF PHARMACEUTICALS AND HEAVY METALS 
IN SELECTED HERBAL MEDICINE USING GC-MS AND ICP-OES 
4.1 Introduction 
The HMs analysed in this study were obtained as described in Section 4.2.1 to detect and 
quantify any possible pharmaceutical compounds and heavy metals using the method 
validated in Chapter 3. The variability of target compound within samples and location were 
also assessed. All HM samples were in powder form and prepared for GC-MS and ICP-OES 
analysis as described in Section 3.6.2.2 and 3.6.3.2 respectively. 
4.2 Materials and method  
The materials and method used for the analysis of HM for pharmaceutical adulterants and 
heavy metals are as shown in Section 3.6. The samples were thoroughly mixed; weighed 
and extracted, digested samples were made up to relevant concentration for GC-MS 
analysis and ICP-OES analysis. 
4.2.1 Selection and sampling of herbal medicines   
The HM samples selected were the 10 types most commonly used in Ekiti State. These 
were identified from the result the of survey study presented in Chapter 2 (Table 2.12). The 
details of the selected HM are shown in Table 4.1.  
Analysed HM samples were obtained in replicate from five locations of Ekiti State, as shown 
and labelled 1 to 5 in Figure 4.1. This was essential to assess variability between locations. 
                      
Figure 4.1: Map of Ekiti State showing various locations from which HM samples were 
obtained 
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Some HM samples were packaged in capsules, while others were powders wrapped in 
newspaper sheets or transparent plastic bags (see Appendix XVII). The HMs were all made 
up of various constituents, as declared, although some did not declare any (see Table 4.1). 
Sampling of the HM for analysis was carried out as follows: 
I. Encapsulated HM samples in blister packs (HM3, HM6 and HM9 were samples of 
this type); two capsules were picked at random from 2 blister packs in each sample 
package. This was repeated for the four other replicates obtained from other 
locations, making a total of 20 capsules for each HM type. A total of 60 capsules 
were sampled and analysed for all blister pack HM. 
 
II. Encapsulated HM samples not in a blister pack (HM1); four capsules were picked at 
random from their plastic bottles. This was done for the four other plastic bottles, 
making a total of 20 capsules. 
 
III. Powdered samples packaged in paper sheets (HM2, HM4, HM5, HM7, HM8 and 
HM10); each was divided into two equal parts and samples weighed out from each 
bit. Four other replicates were weighed out using this method, allowing for 10 
samples to be taken for each HM type to ensure representative sampling. A total of 
60 were sampled and analysed for this type of HM. A summary of the sampling 
method is shown in Figure 4.2. 
 
 
         Figure 4.2: Herbal medicine sampling method for analytical studies 
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Table 4.1: Table of information on selected HM samples 
HM 
No 
Product 
name 
NAFDAC 
number 
Manufacturer Indication(S) Dose and 
duration 
Content 
HM1 Body pain Nonea Yemkem 
international 
Pain 3 capsules 
twice daily 
40% horse bone 
30% bitter cola 
30% potash 
 
HM2 Male tonic Nonea Non specified Low sperm 
count and 
increased 
sexual power 
None None declared 
 
 
 
 
HM3 Supa A1 A7-0374L Yemkem 
international 
Immune 
booster, male 
and female 
infertility, 
jaundice and 
sickle cell 
disease. 
 
2 capsules 
twice daily 
15% cinchona 
succirubora and 
othersb 
HM4 Wadco total 
blood cure 
Nonea Wadco health 
foundation 
Pain, yellow 
fever, typhoid, 
rheumatism 
 
One spoon 
twice daily 
 
None declared 
HM5 Wadco pile 
& dysentery 
Nonea Wadco health 
foundation 
Pain, 
dysentery, 
pile, infertility 
 
Daily for 
two days 
None declared 
HM6 M&T 
Capsule 
A7-0294L Yemkem 
international 
Malaria, 
typhoid 
3 capsules 
twice daily 
10% piper 
nigrum and 
othersc 
 
HM7 YK original 
malaria 
Nonea Dr. Abdul 
Kareem Yakub 
Malaria, pains, 
fever and body 
weakness 
 
Twice daily None declared 
HM8 Aromalegun Nonea Non specified Pains, 
sleeplessness 
Twice daily 
over two 
days 
 
None declared 
HM9 Eroxy 5000 A7-0303L Yemkem 
international 
Pile, pain, 
haemorrhoid, 
indigestion, 
energy and 
libido 
 
3 capsules 
twice daily 
25% garlic and 
othersd 
HM10 Original 
malaria/ 
yellow fever 
and typhoid 
Nonea Non specified Malaria, 
typhoid, pain, 
sleeplessness 
and fever 
Twice over 
two days 
None declared 
a 
uncertified HM ;
 b
70% Markhamia tomantoas 20% Alstonia congensis 
c
20% khaya ivorensis,50% colocasle antiguorum, 15% 
theobroma cacao 
d
2% Eugqnia caryo phylatta, 2% piper nigrum, 16% zinigiba officianale, 15% Garcinia cola, 10% each of 
(Plumbayo zeylanica, Lantana,Eosinium and Entandrophrapma utile) 
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4.3 Results and discussion of analysis of herbal medicine using GC-MS 
4.3.1 Primary Identification of pharmaceutical compounds in herbal medicine  
Prior to analysis of HM samples for identification of pharmaceutical compounds using GC-
MS known analytical standards of the pharmaceuticals of interest were run to acquire their 
retention times and mass spectra, as shown in Section 3.7.1. This analysis focused on 
samples that might contain the target compounds shown in Table 3.1; hence, where 
analytes of interest were identified and confirmed, samples were then taken forward to the 
quantification stage. 
However, none of the HM samples was observed to contain any of the analytes of interest 
using the method of identification outlined above in Section 3.7.1, or if present were below 
the limit of detection of this study.  
 
Figure 4.3: Chromatogram (TIC) of HM sample 3 showing internal standard (IS) fluoxetine-d5 
(0.25 mg/ml). 
 A sample TIC chromatogram of the HM sample (Figure 4.3, others in Appendix X) showed 
the presence of various tentatively identified organic constituents such as phytic acid, 
anabasine (plant alkaloids) and farneso (plant terpenes) and the internal standard (IS). They 
were plant matrices which were expected to be present. Hence such detection may attest to 
the suitability of the analytical method for the detection of constituent compounds in selected 
HM samples in this research. Regardless, the extraction of target analytes from spiked HM 
samples has been previously performed in this study (Section 3.6.4.6), including matrix 
effect and recovery study (Section 3.7.7 and 3.7.8). Therefore detection of the HM organic 
constituents may not have interfered with the detection of target analyte. However, despite 
the suitability of the TIC chromatogram of the mixed standard (Figure 3.2), a direct 
comparison of both chromatograms for the purpose of identification will be inaccurate 
because of the detected multiple organic constituents. Therefore EIC was used with the ions 
contained in Table 3.4 for each target analyte in the analysed HM samples. As none of the 
138 
target analytes was present in the analysed HM samples, further to confirm this, these 
samples were analysed in SIM using three ions at the retention times as shown in Table 3.4 
at + and -1 minute. Results also showed none of the target compounds was present. 
Figure 4.4: SIM chromatogram of HM sample 3 showing only the IS peak 
 (m/z: 43, 109 and 314) 
 
As seen in (Figure 4.4), no peaks were detected (except the internal standard) at the 
retention time of the studied analytes using selected ion monitoring. This was the same for 
all the HM samples analysed, providing further confirmation of the absence of the target 
analyte in the HM samples. The peak of the IS was distinct, as can be seen in (Figure 4.5), 
which also asserts the suitability of the method. 
Figure 4.5: SIM chromatogram showing IS peak in HM sample 3 (m/z: 43, 109 and 314) 
Absence of the target analytes was further ascertained by analysis of HM samples using 
another GC-MS (Shimadzu QP 2010) with the same parameters as those previously used 
with the Clarus GC-MS (Table 3.2) also failing to detect any of the target analytes. Therefore 
no quantification was carried out as none of the target analytes was detected. 
IS 
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The findings of this analysis differ from those of HM obtained from other countries where 
pharmaceutical compounds have been detected (Garg et al., 2011; Posadzki, Watson and 
Ernst, 2013; Justa, Neves and Caldas, 2015). The LOD of some analytes in this study 
methods was lower than the detected concentrations of the same analytes in other 
publications (Table 3.8). Hence these analytes would have been more likely to be detected if 
present using the method validated in this research.    
However, further analysis of the HM samples for possible heavy metals was carried out, as 
discussed in Section 4.4. 
4.4 Result and discussion of analysis of herbal medicine using ICP-OES 
4.4.1 Elemental detection and quantification in herbal medicine samples 
Following selected sample preparation via wet digestion (Section 3.8.4) and validation of the 
ICP-OES method (Section 3.8) all studied HM samples (Table 4.1) were analysed for 
selected heavy metals (Section 3.3). For all HM samples, of the 10 metals 9 were detected 
(i.e., As, Cd, Cr, Cu, Pb, Mn, Ni, Se and Zn) while Hg was not detected. The nine metals 
were detected above LOD and LOQ (Table 3.17).  
To quantify the heavy metals detected in the HM samples the regression equation as shown 
in Table 3.14 was used.  For example, according to the regression equation for chromium  
y= 1.0867x – 0.0185  
Because the mean intensity ratio (y) is known, the actual concentration of the sample can be 
calculated from the equation: 
x = (y+0.0185) / 1.0867 
So for HM1 as an example, the value of y which is the mean intensity ratio when analysed 
for chromium was 0.3564 
Therefore x is calculated as shown below where y= 0.3564  
x = (0.3564+0.0185) / 1.0867=0.345 ppm (µg/ml) 
 This shows that 0.345 µg/ml of chromium is contained in HM1. But then this is inconsistent 
with the original concentration calculated from the weight of the sample dissolved (1g of HM 
sample in 25 ml deionised water) (Section 3.6.3.2.2) with a concentration of 0.04 g/ml. 
Therefore the actual concentration of chromium is calculated by dividing the initially obtained 
concentration of chromium by the sample concentration: 
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0.345 µg/ml / 0.04 g/ml = 8.625 µg/g (ppm) 
Hence HM1 contains 8.625 µg/g of chromium  
These calculations were repeated for the other HM samples for the target metals detected. 
The results are presented in Table 4.2. 
The permissible level of heavy metals varies from country to country, as seen in Table 4.3. 
Unfortunately, Nigeria has no guideline yet on the permissible level of heavy metals in herbal 
products consumed in the country. Therefore WHO recommended values (National 
Sanitation Foundation draft proposal values) are adopted in this study as permissible limits 
(WHO, 2007) as shown in Table 4.3.  
141 
Table 4.2: Table showing the average concentration of heavy metals detected in HM samples                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                 
 
 
 
 
 
 
Values in red are above the permissible limit.   ND: Not detected    * WHO, 2007 
Permissible 
limits* 
2 ppm 0.3 ppm 2 ppm 3 ppm 10 ppm 0.1 ppm 44.6 to 339  
ppm 
1.6 ppm 25 ppm 100 ppm 
HM  samples 
(n=12) 
Arsenic 
(ppm) 
Cadmium 
(ppm) 
Chromium 
(ppm) 
Copper 
(ppm) 
Lead 
(ppm) 
Mercury 
(ppm) 
Manganese 
(ppm) 
Nickel 
(ppm) 
Selenium 
(ppm) 
Zinc 
(ppm) 
HM1 0.233±0.018 0.669±0.048 8.625±0.615 15.134±0.898 3.972±0.264 ND 54.841±3.376 5.295±0.309 7.950±0.423 83.864±6.003 
HM2 0.607±0.117 0.558±0.045 2.779±0.255 31.953±4.424 33.374±3.720 ND 91.469±2.813 5.148±0.910 7.965±0.435 131.428±6.662 
HM3 0.473±0.032 0.531±0.032 1.774±0.091 14.753±0.909 1.396±0.052 ND 193.544±7.813 2.883±0.114 2.281±0.114 24.712±1.846 
HM4 0.292±0.030 0.597±0.055 1.686±0.278 13.565±1.323 3.057±0.671 ND 85.431±2.846 1.936±0.387 5.342±0.943 25.585±5.763 
HM5 0.390±0.035 0.705±0.122 4.712±0.561 57.175±4.806 5.907±0.322 ND 134.822±3.348 2.948±0.152 3.225±0.632 86.289±6.161 
HM6 0.250±0.037 0.465±0.060 0.738±0.042 11.343±0.339 2.727±0.226 ND 88.774±9.885 1.406±0.299 9.023±0.789 19.286±1.269 
HM7 0.302±0.037 0.473±0.029 0.538±0.055 4.912±0.669 1.612±0.207 ND 38.644±3.305 1.384±0.148 5.208±0.203 5.557±0.748 
HM8 0.350±0.062 0.491±0.028 3.536±0.424 38.367±1.134 3.122±0.291 ND 30.578±3.292 8.234±0.352 3.016±0.669 93.070±3.898 
HM9 0.255±0.039 0.458±0.047 3.908±0.372 58.888±6.604 1.772±0.117 ND 91.067±4.840 5.121±0.568 2.524±0.463 31.776±3.518 
HM10 0.527±0.084 0.497±0.044 3.299±1.035 13.311±0.619 2.900±0.909 ND 63.151±1.341 1.872±0.481 4.050±0.789 14.891±1.665 
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Table 4.3: Table of permissible levels of heavy metals in various countries (WHO, 2007) 
 
      TTM = Total toxic metals; RHM = Raw herbal material; FHB = Finished herbal product; HMA = Herbal material; HM = herbal medicine; NSFDP = National sanitation foundation draft proposal 
 
Countries Product type  As     Pb    Cd        Cr Hg     Cu  TTM as 
Pb 
For herbal medicines 
 
Canada RHM 5 ppm 10 ppm 0.3 ppm 2 ppm 0.2 ppm - - 
FHP 0.01 mg/day 0.02 mg/day 0.006 mg/day 0.02 mg/day 0.02 mg/day - - 
China HM 2 ppm 10 ppm 1 ppm - 0.5 ppm - 20 ppm 
Malaysia FHP 5 mg/kg 10 mg/kg - - 0.5 mg/kg - - 
Republic of Korea HMA - - - - - - 30 ppm 
Singapore FHP 5 ppm 20 ppm - - 0.5 ppm 150 ppm - 
Thailand HMA, FHB 4 ppm 10 ppm 0.3 ppm - - - - 
WHO recommendations 10 mg/kg 0.3 mg/kg - - - - - 
For other herbal products 
 
NSFDP (Raw Dietary Supplement) 
 
5 ppm 10 ppm 0.3 ppm 2 ppm - - - 
NSFDP (Finished Dietary Supplement) 0.01 mg/day 0.02 mg/day 0.06 mg/day 0.02 mg/day 0.02 mg/day - - 
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The average batch element concentrations of target metals in each HM sample are 
discussed according to individual metals from Sections 4.4.2 to 4.4.11. 
4.4.2 Arsenic 
 The concentration of arsenic in all the HMs was below the permissible limits of 2 ppm 
(WHO, 2007). HM2 and HM10 appear to have a large standard deviation in the average 
concentration of arsenic (Figure 4.6). This may be a result of variation of arsenic across the 
five locations sampled, as discussed in Section 4.4.13 
                 
                 Figure 4.6: Average concentration of arsenic detected in HM samples  
The results from Figure 4.6 show that the concentration of arsenic in HM samples ranged 
between 0.233±0.018 ppm for HM1 and 0.607±0.117 ppm for HM2. These values are above 
the LOQ in this research (Table 3.17) and are similar to concentrations of arsenic obtained 
from a previous study (0.301-1.108 ppm) which analysed HM samples from other parts of 
Nigeria (Adepoju-Bello et al., 2012).  
However, arsenic is a naturally occurring constituent of the earth‘s crust and is largely 
abundant in the environment, in the air, land and water. This element can dissolve in water, 
so it can contaminate rivers, lakes or underground water by dissolving in rain, snow, or 
through improperly disposed industrial waste, used as insecticide and herbicide or 
preservative for wood (Fergusson, 1990). As a result, groundwater contamination with 
arsenic is a serious public health threat worldwide. This is because of people‘s exposure to 
e.g. high levels of inorganic arsenic from contaminated water used for irrigation of 
agricultural plant and various industrial processes (WHO, 2016).  
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Arsenic has also been reported in seafood, especially in the oil-producing states of Nigeria 
(Chinyere et al., 2012; Kingsley and Reginia, 2016). Hence its accumulation in plants 
supplied by the same river may not be unusual. In Ekiti State high concentrations of arsenic 
above permissible limit has been found in farmland (Isinkaye, 2012). This may be due to 
continual applications of pesticide and fertiliser (Atafar et al., 2010). Conversely, the effect of 
chronic arsenic exposure and its bioaccumulation from ingested arsenic-contaminated plant 
products has been investigated in various countries and found to be associated with 
detrimental health effects such as cancer and vascular disease (Gibb et al., 2011; Argos et 
al., 2010). Oral exposure, as in the case of HM, accounts for the majority of exposure routes 
in the general population (ATSDR, 2014).  
4.4.3 Cadmium 
All HM samples had cadmium levels above the permissible limits of 0.3 ppm (WHO, 2007). 
As seen in Figure 4.7, the highest concentration was in HM5 (0.705±0.122 ppm), an 
uncertified HM (Table 4.1), followed by HM1 (0.669±0.048 ppm), a certified HM sample. 
Cadmium levels were above the LOQ (Table 3.17) in all the HM samples. 
              
                         Figure 4.7: Average concentration of cadmium in HM samples 
The concentration of cadmium in the HMs ranged between 0.705±0.122 ppm for HM5 and 
0.458±0.047 ppm for HM9. This is low compared with values reported in HMs previously 
analysed in Nigeria (0.261 to 40.288 ppm) (Adepoju-Bello et al., 2012). The difference in the 
findings of this research may be associated with the variation in the location where samples 
were obtained, as per batch variation, which is further discussed in Section 4.4.13. 
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Cadmium is found in the earth‘s crust at about 0.1 ppm and often as an impurity in lead or 
zinc deposits (Wedepohl, 1995). Cadmium is used in commerce, e.g. the production of paint 
pigments, batteries, steel galvanisation, lasers, cosmetics and television screens (U.S. 
Geological Survey, 2012). The management of electronic waste is still problematic in Nigeria 
and dumpsites are a mixture of varying types of waste ranging from electronic to biological. 
The presence of high amounts of cadmium at dumpsites in Ekiti State and the 
bioaccumulation of the metal in plants, especially common edible vegetables, has previously 
been reported (Awokunmi, Adefemi and Asaolu, 2015). Additionally, in Nigeria and most 
developing nations, the marked increase in population and a need for mostly western used 
personal cars (known as ―tokunbo‖) alongside an increase in automobile repair/workshops 
have contributed to increased environmental pollution. Suffice to say a marked increase in 
cadmium concentration in roadside vegetation and auto mechanic workshops in Nigeria has 
been reported (Fakayode and Olu-Owolabi, 2003; Ololade, 2014). These human activities 
may have contributed to the presence of Cd above the permissible limit in all the HM 
samples analysed; as it seems the source of environmental pollution especially from cars 
and their related products are a common contributing factor regardless of location. 
Noteworthy also is the publication of results of soil analysis in some areas of Ekiti State, 
which reported moderate cadmium pollution especially around sawmills (Ajibulu et al., 2013).  
 
It has been reported that contamination of drugs and dietary supplements (designation for 
HM in the USA) may also be responsible for overexposure to cadmium (Abernethy et al., 
2010). Ingestion of cadmium is one of the main routes of human exposure and intestinal 
absorption is higher in people who suffer calcium, zinc or iron deficiency (Nordberg, 2007). 
High cadmium exposure can produce long-term health effects. Cadmium toxicity mainly 
affects the kidney in humans primarily at the proximal tubule where cadmium is deposited 
causing Fanconi syndrome from cadmium-induced oxidative damage and also chronic 
glomerulonephritis (Thévenod, 2003; Fujiwara, Lee, and Tokumoto, 2012; Kim et al., 2015; 
Sabath and Robles-Osorio, 2012). The survey results of HM use reported in this research 
showed that 85% of the population (n=1265) used HM in Ekiti State (Table 2.8), of which the 
most commonly used types analysed in this research are now found to contain cadmium 
above permissible limits. More worrying are the findings on the challenges of renal care in an 
Ekiti State renal centre, which reported that chronic glomerulonephritis was the most 
prevalent (45.3%) kidney injury and one of the leading causes of end-stage renal failure in 
the facility (one of only two such facilities in the state) (Oluyombo et al., 2014). Therefore 
there may be a correlation between the renal findings and the findings of this research.  
Cadmium has no physiological benefit to humans even at trace level (ATSDR, 2008). It 
affects the cardiovascular system in several ways such as its role in inducing hypertension 
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(Gallagher and Meliker, 2010), diabetes (Edwards and Prozialeck, 2009), peripheral arterial 
disease (Navas-Acien et al., 2005), sudden cardiac death (Menke et al., 2009) and 
myocardial infarction (Everett and Frithsen, 2008). Besides its acute toxicity, cadmium 
bioaccumulation in the renal cortex and liver is one of its chronic toxic effects, as a result of 
its long biological half-life (Hammer and Hammer, 2004; Adepoju-Bello and Alabi, 2005). 
Hence, with the results in this study showing the presence of cadmium above the 
permissible limit in all the HM samples analysed, it has become a serious public health 
concern, which this research intends to highlight for prompt action. Toxicity at low chronic 
exposure is also a cause for concern, as discussed in Section 4.4.12. 
4.4.4 Chromium  
Some of the HM samples had concentrations of chromium higher than the permissible level 
of 2 ppm. Samples HM1, HM2, HM5, HM8, HM9 and HM10 had levels of chromium higher 
than permissible limits, while HM3, HM4, HM6 and HM7 had concentrations of chromium 
below the permissible level (Table 4.2).  
The concentrations of chromium in Government certified HM1 (8.630±0.615 ppm) and HM9 
(3.908±0.372) were above the permissible limit (2 ppm) and HM1 contained the highest 
concentration of chromium. This points to the need for a more comprehensive testing 
protocol for HM certification in Nigeria.   
              
Figure 4.8: Average concentration of chromium in HM samples 
 
The range of chromium concentration was between 8.630±0.615 ppm and 0.538±0.055 ppm 
with HM7 an uncertified HM containing the lowest concentration of chromium (Figure 4.8). 
Various publications on HM samples obtained from the Niger Delta area of Nigeria and 
Lagos State reported no chromium was detected (Ekeanyanwu et al., 2013; Idu, Oghale and 
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Jimoh, 2015). Nonetheless, another study on HMs obtained in the same Niger Delta area 
detected chromium levels similar to those in this study at 4.16% above WHO permissible 
limits (Igweze, Orisakwe and Obianime, 2012) . While the disparities may be as a result of 
various human activities in these regions, Chromium concentration or its detection may also 
vary according to the type and source of HM analysed.  
 
Chromium occurs naturally in plants, animals, soil and rocks with oxidation states in a range 
of chromium (-II) to chromium (VI). Hexavalent chromium (Cr(VI) is toxic and carcinogenic, 
unlike chromium metal and Cr(III) ions (EPA 1984a, 2000; Salnikow and Zhitkovich, 2008). 
No speciation was performed in this research, hence total chromium was analysed. Natural 
processes and industries such as textile, leather, chemical and steel manufacture are 
responsible for chromium entering the environment. Various activities from chromate mining, 
such as seepage and improper disposal of mining and manufacturing tools have also been 
reported to contribute to groundwater contamination (Rom, 2007). 
 
 Impact evaluation of small-scale mining activities on groundwater quality and vegetation in 
some part of Ekiti State reported no significant impact (Talabi et al., 2015). On the other 
hand, a report from neighbouring Osun State (See Section 2.3.1) showed heavy metals 
geoaccumulation at a level up to extreme contamination at an illegal gold mining site (Olujimi 
et al., 2015). Also, the study of some auto-mechanic workshop soil in Ondo State (another 
neighbouring state; see Section 2.3.1) reported chromium concentration within permissible 
limit (Ololade, 2014). Other studies have reported statistically significant differences in 
chromium concentration between soil around petroleum product handling facilities and 
control samples in Lagos (Adeniyi and Afolabi, 2002). This is because heavy metals are 
associated with petroleum products (Albers, 2003) and thus activities of petroleum handling 
facilities can harm vegetation. Another study on soil samples from sawmill areas in Ekiti 
State reported concentrations of chromium suggesting natural origin with a little 
anthropogenic contribution (Ajibulu, 2013). All these sources potentially contribute to the 
presence of chromium in HM samples. 
 
Chromium (III) is a nutrient essential to humans that is involved in the metabolism of protein, 
fat and glucose by potentiation of insulin activities. But exposure to high levels through its 
ingestion can result in adverse health effects such as increased cancer risk, liver damage 
and intestinal bleeding (ASTDR, 2013). The toxicity of chromium in humans through HM 
exposure may not be acute, but there is a preferential accumulation of chromium in the 
kidney leading to tubular damage as a result of chronic exposure (Wedeen and Qian, 1991). 
This associated kidney injury is as discussed for cadmium in Section 4.4.3 and the oral 
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exposure limit is further discussed in Section 4.4.12. The mechanism of kidney injury is also 
via oxidative stress (Zendehdel et al., 2015) as with cadmium.  
4.4.5 Copper 
All the HM samples had a concentration of copper above the permissible limit (3 ppm). HM9 
(a certified HM) had the highest concentration of copper (58.888±6.604 ppm), followed by 
HM5, an uncertified HM (57.175±4.806 ppm) (Figure 4.9). The concentration of copper in the 
HM samples ranged between 4.912±0.669 ppm and 58.888±6.604 ppm.  
 
                  
Figure 4.9: Average concentration of copper in HM samples 
 
This concentration range is higher than that reported in HM samples obtained in Lagos, and 
particularly HM9 which was analysed by another study and reported to contain 0.20 ppm of 
copper (Onwordi ,Agbo and Ogunwande, 2015) compared with 58.888±6.604 ppm obtained 
in this study. The HM9 sample analysed in the study mentioned above was in liquid form, not 
the powdered form analysed in this study. This difference may be responsible for the wide 
disparity in concentration due to differences in the sample preparation method used for both 
types of sample (Gauglitz and Moore, 2014). Another study has also reported a higher 
concentration of copper and other heavy metals in powder samples than in their liquid form 
(Idu, Oghale and Jimoh, 2015). 
  
HM6 in this study had 11.343±0.339 ppm of copper compared to 2.35 ppm of the same 
sample analysed in a previous study (Onwordi, Agbo and Ogunwande, 2015). The varying 
concentration of copper may be a result of a difference in the source of raw materials or 
0
10
20
30
40
50
60
70
A
ve
ra
ge
 c
o
n
ce
n
tr
at
io
n
 o
f 
 C
o
p
p
e
r 
  (
p
p
m
) 
HM Samples 
149 
batch manufacturing process, although, as discussed in Section 4.4.13, there was no 
significant variation between the various batch concentrations of copper in HM samples 
analysed in this research (Appendix XIII). This insignificant variation in copper concentration 
found in this study may weaken the postulation as to the difference between concentration 
reported from Onwordi, Agbo and Ogunwande, (2015). But then the distance between the 
locations of the two studies may further assert variations as a result of a difference in the 
source of the raw materials used, or in the batch manufacturing process. Nevertheless, the 
high concentration of copper in the analysed samples is a serious safety concern.  
 
Drinking water, food and copper supplements are the main sources of copper exposure from 
the environment. The copper content in plants varies according to the quality of the soil, 
source of water, geography, season and use of fertilisers which influences the concentration 
in plants (McLaughlin et al., 2000). Although studies of some selected farmland in Ekiti 
reported copper concentration in soil below the permissible limit (Adeyeye, 2005; Isinkaye, 
2012), on the other hand a study of the soil and plants on dumpsites in Ekiti State revealed 
the concentration of copper above the WHO permissible limit in the soil sample and its high 
bioaccumulation in plant found at the dump site (Ayeni, Ajayi and Odeyemi, 2017). This is 
similar to findings from other parts of Nigeria (Ideriah et al., 2010; Idera and Oladele, 2015). 
Hence these may be responsible for the high concentration of copper in HMs found in Ekiti 
State (Table 4.2), although the source of the plants used for HM production cannot be 
established. Additionally, a significant concentration of copper was found in the soil of 
petroleum handling facilities above that of a control sample (Adeniyi and Afolabi, 2002) and 
auto workshop soil also showed a concentration above the WHO limit (Ololade, 2014). Thus 
there are indications that copper accumulation in soil and plant is directly linked to various 
human activities such as petroleum handling and waste disposal.  
 
But then copper is a vital micronutrient and constituent of various proteins involved in a 
number of biological pathways essential to life (Rucker et al., 1998; Sánchez-Ferrer et al., 
1995). At excess levels, copper can be toxic, with liver damage the most noticeable chronic 
effect (Zietz et al., 2003). At lower doses initial adverse reaction after acute exposure to 
copper is the vagal stimulation of the stomach, leading to a reflex response of nausea and 
vomiting (Araya et al., 2004). HM9 and HM5, for example, are being used by 13.69% and 
5.78% of the sample population respectively (n=1018) (Table 2.12). These samples contain 
58.888±6.604 ppm and 57.175±4.806 ppm of copper respectively (Table 4.2) which is 19 
times higher than the permissible limit (3 ppm). This high concentration may be responsible 
for nausea and vomiting that was experienced by 18.7% of respondents (n=1075) in this 
research (Table 2.17).  
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While this may be an acute reaction, the effect of chronic exposure through prolonged use 
may lead to serious problems such as liver injury. Hence, inorganic constituents such as 
copper may contribute as much to HM-induced liver injury as those caused by the organic 
constituents reported in a previous publication (Ma, Peng and Hu, 2014). In addition, a study 
from a Nigerian tertiary hospital reported that 45.5% of the risk factors for liver disease in the 
hospital were due to the use of herbs (Nwokediuko et al., 2013). Although a similar report is 
not available for Ekiti State, findings from Nwokediuko et al (2013) did not specify which 
constituent was responsible for the liver damage (organic or inorganic). Hence the need for 
further study in this regard, as recommended in Section 5.2. 
4.4.6 Lead 
As shown in Figure 4.10, the highest concentration of lead (33.374±3.720 ppm) was found in 
HM2 (a non-certified HM), exceeding the permissible limit of 10 ppm and 3 times above. 
Conversely, all other HMs had lead concentrations below the permissible limit.  
            
Figure 4.10: Average concentration of Lead in HM samples 
 
The range of lead concentration was between (1.396±0.052 ppm and 33.374±3.720 ppm). 
This was similar to the range (1.54 to 33.80 ppm) reported in Nigeria (Onwordi, Agbo and 
Ogunwande, 2015) and those obtained from some Chinese HMs (Zheng et al., 2013). The 
concentration of lead (2.727±0.226 ppm) in HM6 (certified HM sample; M&T capsule) 
obtained from this study was similar to that reported for the same HM (2.850 ppm) obtained 
from a different location (Onwordi, Agbo and Ogunwande, 2015). This may suggest 
consistency in lead concentration in the HM sample from the manufacturer and also the 
robustness of the method used in this study. Nor was there any significant variation in the 
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average concentration of lead detected in each HM sample except for HM2, HM8 and HM 10 
(Appendix XIII). There was also no significant variation in lead concentration between 
batches of HM sample, with the exception of HM8  
 
 Lead is a toxic metal which occurs naturally in the Earth‘s crust. Its extensive use has led to 
serious contamination of the environment, unsafe human exposure and public health issues 
in several more parts of the world (CDC, 2013c). Major sources of environmental 
contamination include industries such as smelting, mining, recycling and manufacturing and 
the persistent use of leaded products (paint, gasoline and aviation fuel) in some countries 
(Nigeria included) (Flora, Flora and Saxena, 2006). The initiative proposed to reduce the 
concentration of lead in gasoline to 0.15 g/L and finally to zero in Nigeria only exists on 
paper (Orisakwe, 2009). This is due to government negligence; predominance of old 
European used vehicles manufactured to run on lead gasoline and modern cars 
manufactured to use lead-free gasoline using leaded gasoline (Orisakwe, 2014). Lead is 
also used in various products such as ceramic glaze, paint, pigments, stained glass, lead 
crystal glassware, toys and jewellery and in some traditional medicines (Flora, Flora and 
Saxena, 2006). These human activities contaminate soil and water bodies with lead, which is 
eventually driven into the fauna and flora (Mclaughlin et al., 2000; Kingsley and Regina, 
2016; Adewumi et al., 2017). 
 
The elevated concentration of lead in soil samples above WHO permissible limit has been 
reported in petroleum handling areas in Nigeria (Adeniyi and Afolabi, 2002; Ololade, 2014; 
Nwaichi, Wegwu and Nwosu, 2014). This is not unusual considering the earlier discussion 
on the use of leaded gasoline. With 82.0% of respondents within the low-income group in 
this research (Table 2.6) and the high use of old vehicles designed to use leaded gasoline, it 
is inevitable that there will be a consequent environmental effect. Dumpsites and highway 
vegetation in Ekiti State have also been found to contain significant concentrations of lead 
(Awokumi et al., 2015) (Ajibulu et al., 2013), although other publications have reported lead 
concentration below the WHO permissible limit in other dump sites in Ekiti State (Shittu et 
al., 2015; Ayeni et al., 2017). Mining has been associated with contamination of soil with 
lead in China (Zhou et al., 2007), and in North West Nigeria (Tsuwang et al., 2014). Although 
cases of illegal mining have been reported in Ekiti State (The Nation, 2015), reports of heavy 
metal contamination as a result have not been documented. Conversely, analysis of 
farmland soil in Ekiti State reported a concentration of Pb below the WHO limit (Isinkaye, 
2012) or not detected in some cases (Adeyeye, 2005). But then, only one of the analysed 
HMs (HM2) had a lead concentration above the permissible limit in this study. 
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Regardless, children are especially predisposed to the harmful consequences of lead and 
may suffer severe and permanent adverse health effects, inhibiting the development of the 
nervous system and brain (Cleveland et al., 2008). Exposure of pregnant women to high 
levels of lead can lead to stillbirth, minor malformation, miscarriage, premature birth and low 
birth weight (Flora, Pachauri and saxena, 2011). The effect of lead in HM may thus relate to 
the findings in Table 2.27 where there was 7.7% HM associated stillbirth, 42.0% HM 
associated spontaneous premature labour (SPL) and 34% HM associated foetal 
abnormality. Although there is no direct correlation, these findings will form the basis for 
further research, as suggested in Section 5.3. Accumulation of lead even at well below 
nontoxic levels, can have serious health effects (Lanphear et al., 2005), hence being below 
permissible levels may not suggest safety. Continuous exposure even at a low dose may be 
detrimental, so the need for estimation of daily oral limit and the availability of clearly written 
HM dosage are essential, as further discussed in Section 4.4.12.  
 
Lead also causes long-term injury in adults, including kidney damage (Navas-Acien et al., 
2007), as discussed in Section 4.4.3 for cadmium and risk of high blood pressure. The 
likelihood of HM-induced hypertension by heavy metal constituents such as lead, cadmium 
and arsenic (Gyamlani and Geraci, 2007) may be a vital contributor to the high prevalence of 
hypertension (55.5%) in Ekiti State (Olamoyegun et al., 2016), the more so considering that 
85.0% of respondents used HM (Table 2.8) and heavy metals known to induce hypertension 
(lead, cadmium and arsenic) have been found in commonly used HM in this study. Therefore 
the need for stricter measures for certification of HM and monitoring has become essential. 
4.4.7 Mercury 
Mercury was not detected in any of the HMs using the validated method in this study, which 
may be due to non-use of hydride generation ICP-OES. However, some of the HMs were 
analysed externally at Analytix Limited using a Direct Mercury Analyser DMA-80 
autosampler system (Appendix XIV) as part of its marketing offer. Considering mercury 
volatility, the analyser among other operating mechanisms traps mercury vapour for 
analysis; this is one of its advantages (Analytix, 2018). 
The concentrations reported were HM1 (Sample 1) 7.65 ppb, HM2 (Sample 2) 15.80 ppb, 
HM4 (Sample 4) 0.203 ppb which were below the permissible limit of mercury (0.1 ppm) in 
herbal product (FAO/WHO, 1984). Other publications have reported the detection of mercury 
in HM samples (Adepoju-Bello et al., 2012) and some above permissible limits (Osadolor et 
al., 2015; Martena et al., 2009), although some others did not detect mercury (Idu, Oghale 
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and Jimoh, 2015).  Thus mercury content of HM likely varies with location and detection in 
HM may depend on the method LOD, which should be lower than the permissible limit. 
 
Mercury exists as elemental mercury mainly in nature or as sulphide and exists in the earth‘s 
crust at about 0.5 ppm.  Anthropogenic mercury sources include mining (mercury and gold in 
particular) (Zeitz, Orr and Kaye, 2002). Human mercury exposure occurs mainly via 
ingestion of mercury attached to organic moieties (methyl, ethyl or dimethyl mercury) (WHO, 
1991; Richardson, 1996). Mining has been associated with significantly high concentrations 
of mercury in the soil of the northwestern part of Nigeria (Tsuwang et al., 2014). The 
contribution of oil spillage in the Niger Delta area to high mercury concentration in soil and 
water above WHO permissible limit has been reported (Odunaike et al., 2013). High levels of 
mercury in the Ibadan southwest waterbody as a result of improper disposal of industrial 
effluent (into waterbody) have also been reported (Fakayode, 2005). A high concentration of 
mercury in the soil around automobile waste dump sites has been documented (Iwegbue, 
2006b). All these human activities have an effect on the concentration of mercury in plant 
and by extension in HM. 
 
Chronic exposure to elemental mercury at low-grade induces milder clinical findings and 
symptoms such as anorexia, gastrointestinal distress, weakness, fatigue and weight loss 
(Lucchini et al., 2002). At higher levels of exposure fine tremor with coarse shaking occurs 
and also gingivitis, erethism, excessive salivation and immune dysfunction (Meyer-Baron, 
schaeper and Seeber, 2002; Park et al., 2000). Concentrations of mercury in HMs analysed 
were below the permissible limit. However, this does not render redundant precautionary 
screening of HM for mercury content for public health safeguarding. 
4.4.8 Manganese 
The highest concentration of manganese (193.544±7.813 ppm) was found in HM3 (Figure 
4.11), although this concentration and those obtained for other HM samples are all within the 
permissible limit of 339 ppm. The range of manganese concentration detected in the HMs 
was between 30.578±3.292 ppm and 193.544±7.813 ppm, which is within the permissible 
range of 44.6 ppm and 339 ppm (Table 4.2). Similar studies have reported much lower 
manganese concentrations in selected HM in Nigeria; 0.475 ppm and 1.446 ppm  (Umar et 
al., 2016) and 0.012 ppm to 0.702 ppm (Ekeanyanwu et al., 2013). However, a higher 
concentration range as found in this study has been reported in selected HM from China 
(Zheng et al., 2013) and dry plant mass in Romania (Senila et al., 2014).  
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                      Figure 4.11: Average concentration of manganese in HM samples 
 
Statistical analysis, however, shows only HM6 and HM8 had a significant variation in the 
concentration of manganese obtained from different locations (Appendix XIII). 
 
Manganese is found in the environment mainly in its oxidised form either as Mn3O4 or MnO2 
(Nadaska, Lesny and Michalik, 2012). It is an element essential to human health as a co-
factor in many enzymes and it is a requirement in normal growth, maintenance of immune 
cell activities and nerves, regulation of blood vitamins and sugar amid other functions 
(Guilarte, 2010; Aschner et al., 2007). Manganese is required at small levels through dietary 
intake, but exposure to food or water contaminated with high levels can portend toxic 
outcomes.  
 
Industries such as mining of manganese dioxide, manufacturing of (dry-cell battery steel, 
aluminium cans, electronics,) smelting, welding, fungicides, pesticides and fertilisers have 
contributed to the increased manganese levels in the environment with eventual human 
toxicity (Keen and Lonnerdal, 1995; Ono, Komai and Yamada, 2002; Wang et al., 1998; 
Ferraz et al., 1988). Some of these activities also take place in Ekiti State, especially the use 
of pesticides, fungicides and fertilisers. However, the concentration of manganese in Ekiti 
farmland was found to be within acceptable limits (Isinkaye, 2012). Also, manganese uptake 
did not exceed the WHO limits for crops in test samples in an oil spill area in Nigeria 
(Nwaichi et al., 2014). In addition, the concentration of manganese in Ekiti dumpsite soils 
was reported to be generally lower than the permissible limits, but concentrations were 
higher than the permissible limit in plants (Shittu et al., 2015). This may indicate atmospheric 
deposition of the heavy metal in plants.  
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The major pathway for Mn absorption is oral via the gastrointestinal tract (Nadaska, Lesny 
and Michalik, 2012). Manganese toxicity is prominent in the central nervous system (Huang 
et al., 1993; Calne et al., 1994) although cardiovascular (Brurok et al., 1997) and liver 
(Goering, 2003), as well as reproductive and developmental toxicities (Sanchez et al., 1993), 
have also been noted. Hence the effect of manganese toxicity may be responsible for some 
of the HM-related obstetric outcomes and casualties highlighted in this study (Section 2.15). 
However, all analysed HM in this study had a manganese concentration within the 
permissible limit; but this does not render otiose further monitoring for quality control. 
4.4.9 Nickel 
 From Figure 4.12 it can be observed that the concentration of nickel was highest in HM8, an 
(uncertified) sample (8.234±0.352 ppm), which is 5 times higher than the permissible limit at 
1.6 ppm (WHO, 2007). Other HM samples above the permissible limit include certified 
samples HM1, HM2, HM9 and uncertified samples HM3, HM5 and HM10, while HM4, HM6 
and HM7 had a concentration of nickel below the permissible limit (Table 4.2). 
 
 
                  
                           Figure 4.12: Average concentration of nickel in HM samples 
 
The concentration of nickel ranged between (1.384±0.148 ppm and 8.234±0.352 ppm), 
which is lower compared with those found in selected HMs previously analysed in Nigeria 
(0.730 ppm to 54.000 ppm) (Onwordi, Agbo and Ogunwande, 2015) but close to those 
reported in China (0.4132 to 5.1210 ppm) (Zheng et al., 2013) and Turkey (0.650 to 8.690 
ppm) (Soylak et al., 2004). Nonetheless, the concentration of nickel in HM6 (1.706±0.299 
ppm) (Table 4.2) was close to that reported for the same HM (M&T capsule) in a previous 
0
1
2
3
4
5
6
7
8
9
10
A
ve
ra
ge
 c
o
n
ce
n
tr
at
io
n
 o
f 
 N
ic
ke
l 
  (
p
p
m
) 
HM Samples 
156 
article at 2.480 ppm (Onwordi, Agbo and Ogunwande, 2015). The difference could be as a 
result of variation in the location, although findings from this study showed no significant 
variation in concentration of nickel between locations (Appendix XIII). The inter-batch 
variation in this study was an intra-state variation in location, while the sample obtained for 
the analysis in the publication mentioned was obtained in Lagos. This may suggest inter-
state variation, probably as a result of a different manufacturing factory or source of the raw 
material, though both concentrations (cited and observed in this study) were above 
permissible limits. 
 
Nickel is naturally occurring and essential trace metal for the nutritional needs of plants 
(Scott-Fordsmand, 1997; Barceloux, 1999; Klaassen, 1996). The major sources of trace 
metal pollution (especially As, Cr, Cu, Mn and Ni) in water bodies are non-ferrous metal 
smelters and domestic wastewater effluents with easy accumulation of these metals in 
aquatic plants (WHO, 1991; Barałkiewicz and Siepak, 1999). Nickel gets into the ambient air 
from activities such as combustion of fuel oil, diesel oil and coal, including the incineration of 
various wastes (Clayton and Clayton, 1994; Von-Burg, 1997) and may eventually find its way 
into flora. 
 
Nickel is widely distributed evenly through the soil, but essentially accumulates on the 
surface of soil through deposition from various agricultural and industrial activities. A few 
foods may have acquired nickel through the manufacturing process, but in many cases, it is 
present naturally (WHO, 1991). The concentration of nickel in dumpsite soils was reported to 
be generally lower than the permissible limits but was higher than the permissible thresholds 
in the plants which grew on them (Shittu et al., 2015). There was report of a rapid increase in 
the level of Pb, Cd, Cu, Ni, and Zn with proximity to highways; with the metal concentration 
at a 50 m distance from the road nearing that of the natural background concentrations of 
the metals at the control sites. This may suggest metal deposits from automobile fuel 
combustion (Fakayode and Olu-Owolabi, 2003). Nonetheless, the concentration of nickel 
found in dumpsite soil in Ekiti State was below WHO limits; likewise, the nickel concentration 
found in the plants grown on them (Ayeni, Ajayi and Odeyemi, 2017). The effect of poor 
petroleum product handling on the environment has been reported, with a significant amount 
of nickel found in the soil around petroleum handling areas in Nigeria (Adeniyi and Afolabi, 
2002) as also seen in other parts of the World (Davies,1997). Also, nickel concentration was 
above WHO limit in soil samples taken from auto workshops in southwest Nigeria (Fakayode 
and Olu-Owolabi, 2003; Ololade, 2014). These factors may also account for bioaccumulation 
of nickel in Ekiti State flora; which may eventually end up in the HMs studied. 
157 
Oral exposure is the main route of nickel toxicity which mainly targets the kidney and also 
affects the immune system, blood and the cardiovascular systems (Young, 1995; Nielsen et 
al., 1999). In addition, general population exposure to nickel is primarily through oral 
ingestion via contaminated water and food (Cempel and Nikel, 2006), of which HM is a part. 
Hence the focus of toxicity again targets the kidneys as with other metals such as arsenic, 
cadmium, lead and mercury. At present, there is no information on the chronic toxicity of 
nickel in humans. 
4.4.10 Selenium 
Selenium concentrations in all the HM samples were below the 25 ppm permissible limit 
(WHO, 2007). The highest concentration was found in HM6 at 9.023±0.789 ppm and the 
lowest concentration found in HM3 at 2.281±0.114 ppm (Figure 4.13).  
  
                
                        Figure 4.13: Average concentration of selenium in HM samples 
 
The range of selenium concentration in this study is similar to that reported in HM from 
previous studies (0.232 to 6.460 ppm) in China (Zheng et al., 2013). 
There was no significant variation in the concentration of selenium across the various 
locations for each HM sample (Appendix XIII). This is with the exception of HM7 (uncertified 
HM), which showed a significant variation in selenium concentration between different 
locations. 
  
Selenium is a naturally occurring mineral required for good health and is abundant in a 
diverse diet from vegetables grown on seleniferous soils, grains, cereals and animal 
products such as fish, milk, eggs and meat (Lipiec et al., 2010; Fairweather-Tait et al., 2010; 
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Surai et al., 2009). The selenium dietary intake is influenced naturally by the selenium 
composition of soils on which the plant is grown (Thompson, 2004). Industries such as coal 
burning, mining and smelting of sulphide ores further contribute significantly to the pollution 
of the environment with selenium, including the soil (ATSDR, 2009). Previous analysis of 
farmland soil samples in Ekiti State did not detect selenium (Adeyeye, 2005). Analysis of soil 
in Kogi State showed one of the examined sites had selenium level above WHO limits (Oklo 
et al., 2013). Another study reported the concentration of selenium above the WHO limit in 
shallow groundwater in the residential and commercial areas of the metropolis of Ibadan, 
Nigeria (Effiong, 2017). These publications indicate that the bioavailability of selenium varies 
across locations, as reported by Thompson (2004), and its bioavailability in plants.  
 
Selenium is essential in the regulation and maintenance of numerous cellular functions such 
as signal transduction, enzyme catalysis and at trace level for brain function (Rayman, 
2000). However, it can result in acute or chronic toxicity at increased serum concentrations 
(Nuttall, 2006). At higher concentrations in soil selenium is taken up by plants leading to 
acute or chronic selenium toxicity in humans when consumed (Fan and Kizer, 1990; ATSDR, 
2003). Its effect at increased levels is associated with several clinical findings and symptoms 
such as fatigue, nausea, memory loss, muscle and joint pain, musculoskeletal complaints, 
nail discoloration or brittleness, diarrhoea and vomiting (MacFarquhar, Broussard and 
Melstrom, 2010). Of all the metals, selenium has the smallest range between dietary 
deficiency and toxicity, deficient below 40 μg/day and toxic over 400 μg/day (Nuttal, 2006). 
As a result, selenium requires meticulous control of its human exposure. From the point of 
view of this study, this may not be a source of concern, considering concentrations were all 
below permissible limits. However, precautionary screening is essential as a requirement for 
certification of HMs in Ekiti State.  
4.4.11 Zinc 
Figure 4.14 shows HM2 (uncertified sample) had the highest concentration of zinc 
(131.428±6.662 ppm) and was the only one with a concentration above the permissible limit 
of 100 ppm (WHO, 2017). The range in zinc concentration was between 5.557±0.748 ppm 
and 131.428 ppm. This is higher than those reported previously in Nigerian HM, 8.500 and 
38.900 ppm (Onwordi, Agbo and Ogunwande, 2015), 0.030 ppm and 0.420 ppm (Idu, 
Oghale and Jimoh, 2015), in Turkey 7.840 and 47.600 ppm (Soylak et al., 2004) and in 
Romania 18.800 and 64.400 ppm (Senila et al., 2014). But it is similar to the range detected 
in HM in China (6.574 and 162.410 ppm) (Zheng et al., 2013). The concentration of zinc in 
HM6 from this research (19.286±1.269 ppm) (Table 4.2) was higher than that previously 
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reported for the same sample (2.350 ppm) obtained from another state of Nigeria (Onwordi, 
Agbo and Ogunwande, 2015). 
 
             
                        Figure 4.14: Average concentration of Zinc in HM samples 
 
The explanation for this is similar to those with similar findings discussed earlier. Significant 
variation was observed in the concentration of zinc in HM6 samples obtained from different 
locations in the state (Appendix XIII). Likewise, there was no significant variation in the 
concentration of zinc across various locations in the state for the remaining HM samples, as 
further discussed in Section 4.4.13. 
 
Human metabolism including the translation and replication of genetic material is driven by 
proteins and enzymes which contain zinc (Keith, Chih-chin and Carol, 2000). Zinc enters the 
environment through natural and anthropogenic activities. However, anthropogenic sources 
significantly account for more zinc in the environment than natural sources (Davies and 
Jones, 1988). The major sources of anthropogenic zinc in the environment (air, soil and 
water) are associated with metallurgic and mining activities (Wuana and Okieimen, 2011); in 
addition to the use of zinc in commercial products such as wood preservatives and fertilisers 
(Chaney, 1993). 
 
In Ekiti State some of these activities, such as illegal mining, application of fertilisers and 
improper waste disposal are pursued and possibly contribute to anthropogenic zinc deposits. 
A study reported levels of zinc above the permissible limit in some agricultural farmlands 
(Adeyeye, 2005) in Ekiti State, although another study reported zinc levels in agricultural 
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farmlands below the permissible limit (Isinkaye, 2012). This may be a reflection of various 
activities going on in the various locations; and may be a result of the persistent application 
of zinc-containing fertiliser or pesticides on the latter (Jones and Jarvis, 2015). However, the 
concentration of zinc in an Ekiti State dumpsite soils was reported to be lower than the 
permissible limits (Shittu et al., 2015). Additionally, the uptake of zinc in plants found in oil- 
spill affected agricultural areas of Nigeria resulted in levels below the permissible limit for 
plants (Nwaichi et al., 2014). Another study reported Zn levels above the permissible limit in 
an auto workshop (Ololade, 2014). In addition, a published report showed an association 
between fuel combustion in cars with zinc deposits in plants (Fakayode and olu-owolabi, 
2002) and contributions from an atmospheric source (Shittu et al., 2015). However, the 
results from this research showed all the HM samples had Zn levels below the WHO 
permissible limits, with the exception of HM2. So the presence of zinc in HM2 may reflect the 
activity around the source and the materials used in the manufacturing process. None of this 
can be ascertained because HM2 is not certified, with little or no information available on its 
content (see Table 4.1). 
 
Absorption of toxic a concentration of zinc results in immediate symptoms such as nausea, 
abdominal pain, vomiting and later effects such as dizziness, lethargy and anaemia (Porea, 
Belmont and Mahoney, 2000). Chronic toxicity of zinc has been reported to be associated 
with copper deficiency (Ogiso et al., 1974). Copper deficiency presents with common 
symptoms which include leukopenia, anaemia, neutropenia, hypocupremia, impaired iron 
mobilisation, elevated plasma cholesterol and Low-Density Lipoproteins (LDL): High-Density 
Lipoproteins (HDL) cholesterol and abnormal cardiac activities (Sandstead, 1995; Fiske, 
McCoy and Kitchens, 1994). Hence HM2 with a zinc concentration above the permissible 
limit may be unhealthy, especially with prolonged use. The daily oral limit is discussed in 
section 4.4.12 
4.4.12:  Estimation of daily metal intake 
With little or no information available, the amount of metal per dose cannot be estimated for 
some of the HM samples. This applies to all uncertified samples with no or an ambiguous 
prescription such as ―daily for two days‖ (HM5) or ―one spoon twice daily‖ (HM4) (Table 4.1). 
Nonetheless, certified HM samples had their prescription properly written out, which is a 
regulatory requirement. Hence it was possible to estimate the daily metal intake. 
For example, Cd in HM1 has a concentration of 0.723 ppm (Table 4.2), which is the same as 
0.723 µg/g 
Each capsule‘s (HM1) content weighed 0.366 g  
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Therefore each capsule contains 0.366 X 0.723 = 0.241 µg of Cd. 
According to Table 4.1, the dosage for HM1 is 3 capsules twice daily. Thus a total of 6 
capsules a day is recommended for HM1 according to the manufacturer. 
Therefore daily intake of Cd from HM1 = 6 X 0.241 = 1.446 µg/day 
 Calculations for the other target metals that were above permissible limits in the HM 
samples that had a prescription are contained in Table 4.4 below. 
Table 4.4: Daily oral exposure of metals in some HM sample 
Metals HM1 
(0.366 g/capsule) 
HM3 
(0.322 g/capsule) 
HM6 
(0.277 g/capsule) 
HM9 
(0.342 g/capsule) 
 Amount 
in 
capsule 
(µg) 
Daily 
intake 
(µg/day)  
Amount 
in 
capsule 
(µg) 
Daily 
intake 
(µg/day) 
Amount 
in 
capsule 
(µg) 
Daily 
intake 
(µg/day) 
Amount 
in 
capsule 
(µg) 
Daily 
intake 
(µg/day) 
Cd 0.241 1.446 0.171 0.684 0.129 0.774 0.157 0.942 
Cr 3.159 18.952 - - - - 1.337 8.022 
Cu 5.539 33.234 4.751 19.004 3.142 18.85 20.140 120.000 
Ni 1.055 6.33 0.928 3.712 - - 1.752 10.512 
Cd = Cadmium; Cr = Chromium; Cu = Chromium;   Ni = Nickel 
Cadmium has a daily oral limit of 60 µg/day, chromium a daily limit of 20 µg/day (Table 4.3). 
The daily oral limit for copper and nickel are not stated. From these set limits the HM 
samples are within the daily oral limit of cadmium and chromium. This indicates that though 
the concentration of metals may be above the permissible limit in the HM, the quantity taken 
determines the amount of metals consumed by a user. While this may be true, the duration 
and frequency of use may have a significant impact on the amount of heavy metals which 
may gradually accumulate in the user even at levels below permissible limits. As an 
example, chronic low exposure to cadmium caused a decline in glomerular filtration rate 
(GFR) and damage to the renal proximal tubular in experimental animals (Thijssen et al., 
2007). 
But most of the HM samples did not include the duration of use, and it is important in 
discussing bioaccumulation of metals in humans. Therefore regulatory steps need to be 
taken to ensure prescriptions are properly written to ensure safety. In addition, sourcing of 
plant materials for HM is essential considering various activities affect their heavy metal 
composition, as discussed in Section 4.4.2 to 4.4.11. Accordingly, the intra-batch and inter-
batch concentration of heavy metals in HM samples is analysed. 
4.4.13: Intra-batch and Inter-batch concentration variability 
The elemental variation between samples from each HM (Intra-batch variation) and the 
variation of the average elemental concentration in HMs between different geographical 
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locations (inter-batch variation) were examined and presented in Tables 4.5 and 4.6 for HM 
1 (others in Appendix XIII). A two-way ANOVA statistical analysis was then carried out to 
determine how significant these variations were. The result of the statistical analysis is 
presented in Table 4.7 for HM1, the other results in Appendix XIII. 
As earlier discussed for the individual metals analysed in Section 4.4.2 to 4.4.11, statistical 
analysis of intra-batch variability showed varying results. Analysis of target metals in HM 1, 
for example (Table 4.7), showed some had significant intra-batch variation, as seen with 
arsenic across all batches (others in Appendix XI). This may indicate inconsistency in the 
within-batch samples as it contains various constituents (Table 4.1). However, adequate 
steps were taken to ensure the homogeneity of the samples through their thorough mixing 
before analysis (Section 3.6.3.2). On the other hand, cadmium only had significant intra-
batch variability across three batches. Furthermore, analysis of Cd from the 4th batch 
(location 4) and 5th batch (location 5) of HM1 showed no significant intra-batch variation, 
which may suggest consistency within the sample.  
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                          Table 4.5:   Intra-batch concentration of metals in HM1  
Element Concentration (ppm) 
Arsenic  Sample 1 
n=3 
Sample 2 
n=3 
Sample 3 
n=3 
Sample 4 
n=3 
Average Conc 
Location 1 0.228±0.018 0.231±0.014 0.212±0.012 0.228±0.015 0.225±0.015 
Location 2 0.212±0.012 0.249±0.013 0.253±0.010 0.254±0.013 0.242±0.012 
Location 3 0.218±0.012 0.209±0.019 0.213±0.022 0.234±0.012 0.219±0.016 
Location 4 0.263±0.013 0.237±0.016 0.293±0.017 0.244±0.017 0.259±0.016 
Location 5 0.230±0.017 0.198±0.017 0.233±0.015 0.214±0.014 0.219±0.016 
 
Cadmium Location 1 0.991±0.041 0.919±0.034 0.882±0.032 0.881±0.042 0.918±0.037 
Location 2 0.741±0.042 0.729±0.024 0.672±0.039 0.641±0.033 0.696±0.036 
Location 3 0.731±0.042 0.719±0.036 0.682±0.038 0.626±0.037 0.690±0.036 
Location 4 0.714±0.043 0.702±0.028 0.665±0.022 0.599±0.047 0.676±0.037 
Location 5 0.674±0.038 0.662±0.028 0.625±0.029 0.559±0.041 0.637±0.034 
 
Chromium Location 1 8.333±0.760 8.226±0.865 8.139±0.509 9.034±0.367 8.437±0.629 
Location 2 7.881±0.652 7.796±0.343 8.693±0.588 7.990±0.685 8.089±0.565 
Location 3 9.097±0.733 9.791±0.336 8.892±0.470 8.985±0.838 9.189±0.596 
Location 4 8.119±0.756 8.022±0.674 8.225±0.931 8.921±0.531 8.327±0.726 
Location 5 9.016±0.768 8.812±0.503 9.714±0.363 8.903±0.586 9.111±0.558 
       
Copper Location 1 15.441±1.317 16.453±0.815 14.500±0.957 15.557±1.219 15.486±1.079 
Location 2 14.472±0.915 15.176±0.815 14.271±0.573 14.368±0.882 14.574±0.795 
Location 3 14.726±1.019 13.989±0.756 14.815±0.791 14.079±0.917 14.437±0.874 
Location 4 13.861±0.835 14.573±0.437 13.684±0.571 13.771±0.659 13.979±0.629 
Location 5 17.096±1.324 17.798±0.926 16.892±1.065 16.987±1.142 17.196±1.114 
 
Lead Location 1 4.805±0.445 4.675±0.187 4.283±0.150 4.474±0.593 4.560±0.344 
Location 2 4.180±0.263 4.357±0.145 3.838±0.176 3.987±0.235 4.091±0.205 
Location 3 2.560±0.420 2.672±0.095 2.276±0.055 2.367±0.309 2.468±0.219 
Location 4 4.397±0.595 4.903±0.068 4.075±0.261 4.238±0.354 4.403±0.320 
Location 5 4.386±0.471 4.722±0.145 4.063±0.103 4.183±0.200 4.339±0.230 
 
Manganese Location 1 61.709±3.203 59.874±1.413 53.658±1.788 51.965±2.497 56.801±2.225 
Location 2 57.855±4.069 60.020±2.675 49.803±2.963 53.110±3.743 55.197±3.362 
Location 3 58.141±3.731 61.305±2.667 52.089±2.767 51.396±3.620 55.733±3.196 
Location 4 56.813±4.556 59.318±3.028 52.490±2.623 47.653±4.143 54.068±3.587 
Location 5 55.452±5.530 56.788±3.954 50.129±4.044 47.249±4.509 52.404±4.509 
 
Nickel Location 1 6.188±0.369 5.853±0.190 5.137±0.228 5.444±0.299 5.655±0.271 
Location 2 4.476±0.294 4.540±0.155 3.724±0.184 4.031±0.262 4.193±0.224 
Location 3 6.170±0.374 6.335±0.268 5.518±0.278 5.425±0.363 5.862±0.321 
Location 4 4.936±0.391 5.441±0.338 4.613±0.298 4.657±0.450 4.912±0.369 
Location 5 6.069±0.386 6.405±0.329 5.747±0.338 5.190±0.384 5.853±0.359 
 
Selenium Location 1 9.402±0.702 9.067±0.523 8.351±0.561 8.658±0.632 8.869±0.604 
Location 2 9.078±0.347 9.143±0.207 8.327±0.236 8.633±0.314 8.795±0.276 
Location 3 6.685±0.310 7.594±0.215 6.778±0.225 7.430±0.321 7.122±0.268 
Location 4 8.613±0.370 9.441±0.410 9.256±0.463 8.257±0.522 8.892±0.441 
Location 5 6.287±0.566 6.623±0.509 5.965±0.518 5.408±0.564 6.071±0.539 
 
Zinc Location 1 89.709±7.725 95.374±4.935 80.658±3.310 81.964±5.879 86.926±5.462 
Location 2 86.643±8.979 90.708±5.584 79.892±4.281 80.199±8.319 84.360±6.791 
Location 3 87.800±5.941 89.964±2.190 80.148±4.290 82.055±6.143 84.992±4.641 
Location 4 85.239±5.742 82.425±5.690 71.597±5.649 73.241±5.801 78.126±5.721 
Location 5 90.635±9.518 88.970±5.764 81.312±6.515 78.755±7.811 84.918±7.402 
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In  HM samples obtained across 5 locations, there was no significant inter-batch variability of 
all target elements in HMs 2, 3, 4, 5, 9 and 10 (Appendix XIII). There was a significant inter-
batch variation of arsenic in HM1 (Table 4.7). Other HMs had significant inter-batch variation 
of Mn and Zn in HM6; Se in HM 7; Mn and Pb in HM 6. Herbal medicines 1 and 6 are 
manufactured by the same registered herbal medicine company in Nigeria. Hence, to meet 
commercial demand, it possibly sources its raw material from different places with likely 
anthropogenic contamination from e.g. petrochemicals and agrochemicals, as discussed 
earlier in Sections 4.4.2 to 4.4.11. This may be responsible for the significant inter-batch 
variation in arsenic for HM1 (P = 0.001) (Table 4.7), manganese and zinc in HM6 (P = 0.027 
and 0.010 respectively) (Appendix XIII). 
      
Table 4.6: Inter-batch concentration of metals in HM1 
*Locations where HM samples were obtained (refer to section 3.4.6 chapter 3). 
 
The manufacturing process may also be a possible contributor to heavy metal 
contamination, e.g. from transport, the contact surface material of processing equipment, 
use of contaminated water, additives, preservatives and packaging (Morgan, 1999), which 
may vary across batches. The contribution of the manufacturing process to batch variability 
may be more prominent in small government-unregistered manufacturer which still employs 
a crude process in the manufacture of their products, as may be observed in HM 7 and 8 
appearance and packaging (Appendix XVII). These crude manufacturing processes possibly 
keep production cost minimal and thus enhance profit. 
Element Concentration (ppm) 
 *Location 1 
n=12 
*Location 2 
n=12 
*Location 3 
n=12 
*Location 4 
n=12 
*Location 5 
n=12 
Average conc 
Arsenic  0.225±0.015 0.242±0.012 0.219±0.016 0.259±0.016 0.219±0.016 0.233±0.018 
 
Cadmium 0.918±0.037 0.696±0.036 0.690±0.036 0.676±0.037 0.637±0.034 0.723±0.036 
 
Chromium 8.437±0.629 8.089±0.565 9.189±0.596 8.327±0.726 9.111±0.558 8.630±0.615 
 
Copper 15.486±1.079 14.574±0.795 14.437±0.874 13.979±0.629 17.196±1.114 15.134±0.898 
 
Lead 4.560±0.344 4.091±0.205 2.468±0.219 4.403±0.320 4.339±0.230 3.972±0.264 
 
Manganese 56.801±2.225 55.197±3.362 55.733±3.195 54.068±3.587 52.404±4.509 54.841±3.376 
 
Nickel 5.655±0.271 4.193±0.224 5.862±0.321 4.912±0.369 5.853±0.359 5.295±0.309 
 
Selenium 8.869±0.604 8.795±0.276 7.121±0.268 8.892±0.441 6.071±0.539 7.950±0.423 
 
Zinc 86.926±5.462 84.360±6.791 84.992±4.641 78.126±5.721 84.918±7.402 83.864±6.003 
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Table 4.7: Intra-batch and inter-batch variability of heavy metals in HM1 
  
   Metals / Location Intra-batch variability Inter-batch variability 
P- value Sig. P-value Sig. 
Arsenic     
Location 1 0.003 Yes  
 
0.001 
 
 
Yes 
Location 2 0.003 Yes 
Location 3 0.018 Yes 
Location 4 0.010 Yes 
Location 5 0.008 Yes 
Cadmium     
Location 1 0.010 Yes  
 
0.111 
 
 
No 
Location 2 0.004 Yes 
Location 3 0.029 Yes 
Location 4 0.113 No 
Location 5 0.398 No 
Chromium     
Location 1 0.058 No  
 
0.282 
 
 
No 
Location 2 0.021 Yes 
Location 3 0.008 Yes 
Location 4 0.314 No 
Location 5 0.397 No 
Copper     
Location 1 0.068 No  
 
0.243 
 
 
No 
Location 2 0.002 Yes 
Location 3 0.070 No 
Location 4 0.003 Yes 
Location 5 0.040 Yes 
Lead     
Location 1 0.011 Yes  
 
0.954 
 
 
No 
Location 2 0.002 Yes 
Location 3 0.001 Yes 
Location 4 0.016 Yes 
Location 5 0.094 No 
Manganese     
Location 1 0.728 No  
 
   0.399 
 
 
  No 
Location 2 0.034 Yes 
Location 3 0.081 No 
Location 4 0.828 No 
Location 5 0.496 No 
Nickel     
Location 1 0.002 Yes  
 
0.691 
 
 
No 
Location 2 0.003 Yes 
Location 3 0.004 Yes 
Location 4 0.218 No 
Location 5 0.013 Yes 
Selenium     
Location 1 0.001 Yes  
 
0.398 
 
 
No 
Location 2 0.119 No 
Location 3 0.879 No 
Location 4 0.120 No 
Location 5 0.721 No 
Zinc     
Location 1 0.173 No  
 
0.665 
 
 
No 
Location 2 0.717 No 
Location 3 0.039 Yes 
Location 4 0.082 No 
Location 5 0.665 No 
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The effect of manufacturer‘s inter and intra-batch variability of excipients in pharmaceutical 
products on processability, quality, and performance of the finished drug product cannot be 
underestimated (Chatlapalli and Rohera, 2002), because it affects quality assurance. 
Likewise, intra and inter-batch variations of impurities of illicit drugs have been used to 
characterise the source and route of some illicit drugs (Kunalan et al., 2009). Variability in 
HM metal concentration may also be used to evaluate the impact of the activities going on in 
the areas where the raw materials are sourced (if declared), although other factors may also 
contribute to such variability. Regardless, detection and variability of heavy metals in HM still 
raises concerns with regard to their safety, as discussed earlier in Section 1.6. 
 In this study, there was inter-batch and intra-batch variation of target metals analysed in the 
various HM samples, as seen in Tables 4.5 and 4.6 respectively for HM1 (others in Appendix 
XI and XII). Challenges in HM quality control such as variable quality and source of the raw 
material together with the varying chemical and natural components of plant materials have 
been said to be possible contributors to inter-batch variation (Kunle et al., 2012). Since the 
source of the raw material possibly contributes to the presence of metals in HM samples, 
documentation of such by manufacturers has become imperative for detailed and correlation 
studies. However, most of the HM analysed in this research had no information on the 
source of the raw material. 
4.4.14 Summary 
In summary, all the HM samples both certified and uncertified, contain heavy metals and 
some above permissible limits. The presence of these metals in soil and water bodies with 
subsequent bioaccumulation in plants results from various human activities. Improper waste 
disposal, mining, poor handling of petrochemical products, by-products of car fuel 
combustion and other human activities that are peculiar to the study environment have been 
reported markedly to increase heavy metal deposits in plants (Section 4.4.2 to 4.4.11). This 
may also contribute to significant inter-batch and intra-batch variation, depending on where 
the plant products are sourced.  Table 4.8 below gives a brief overview of the HM samples 
and their status with regard to the permissible limits. The green cells indicate metals present 
within the permissible limit; the red cells indicate those above permissible limits, while the 
purple cells indicate undetected metals.  
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Table 4.8: Table showing HM sample metals above and below the permissible limit 
 Arsenic 
 
Cadmium 
 
Chromium 
 
Copper 
 
Lead 
 
Mercury 
 
Manganese 
 
Nickel 
 
Selenium 
 
Zinc 
 
HM1           
HM2           
HM3           
HM4           
HM5           
HM6           
HM7           
HM8           
HM9           
HM10           
 
 
 
According to Table 4.8, HM2 had the most metals (6) above the permissible limit and was 
the only HM sample containing lead and zinc above such limit. Herbal medicine 2 is an 
uncertified herbal product, bearing no manufacturer‘s name, content or dosage (Table 4.1). 
However, its appearance is similar to that of the charred products of unknown substances 
(Appendix XVII). The charring, which is likely a production process, may have further 
contributed to the presence of metals.  
While the estimation of oral intake was not possible for some of the HM samples, due to the 
absence of needed information, other HM samples provided this (Table 4.1). However, 
despite being able to estimate the daily oral intake of metals from some of the HM samples, 
lack of information on duration of use poses a further setback. This is because 
bioaccumulation of metals to toxic levels is possible from continuous exposure even below 
permissible limits, as discussed in sections 4.4.2 to 4.4.11. Noteworthy is the fact that 53% 
of the respondents in this study used HM more than 10 times in the preceding 2 years (Table 
2.11). 
 
 
 
 Below permissible limit  Above permissible limit  Not detected 
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CHAPTER 5: HERBAL MEDICINE USE IN EKITI STATE; GENERAL DISCUSSION OF 
EPIDEMIOLOGICAL AND ANALYTICAL FINDINGS 
5.1 General discussion  
The high awareness (100%) of HM in this study population (Section 2.12.4) may be a result 
of the many historical perspectives of HM use (Olayiwola, 1987). The introduction of 
orthodox medical care and its advances in Ekiti State provided a choice in health care 
decisions for the populace. Whilst orthodox medicine with the use of pharmaceutical 
compounds has developed through rigorous scientific procedure, the same cannot be said of 
African traditional medicine, which has HM at the heart of its practice. As a result, the safety 
and efficacy of HM remain problems, though in this study 85.0% of the respondents 
(n=1265) have used HM in the last 2 years (Table 2.8) and 53.0% have used it over 10 times 
in the same period. Conversely, deaths or hospitalisations due to HMs are rare (Nasri and 
Shirzad, 2013), but a lot of concerns have been expressed about the adulteration and 
contamination of HM and subsequent health consequences (Ang and Lee, 2000; Ang, 2008; 
Ernst, 2002a; Snyman et al., 2005).   
In a country like Nigeria, HM samples and associated products are sold without any 
compulsory toxicological or safety assessment, due to lack of effective analytical 
instrumentation and weak regulations to guide the manufacturing process and quality control 
standards. In addition, these herbal products are persistently provided to consumers without 
a prescription in many instances (Bandaranayake, 2006), as highlighted in this study, 
especially in the case of uncertified HMs (Table 4.1). This is coupled with the fact that 
hazards associated with a substandard product are not fully understood by the consumer. 
Accordingly, a NAFDAC registration number (as seen in Table 4.1) often distinguishes 
certified HM from uncertified to ensure safety in Nigeria (Ofuani, Kuye and Ogundele, 2015), 
and this was recognised by 90.0% of the respondents in this study (Table 2.7). This makes 
consumers depend fully on the NAFDAC registration number printed on the product to show 
that the product has passed through thorough clinical or laboratory tests and is certified fit for 
consumption and distribution. However, 37.3% of the respondents (n=1075) still used 
uncertified HM, while 31.9% used both uncertified and certified (Table 2.10). 
Lots of counterfeited products have been sold to consumers in Nigeria with fake NAFDAC 
numbers or without one, yet only NAFDAC agents know if a registration number is authentic 
or fake (Oladosu, Taiwo and Oyeleye, 2016). Though NAFDAC numbers can be verified 
online to ascertain the authenticity of any product (Hoax, 2012), this will add to the end-user 
cost of the product as a result of the financial implication of product registration and provision 
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of such service. It is notable that 31.9% of the sample population (n=1360) cited affordability 
as a strong reason for choosing HM (Table 2.13); the most common reason for use among 
people 70 years and above (Figure 2.2) and those with no formal education (Figure 2.5). 
Hence these groups are likely to be affected.  High hospital costs was a common reason 
(33.5%) cited for avoiding hospital treatment (Table 2.14) (n=1181) and the most common 
reason given by those with no formal education (Figure 2.6). Thus it would appear to be in 
the interest of manufacturers of HM to keep the cost of HM as low as possible, keeping it 
more affordable than conventional medicine. 
The majority (83.6%) of respondents (n=1075) believed HM to be effective (Table 2.15). 
Some publications have reported that patients view the use of HM in a positive light and are 
satisfied with its therapeutic effect, while also expressing their disappointment at the 
effectiveness and safety of orthodox medicine (Huxtable, 1990; Abbot and Ernst, 1997). 
Conversely, 57.0% of respondents regard HM as unsafe (Table 2.16). This may be 
interpreted to suggest that people use HM because it is effective and affordable, among 
other reasons, but are concerned about its safety. This concern is confirmed with the 
detection of heavy metals in HM and its potential bioaccumulation in the body with 
consequent harm to health (Section 4.4.2 to 4.4.11). Yet what are the choices available to 
respondents? 
The increased use of HM has been attributed to limited availability and affordability of 
orthodox medicine (Omotosho, 2010). Poor service delivery and high hospital costs have, 
among other reasons, been identified in this study as discouraging patronage of the 
orthodox health system (Table 2.9). Also of note is the high disparity in income groups, 
especially considering that low-income groups were the majority (82.0%) in the study 
population (Table 2.6) and out-of-pocket expenditure accounts for about 69% of health care 
financing in Nigeria (Figure 2.7). On the other hand, however, the majority of low-income 
earners cited their disinclination to use hospitals to poor service delivery (Figure 2.9) and 
cited effectiveness as their main reason for HM use (Figure 2.4). Considering the 
aforementioned factors, the reality may be that orthodox medical care is not within the reach 
of most of the population. However, findings in this study suggest an alternate hypothesis: 
that, despite low income, the need for effective, efficient and dignified treatment is desirable. 
Being of low income should not imply deserving poor service delivery in the orthodox health 
care setting, or deserving of medication which may not be effective after all. A publication 
further supports this point in its dual population survey finding in Nigeria, reporting a vast 
majority believe it takes a longer time to see a doctor in an orthodox than in a traditional 
medicinal setting. It also reported that a vast majority of the respondents believe the 
caregiver devotes more time to the patient in the traditional than in the orthodox setting 
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(Nottidge, Akpanudo and Akinbami, 2011). It may appear that people try to avoid Orthodox 
health facilities as much as possible while trying to maximise a perceived effective, 
affordable and available alternative. Although it may not be safe, it is provided in a 
sympathetic environment with freedom to express fears and optimism without intimidation 
(Section 1.5.1). However, this does not downplay the fact that safety of HM is becoming a 
major problem as discussed in Section 1.6.2 and also from results obtained in this study 
about the potential toxicity of HM (Section 4.4). 
Thus, the negative contributions of human activities such as mining, petrochemical handling, 
waste disposal, and illegal adulteration, especially in Ekiti State, may have contributed to HM 
toxicity through contamination with heavy metals and adulteration with pharmaceutical 
compounds. The GC-MS analysis of the 10 most commonly used HM samples in this study 
(Table 2.12) detected none of the target pharmaceutical compounds. This is a positive 
finding of public health importance. Also, the non-detection of pharmaceutical compounds in 
HM samples is consistent with findings from the survey aspect of this research. This is 
because adulteration of HM samples with an expensive orthodox medication will increase 
the cost of the HM; a consequence for its affordability. It is notable that affordability was the 
main reason (31.9%), after effectiveness, cited for use of HM (Table 2.13) and high hospital 
cost, after poor service delivery, was the main reason (33.5%) cited for the avoidance of 
orthodox health facilities (Table 2.14). Likewise, adulteration with a perceived ineffective 
orthodox medicine will be counterproductive. On the other hand, a publication reported the 
adulteration of HM with HIV drugs in Nigeria (Gini et al., 2016). But then HIV medication is 
free in Nigeria (NACA, 2017); therefore its use as an adulterant in a proclaimed HIV-curing 
HM may not be at an additional cost to its manufacturer.  
The analyte of interest in this study included nine selected commonly abused 
pharmaceutical compounds and one central nervous system (CNS) stimulant 
(acetaminophen, caffeine, chlorpheniramine, codeine, dexamethasone, diazepam, 
diclofenac, fluoxetine, ibuprofen, tramadol) (Table 3.1). These substances have been 
reported to be present in some HMs (Vaclavik et al., 2014a and 2014b) and are also known 
to be medicines commonly misused in Ekiti State (Akindutire and Adegboyega, 2012; 
Atoyebi and Atoyebi, 2013). The epidemic of drug abuse, especially codeine, in Nigeria was 
brought to light in a recent British Broadcasting Cooperation (BBC) documentary (2018), 
resulting in the closure of three pharmaceutical companies implicated by NAFDAC 
(Vanguard newspaper, 2018). With the exception of HM2 and HM3, all the HMs offered pain 
relief as one of their many therapeutic benefits. Therefore it was thought likely that being the 
most commonly used types identified from the survey (Table2.12), they would contain some 
of the commonly abused analgesics or CNS stimulants that are taken by members of the 
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study population. That was not the case as none was detected in this study. Additionally, the 
commonest CNS stimulant (caffeine) and analgesics such as tramadol, which may enhance 
performance, was expected to be present in HM2 which claimed to increase sexual power 
(Table 4.1) but was not detected.  
The non-detection of the pharmaceutical compounds may be due to their presence below 
the detection limit of the method used in this study, therefore requiring a more sensitive 
method. However, mass spectral changes when compared to the background reading 
especially during method validation studies (Section 3.7) would have highlighted such 
presence. Hence the non-detection of these pharmaceutical compounds may suggest a lack 
of adequate knowledge or technology to successfully implement such adulteration. It may 
also suggest a sincere commitment to herbal medicine development to compete with 
orthodox medicine or unfavourable socioeconomic parameters. The finding from this study 
supports the latter suggestion, considering 82.0% of the respondents (n=1265) are low- 
income earners (Table 2.6) whilst the two other suggestions about lack of adequate 
knowledge or technology and a sincere commitment to herbal medicine development cannot 
be substantiated from the findings in this study.   
In as much as non-adulteration is a positive finding in this research, the same could not hold 
for heavy metal analysis. Though most of the contamination of HM may not be deliberate, it 
may also be a product of human activities on the environment (Lokhande, Singare and 
Pimple, 2011). All the HM samples contained a minimum of two heavy metals (Cd and Cu) 
above the WHO permissible limits (Table 4.2). The highest level of heavy metals above the 
permissible limits was in HM2. It is an uncertified HM used to cure low sperm count and 
increase sexual power (Table 4.1), and the only sample which contained lead and zinc 
above the permissible limit. 
Masculinity and male sexuality in Nigeria are interrelated in such a way that men still 
dominate decisions on sexual matters. On the other hand, femininity and female sexuality 
are associated with being seductive, passive, cooperative and submissive (Oladeji, 2008; 
Adebayo and Olonisakin, 2014b). As a result, there is a high expectation of sexual 
performance in men, associated with their remaining in charge. This high expectation has 
possibly led to the high use of sexual performance enhancers in Nigeria and their potential 
danger has dominated public discussion for some time (Vanguard, 2011). However, the use 
of herbs to improve sexual performance has resulted in little or no therapeutic effect even 
after prolonged use (Osakinle and Omoniyi, 2010). The prolonged use of one such sexual 
enhancer, HM2, will probably do more harm to the consumer. HM2 was found to have a high 
concentration of lead and zinc (Table 4.2) which have been reported to decrease libido and 
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cause other reproductive problems at toxic levels (Pinon-Lataillade et al., 1995 and Telisman 
et al., 2000). This fact is consistent with the finding of Osakinle and Omoniyi (2010) on the 
uselessness of such HM and their toxic potential. Besides, 57.3% of respondents in this 
study who took HM (n=1087) also believe that uncertified HM (such as HM2) is not safe. 
All the HM samples contain cadmium above the permissible limit. Though it is a heavy metal 
with exposure pervasive in humans, at toxic levels it affects male fertility (Akinloye et al., 
2006 and Telisman et al., 2007) and women‘s reproductive health (Nagata et al., 2005). The 
toxicity of metals detected in this study has been further discussed in Section 4.4.2 to 4.4.11. 
The prevalence of secondary infertility was reported in 2015 to be 83.7% in Ekiti State (Peter 
and Temi, 2016), meaning that most men were previously fertile. The finding from this study 
could, therefore, provide a link between the high use of HM contaminated with heavy metals 
and the prevalence of male infertility in the state. This may provide the basis for further 
research to establish a direct correlation by analysis of specific HM samples used by 
patients who present in the urology clinic over a period of time for heavy metals. A study 
reported that of the 218 patients who attended the fertility clinic in a Nigerian tertiary hospital, 
84% with an abnormal seminal fluid analysis result had a history of herbal use, while only 
16% of the patients who had no history of herbal use had an abnormal result (Enuh et al., 
2012). Besides, there are other medical conditions that may be directly or indirectly linked to 
the use of HM, as discussion of individual metals in Sections 4.4.2 to 4.4.11 has shown how 
they contribute to the development of various diseases (Navas-Acien et al., 2007; .Park et 
al., 2000; Calne et al., 1994; MacFarquhar, Porea, Belmont and Mahoney, 2000; Broussard 
and Melstrom, 2010). In the absence of this type of research which combines 
epidemiological and toxicological analysis of HM, there is a greater likelihood of 
misdiagnosis as most medical professionals have underestimated the potential toxicity of 
some HM (Giveon et al., 2003). 
Lack of this knowledge may be responsible for the low HM-related casualty and fatality 
observed in this study (Section 2.13). In retrospect, many of the other medical conditions 
forming the bulk of casualty and fatality figures in the medical records examined might have 
been attributed to HM use through heavy metals exposure, although there may be other 
confounding conditions. The effect of HM seems to have been underestimated, considering 
other important causation of medical conditions; so doctors may not specifically ask patients 
about HM use. Conversely, the benefit of HM cannot be underestimated, as many reports 
have highlighted this as discussed in Sections 1.3 and 1.4. It remains a growing and popular 
alternative to orthodox medicine, but its safety needs to be improved. As suggested by the 
majority (46.5%) of respondents in this study (n=1242) (Table 2.19), the government needs 
173 
 
to improve its regulation and monitoring of HM use to make it safer for the health of the 
populace.  
In summary, this study has successfully addressed the research questions (see Section 
1.10.1) as extensively discussed in Chapters 2 and 4. It deployed analytical method which 
was considered suitable for both pharmaceutical and heavy metal analysis through its 
validation (Section 3.8). Heavy metal concentrations were detected and quantified in HM 
samples above the WHO recommended permissible limit as a result of calculated LOD and 
LOQ values which were lower than those permissible levels (Table 4.3). However, for the 
analysis of pharmaceutical compounds, the calculated LOD values were either lower or 
higher than those reported in previous publications (Table 3.8). Hence comparatively, the 
lower LOD values indicate an improved sensitivity of the validated method in this study for 
the analysis of some pharmaceutical compounds such as ibuprofen, dexamethasone, and 
caffeine while higher values indicate less sensitivity (Table 3.8). The use of other analytical 
techniques previously deployed for analysis of HM e.g. LC-MS and HPLC (Wu et al., 2012; 
Becue; Van Poucke and Van Peteghem, 2011) may improve the sensitivity of the latter such 
as reported for diclofenac in herbal product using Liquid Chromatography with time-of-flight 
mass spectrometry (LC/TOF-MS) (Savaliya et al., 2009). However this study ensured that 
the procedure leading to the non-detection of the target pharmaceutical compounds was 
scientifically valid and acceptable as shown in Section 4.3.1.   
In the case of population-based survey, it adopted various methods and approaches (e.g. 
use of both self and interview-administered questionnaires, open and close-ended 
questions, multi-sampling method, and use of more than one independent coder) in other to 
reduce bias (e.g. sampling bias, recall bias, data collection and interpretive bias) and to 
achieve the inclusivity necessary to obtain a valid result (Section 2.1 - 2.9). Nevertheless, a 
survey of farm settlements which was not carried out as part of this study may have 
improved inclusivity of more farmers as an example (Table 2.6), who had gone to the farm 
when survey was carried out in their towns. This may be improved on in future studies. 
 In analysing hospital data, the findings provided an idea of the health burden associated 
with HM use within the study population (Section 2.13). However, proper documentation of 
HM use in patient medical records could have brought about a better result.  Nonetheless, 
the limitations from the analysis of hospital data and the survey (Section 2.15) did not impact 
the results obtained in this research in any significant way.  
Finally, herbal medicine and its toxicity served as a tool to assess health-seeking behaviour 
and related factors in Ekiti State, as an alternative to an orthodox medical system offering 
unsatisfactory service.  
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CHAPTER 6: CONCLUSION, RECOMMENDATIONS AND FUTURE WORK 
6.1 Conclusion 
 
This research has examined the use and epidemiology of herbal medicine in Ekiti State and 
analysed HM sample for toxic constituents. A multidisciplinary approach combining methods 
from public health and analytical chemistry was used. Conclusions are drawn in this chapter 
from the findings of this research and answer provided to each of the five research questions 
posed in Section 1.11.1 
What are the pattern and use of herbal medicine in Ekiti State and the influence of socio-
economic factors?  
The result of this study indicates a high use of HM within the study population and a pattern 
that shows a dissociation between knowledge of the risk associated with HM use and their 
use by the respondents. The study showed that majority of the respondents used HM and 
also more frequently in the previous two years. However, despite knowing the difference 
between government-certified and uncertified HM, the uncertified type was the most 
commonly used. This is a serious concern which should warrant serious public health 
intervention. Furthermore, in answering part of the research question, findings showed that 
the socioeconomic factors may not have been the major influence determining HM use 
within the study population. Although there was a significant association found between the 
use of HM and the age, gender, level of education, religion, annual income and occupation 
of the respondents, HM use was found to be highest in the middle-income class.  
 Across all the income classes, the principal reason cited for HM use was its effectiveness 
amidst other reasons such as affordability, availability and natural properties. The 
effectiveness of HM was corroborated in this study, as the majority of respondents who used 
HM saying it was effective for the intended purpose. What then are the issues causing 
disinclination in the use of available orthodox health facilities in Ekiti State? These are 
answered by the second research question. 
What are the reasons for not using orthodox healthcare facilities in Ekiti State? 
The result from this research suggests that if service delivery was improved and the cost of 
orthodox health facilities were reduced there would likely be an increase in patronage. This 
is so because a few of the respondents did attend hospital, but poor service delivery in 
orthodox health-care facilities was the main reason given for their avoidance, regardless of 
respondents‘ income class. Other reasons cited by respondents were high hospital cost and 
unorthodox belief. Increased patronage of orthodox health facilities may reduce the high use 
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of HM and especially uncertified HM as highlighted in this study and may also reduce the 
mortality and morbidity in the study population. The effect of this HM use on the health of the 
population is examined by the third research question. 
What are the casualty and fatality figures associated with herbal medicine use in Ekiti State 
between the years 2010 and 2014? 
Analysis of hospital records showed low HM-associated casualty and fatality figures. This 
means that, compared with other disease conditions accounting for hospital admission and 
death in Ekiti State, HM‘s contribution was minimal. However with questions not always 
being asked by clinicians about the use of HMs in admissions, perhaps the information is 
also limited in patient‘s records and awareness needs to be improved. The findings from this 
study, for example, showed detection of heavy metals in most commonly used HM within the 
study population at concentrations above WHO permissible limits. Hence, it is likely that 
heavy metals from HM use could have contributed significantly to the pathophysiology of 
some of the disease conditions (e.g. hypertension, diabetes, and renal failure) found in the 
hospital record as pointed out in the discussions in Section 4.4.2 to 4.4.11. This highlights 
the importance of taking a history of HM use from patients by clinicians and the 
dissemination of this research finding, for example, will be helpful in raising the much 
needed awareness. The fourth research question contextualizes the issues by examining the 
potential toxicity of HM. 
What heavy metals and organic constituents are present in both uncertified and certified 
herbal medicine used in Ekiti State?  
Analysis of selected HM detected none of the target pharmaceuticals, but heavy metals were 
detected above the WHO permissible limit. Cadmium and copper were present in all 
analysed HM samples at levels above the WHO permissible limits, while some other HMs 
had chromium, lead, nickel and zinc above the limit. There was significant intra-batch and 
inter-batch variation of heavy metals in some of the HMs analysed. This may indicate the 
non-homogenous nature of some of the samples as steps to homogenise them were 
thoroughly carried out in this study during sample preparation. Hence, there may be variation 
in the manufacturing process or the source of the raw materials. These variations may 
impact the concentration of constituents in the final product significantly, thus a 
harmonisation of manufacturing standard and declaration of source of raw materials may be 
helpful as further discussed in Section 6.2.1. 
Some of the HM samples analysed, such as HM1, HM3, HM6, and HM9, are certified and 
manufactured by big companies with likely influence on regulatory and enforcement 
176 
 
agencies. As a result, regulatory and enforcement efforts may be resisted by the 
manufacturers; as may be the dissemination of these research findings. Hence, enforcement 
of safety guidelines may be a herculean task, but this should not discourage improved efforts 
at ensuring the safety of HM production and use. 
The non-detection of pharmaceutical compounds may be an indication that pharmaceutical 
adulteration of HM is not a problem in the study population, unlike other parts of the world. 
Perhaps, other sensitive analytical technique may be deployed in future analysis. However, 
detection of heavy metals increases concern about the safety of HM and the potential harm 
to people who use it, especially over a long period. Thus, a call for a more thorough analysis 
of HMs in Nigeria is needed as further discussed in Section 6.2.1. This need for action and 
intervention to safeguard the health of the public brings about the fifth research question. 
What policy recommendations can be proposed in light of the findings from this study? 
The various findings from this research call for quick and holistic intervention by all 
stakeholders. The points of intervention have been identified and recommendations made 
based on this research findings. They bother on areas of government, corporate and 
individual responsibilities which are discussed extensively in Section 6.2. The 
implementation of the recommendations by those concerned will mitigate the negative 
consequences highlighted in this study. 
6.2 Recommendation 
Findings of this research emphasise the need for multi-level recommendations because of 
the various players (state, manufacturers, and users) associated with HM regulation, 
production, marketing and use.  
6.2.1 Recommendation to policymakers and regulatory agencies  
A lot of human activities such as use of herbicides and pesticides, indiscriminate refuse 
dumping, and disregard of safety in petrochemical-related activities have been found to be 
likely contributors to the presence of heavy metals in plants used in HM. Therefore it is 
important to ensure best practice in the handling of petrochemical products and waste 
disposal. Likewise, the approval and use of any type of herbicide and pesticide should 
consider their impact on the environment, especially from their heavy metal content. 
The variation in heavy metal concentration which was significant in some HMs analysed 
highlights the need to make HM manufacturers declare the source of plants used in their 
products by the appropriate government agency. This is essential to correlate the heavy 
177 
 
metal content of HM and human activities from the source environment to ensure safety. The 
likely contribution of various manufacturing processes to the presence of heavy metals and 
variation in HM means that there is a need to ensure manufacturing procedures and tools 
does not contribute to heavy metal constituents in the finished product. There is also a need 
to include heavy metal analysis as standard screening steps preliminary to certification of 
HM in areas where this has not been implemented. 
The certification of HM helps to ensure the safety of the general populace. However, 
uncertified HM was the type acknowledged by respondents to be in greatest use. This 
means that a lot needs to be done to ensure improved certification of HM. A way of 
achieving this is to review the process of certifying HM and its cost implication. This is 
important, considering that affordability of HM was the second most frequently cited reason 
for the use of HM. Thus a certification process that will make HM very expensive may be 
counterproductive.  There is also a need to improve regulation of the use of extemporaneous 
HM as it contributes to the number of uncertified HMs in circulation in the study population. 
The inclusion of HM in the state pharmacovigilance strategy is also much needed. 
Public enlightenment on the use of uncertified HM is needed to reduce its incidence. 
However, that some certified HMs were found to contain heavy metals above the permissible 
limit also means that a lot needs to be done to ensure the safety of certified HMs as earlier 
recommended. 
6.2.2 Recommendation to orthodox health-care management 
Poor service delivery in orthodox care was highlighted as the main reason for avoidance of 
its use. This underscores the need for proper training and retraining of health professionals 
in effective service delivery, human relations, and respect for human dignity. The institution 
of an appropriate reward and sanction system in the health profession may help to achieve 
desirable results. Adequate monitoring of health facilities and professionals by the relevant 
authorities and prompt response to complaint and needs is also vital. 
An evaluation of high hospital cost as one of the main reason for avoidance of orthodox 
health facilities along with the affordability of HM as the second reason for HM use points to 
the impact of cost in healthcare decision making. Accordingly, a reduction in out-of-pocket 
expenditure on health through improvement of universal health coverage and inclusion by 
the provision of health insurance are required. These will be beneficial to the vast majority of 
the study population who, according to this study, are in the low-income class. 
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Poor record-keeping practice in most hospitals was identified as one of the limitations to the 
evaluation of casualty and fatality figures associated with HM use. Therefore there needs to 
be an enforcement of proper record keeping of health data in all hospitals, which is essential 
to accurate health research, planning and intervention. 
The reference to HM use casually in the medical records of patients was also observed in 
this study. Thus there is a need expressly to ask patients for details of any use of HM and 
maintain its detailed history. Such findings should also be properly documented in medical 
notes. This will likely discourage non-disclosure and underreporting of HM use. 
6.2.3 Recommendation to HM users 
The majority of respondents believe it is not safe to take uncertified HM but a majority still 
take it. It is important that users of HM consider safety above other factors in their healthcare 
decision making. In addition, where technology is available to verify NAFDAC numbers users 
should endeavor to utilise such. 
6.2.4 Recommendation to HM manufactures 
Manufacturers of HM should put in place protocols (e.g. testing mechanism for level of 
metals) which will ensure that their products are safe. They should also invest more in HM 
research and development, which will benefit them and the public. 
 6.3 Future work 
As this research has taken place in Ekiti State using a multi-disciplinary approach, 
opportunities also exist for future study. 
A nation-wide study of the pattern and use of HM may produce new findings and will also 
help the comparison of findings across different parts of Nigeria. This will require a bigger 
sample and financial commitment but it will be beneficial to both the government and the 
Nigerian nation. 
Analysis of HM used by hospital patients for the presence of heavy metals and their 
correlation with medical conditions through analysis of biological samples e.g. of blood, hair, 
post-mortem liver and kidney for such heavy metals. This may be particularly useful in 
suspected HM with associated heavy metal poisoning.  
As HM can be purchased from different countries, a transnational study of there content 
could also be carried out. 
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Appendices 
 
Appendix I: Linearity plot of pharmaceutical standard (mean peak area ratio (n=3) against concentration)  (a) Acetaminophen, (b) Dexamethasone, 
(c) Tramadol, (d) Fluoxetine, (e) Codeine, (f) Chlorpheniramine, (g) Diclofenac, (h) Caffeine and (i) Diazepam. 
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Appendix II:  Graph of Mean Peak Area Ratio (n=3) over 50 hours stability trial, 0.008 mg/ml (a) Acetaminophen, (b) Caffeine, (c) Chlorpheniramine, 
(d) Codeine, (e) Dexamethasone, (f) Diazepam, (g) Diclofenac, (h) Fluoxetine and (i) Tramadol. 
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Appendix III:  Graph of Mean Peak Area Ratio (n=3) over 50 hours stability trial, 0.08 mg/ml (a) Acetaminophen, (b) Caffeine, (c) Chlorpheniramine, 
(d) Codeine, (e) Dexamethasone, (f) Diazepam, (g) Diclofenac, (h) Fluoxetine and (i) Tramadol 
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Appendix IV:  Graph of Mean Peak Area Ratio (n=3) over 50 hours stability trial, 0.8 mg/ml (a) Acetaminophen, (b) Caffeine, (c) Chlorpheniramine, 
(d) Codeine, (e) Dexamethasone, (f) Diazepam, (g) Diclofenac, (h) Fluoxetine and (i) Tramadol . 
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Appendix V: Log-linear plot of target analyte (a) Dexamethasone, (b) Tramadol, (c) Acetaminophen, (d) Fluoxetine, (e) Codeine, (f) 
chlorpheniramine, (g) Diclofenac, (h) caffeine, (i) Diazepam 
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Appendix VI: Residual plot of target compounds (Peak area ratio of analyte/concentration versus log concentration) : (a) Dexamethasone, (b) 
Fluoxetine, (c) Chlorpheniramine, (d) Codeine, (e) Diclofenac, (f) Tramadol, (g)  Acetaminophen, (h) Caffeine, (i) Diazepam.  
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Appendix  VII : Linearity plot of elemental standard (mean intensity ratio (n=3) against concentration : (a) Arsenic, (b) Cadmium, (c) Copper, (d) 
Lead, (e) Manganese, (f) Mercury, (g) Nickel, (h) Selenium and  (i) Zinc 
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                                               (g)                                                                                            (h)                                                                                 (i) 
Appendix VIII : Residual plot of  target element : (a) Arsenic, (b) Cadmium, (c) Copper,  (d) Lead, (e) Manganese, (f) Mercury,  (g) Nickel, (h) 
Selenium and (i) Zinc 
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 (d) (e) (f) 
                
              (g) (h) (i) 
  
Appendix IX :  Log-linear plot of target element:  (a) Arsenic, (b) Cadmium, (c) Copper, (d) Lead, (e) Manganese, (f) Mercury, (g) Nickel, (h) Selenium 
and (i) Zinc 
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Appendix X: TIC chromatogram of HM samples 1 to 10 showing internal standard (IS) 
(a) HM Sample 1 
 
(b) HM Sample 2 
                    
(c) HM Sample 4 
 
    
 
 
 
 
IS 
IS 
IS 
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(d) HM Sample 5 
              
   
   (e) HM Sample 6 
                
    (f) HM Sample 7 
               
 
 
 
 
 
IS 
IS 
IS 
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(g) HM Sample 8 
         
(h) HM Sample 9 
 
         
(i) HM Sample 10 
       
IS 
IS 
IS 
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Appendix XI:  Table of intra-batch of metals in herbal medicine samples 
(a) Intra-batch concentration of metals in HM2 
Intra-batch concentration of metals in HM2 
Element Location Sample 1 Sample 2 Average 
Conc 
Arsenic Location 1 0.787±0.058 0.841±0.045 0.814±0.038 
Location 2 0.514±0.035 0.547±0.003 0.530±0.023 
Location 3 0.572±0.017 0.558±0.011 0.565±0.010 
Location 4 0.553±0.021 0.562±0.017 0.558±0.006 
Location 5 0.581±0.039 0.554±0.022 0.568±0.019 
 
cadmium Location 1 0.681±0.038 0.725±0.025 0.703±0.031 
Location 2 0.442±0.037 0.475±0.005 0.458±0.023 
Location 3 0.595±0.026 0.621±0.021 0.608±0.019 
Location 4 0.628±0.017 0.587±0.013 0.607±0.029 
Location 5 0.609±0.036 0.582±0.018 0.596±0.019 
 
Chromium Location 1 2.864±0.167 3.104±0.122 2.984±0.170 
Location 2 2.943±0.274 3.015±0.014 2.979±0.051 
Location 3 2.364±0.086 2.467±0.080 2.415±0.073 
Location 4 2.740±0.222 3.075±0.132 2.907±0.237 
Location 5 2.452±0.188 2.764±0.082 2.608±0.221 
 
Copper Location 1 37.158±3.645 38.323±1.855 37.741±0.824 
Location 2 33.011±2.647 29.266±3.321 31.138±2.648 
Location 3 36.922±2.380 33.177±4.269 35.050±3.324 
Location 4 30.490±2.500 27.330±2.787 28.910±2.234 
Location 5 28.528±2.437 25.325±1.417 26.927±2.265 
 
Lead Location 1 27.608±2.672 26.773±0.882 27.191±0.591 
Location 2 34.746±2.347 30.401±3.021 32.574±3.072 
Location 3 38.238±1.431 33.493±3.320 35.866±2.375 
Location 4 36.900±2.483 33.740±2.770 35.320±2.234 
Location 5 37.521±2.420 34.317±1.400 35.919±2.265 
 
Manganese Location 1 98.029±6.475 92.284±8.769 95.157±4.062 
Location 2 96.003±1.752 87.786±4.042 91.894±5.810 
Location 3 95.089±1.699 87.396±6.552 91.243±4.125 
Location 4 90.039±5.011 93.544±2.483 91.792±2.479 
Location 5 89.920±7.631 84.598±3.145 87.259±3.764 
 
Nickel Location 1 6.474±0.234 6.573±0.335 6.524±0.071 
Location 2 5.669±0.247 5.376±0.275 5.522±0.207 
Location 3 4.283±0.216 4.070±0.211 4.176±0.151 
Location 4 4.899±0.338 4.350±0.336 4.624±0.388 
Location 5 4.687±0.050 5.102±0.096 4.894±0.294 
 
Selenium Location 1 7.991±0.607 8.822±0.678 8.407±0.588 
Location 2 7.388±0.327 7.094±0.368 7.241±0.207 
Location 3 8.183±0.291 7.970±0.223 8.076±0.151 
Location 4 8.251±0.398 7.702±0.336 7.976±0.388 
Location 5 8.944±0.454 9.316±0.379 9.130±0.263 
 
Zinc Location 1 131.958±5.203 126.213±8.497 129.086±4.062 
Location 2 139.250±3.202 131.034±5.492 135.142±5.810 
Location 3 129.551±2.949 121.857±7.802 125.704±5.375 
Location 4 139.469±6.201 142.974±3.673 141.222±2.479 
Location 5 128.650±5.686 123.328±1.200 125.989±3.764 
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(b) Intra-batch concentration of metals in HM3 
Intra-batch concentration of metals in HM3 
Element Location Sample 1 Sample 2 Sample 3 Sample 4 Average 
Conc 
Arsenic Location 1 0.385±0.018 0.328±0.013 0.331±0.007 0.369±0.010 0.353±0.012 
Location 2 0.386±0.031 0.448±0.025 0.461±0.058 0.417±0.037 0.428±0.038 
Location 3 0.454±0.033 0.467±0.039 0.393±0.038 0.402±0.033 0.429±0.036 
Location 4 0.669±0.099 0.788±0.012 0.769±0.040 0.705±0.011 0.733±0.040 
Location 5 0.458±0.042 0.431±0.025 0.387±0.030 0.409±0.035 0.421±0.032 
 
cadmium Location 1 0.618±0.041 0.632±0.033 0.564±0.030 0.561±0.036 0.594±0.035 
Location 2 0.608±0.046 0.594±0.014 0.533±0.020 0.563±0.025 0.574±0.026 
Location 3 0.715±0.031 0.640±0.030 0.650±0.026 0.701±0.026 0.676±0.028 
Location 4 0.538±0.039 0.468±0.108 0.474±0.019 0.546±0.020 0.506±0.047 
Location 5 0.387±0.030 0.409±0.035 0.431±0.025 0.458±0.042 0.421±0.033 
 
Chromium Location 1 2.561±0.081 2.321±0.125 2.080±0.119 2.245±0.136 2.303±0.115 
Location 2 1.858±0.316 1.891±0.056 1.783±0.048 1.582±0.068 1.778±0.122 
Location 3 1.672±0.077 1.775±0.018 1.459±0.072 1.597±0.076 1.626±0.061 
Location 4 1.740±0.134 1.748±0.045 1.547±0.037 1.670±0.132 1.676±0.087 
Location 5 1.472±0.149 1.646±0.043 1.401±0.032 1.423±0.053 1.486±0.069 
 
Copper Location 1 13.643±1.060 14.740±0.930 12.527±1.012 12.909±1.035 13.455±1.010 
Location 2 13.858±1.390 14.354±1.130 13.783±1.122 11.582±1.141 13.394±1.196 
Location 3 16.730±0.745 14.833±0.686 13.517±0.740 14.655±0.744 14.934±0.729 
Location 4 15.856±1.133 17.935±1.045 15.734±1.038 15.926±1.135 16.363±1.088 
Location 5 15.785±0.485 16.030±0.496 16.857±0.602 13.807±0.507 15.619±0.523 
 
Lead Location 1 1.270±0.034 1.250±0.022 1.029±0.026 1.199±0.083 1.187±0.041 
Location 2 1.435±0.284 1.437±0.024 1.165±0.035 1.366±0.016 1.351±0.090 
Location 3 1.298±0.022 1.511±0.049 1.614±0.025 1.436±0.032 1.465±0.032 
Location 4 1.558±0.015 1.356±0.007 1.549±0.104 1.479±0.102 1.486±0.057 
Location 5 1.407±0.003 1.652±0.014 1.479±0.120 1.429±0.024 1.492±0.040 
 
Manganese Location 1 202.923±9.411 193.179±8.705 187.872±7.996 210.088±2.621 198.515±7.183 
Location 2 197.855±10.276 200.020±3.881 185.803±9.170 180.110±11.950 190.947±8.819 
Location 3 197.411±8.780 200.575±7.716 183.359±7.816 190.666±8.669 193.003±8.245 
Location 4 198.873±7.132 196.378±5.604 180.550±3.199 184.713±6.719 190.128±5.663 
Location 5 199.675±10.175 201.011±8.599 188.352±8.689 191.472±9.154 195.128±9.154 
 
Nickel Location 1 2.640±0.154 2.951±0.098 2.470±0.137 2.711±0.143 2.693±0.133 
Location 2 3.058±0.330 3.091±0.070 2.983±0.062 2.782±0.081 2.978±0.136 
Location 3 3.167±0.085 3.270±0.026 2.954±0.080 3.092±0.084 3.121±0.069 
Location 4 2.806±0.174 3.042±0.084 2.614±0.077 2.737±0.172 2.800±0.127 
Location 5 3.056±0.073 2.518±0.062 2.883±0.179 2.833±0.108 2.823±0.105 
 
Selenium Location 1 2.192±0.137 2.432±0.091 1.951±0.130 2.121±0.147 2.174±0.126 
Location 2 2.036±0.334 2.068±0.074 1.961±0.066 1.759±0.085 1.956±0.140 
Location 3 3.296±0.086 3.474±0.028 3.158±0.082 3.371±0.087 3.325±0.071 
Location 4 1.943±0.060 2.371±0.067 2.136±0.157 2.066±0.155 2.129±0.109 
Location 5 1.833±0.198 2.006±0.092 1.668±0.081 1.783±0.127 1.823±0.124 
 
Zinc Location 1 27.035±3.2033 23.291±2.357 24.984±1.788 28.700±1.413 26.003±2.190 
Location 2 27.879±2.759 25.944±0.864 24.128±2.562 24.435±2.900 25.597±2.271 
Location 3 27.431±2.631 26.596±0.880 24.780±0.980 22.685±2.833 25.373±1.831 
Location 4 24.572±2.341 25.758±1.640 23.930±0.900 21.574±1.751 23.959±1.658 
Location 5 24.596±1.480 23.932±0.612 20.273±1.363 21.717±1.659 22.630±1.278 
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(c) Intra-batch concentration of metals in HM4 
Intra-batch concentration of metals in HM4 
Element Location Sample 1 Sample 2 Average 
Conc 
Arsenic Location 1 0.279±0.021 0.313±0.008 0.296±0.024 
Location 2 0.284±0.037 0.317±0.005 0.300±0.023 
Location 3 0.251±0.013 0.238±0.007 0.244±0.010 
Location 4 0.307±0.015 0.346±0.011 0.327±0.028 
Location 5 0.305±0.030 0.277±0.012 0.291±0.019 
 
Cadmium Location 1 0.613±0.027 0.657±0.014 0.635±0.031 
Location 2 0.568±0.040 0.641±0.008 0.604±0.051 
Location 3 0.755±0.046 0.801±0.041 0.778±0.033 
Location 4 0.635±0.037 0.594±0.033 0.615±0.029 
Location 5 0.509±0.038 0.482±0.021 0.496±0.019 
 
Chromium Location 1 1.731±0.167 1.971±0.122 1.851±0.170 
Location 2 1.800±0.269 1.883±0.009 1.841±0.059 
Location 3 1.805±0.069 1.908±0.064 1.856±0.073 
Location 4 1.606±0.192 1.741±0.102 1.673±0.096 
Location 5 1.150±0.148 1.264±0.042 1.207±0.081 
 
Copper Location 1 13.605±1.282 14.770±0.327 14.188±0.824 
Location 2 13.810±1.060 12.065±1.028 12.937±1.234 
Location 3 13.785±0.843 12.340±0.832 13.063±0.838 
Location 4 12.689±0.500 11.529±0.787 12.109±0.820 
Location 5 16.628±1.437 14.425±1.417 15.527±1.558 
 
Lead Location 1 3.490±0.203 3.730±0.158 3.610±0.170 
Location 2 2.695±0.299 2.784±0.039 2.739±0.063 
Location 3 2.930±0.102 3.034±0.097 2.982±0.073 
Location 4 3.638±0.253 3.973±0.163 3.805±0.237 
Location 5 2.040±0.164 2.253±0.058 2.146±0.150 
 
Manganese Location 1 85.843±3.974 80.098±6.268 82.971±4.062 
Location 2 90.240±2.452 82.024±4.742 86.132±5.810 
Location 3 91.519±5.399 83.826±10.252 87.673±7.825 
Location 4 80.219±6.171 83.724±3.643 81.972±2.479 
Location 5 91.070±6.271 85.748±1.785 88.409±3.764 
 
Nickel Location 1 1.380±0.088 1.282±0.043 1.331±0.070 
Location 2 1.971±0.269 1.788±0.009 1.879±0.129 
Location 3 2.280±0.058 2.383±0.053 2.331±0.073 
Location 4 1.815±0.201 2.050±0.111 1.932±0.166 
Location 5 2.052±0.190 2.364±0.084 2.208±0.221 
 
Selenium Location 1 4.960±0.277 5.591±0.348 5.276±0.446 
Location 2 5.565±0.427 5.271±0.468 5.418±0.207 
Location 3 6.433±0.201 6.220±0.133 6.326±0.151 
Location 4 6.141±0.503 5.592±0.441 5.866±0.388 
Location 5 3.618±0.323 4.033±0.370 3.825±0.294 
 
Zinc Location 1 25.332±2.096 22.587±1.790 23.960±1.941 
Location 2 23.234±0.708 21.018±1.198 22.126±1.567 
Location 3 24.958±1.533 22.265±2.386 23.611±1.959 
Location 4 34.049±2.411 37.554±0.883 35.802±2.479 
Location 5 23.586±2.628 21.264±1.142 22.425±1.643 
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(d) Intra-batch concentration of metals in HM5 
Intra-batch concentration of metals in HM5 
Element Location Sample 1 Sample 2 Average 
Conc 
Arsenic Location 1 0.400±0.028 0.434±0.014 0.417±0.024 
Location 2 0.407±0.050 0.440±0.018 0.423±0.023 
Location 3 0.395±0.013 0.382±0.007 0.388±0.010 
Location 4 0.316±0.034 0.355±0.030 0.336±0.028 
Location 5 0.400±0.043 0.372±0.025 0.386±0.019 
 
cadmium Location 1 0.854±0.072 0.898±0.059 0.876±0.031 
Location 2 0.792±0.060 0.825±0.028 0.808±0.023 
Location 3 0.701±0.045 0.727±0.040 0.714±0.019 
Location 4 0.765±0.020 0.724±0.016 0.744±0.029 
Location 5 0.589±0.032 0.562±0.015 0.576±0.019 
 
Chromium Location 1 4.364±0.319 4.695±0.390 4.530±0.234 
Location 2 4.228±0.319 3.934±0.361 4.081±0.207 
Location 3 4.898±0.190 4.685±0.121 4.791±0.151 
Location 4 5.879±0.434 5.330±0.372 5.605±0.388 
Location 5 4.348±0.323 4.763±0.370 4.555±0.294 
 
Copper Location 1 59.833±3.452 66.998±1.662 63.416±5.066 
Location 2 58.072±3.216 54.327±3.890 56.200±2.648 
Location 3 52.053±3.102 48.308±4.991 50.181±4.046 
Location 4 60.640±2.870 57.480±3.157 59.060±2.234 
Location 5 58.618±4.164 55.415±3.144 57.017±2.265 
     
Lead Location 1 6.040±0.515 6.439±0.616 6.240±0.283 
Location 2 6.099±0.347 5.806±0.375 5.952±0.207 
Location 3 5.683±0.424 5.470±0.419 5.576±0.151 
Location 4 5.849±0.438 5.300±0.436 5.574±0.388 
Location 5 5.987±0.385 6.402±0.432 6.194±0.294 
 
Manganese Location 1 136.256±6.657 130.511±9.951 133.383±4.062 
Location 2 141.475±4.709 133.259±6.999 137.367±5.810 
Location 3 136.958±1.797 129.264±6.650 133.111±4.223 
Location 4 127.799±4.631 134.304±2.103 131.052±4.600 
Location 5 141.860±5.171 136.538±0.685 139.199±3.764 
 
Nickel Location 1 3.025±0.215 3.265±0.170 3.145±0.170 
Location 2 2.901±0.306 3.098±0.047 2.999±0.139 
Location 3 2.810±0.286 3.014±0.280 2.912±0.144 
Location 4 2.790±0.242 3.125±0.152 2.957±0.237 
Location 5 2.571±0.222 2.883±0.116 2.727±0.221 
 
Selenium Location 1 3.021±0.206 3.261±0.161 3.141±0.170 
Location 2 2.301±0.319 2.390±0.059 2.345±0.063 
Location 3 2.910±0.194 3.213±0.189 3.061±0.215 
Location 4 3.898±0.283 4.233±0.193 4.065±0.237 
Location 5 3.405±0.258 3.617±0.152 3.511±0.150 
     
Zinc Location 1 92.019±6.484 86.274±8.778 89.147±4.062 
Location 2 92.380±3.839 84.164±6.129 88.272±5.810 
Location 3 86.281±5.041 78.587±9.894 82.434±7.468 
Location 4 91.430±6.528 95.935±4.000 93.682±3.186 
Location 5 80.570±7.061 75.248±2.575 77.909±3.764 
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(e) Intra-batch concentration of metals in HM 6 
        
 
 
Intra-batch concentration of metals in HM 6 
Element Location Sample 1 Sample 2 Sample 3 Sample 4 Average 
Conc 
Arsenic Location 1 0.333±0.025 0.317±0.017 0.279±0.014 0.276±0.020 0.301±0.019 
Location 2 0.235±0.023 0.242±0.011 0.217±0.019 0.207±0.024 0.225±0.019 
Location 3 0.246±0.022 0.245±0.017 0.225±0.017 0.216±0.021 0.233±0.019 
Location 4 0.277±0.019 0.297±0.014 0.255±0.014 0.271±0.025 0.275±0.018 
Location 5 0.221±0.023 0.239±0.005 0.195±0.011 0.206±0.016 0.215±0.014 
 
cadmium Location 1 0.534±0.033 0.548±0.025 0.480±0.022 0.477±0.028 0.510±0.027 
Location 2 0.541±0.044 0.527±0.012 0.466±0.018 0.496±0.023 0.507±0.024 
Location 3 0.518±0.023 0.504±0.018 0.453±0.018 0.443±0.022 0.480±0.020 
Location 4 0.556±0.019 0.565±0.015 0.492±0.014 0.487±0.103 0.525±0.038 
Location 5 0.461±0.033 0.433±0.015 0.389±0.021 0.411±0.0257 0.424±0.024 
 
Chromium Location 1 0.768±0.053 0.711±0.048 0.641±0.042 0.792±0.045 0.728±0.047 
Location 2 0.736±0.021 0.798±0.015 0.811±0.048 0.767±0.026 0.778±0.027 
Location 3 0.769±0.033 0.755±0.027 0.704±0.027 0.694±0.032 0.730±0.030 
Location 4 0.712±0.048 0.731±0.020 0.648±0.019 0.612±0.107 0.676±0.048 
Location 5 0.813±0.043 0.785±0.026 0.742±0.031 0.763±0.036 0.776±0.034 
 
Copper Location 1 11.125±0.545 12.222±0.415 10.009±0.497 10.391±0.520 10.937±0.495 
Location 2 12.645±1.280 12.778±0.285 11.570±1.012 10.369±1.420 11.840±0.999 
Location 3 11.580±0.769 11.683±0.428 10.367±0.219 10.956±0.672 11.146±0.522 
Location 4 11.005±0.799 10.935±0.847 10.812±0.218 13.013±0.461 11.441±0.581 
Location 5 11.908±0.912 9.858±1.092 11.543±0.795 12.081±0.044 11.348±0.711 
 
Lead Location 1 2.931±0.199 3.171±0.154 2.690±0.193 2.860±0.210 2.913±0.189 
Location 2 2.680±0.301 2.713±0.041 2.605±0.033 2.404±0.052 2.601±0.107 
Location 3 2.441±0.051 2.544±0.043 2.228±0.046 2.366±0.050 2.395±0.035 
Location 4 2.807±0.186 3.043±0.096 2.615±0.089 2.738±0.184 2.801±0.138 
Location 5 2.934±0.162 3.107±0.056 2.7685±0.045 2.884±0.091 2.923±0.088 
 
Manganese Location 1 77.823±4.526 76.988±2.736 67.772±2.111 68.078±3.820 72.665±3.298 
Location 2 93.855±4.886 95.020±1.491 86.803±3.780 81.110±6.560 89.197±4.179 
Location 3 103.694±5.147 106.859±3.083 89.643±2.183 96.949±5.036 99.286±3.862 
Location 4 100.769±2.702 98.274±2.174 87.446±0.769 86.609±3.289 93.274±7.293 
Location 5 93.992±7.726 95.328±6.151 82.670±6.240 85.789±6.705 89.445±6.706 
 
Nickel Location 1 1.572±0.050 1.812±0.005 1.504±0.044 1.500±0.061 1.597±0.147 
Location 2 1.263±0.300 1.295±0.040 1.167±0.032 1.178±0.051 1.226±0.063 
Location 3 1.931±0.067 2.034±0.059 1.718±0.038 1.856±0.066 1.884±0.058 
Location 4 1.908±0.174 2.143±0.084 1.715±0.077 1.838±0.172 1.901±0.180 
Location 5 1.906±0.150 2.079±0.044 1.835±0.033 1.856±0.079 1.919±0.111 
 
Selenium Location 1 10.002±0.865 11.099±0.547 9.186±0.764 9.268±0.840 9.889±0.886 
Location 2 8.135±0.684 8.268±0.515 7.060±0.517 7.858±0.571 7.830±0.541 
Location 3 9.869±0.629 9.972±0.287 8.656±0.079 9.245±0.532 9.435±0.382 
Location 4 8.798±0.689 9.033±0.351 8.305±0.108 8.728±0.737 8.716±0.471 
Location 5 9.581±0.712 9.654±0.344 9.216±0.595 8.531±0.892 9.246±0.636 
 
Zinc Location 1 21.398±2.337 23.063±0.547 20.347±0.922 19.654±1.491 21.115±1.483 
Location 2 21.432±1.807 19.497±0.9124 17.681±1.610 17.988±1.948 19.149±1.717 
Location 3 20.431±2.231 21.596±0.480 19.780±0.580 17.687±2.433 19.873±1.640 
Location 4 19.132±1.941 19.818±1.240 18.490±0.500 16.134±1.351 18.394±1.601 
Location 5 19.113±1.180 18.449±0.312 17.791±1.063 16.234±1.359 17.897±1.233 
    
254 
 
 
(f) Intra-batch concentration of metals in HM7 
Intra-batch concentration of metals in HM7 
Element Location Sample 1 Sample 2 Average Conc 
Arsenic Location 1 6.473±0.438 6.772±0.539 6.623±0.212 
Location 2 5.518±0.362 4.924±0.440 5.221±0.419 
Location 3 4.739±0.406 4.426±0.401 4.582±0.221 
Location 4 6.015±0.385 5.466±0.383 5.741±0.388 
Location 5 5.412±0.370 5.827±0.416 5.619±0.294 
 
cadmium Location 1 0.510±0.030 0.554±0.016 0.532±0.031 
Location 2 0.478±0.040 0.511±0.007 0.494±0.023 
Location 3 0.537±0.029 0.563±0.024 0.550±0.019 
Location 4 0.529±0.015 0.488±0.012 0.509±0.029 
Location 5 0.462±0.033 0.435±0.016 0.449±0.019 
 
Chromium Location 1 0.582±0.037 0.666±0.024 0.624±0.060 
Location 2 0.494±0.051 0.527±0.018 0.510±0.023 
Location 3 0.545±0.038 0.571±0.033 0.558±0.019 
Location 4 0.528±0.025 0.488±0.022 0.508±0.029 
Location 5 0.501±0.035 0.474±0.018 0.487±0.019 
 
Copper Location 1 5.145±0.178 5.776±0.249 5.460±0.446 
Location 2 5.030±0.369 4.737±0.410 4.884±0.207 
Location 3 5.033±0.230 4.820±0.162 4.926±0.151 
Location 4 5.741±0.466 5.192±0.404 5.466±0.388 
Location 5 3.618±0.323 4.033±0.370 3.825±0.294 
 
Lead Location 1 1.372±0.039 1.273±0.034 1.323±0.070 
Location 2 1.717±0.270 1.534±0.010 1.625±0.129 
Location 3 1.712±0.068 1.815±0.063 1.764±0.073 
Location 4 1.725±0.221 1.960±0.131 1.842±0.166 
Location 5 1.350±0.164 1.662±0.058 1.506±0.221 
 
Manganese Location 1 41.428±4.485 45.593±2.695 43.511±2.945 
Location 2 38.997±1.747 35.252±2.421 37.124±2.648 
Location 3 40.482±2.476 36.737±4.365 38.610±3.420 
Location 4 41.040±2.141 37.880±2.429 39.460±2.234 
Location 5 36.118±2.527 32.915±1.507 34.517±2.265 
 
Nickel Location 1 1.350±0.078 1.252±0.033 1.301±0.070 
Location 2 1.729±0.264 1.547±0.005 1.638±0.129 
Location 3 1.260±0.088 1.363±0.083 1.311±0.073 
Location 4 1.325±0.101 1.460±0.011 1.392±0.096 
Location 5 1.238±0.130 1.321±0.024 1.279±0.059 
 
Selenium Location 1 5.098±0.245 5.729±0.316 5.414±0.446 
Location 2 5.509±0.439 5.215±0.481 5.362±0.207 
Location 3 5.157±0.181 4.944±0.112 5.051±0.151 
Location 4 5.217±0.273 4.668±0.211 4.942±0.388 
Location 5 5.061±0.433 5.476±0.480 5.269±0.294 
 
Zinc Location 1 6.473±0.438 6.772±0.539 6.623±0.212 
Location 2 5.518±0.362 4.924±0.440 5.221±0.419 
Location 3 4.739±0.406 4.426±0.401 4.582±0.221 
Location 4 6.015±0.385 5.466±0.383 5.741±0.388 
Location 5 5.412±0.370 5.827±0.416 5.619±0.294 
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(g) Intra-batch concentration of metals in HM8 
Intra-batch concentration of metals in HM8 
Element Location Sample 1 Sample 2 Average Conc 
Arsenic Location 1 0.403±0.029 0.457±0.016 0.430±0.038 
Location 2 0.314±0.038 0.347±0.005 0.330±0.023 
Location 3 0.380±0.016 0.366±0.010 0.373±0.010 
Location 4 0.256±0.015 0.265±0.012 0.261±0.006 
Location 5 0.370±0.032 0.342±0.015 0.356±0.019 
 
cadmium Location 1 0.541±0.024 0.585±0.011 0.563±0.031 
Location 2 0.542±0.037 0.615±0.005 0.578±0.051 
Location 3 0.365±0.041 0.411±0.035 0.388±0.033 
Location 4 0.562±0.035 0.521±0.031 0.542±0.029 
Location 5 0.489±0.033 0.462±0.016 0.476±0.019 
 
Chromium Location 1 2.862±0.125 3.102±0.080 2.982±0.170 
Location 2 3.948±0.278 3.737±0.019 3.842±0.149 
Location 3 3.154±0.091 3.257±0.085 3.205±0.073 
Location 4 3.803±0.272 4.138±0.182 3.970±0.237 
Location 5 3.522±0.188 3.834±0.082 3.678±0.221 
 
Copper Location 1 36.698±4.654 37.863±2.864 37.281±0.824 
Location 2 40.485±1.747 36.740±2.421 38.613±2.648 
Location 3 39.042±1.336 35.297±3.225 37.169±2.280 
Location 4 40.524±3.040 37.364±3.327 38.944±2.234 
Location 5 41.430±2.437 38.227±1.417 39.829±2.265 
 
Lead Location 1 2.790±0.153 3.030±0.108 2.910±0.170 
Location 2 2.985±0.315 3.074±0.055 3.029±0.063 
Location 3 3.194±0.102 3.297±0.097 3.245±0.073 
Location 4 2.688±0.233 3.023±0.143 2.855±0.237 
Location 5 3.462±0.168 3.674±0.062 3.568±0.150 
 
Manganese Location 1 29.102±3.225 28.267±1.435 28.685±0.591 
Location 2 33.087±2.057 29.742±2.731 31.415±2.365 
Location 3 29.683±2.141 26.938±3.030 28.311±2.585 
Location 4 37.589±1.791 34.429±2.078 36.009±2.234 
Location 5 30.074±2.544 26.870±1.523 28.472±2.265 
 
Nickel Location 1 7.643±0.723 8.474±0.794 8.059±0.588 
Location 2 8.318±0.327 8.024±0.408 8.171±0.207 
Location 3 9.035±0.291 8.343±0.223 8.689±0.489 
Location 4 8.739±0.461 8.190±0.399 8.464±0.388 
Location 5 7.578±0.259 7.993±0.306 7.785±0.294 
 
Selenium Location 1 2.844±0.232 3.084±0.187 2.964±0.170 
Location 2 2.368±0.273 2.441±0.013 2.404±0.051 
Location 3 2.405±0.069 2.508±0.064 2.456±0.073 
Location 4 3.040±0.272 3.375±0.182 3.207±0.237 
Location 5 3.890±0.195 4.203±0.089 4.046±0.221 
 
Zinc Location 1 92.565±8.811 98.310±5.517 95.438±4.062 
Location 2 94.327±1.768 88.111±4.058 91.219±4.396 
Location 3 90.958±3.767 83.264±8.620 87.111±6.193 
Location 4 93.735±2.139 99.533±4.667 96.634±4.100 
Location 5 97.608±5.686 92.286±1.200 94.947±3.764 
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(h) Intra-batch concentration of metals in HM9 
 
 
 
 
 
Intra-batch concentration of metals in HM 9 
Election Location Sample 1 Sample 2 Sample 3 Sample 4 Average 
Conc 
Arsenic Location 1 0.243±0.019 0.237±0.011 0.209±0.008 0.205±0.014 0.224±0.019 
Location 2 0.250±0.019 0.257±0.007 0.232±0.015 0.222±0.020 0.240±0.016 
Location 3 0.319±0.024 0.318±0.018 0.298±0.018 0.288±0.023 0.306±0.015 
Location 4 0.289±0.021 0.310±0.016 0.267±0.015 0.283±0.027 0.287±0.018 
Location 5 0.227±0.020 0.244±0.003 0.200±0.008 0.212±0.013 0.221±0.019 
 
Cadmium Location 1 0.554±0.021 0.568±0.013 0.500±0.010 0.496±0.016 0.530±0.037 
Location 2 0.448±0.043 0.434±0.010 0.373±0.016 0.403±0.021 0.414±0.034 
Location 3 0.558±0.019 0.544±0.014 0.493±0.014 0.483±0.018 0.519±0.037 
Location 4 0.453±0.013 0.462±0.009 0.389±0.008 0.383±0.096 0.422±0.041 
Location 5 0.515±0.031 0.487±0.013 0.443±0.019 0.465±0.024 0.478±0.031 
 
Chromium Location 1 4.462±0.156 4.702±0.111 4.221±0.150 4.390±0.167 4.444±0.200 
Location 2 3.940±0.279 3.973±0.019 3.865±0.011 3.664±0.031 3.861±0.139 
Location 3 3.441±0.076 3.544±0.067 3.228±0.070 3.366±0.075 3.395±0.133 
Location 4 3.918±0.192 4.153±0.102 3.725±0.095 3.848±0.190 3.911±0.180 
Location 5 3.940±0.197 4.114±0.091 3.775±0.080 3.891±0.126 3.930±0.141 
 
Copper Location 1 57.159±5.474 58.324±3.684 51.108±3.059 51.414±4.768 54.501±3.774 
Location 2 56.953±3.526 58.118±0.131 49.901±2.420 49.208±4.200 53.545±4.641 
Location 3 72.342±5.147 71.507±3.083 65.291±2.183 65.597±7.036 68.684±4.362 
Location 4 57.930±4.150 59.435±3.622 51.607±2.217 50.770±4.737 54.935±4.383 
Location 5 65.819±6.731 67.155±5.156 60.497±5.245 57.616±5.711 62.772±4.482 
 
Lead Location 1 1.831±0.056 2.071±0.011 1.763±0.050 1.759±0.067 1.856±0.147 
Location 2 1.943±0.326 1.975±0.066 1.847±0.058 1.858±0.077 1.906±0.063 
Location 3 1.668±0.058 1.771±0.050 1.455±0.029 1.593±0.057 1.622±0.049 
Location 4 1.755±0.125 1.990±0.035 1.721±0.028 1.685±0.123 1.788±0.138 
Location 5 1.674±0.145 1.624±0.074 1.603±0.028 1.847±0.039 1.687±0.111 
 
Manganese Location 1 95.176±4.519 94.011±6.309 87.960±3.894 88.266±7.603 91.353±3.774 
Location 2 98.240±2.131 97.075±5.526 90.023±4.420 89.330±6.200 93.667±4.641 
Location 3 88.321±6.242 87.486±4.178 81.269±3.278 73.576±8.131 82.663±5.457 
Location 4 97.535±5.545 90.375±6.133 91.212±3.612 99.040±3.017 94.540±4.383 
Location 5 96.159±8.281 87.956±10.261 90.837±3.795 97.495±5.706 93.112±4.482 
 
Nickel Location 1 5.403±0.481 5.393±0.374 5.112±0.459 5.281±0.560 5.297±0.136 
Location 2 4.996±0.588 5.028±0.329 4.713±0.321 4.419±0.340 4.789±0.284 
Location 3 5.978±0.486 6.450±0.478 5.765±0.481 5.903±0.485 6.024±0.297 
Location 4 4.918±0.192 5.153±0.102 4.725±0.095 4.848±0.190 4.911±0.180 
Location 5 4.592±0.197 4.765±0.091 4.427±0.080 4.542±0.126 4.581±0.141 
 
Selenium Location 1 2.826±0.184 3.066±0.139 2.585±0.178 2.754±0.195 2.808±0.200 
Location 2 2.648±0.279 2.944±0.019 2.573±0.011 2.371±0.031 2.634±0.237 
Location 3 3.121±0.097 3.224±0.089 2.908±0.092 3.046±0.096 3.075±0.133 
Location 4 2.144±0.258 2.379±0.168 1.951±0.161 2.074±0.256 2.137±0.180 
Location 5 1.975±0.193 2.149±0.087 1.810±0.076 1.925±0.122 1.965±0.141 
 
Zinc Location 1 34.052±3.075 35.717±1.285 33.001±1.660 32.307±2.229 33.769±1.483 
Location 2 29.786±2.137 27.851±1.242 26.035±1.940 26.341±2.278 27.503±1.717 
Location 3 37.121±2.571 38.286±0.821 36.470±0.921 34.376±2.774 36.563±1.640 
Location 4 32.038±2.482 32.724±1.781 31.396±1.042 29.040±1.893 31.299±1.601 
Location 5 30.959±1.990 30.295±1.122 29.637±1.873 28.080±2.169 29.743±1.233 
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(i) Intra-batch concentration of metals in HM10 
Intra-batch concentration of metals in HM10 
Element  Sample 1 Sample 2 Average Conc 
Arsenic Location 1 0.485±0.028 0.539±0.015 0.512±0.038 
Location 2 0.482±0.027 0.515±0.005 0.498±0.023 
Location 3 0.561±0.049 0.588±0.043 0.574±0.019 
Location 4 0.611±0.019 0.660±0.016 0.636±0.034 
Location 5 0.427±0.033 0.399±0.016 0.413±0.019 
 
cadmium Location 1 0.533±0.037 0.587±0.024 0.560±0.038 
Location 2 0.491±0.048 0.524±0.015 0.507±0.023 
Location 3 0.636±0.019 0.623±0.014 0.629±0.010 
Location 4 0.486±0.025 0.494±0.022 0.490±0.006 
Location 5 0.483±0.037 0.456±0.019 0.470±0.019 
 
Chromium Location 1 2.144±0.151 2.294±0.106 2.219±0.106 
Location 2 2.512±0.279 2.585±0.019 2.548±0.051 
Location 3 4.631±0.325 4.704±0.319 4.667±0.052 
Location 4 3.899±0.233 4.234±0.143 4.067±0.237 
Location 5 2.838±0.165 3.151±0.059 2.994±0.221 
 
Copper Location 1 13.138±1.662 14.303±0.707 13.721±0.824 
Location 2 13.075±0.653 12.330±0.621 12.703±0.527 
Location 3 14.154±0.913 12.709±0.902 13.432±0.908 
Location 4 14.629±0.533 13.469±0.820 14.049±0.820 
Location 5 13.751±1.490 11.547±1.470 12.649±1.558 
     
Lead Location 1 2.540±0.263 2.780±0.218 2.660±0.170 
Location 2 2.355±0.316 2.444±0.056 2.399±0.063 
Location 3 3.530±0.092 3.634±0.086 3.582±0.073 
Location 4 3.888±0.256 4.223±0.166 4.055±0.237 
Location 5 1.699±0.155 1.911±0.049 1.805±0.150 
 
Manganese Location 1 66.749±3.394 61.004±5.688 63.877±4.062 
Location 2 68.474±1.839 60.258±4.129 64.366±5.810 
Location 3 65.834±0.817 62.141±5.670 63.988±3.243 
Location 4 59.445±4.141 62.950±1.613 61.198±2.479 
Location 5 64.990±4.186 59.668±2.700 62.329±3.764 
 
Nickel Location 1 2.582±0.063 2.722±0.058 2.652±0.099 
Location 2 1.932±0.266 2.015±0.006 1.973±0.059 
Location 3 1.555±0.037 1.354±0.032 1.454±0.142 
Location 4 1.466±0.212 1.601±0.122 1.533±0.096 
Location 5 1.691±0.163 1.806±0.057 1.748±0.081 
 
Selenium Location 1 3.701±0.316 4.132±0.387 3.917±0.305 
Location 2 4.627±0.317 4.133±0.358 4.380±0.349 
Location 3 2.860±0.183 2.647±0.115 2.754±0.151 
Location 4 4.980±0.503 4.614±0.441 4.797±0.259 
Location 5 4.196±0.262 4.611±0.309 4.404±0.294 
 
Zinc Location 1 16.751±1.999 17.916±1.044 17.334±0.824 
Location 2 13.300±0.860 12.855±0.828 13.077±0.315 
Location 3 15.169±0.715 13.724±0.704 14.447±0.710 
Location 4 14.479±0.670 13.319±0.957 13.899±0.820 
Location 5 16.298±1.337 15.095±1.417  15.697±0.851 
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Appendix XII:  Table of inter-batch concentration of metals in herbal medicine 
samples 
(a) Inter-batch concentration of metals in HM2 
Inter-batch concentration of metals in HM2 
 Location 1 Location 
2 
Location 
3 
Location 
4 
Location  
5 
Average conc 
Arsenic 0.814±0.051 0.530±0.019 0.565±0.014 0.558±0.019 0.568±0.030 0.607±0.117 
cadmium 0.582±0.031 0.481±0.040 0.563±0.013 0.570±0.018 0.594±0.032 0.558±0.045 
Chromium 2.984±0.145 2.979±0.144 2.415±0.083 2.907±0.177 2.608±0.135 2.779±0.255 
Copper 37.741±2.750 31.138±2.984 35.050±3.324 28.910±2.643 26.927±1.927 31.953±4.424 
Lead 27.191±1.777 32.574±2.684 35.866±2.375 35.320±2.626 35.919±1.910 33.374±3.720 
Manganese 95.157±7.622 91.894±2.897 91.243±4.125 91.792±3.747 87.259±5.388 91.469±2.813 
Nickel 6.524±0.284 5.522±0.261 4.176±0.213 4.624±0.337 4.894±0.073 5.148±0.910 
Selenium 8.407±0.642 7.241±0.348 8.076±0.257 7.976±0.367 8.125±0.227 7.965±0.435 
 Zinc 129.086±6.850 135.142±4.347 125.704±5.375 141.222±4.937 125.989±3.443 131.428±6.662 
   
(b) Inter-batch concentration of metals in HM3 
 
Inter-batch concentration of metals in HM3  
Element Location  
1 
Location 
2 
Location 
3 
Location 
4 
Location  
5 
Average conc 
Arsenic 0.353±0.012 0.428±0.038 0.429±0.036 0.733±0.040 0.421±0.033 0.473±0.032 
cadmium 0.548±0.041 0.654±0.045 0.626±0.026 0.505±0.026 0.321±0.020 0.531±0.032 
Chromium 2.303±0.115 1.778±0.122 1.626±0.061 1.676±0.087 1.486±0.069 1.774±0.091 
Copper 13.455±1.010 13.394±1.196 14.934±0.729 16.363±1.088 15.619±0.523 14.753±0.909 
Lead 1.187±0.041 1.351±0.090 1.465±0.032 1.486±0.057 1.492±0.040 1.396±0.052 
Manganese 198.515±7.183 190.947±8.819 193.003±8.245 190.128±5.663 195.128±9.154 193.544±7.813 
Nickel 2.693±0.133 2.978±0.136 3.121±0.069 2.800±0.127 2.823±0.105 2.883±0.114 
Selenium 2.174±0.126 1.956±0.140 3.325±0.071 2.129±0.109 1.823±0.124 2.281±0.114 
Zinc 26.002±2.190 25.597±2.271 25.374±1.831 23.959±1.658 22.630±1.278 24.712±1.846 
 
(c) Inter-batch concentration of metals in HM4 
Inter-batch concentration of metals in HM4 
Element Location 1 Location 
2 
Location 
3 
Location 
4 
Location 5 Average conc 
Arsenic 0.296±0.014 0.300±0.021 0.244±0.010 0.327±0.013 0.291±0.021 0.292±0.030 
cadmium 0.635±0.020 0.604±0.024 0.778±0.043 0.615±0.035 0.496±0.029 0.626±0.101 
Chromium 1.592±0.077 1.600±0.078 1.624±0.100 1.502±0.104 1.328±0.100 1.529±0.122 
Copper 14.188±0.805 12.937±1.044 13.063±0.838 12.109±0.643 15.527±1.427 13.565±1.323 
Lead 3.610±0.181 2.739±0.169 2.982±0.099 3.805±0.208 2.146±0.111 3.057±0.671 
Manganese 82.971±5.121 86.132±3.597 87.673±7.825 81.972±4.907 88.409±4.028 85.431±2.846 
Nickel 1.331±0.066 1.879±0.139 2.331±0.055 1.932±0.156 2.208±0.137 1.936±0.387 
Selenium 5.276±0.312 5.418±0.448 6.326±0.167 5.866±0.472 3.825±0.347 5.342±0.943 
Zinc 23.960±1.943 22.126±0.953 23.611±1.959 35.802±1.647 22.425±1.885 25.585±5.763 
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(d) Inter-batch concentration of metals in HM5 
 
Inter-batch concentration of metals in HM5 
 Location 1 Location 
2 
Location 
3 
Location 
4 
Location 5 Average conc 
Arsenic 0.417±0.021 0.423±0.034 0.388±0.010 0.336±0.032 0.386±0.034 0.390±0.035 
cadmium 0.743±0.052 0.791±0.038 0.622±0.016 0.831±0.022 0.538±0.021 0.705±0.122 
Chromium 4.530±0.354 4.081±0.340 4.791±0.155 5.605±0.403 4.555±0.347 4.712±0.561 
Copper 63.416±2.557 56.200±3.553 50.181±4.046 59.060±3.013 57.017±3.654 57.175±4.806 
Lead 6.240±0.565 5.952±0.361 5.576±0.421 5.574±0.437 6.194±0.409 5.907±0.322 
Manganese 133.383±8.304 137.367±5.854 133.111±4.223 131.052±3.367 139.199±2.928 134.822±3.348 
Nickel 3.145±0.193 2.999±0.177 2.912±0.283 2.957±0.197 2.727±0.169 2.948±0.152 
Selenium 3.141±0.184 2.345±0.189 3.061±0.191 4.065±0.238 3.511±0.205 3.225±0.632 
Zinc 89.147±7.631 88.272±4.984 82.434±7.468 93.682±5.264 77.909±4.818 86.289±6.161 
 
(e) Inter-batch concentration of metals in HM6 
Inter-batch concentration of metals in HM6 
 Location 1 Location 
2 
Location 
3 
Location 
4 
Location 
 5 
Average conc 
Arsenic 0.301±0.019 0.225±0.019 0.233±0.017 0.275±0.018 0.215±0.014 0.250±0.037 
cadmium 0.487±0.031 0.424±0.037 0.458±0.030 0.556±0.022 0.401±0.018 0.465±0.060 
Chromium 0.728±0.047 0.778±0.027 0.730±0.030 0.676±0.048 0.776±0.034 0.738±0.042 
Copper 10.937±0.495 11.840±0.999 11.146±0.522 11.441±0.581 11.348±0.711 11.343±0.339 
Lead 2.913±0.189 2.601±0.107 2.395±0.035 2.801±0.138 2.923±0.088 2.727±0.226 
Manganese 72.665±3.298 89.197±4.179 99.286±3.862 93.274±2.233 89.445±6.706 88.774±9.885 
Nickel 1.597±0.040 1.226±0.106 1.885±0.058 1.901±0.127 1.919±0.076 1.706±0.299 
Selenium 9.889±0.754 7.830±0.572 9.435±0.382 8.716±0.471 9.246±0.636 9.023±0.789 
Zinc 21.115±1.324 19.149±1.569 19.873±1.431 18.393±1.258 17.896±0.978 19.286±1.269 
 
(f) Inter-batch concentration of metals in HM7 
Inter-batch concentration of metals in HM7 
Election Location  
1 
Location 
2 
Location 
3 
Location 
4 
Location 
 5 
Average conc 
Arsenic 0.348±0.015 0.324±0.027 0.308±0.017 0.268±0.012 0.261±0.018 0.302±0.037 
cadmium 0.469±0.026 0.487±0.036 0.504±0.027 0.477±0.020 0.427±0.024 0.473±0.029 
Chromium 0.624±0.030 0.510±0.035 0.558±0.036 0.508±0.023 0.487±0.027 0.538±0.055 
Copper 5.460±0.213 4.884±0.390 4.926±0.196 5.466±0.435 3.825±0.347 4.912±0.669 
Lead 1.323±0.036 1.625±0.140 1.764±0.066 1.842±0.176 1.506±0.111 1.612±0.207 
Manganese 43.511±3.590 37.124±2.084 38.610±3.420 39.460±2.285 34.517±2.017 38.644±3.305 
Nickel 1.301±0.056 1.638±0.134 1.311±0.085 1.392±0.056 1.279±0.077 1.384±0.148 
Selenium 5.414±0.280 5.362±0.460 5.051±0.147 4.942±0.242 5.269±0.457 5.208±0.203 
Zinc 6.623±0.488 5.221±0.401 4.582±0.403 5.741±0.384 5.619±0.393 5.557±0.748 
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(g) Inter-batch concentration of metals in HM8 
Inter-batch concentration of metals in HM8 
Element Location 
 1 
Location 
2 
Location 
3 
Location 
4 
Location  
5 
Average conc 
Arsenic 0.430±0.022 0.330±0.021 0.373±0.013 0.261±0.013 0.356±0.023 0.350±0.062 
cadmium 0.529±0.017 0.501±0.035 0.480±0.033 0.491±0.028 0.452±0.020 0.491±0.028 
Chromium 2.982±0.103 3.842±0.148 3.205±0.088 3.970±0.227 3.678±0.135 3.536±0.424 
Copper 37.281±3.759 38.613±2.084 37.169±2.280 38.944±3.183 39.829±1.927 38.367±1.134 
Lead 2.910±0.131 3.029±0.185 3.245±0.099 2.855±0.188 3.568±0.115 3.122±0.291 
Manganese 28.685±2.330 31.415±2.394 28.311±2.585 36.009±1.934 28.472±2.034 30.578±3.292 
Nickel 8.059±0.758 8.171±0.368 8.689±0.257 8.464±0.430 7.785±0.283 8.234±0.352 
Selenium 2.964±0.210 2.404±0.143 2.456±0.066 3.207±0.227 4.046±0.142 3.016±0.669 
Zinc 95.438±7.164 91.219±2.913 87.111±6.193 96.634±3.403 94.947±3.443 93.070±3.898 
 
(h) Inter-batch concentration of metals in HM9 
Inter-batch concentration of metals in HM9 
Element Location  
1 
Location 
2 
Location 
3 
Location 
4 
Location  
5 
Average conc 
Arsenic 0.224±0.013 0.240±0.015 0.306±0.021 0.287±0.020 0.221±0.011 0.255±0.039 
cadmium 0.499±0.019 0.492±0.036 0.481±0.021 0.389±0.020 0.430±0.024 0.458±0.047 
Chromium 4.444±0.146 3.861±0.085 3.395±0.072 3.911±0.145 3.930±0.123 3.908±0.372 
Copper 54.501±4.246 53.545±2.569 68.684±4.362 54.935±3.681 62.772±5.711 58.888±6.604 
Lead 1.856±0.046 1.906±0.132 1.622±0.049 1.788±0.078 1.687±0.071 1.772±0.117 
Manganese 91.353±5.581 93.667±4.569 82.663±5.457 94.540±4.577 93.112±7.011 91.067±4.840 
Nickel 5.297±0.468 4.789±0.394 6.024±0.482 4.911±0.145 4.581±0.123 5.121±0.568 
Selenium 2.808±0.174 2.634±0.085 3.075±0.093 2.137±0.211 1.965±0.119 2.524±0.463 
Zinc 33.769±2.062 27.503±1.899 36.563±1.772 31.299±1.799 29.743±1.788 31.776±3.518 
 
(i) Inter-batch concentration of metals in HM10 
Inter-batch concentration of metals in HM 10 
Element Location  
1 
Location 
2 
Location 
3 
Location 
4 
Location 
 5 
Average conc 
Arsenic 0.512±0.021 0.498±0.016 0.574±0.046 0.636±0.018 0.413±0.024 0.527±0.084 
cadmium 0.492±0.021 0.526±0.046 0.542±0.014 0.496±0.026 0.427±0.029 0.497±0.044 
Chromium 2.219±0.129 2.548±0.149 4.667±0.322 4.067±0.188 2.994±0.112 3.299±1.035 
Copper 13.721±1.185 12.703±0.637 13.432±0.908 14.049±0.676 12.649±1.480 13.311±0.619 
Lead 2.660±0.241 2.399±0.186 3.582±0.089 4.055±0.211 1.805±0.102 2.900±0.909 
Manganese 63.877±4.541 64.366±2.984 63.988±3.243 61.198±2.877 62.329±3.443 63.151±1.341 
Nickel 2.652±0.060 1.973±0.136 1.454±0.035 1.533±0.167 1.748±0.110 1.872±0.481 
Selenium 3.917±0.351 4.380±0.338 2.754±0.149 4.797±0.472 4.404±0.286 4.050±0.789 
Zinc 17.334±1.522 13.077±0.844 14.447±0.710 13.899±0.813 15.697±1.377 14.891±1.665 
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Appendix XIII: Table of P values for significance of intra-batch and inter-batch 
variability of heavy metals composition in HMs 
                          (a) Intra-batch and inter-batch variability of heavy metals in HM2  
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
 
 
 
 
                         
 
HM2 Intra-batch 
variability 
Inter-batch variability 
P- value Sig. P-value Sig. 
Arsenic     
Location 1 0.031 Yes  
 
0.451 
 
 
No 
Location 2 0.215 No 
Location 3 0.431 No 
Location 4 0.057 No 
Location 5 0.327 No 
Cadmium     
Location 1 0.177 No  
 
0.211 
 
 
No 
Location 2 0.266 No 
Location 3 0.036 Yes 
Location 4 0.566 No 
Location 5 0.972 No 
Chromium     
Location 1 0.190 No  
 
0.125 
 
 
No 
Location 2 0.140 No 
Location 3 0.028 Yes 
Location 4 0.399 No 
Location 5 0.238 No 
Copper     
Location 1 0.899 No  
 
0.462 
 
 
No 
Location 2 0.172 No 
Location 3 0.660 No 
Location 4 0.011 Yes 
Location 5 0.304 No 
Lead     
Location 1 0.616 No  
 
0.642 
 
 
No 
Location 2 0.096 No 
Location 3 0.485 No 
Location 4 0.022 Yes 
Location 5 0.061 No 
Manganese     
Location 1 0.074 No  
 
0.528 
 
 
No 
Location 2 0.218 No 
Location 3 0.095 No 
Location 4 0.481 No 
Location 5 0.814 No 
Nickel     
Location 1 0.110 No  
 
0.604 
 
 
 
No 
Location 2 0.345 No 
Location 3 0.142 No 
Location 4 0.019 Yes 
Location 5 0.011 Yes 
Selenium     
Location 1 0.390 No  
 
0.390 
 
 
 
No 
Location 2 0.147 No 
Location 3 0.117 No 
Location 4 0.047 Yes 
Location 5 0.014 Yes 
Zinc     
Location 1 0.146 No 
 0.673 
 
 
 
No 
Location 2 0.098 No 
Location 3 0.148 No 
Location 4 0.357 No 
Location 5 0.442 No 
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                             (b) Intra-batch and inter-batch variability of heavy metals in HM3  
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
HM3 Intra-batch 
variability 
Inter-batch variability 
P- value Sig. P-value Sig. 
Arsenic     
Location 1 0.001 Yes 
0.114836 
 
 
No 
Location 2 0.027 Yes 
Location 3 0.004 Yes 
Location 4 0.007 Yes 
Location 5 0.002 Yes 
Cadmium     
Location 1 0.003 Yes  
 
0.481 
 
 
No 
Location 2 0.016 Yes 
Location 3 0.012 Yes 
Location 4 0.667 No 
Location 5 0.002 Yes 
Chromium     
Location 1 0.014 Yes  
 
0.937 
 
 
No 
Location 2 0.237 No 
Location 3 0.001 Yes 
Location 4 0.785 No 
Location 5 0.013 Yes 
Copper     
Location 1 0.240 No  
 
0.364 
 
 
No 
Location 2 0.099 No 
Location 3 0.065 No 
Location 4 0.073 No 
Location 5 0.914 No 
Lead     
Location 1 0.007 Yes  
 
0.224 
 
 
No 
Location 2 0.037 Yes 
Location 3 0.015 Yes 
Location 4 0.138 No 
Location 5 0.002 Yes 
Manganese     
Location 1 0.062 No  
 
0.077 
 
 
No 
Location 2 0.029 Yes 
Location 3 0.259 No 
Location 4 0.143 No 
Location 5 0.089 No 
Nickel     
Location 1 0.002 Yes  
 
0.570 
 
 
No 
Location 2 0.009 Yes 
Location 3 0.004 Yes 
Location 4 0.224 No 
Location 5 0.007 Yes 
Selenium     
Location 1 0.007 Yes  
 
0.281 
 
 
No 
Location 2 0.002 Yes 
Location 3 0.002 Yes 
Location 4 0.074 No 
Location 5 0.146 No 
Zinc  No   
Location 1 0.146 No 
0.606 
 
 
 
No 
Location 2 0.007 Yes 
Location 3 0.417 No 
Location 4 0.582 No 
Location 5 0.006 Yes 
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                             (c) Intra-batch and inter-batch variability of heavy metals in HM4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HM4 Intra-batch 
variability 
Inter-batch variability 
P- value Sig. P-value Sig. 
Arsenic     
Location 1 0.024 Yes 0.068 
 
No 
Location 2 0.001 Yes 
Location 3 0.573 No 
Location 4 0.297 No 
Location 5 0.996 No 
Cadmium     
Location 1 0.640 No 0.253 
 
No 
Location 2 0.301 No 
Location 3 0.049 Yes 
Location 4 0.561 No 
Location 5 0.412 No 
Chromium     
Location 1 0.202 No 0.092 
 
No 
Location 2 0.165 No 
Location 3 0.023 Yes 
Location 4 0.459 No 
Location 5 0.147 No 
Copper     
Location 1 0.004 Yes 0.719 
 
No 
Location 2 0.182 No 
Location 3 0.103 No 
Location 4 0.099 No 
Location 5 0.784 No 
Lead     
Location 1 0.015 Yes 0.154 No 
Location 2 0.147 No 
Location 3 0.017 Yes 
Location 4 0.485 No 
Location 5 0.082 No 
Manganese     
Location 1 0.092 No 0.649 
 
No 
Location 2 0.083 No 
Location 3 0.096 No 
Location 4 0.656 No 
Location 5 0.228 No 
Nickel     
Location 1 0.988 No 0.522 
 
No 
Location 2 0.424 No 
Location 3 0.036 Yes 
Location 4 0.593 No 
Location 5 0.169 No 
Selenium     
Location 1 0.818 N0 0.818 
 
No 
Location 2 0.587 No 
Location 3 0.134 No 
Location 4 0.010 Yes 
Location 5 0.020 Yes 
Zinc     
Location 1 0.001 Yes 0.961 
 
No 
Location 2 0.060 No 
Location 3 0.041 Yes 
Location 4 0.250 No 
Location 5 0.900 No 
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                      (d) Intra-batch and inter-batch variability of heavy metals in HM5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HM5 Intra-batch 
variability 
Inter-batch variability 
P- value Sig. P-value Sig. 
Arsenic     
Location 1 0.003 Yes 0.675 
 
No 
 Location 2 0.001 Yes 
Location 3 0.430 No 
Location 4 0.268 No 
Location 5 0.767 No 
Cadmium     
Location 1 0.162 No 0.362 
 
No 
Location 2 0.333 No 
Location 3 0.019 Yes 
Location 4 0.312 No 
Location 5 0.423 No 
Chromium     
Location 1 0.741 No 0.896 
 
No 
Location 2 0.551 No 
Location 3 0.161 No 
Location 4 0.037 Yes 
Location 5 0.101 No 
Copper     
Location 1 0.423 No 0.146 
 
No 
Location 2 0.035 Yes 
Location 3 0.092 No 
Location 4 0.012 Yes 
Location 5 0.083 No 
Lead     
Location 1 0.897 No 0.873 
 
No 
Location 2 0.455 No 
Location 3 0.187 No 
Location 4 0.029 Yes 
Location 5 0.033 Yes 
Manganese     
Location 1 0.580 No 0.379 No 
Location 2 0.132 No 
Location 3 0.376 No 
Location 4 0.418 No 
Location 5 0.218 No 
Nickel     
Location 1 0.481 No 0.288 
 
No 
Location 2 0.061 No 
Location 3 0.027 Yes 
Location 4 0.585 No 
Location 5 0.239 No 
Selenium     
Location 1 0.043 Yes 0.079 
 
No 
Location 2 0.230 No 
Location 3 0.011 Yes 
Location 4 0.328 No 
Location 5 0.056 No 
Zinc     
Location 1 0.604 No 0.876 
 
No 
Location 2 0.158 No 
Location 3 0.078 No 
Location 4 0.401 No 
Location 5 0.353 No 
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                           (e) Intra-batch and inter-batch variability of heavy metals in HM6 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
 
 
 
 
 
 
 
 
HM6 Intra-batch 
variability 
Inter-batch variability 
P- value Sig. P-value Sig. 
Arsenic     
Location 1 0.001 Yes 0.351 
 
No 
Location 2 0.016 Yes 
Location 3 0.429 No 
Location 4 0.152 No 
Location 5 0.110 No 
Cadmium     
Location 1 0.019 Yes 0.256 
 
No 
Location 2 0.014 Yes 
Location 3 0.098 No 
Location 4 0.002 Yes 
Location 5 0.114 No 
Chromium     
Location 1 0.063 No 0.408 
 
No 
Location 2 0.731 No 
Location 3 0.018 Yes 
Location 4 0.001 Yes 
Location 5 0.036 Yes 
Copper     
Location 1 0.135 No 0.891 
 
No 
Location 2 0.446 No 
Location 3 0.036 Yes 
Location 4 0.034 Yes 
Location 5 0.158 No 
Lead     
Location 1 0.007 Yes 0.313 
 
No 
Location 2 0.147 No 
Location 3 0.001 Yes 
Location 4 0.163 No 
Location 5 0.037 Yes 
Manganese     
Location 1 0.122 No 0.027 
 
Yes 
Location 2 0.010 Yes 
Location 3 0.056 No 
Location 4 0.807 No 
Location 5 0.038 Yes 
Nickel     
Location 1 0.004 Yes 0.069 
 
No 
Location 2 0.149 No 
Location 3 0.676 No 
Location 4 0.004 Yes 
Location 5 0.004 Yes 
Selenium     
Location 1 0.481 No 0.594 
 
No 
Location 2 0.003 Yes 
Location 3 0.608 No 
Location 4 0.008 Yes 
Location 5 0.020 Yes 
Zinc     
Location 1 0.018 Yes 0.010 
 
Yes 
Location 2 0.035 Yes 
Location 3 0.038 Yes 
Location 4 0.473 No 
Location 5 0.005 Yes 
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                      (f) Intra-batch and inter-batch variability of heavy metals  in HM7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
 
 
 
 
 
 
 
 
HM7 Intra-batch 
variability 
Inter-batch variability 
P- value Sig. P-value Sig. 
Arsenic     
Location 1 0.004 Yes 0.170 
 
No 
Location 2 0.005 Yes 
Location 3 0.728 No 
Location 4 0.087 No 
Location 5 0.758 No 
Cadmium     
Location 1 0.319 No 0.025 
 
 
Location 2 0.602 No 
Location 3 0.036 Yes 
Location 4 0.618 No 
Location 5 0.599 No 
Chromium     
Location 1 0.399 No 0.284 
 
No 
Location 2 0.455 No 
Location 3 0.039 Yes 
Location 4 0.579 No 
Location 5 0.525 No 
Copper     
Location 1 0.571 No 0.443 
 
No 
Location 2 0.358 No 
Location 3 0.337 No 
Location 4 0.197 No 
Location 5 0.020 Yes 
Lead     
Location 1 0.786 No 0.144 
 
No 
Location 2 0.701 No 
Location 3 0.621 No 
Location 4 0.968 No 
Location 5 0.180 No 
Manganese     
Location 1 0.129 No 0.457 
 
No 
Location 2 0.042 Yes 
Location 3 0.496 No 
Location 4 0.015 Yes 
Location 5 0.053 No 
Nickel     
Location 1 0.622 No 0.296 
 
No 
Location 2 0.262 No 
Location 3 0.038 Yes 
Location 4 0.879 No 
Location 5 0.674 No 
Selenium     
Location 1 0.804 No 0.041 
 
Yes 
Location 2 0.365 No 
Location 3 0.143 No 
Location 4 0.103 No 
Location 5 0.061 No 
Zinc     
Location 1 0.300 No 0.836 
 
No 
Location 2 0.494 No 
Location 3 0.267 No 
Location 4 0.242 No 
Location 5 0.070 No 
267 
(g) Intra-batch and inter-batch variability of heavy metals  in HM8
HM8 Intra-batch 
variability 
Inter-batch variability 
P- value Sig. P-value Sig. 
Arsenic 
Location 1 0.035 Yes 0.111 No 
Location 2 0.049 Yes 
Location 3 0.320 No 
Location 4 0.076 No 
Location 5 0.978 No 
Cadmium 
Location 1 0.583 No 0.556 No 
Location 2 0.081 No 
Location 3 0.051 No 
Location 4 0.474 No 
Location 5 0.562 No 
Chromium 
Location 1 0.107 No 0.645 No 
Location 2 0.707 No 
Location 3 0.017 Yes 
Location 4 0.277 No 
Location 5 0.113 No 
Copper 
Location 1 0.187 No 0.204 No 
Location 2 0.017 Yes 
Location 3 0.170 No 
Location 4 0.009 Yes 
Location 5 0.045 Yes 
Lead 
Location 1 0.057 No 0.005 Yes 
Location 2 0.382 No 
Location 3 0.014 Yes 
Location 4 0.459 No 
Location 5 0.044 Yes 
Manganese 
Location 1 0.206 No 0.002 Yes 
Location 2 0.020 Yes 
Location 3 0.023 Yes 
Location 4 0.012 Yes 
Location 5 0.045 Yes 
Nickel 
Location 1 0.686 No 0.298 No 
Location 2 0.494 No 
Location 3 0.538 No 
Location 4 0.034 Yes 
Location 5 0.161 No 
Selenium 
Location 1 0.024 Yes 0.408 No 
Location 2 0.707 No 
Location 3 0.014 Yes 
Location 4 0.254 No 
Location 5 0.078 No 
Zinc 
Location 1 0.943 No 0.854 No 
Location 2 0.271 No 
Location 3 0.045 Yes 
Location 4 0.507 No 
Location 5 0.142 No 
268 
(h) Intra-batch and inter-batch variability of heavy metals in HM9
HM9 Intra-batch 
variability 
Inter-batch variability 
P- value Sig. P-value Sig. 
Arsenic 
Location 1 0.003 Yes 0.695 No 
Location 2 0.094 No 
Location 3 0.022 Yes 
Location 4 0.001 Yes 
Location 5 0.035 Yes 
Cadmium 
Location 1 0.008 Yes 0.573 No 
Location 2 0.017 Yes 
Location 3 0.025 Yes 
Location 4 0.002 Yes 
Location 5 0.020 Yes 
Chromium 
Location 1 0.002 Yes 0.080 No 
Location 2 0.045 Yes 
Location 3 0.003 Yes 
Location 4 0.405 No 
Location 5 0.002 Yes 
Copper 
Location 1 0.064 No 0.950 No 
Location 2 0.074 No 
Location 3 0.023 Yes 
Location 4 0.154 No 
Location 5 0.001 Yes 
Lead 
Location 1 0.010 Yes 0.069 No 
Location 2 0.089 No 
Location 3 0.004 Yes 
Location 4 0.166 No 
Location 5 0.026 Yes 
Manganese 
Location 1 0.431 No 0.923 No 
Location 2 0.199 No 
Location 3 0.054 No 
Location 4 0.106 No 
Location 5 0.002 Yes 
Nickel 
Location 1 0.006 Yes 0.499 No 
Location 2 0.006 Yes 
Location 3 0.429 No 
Location 4 0.025 Yes 
Location 5 0.071 No 
Selenium 
Location 1 0.127 No 0.923 No 
Location 2 0.565 No 
Location 3 0.002 Yes 
Location 4 0.005 Yes 
Location 5 0.169 No 
Zinc 
Location 1 0.008 Yes 0.341 No 
Location 2 0.196 No 
Location 3 0.034 Yes 
Location 4 0.150 No 
Location 5 0.003 Yes 
269 
(i) Intra-batch and inter-batch variability of heavy metals in HM10
HM10 Intra-batch 
variability 
Inter-batch variability 
P- value Sig. P-value Sig. 
Arsenic 
Location 1 0.578 No 0.911 No 
Location 2 0.337 No 
Location 3 0.034 Yes 
Location 4 0.072 No 
Location 5 0.831 No 
Cadmium 
Location 1 0.090 No 0.169 No 
Location 2 0.312 No 
Location 3 0.161 No 
Location 4 0.305 No 
Location 5 0.385 No 
Chromium 
Location 1 0.264 No 0.983 No 
Location 2 0.108 No 
Location 3 0.209 No 
Location 4 0.566 No 
Location 5 0.875 No 
Copper 
Location 1 0.194 No 0.246 No 
Location 2 0.634 No 
Location 3 0.204 No 
Location 4 0.450 No 
Location 5 0.190 No 
Lead 
Location 1 0.201 No 0.264 No 
Location 2 0.648 No 
Location 3 0.010 Yes 
Location 4 0.929 No 
Location 5 0.025 Yes 
Manganese 
Location 1 0.316 No 0.502 No 
Location 2 0.210 No 
Location 3 0.461 No 
Location 4 0.413 No 
Location 5 0.894 No 
Nickel 
Location 1 0.014 Yes 0.475 No 
Location 2 0.720 No 
Location 3 0.462 No 
Location 4 0.741 No 
Location 5 0.056 No 
Selenium 
Location 1 0.169 No 0.141 No 
Location 2 0.760 No 
Location 3 0.027 Yes 
Location 4 0.045 Yes 
Location 5 0.370 No 
Zinc 
Location 1 0.247 No 0.179 No 
Location 2 0.363 No 
Location 3 0.051 No 
Location 4 0.207 No 
Location 5 0.160 No 
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Appendix XIV: Result of mercury analysis from Analytix laboratory 
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Appendix XV: Participant consent form 
PARTICIPANT CONSENT FORM  version one (5/09/15)
 
 
 
Th
NAME OF PARTICIPANT: 
Title of the project: PATTERN AND USE OF HERBAL MEDICINE IN EKITI STATE NIGERIA: 
IDENTIFICATION OF THE CHEMICAL CONSTITUENTS AND EPIDEMIOLOGICAL STUDY 
Main investigator and contact details: 
Aina olujimi olusola 
Department of forensic and biomedical science 
Anglia Ruskin University Cambridge 
Members of the research team: 
1. I agree to take part in the above research.  I have read the Participant Information Sheet
(version one (05/09/2015) for the study.
I understand what my role will be in this research, and all my questions have been
answered to my satisfaction.
2. I understand that I am free to withdraw from the research at any time, without giving a reason.
3. I am free to ask any questions at any time before and during the study.
4 I understand what will happen to the data collected from me for the research.
5. I have been provided with a copy of this form and the Participant Information Sheet.
6. I understand that quotes from me will be used in the dissemination of the research.
Data Protection:  I agree to the University1 processing personal data which I have supplied.  
I agree to the processing of such data for any purposes connected with the Research Project 
as outlined to me* 
Name of participant (print)………………………….Signed………………..….Date……………… 
1
 “The University” includes Anglia Ruskin University and its Associate Colleges. 
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-------------------------------------------------------------------------------------------------------------------------- 
I WISH TO WITHDRAW FROM THIS STUDY. 
If you wish to withdraw from the research, please speak to the researcher or email them at 
X stating the title of the research. 
You do not have to give a reason for why you would like to withdraw. 
Please let the researcher know whether you are/are not happy for them to use any data from you 
collected to date in the write up and dissemination of the research. 
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Appendix XVI: Questionnaire template 
PATTERN AND USE OF HERBAL MEDICINE IN EKITI STATE NIGERIA 
1. Age (Yrs): 18- 29 30-49      50 -69   70 and above 
2. Sex:  Male         Female 
3. Level of Education:          Uneducated        Primary   Secondary   Tertiary 
4. Religion: ……………………………………………… 
5. Occupation: …………………………………………………. 
6. Annual income (Naira):    Low Income (≤ 600,000)
Middle income (601,000 to 2.4M)          High Income (≥2.4M) 
7. Have you heard about herbal medicine:   Yes    No 
8. Do you know the difference between Government certified and uncertified herbal medicine:   Yes  No  
9. Have you used herbal medicine in the last 2 years?   Yes    No 
10. If No why ? ………………………………………………………………………………………………………………………………………………. 
If yes ticked to question 9 please continue with the rest of the questions. 
11. Which type of herbal medicine have you used in the last 2 years:   certified   Uncertified        Both 
12. What are the names of the herbal medicine you used …………………………………………………….. 
13. How many times have you used uncertified herbal medicine in the last 2 years?
Once-Twice                               3- 10 times                             above 10 times
14. Why do you prefer to use herbal medicine?
……………………………………………………………………………………………………………………………………………………………………… 
15. Why do you not prefer to visit the hospital? ............................................................ 
16. Was the herbal medicine effective for the intended use:   Yes    No 
17. Do you think it is safe to take uncertified herbal medicine:   Yes    NO 
18. What side effect did you experience associated with herbal medicine use?
………………………………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………… 
19. How did you manage the side effect?
……………………………………………………………………………………………………………………………………………………………………… 
20. How do you think the safety of uncertified herbal medicine can be achieved?
………………………………………………………………………………………………………………………………………………………………………
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Appendix XVII: Picture of Selected HM samples 
Sample 
No. 
Sample 
name 
Appearance Sample 
No. 
Sample 
name 
Appearance 
HM1 Body pain HM2 Male tonic 
HM3 Supa A1 HM4 Wadco total 
blood cure 
277 
HM5 Wadco 
pile& 
dysentry 
HM6 M&T Capsule 
HM7 YK 
original 
malaria 
HM8 Aromalegun 
HM9 Eroxy 
5000 
HM10 Original 
malaria/yellow 
fever and 
typhoid 
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Appendix XVIII: Certificate of Certified Reference Material 
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Appendix XIX:  Ethical Approvals 
(a) Anglia Ruskin university ethics approval
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(b) Ekit state hospital management board ethics approval
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(C) Ekiti state University ethics approval
